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II 
Abstract 
Osteosarcoma (OS) is the most common bone cancer in dogs. It is biologically 
aggressive and <20% survive >2 years with standard therapy. Hence, new 
approaches must be considered. TP53 is altered in ~50% of human and canine 
cancers, including OS, making it a candidate for targeted suicide gene therapy 
strategies. Canine OS is considered to be a good model for human OS. The aims 
of this study were to:  
 examine the site incidence of canine OS retrieved from Glasgow University 
Veterinary School (GUVS) histology database; 
 perform TP53 mutational analysis in canine OS cases diagnosed at GUVS;  
 investigate delivery of exogenous wild-type canine TP53 into D17, CMT3, CMT7 
and CMT8 canine OS cell lines;  
 design and construct vectors for a TP53-targeted suicide gene strategy, which 
can selectively target canine OS cells containing accumulated TP53, and 
initially analyse using Dual-Luciferase® reporter assays (DLR); 
 perform suicide gene/prodrug assays using nitroreductase (NTR) in combination 
with CB1954 or nitrofurazone (NFZ) in several canine cell lines;  
 replace luciferase with NTR in vectors for TP53-targeted suicide gene strategy, 
and with CB1954, determine if survival of CMT7 cells possessing accumulated 
TP53 are reduced, in comparison to D17 cells, containing wild-type TP53. 
OS were most commonly found in appendicular areas, followed by axial and 
extraskeletal sites; this agrees with published findings. No TP53 mutations were 
found in 7 biopsies removed from 4 dogs, 5 were OS, due to analysis of a small 
sample number, but still fits within published data. TP53 expression did not have 
a significant negative effect on canine OS cell growth. Contrasting results have 
been shown in canine and human OS cells. Luciferase expression levels following 
transfection with designed constructs were higher in CMT7 cells, than in D17 
cells. Similar results were shown in NTR/CB1954 assays as reductions in cell 
survival only occurred in CMT7 cells but not in D17 cells. NFZ was not suitable as 
a prodrug for NTR in canine cells as there were no differences in cell survival 
with cells not expressing NTR. Hence, the TP53-targeted suicide gene therapy 
strategy appears to selectively reduce survival of canine OS cells possessing 
accumulated TP53, warranting further investigation as a treatment modality for 
OS, in both dogs and humans. 
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1.1 Canine osteosarcoma  
 
1.1.1 Incidence 
Osteosarcoma (OS) accounts for ~5% of all canine neoplasms and is the most 
frequently diagnosed and reported canine bone tumour (Merlo et al., 2008; 
Priester & McKay 1980). OS represents 65-85% of the diagnosed primary bone 
sarcomas; chrondrosarcoma, 8-13%; fibrosarcoma, 1-9% and haemangiosarcoma, 
2-8% (Jongeward 1985). Other tumours, including lymphoma, liposarcoma and 
plasma cell tumours, are rarely observed and in total only account for ~5% 
(Jongeward 1985). OS may be more prevalent in some pure-breeds than others 
(Phillips et al., 2007; Rosenberger et al., 2007; Ru et al., 1998). It is estimated 
that ~10000 dogs are diagnosed with OS per year in the United States (Thomas et 
al., 2009), with reported standardized incidence rates varying between 4.6 – 57 
cases/100000 dogs/year (Dobson et al., 2002; Merlo et al., 2008). 
  
1.1.2 Sites  
Approximately 62-77% of OS occur in the appendicular skeleton, with the 
remainder occurring in the axial skeleton and extraskeletal sites (Brodey & Riser 
1969; Egenvall et al., 2007; Loukopoulos & Robinson 2007).  
The forelimbs are twice more likely to be affected than the hind limbs (Ru et 
al., 1998; Spodnick et al., 1992) but this may vary across breeds (Brodey & Riser 
1969; Rosenberger et al., 2007). The main sites in the foreleg are the distal 
radius and proximal humerus (Jongeward 1985; Spodnick et al., 1992) (Figure 
1.1). Tumours are fairly evenly distributed in the rear limbs between the distal 
femur, distal tibia and proximal tibia, with the proximal femur a slightly less 
common location (Jongeward 1985; Spodnick et al., 1992). The major sites of 
axial skeletal OS are the skull, the spine and the ribs, particularly at the 
costochondral junction (Brodey & Riser 1969; Egenvall et al., 2007; Heyman et 
al., 1992; Jongeward 1985). Extraskeletal OS are rare malignant mesenchymal 
neoplasms of visceral organs and soft tissues that produce osteoid, with no     Chapter 1 ~ Introduction 
 
3 
involvement of bone or periosteal tissue (Langenbach et al., 1998; Patnaik 
1990). The majority are found in the mammary tissue, spleen, gastrointestinal 
tract, liver, kidney and eye, rather than in the soft tissue of extremities (Kuntz 
et al., 1998b; Langenbach et al., 1998; Patnaik 1990).  
Metastasis via the haematogenous route is most common; however, on rare 
occasions extension to regional lymph nodes may occur (Hillers et al., 2005; 
Straw et al., 1990). The lungs are the most commonly reported site for 
metastasis, but tumour spread also occurs in additional bones and/or other soft 
tissue sites, including spine, ribs, long bones, liver and spleen (Brodey & Riser 
1969; Langenbach et al., 1998; Spodnick et al., 1992).  
 
Figure 1.1: The skeleton of the dog. 1, nasal cavity & sinus; 2, maxilla*; 3, skull*; 
4, spine of axis (C2)*; 5, ligamentum nuchae; 6, first thoracic vertebrae (T1)*; 7, 
scapula*; 8, first lumbar vertebrae (L1)*; 9, hip bone (os coxae); 10, sacrum; 11, 
first caudal (tail) vertebrae (Cd1); 12, femur*; 13, stifle; 14, fibula; 15, 
calcaneus (point of hock); 16, metatarsal bones; 17, tarsal bones; 18, tibia*; 19, 
patella; 20, rib*; 21, olecranon (point of elbow); 22, ulna*; 23, metacarpal 
bones; 24, proximal, middle and distal phalanges; 25, carpal bones; 26, radius*; 
27, humerus*; 28, cranial end (manubrium) of sternum; 29, last cervical 
vertebrae (C7); 30, first cervical vertebrae (C1); 31, mandible*. * - sites of 
appendicular and axial OS typically found in dogs. Adapted from Dyce et al., 
1987(Dyce et al., 1987).      Chapter 1 ~ Introduction 
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1.1.3 Demographics 
Canine OS is largely a disease of middle-aged to older dogs, with a median age 
of 7.5 years, although a small early peak in age incidence exists at 18 - 24 
months (Egenvall et al., 2007; Heyman et al., 1992; Jongeward 1985; 
Langenbach et al., 1998; Misdorp & Hart 1979). Primary rib OS tends to develop 
earlier with a mean age of 5.4 years (Heyman et al., 1992) and mammary gland 
OS later with a mean age of 10.6 years (Langenbach et al., 1998). OS is 
classically a sporadic cancer of the long bones in large to giant pure-breeds, but 
a tendency for familial aggregation may exist in St. Bernards, Rottweilers and 
Scottish Deerhound (Bech-Nielsen et al., 1978; Misdorp 1980; Phillips et al., 
2007; Thomas et al., 2009). A high prevalence of OS has also been found in 
Boxers, Great Danes, German Shepherds, Collies, Golden Retrievers, Doberman 
Pinschers, Irish Wolfhound, Greyhounds and Irish Setters (Jongeward 1985; 
Priester & McKay 1980; Rosenberger et al., 2007; Ru et al., 1998). The risk of 
bone sarcoma in dogs weighing >36kg is at least 60 times greater than in dogs 
weighing <10kg (Tjalma 1966). Increasing standard height has also been 
associated with an increased OS risk and has infact been demonstrated to be a 
more predictive risk factor than increasing weight (Ru et al., 1998). Males are 
often reported to be slightly more affected than females (approximate ratio of 
1.5:1.0), but this finding is not consistent amongst all publications, as reports of 
more females than males developing OS and no sex-related differences have 
been published  (Egenvall et al., 2007; Jongeward 1985; Merlo et al., 2008; 
Priester & McKay 1980; Ru et al., 1998). In addition, conflicting evidence exists 
regarding neutering increasing or decreasing the risk of OS and the age at which 
the dog is neutered due to hormonal changes altering skeletal homeostasis 
(Cooley et al., 2002; Priester & McKay 1980; Ru et al., 1998).  
  
1.1.4 Histopathology 
OS is a malignant mesenchymal tumour of progenitor bone cells (Dernell et al., 
2007). These cells produce an extracellular matrix of osteoid and the presence 
of tumour osteoid is the basis for the histological differential diagnosis of OS 
versus other malignant bone sarcomas (Dahlin & Unni 1977; Dernell et al., 2007)     Chapter 1 ~ Introduction 
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(Table 1.1). The histological pattern may vary between tumours or even within 
the same tumour, hence, there are many histological subclassifications of OS 
based on the precursor cell type, amount of matrix and characteristics of the 
cells including osteoblastic, anaplastic, fibroblastic, chondroblastic, osteocytic, 
osteolytic, myofibroblastic, angioblastic, poorly differentiated and telangiectatic 
(Dahlin & Unni 1977; Kadosawa et al., 1999; Misdorp & Hart 1979; Reddick et 
al., 1980). All of these neoplasms may exhibit irregularly placed and abnormally 
large multi-lobed nuclei and possess mitotic figures, including aberrant ones and 
an unusually large quantity of heterochromatin (Kirpensteijn et al., 2002a; 
Misdorp & Hart 1979; Reinhardt et al., 2005). Mild to moderate levels of cellular 
necrosis and extracellular debris, adjacent to normal relatively immature cells, 
can be observed (Kirpensteijn et al., 2002a; Reinhardt et al., 2005). Alkaline 
phosphatase staining has been shown to aid in differentiating OS pathologically 
from other connective tissue tumours (Barger et al., 2005; Britt et al., 2007). In 
dogs, it has not been clearly established that there is a difference in the 
biological behaviour of the different histological subclassifications; however, 
histological grade based on microscopic features may be predictive for increased 
risk of metastasis (Kirpensteijn et al., 2002a).   
Tumour Classification  Distinguishing features 
Osteosarcoma  Cells produce osteoid, not necessarily mineralized 
Chondrosarcoma  Characterized by the production of neoplastic cartilage 
  May be areas of calcification which are not areas of osteoid 
  Bone may also develop in chondrosarcomas by endochondral ossification 
Fibrosarcoma  Cells produce varying amounts of collagenous matrix 
Haemangiosarcoma  Areas of undifferentiated sarcoma with areas of primitive vascular 
channels 
Liposarcoma  Fat may be demonstrated within the tumour cells 
Undifferentiated 
sarcoma 
Cell types very primitive with insufficient organization to produce 
recognisable matrix 
Giant cell tumour  Large numbers of giant cells 
 
Common feature of histopathology of many bony lesions including 
osteosarcoma and some benign tumours 
Myeloma  Population of neoplastic plasma cells 
Lymphoma  Population of neoplastic lymphocytes 
 
Table 1.1: Primary malignant bone sarcomas that occur in dogs and their 
distinguishing features. Modified from Anderson (1996) (Anderson 1996) and Ling 
et al., (1974) (Ling et al., 1974). 
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1.1.5 Aetiology 
Despite advances in veterinary research and molecular techniques, the precise 
aetiology of canine OS and the mechanisms underlying OS progression and 
metastasis are still to be elucidated. It is quite likely that it is multifactorial as 
multiple possible causes have been documented and an accepted model of 
multi-stage carcinogenesis is one that is underpinned by progressive genetic 
changes that drive malignant transformation. An alternative hypothesis has been 
proposed in the past few years, the cancer stem cell (CSC) theory, as cancer 
growth is proposed to be driven by a small population of CSCs (Pang & Argyle 
2009). Recent evidence suggests that canine OS may also be a stem-cell disease 
(Wilson et al., 2008). 
 
1.1.5.1 Physical factors  
A general theory is that OS predominate in the metaphyseal region of the major 
weight-bearing bones, adjacent to late-closing physes, of tall heavy dogs 
(Egenvall et al., 2007; Ru et al., 1998). There appears to be a marked 
correlation between the sites of predilection for OS and the growth rates of 
various metaphyses (Brodey & Riser 1969; Tjalma 1966). Multiple episodes of 
minor trauma and subsequent injury may occur to cells in these physes (Brodey 
1979; Dernell et al., 2007; Tjalma 1966). Hence the induction of mitogenic 
signals may occur that promote the development of mutant lineages that 
manifest themselves as OS years later (Dernell et al., 2007; Tjalma 1966). This 
theory explains the more frequent occurrence of forelimb OS rather than rear, 
as heavy dogs bear more weight on their forelimbs (Brodey 1979).  
OS has been associated with several fracture repair techniques including those 
using metallic implants (Brodey 1979; Stevenson 1991). OS has been concurrently 
seen in dogs with bone infarcts, but it is not clear whether there is any causal 
relationship, between bone infarcts and OS or, quite simply, that the stress of 
repair in the infarcted areas leads to a greatly increased risk of OS (Brodey 1979; 
Dubielzig et al., 1981).     Chapter 1 ~ Introduction 
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Exposure to ionising radiation may induce OS (McChesney-Gillette et al., 1990; 
Powers et al., 1989; Thurman et al., 1973). The majority of radionucleotides 
that can localize in the bone, e.g. 
239Pu,
 226Ra, 
228Ra, 
244Ra, 
90Sr and 
228Th, have 
the potential to cause OS in laboratory beagles (Thurman et al., 1973). 
However, OS is a rare late complication of radiation therapy in dogs (McChesney-
Gillette et al., 1990; McEntee et al., 2004; Powers et al., 1989).  
 
1.1.5.2 Genetic and molecular factors 
There is a body of experimental and clinical research demonstrating that several 
genetic and molecular factors may be involved in the pathogenesis of canine OS 
(Mueller et al., 2007; Thomas et al., 2005). 
  
1.1.5.2.1 Chromosomal abnormalities  
Cytogenetic studies have revealed that the karyotypes found in canine OS are 
typically complex and contain numerous numerical and structural abnormalities 
(Thomas et al., 2009). The majority of OS cells have an aneuploid karyotype and 
often contain chromosomes with an abnormal number of arms and centromeres 
and chromosomal fragments (Thomas et al., 2009). Altogether 27 of the 38 pairs 
of canine acrocentric autosomes and the 2 metacentric sex chromosomes have 
been reported to contain chromosomal aberrations (Mayr et al., 1991; Thomas et 
al., 2005).   
Until recently, the canine karyotype was poorly annotated, partly due to the 
large number of chromosomes making identification of all 78 chromosomes by 
classical banding techniques difficult, but more so because of their regularly 
decreasing size and absence of a clear and diagnostic pattern of R bands (Breen 
2008). The dog karyotype has now been described following the development 
over the past few years of robust genomic techniques for analysing the 
molecular cytogenetics of canine tumours, including OS e.g. metaphase-based 
comparative genomic hybridizations (mCGH) and array CGH (aCGH) (Breen 
2008). A recent study by Thomas et al., (2009) utilising a cytogenetically 
characterized, genome-anchored 10-Mb bacterial artifical chromosome (BAC) set     Chapter 1 ~ Introduction 
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for aCGH revealed that canine OS possessed a vast range of DNA copy number 
aberrations and structural rearrangements throughout the genome, some of 
which were not previously identified by mCGH (Thomas et al., 2009). 
Furthermore, 14 loci found to contain either copy number gain or loss in >30% OS 
studied were located in 8 different chromosomes which included sites for 5 
major cancer-related genes, PTEN, MYC, HRAS, WT1 and KIT (Thomas et al., 
2009). 
 
1.1.5.2.2 Molecular abnormalities  
A number of genes and proteins are thought to be involved in the pathogenesis 
of canine OS, which are summarized in Table 1.2. In particular, point mutations 
in TP53 have been found in 23-100% of canine OS screened (Johnson et al., 1998; 
Kirpensteijn et al., 2008; Mendoza et al., 1998; Setoguchi et al., 2001b; Van 
Leeuwen et al., 1997). Abnormal levels of TP53 mRNA have been observed in 
canine OS cell lines (Levine & Fleischli 2000). Immunohistochemical studies have 
indicated that abnormal, non-functional TP53 commonly accumulates in canine 
OS (Loukopoulos et al., 2003; Sagartz et al., 1996). Genetic evidence also 
indicates that TP53 is one of the most frequently altered genes in canine OS. 
TP53 is a tumour suppressor, as the TP53 gene encodes a transcription factor 
that regulates genes involved in cell cycle, DNA damage response and apoptosis 
(Riley et al., 2008), which are described in further detail in 1.3. Hence the 
absence of a functional TP53 gene or protein may lead to the impairment of 
numerous pathways that TP53 participates in and consequently, contribute to 
unrestrained cellular proliferation and tumourigenesis.  
 
Table 1.2: Molecular factors proposed to be associated with OS tumourigenesis in dogs. Adapted from Dernell et al., (2007) (Dernell et 
al., 2007). 
Factor  Comments  Reference 
TP53  Gene mutations and/or protein accumulation commonly observed in canine OS  (Johnson et al., 1998; Mendoza et al., 1998; Sagartz et al., 1996; Setoguchi et al., 2001b) 
   samples and cell lines  (Inoue & Shiramizu 1999; Kirpensteijn et al., 2008; Loukopoulos et al., 2003;Van Leeuwen et al., 1997) 
MDM2  Gene duplication found in canine OS  (Mendoza et al., 1998) 
PTEN  Gene mutations and/or aberrant expression of protein reported in canine OS  (Levine et al., 2002) 
   samples and cell lines    
ERBB2/HER-2  Protein overexpression demonstrated in canine OS samples and cell lines  (Flint et al., 2004) 
SIS/PDGF  Gene amplification reported in canine OS samples and cell lines  (Kochevar et al., 1990;Levine 2002) 
MYC  Gene amplification and protein overexpression observed in canine OS samples  (Inoue & Shiramizu 1999; Kochevar et al., 1990; Levine 2002) 
   and cell lines    
MET/HGF  Gene mutations and/or protein overexpression may contribute to metastasis in  (Ferracini et al., 2000; Liao et al., 2006; MacEwen et al., 2003) 
   canine OS samples and cell lines   (De Maria et al., 2009; Fieten et al., 2009) 
TrkA  Protein expression may enhance cell mitogenesis and survival in canine OS  (Fan et al., 2008) 
   samples and cell lines and pulmonary metastases    
GH  Gene expression reported in canine OS  (Kirpensteijn et al., 2002b) 
IGF-1/IGF-1R  Protein expression may contribute to ability of canine OS cells to metastasize   (MacEwen et al., 2004) 
Matrix metalloproteinases (MMP-2 & MMP-9)    Elevated protein levels found in canine OS samples and cell lines  (Lana et al., 2000; Loukopoulos et al., 2004) 
Cyclooxygenase enzymes/PGE2  Elevated protein levels in canine OS samples, metastatic tumours and cell lines  (Mohammed et al., 2001; Mohammed et al., 2004; Mullins et al., 2004) 
   reported    
Angiogenic factors  Levels of VEGF in plasma and angiostatin in urine, both measurable in dogs  (Pirie-Shepherd et al., 2002; Thamm et al., 2008; Wergin & Kaser-Hotz 2004) 
   with OS, may contribute to ability of canine OS to metastasize    
Telomerase reverse transcriptase  Gene upregulation observed in canine OS samples and cell lines  (Yazawa et al., 2003a) 
Ezrin  Protein detected in canine OS samples and may be associated with metastasis  (Khanna et al., 2004) 
STAT3  Activation of STAT3 may contrbute to cell proliferation and survival in   (Fossey et al., 2009; Wilson et al., 2008) 
   canine OS samples and cell lines     
OCT4  Gene expressed at high levels in canine OS cell lines and sarcopheres  (Wilson et al., 2008) 
NANOG  Gene expressed at high levels in canine OS cell lines and sarcopheres  (Wilson et al., 2008)     Chapter 1 ~ Introduction 
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1.1.6 Clinical presentation & diagnosis 
Dogs with OS in appendicular sites generally present at clinical examination, 
lameness and/or swelling of the affected limb which is invariably painful 
(Mueller et al., 2007). The history and clinical signs associated with axial and 
extraskeletal OS vary depending on the location of the tumour (Chun & de 
Lorimier 2003). The first clinical signs of OS pulmonary metastasis are rarely 
dogs presenting with respiratory problems, as dogs with radiographically 
detectable pulmonary metastasis may remain asymptomatic for many months; 
rather, their first signs are usually vague as most dogs develop decreased 
appetites and malaise within 1 month (Dernell et al., 2007). 
Imaging plays an important role in aiding a diagnosis and the staging of OS in 
dogs, in conjunction with evaluating tissue biopsies and an assessment of the 
patient‟s overall health status. A complete blood and platelet count, serum 
biochemical profile and urine analysis are usually obtained, as certain 
therapeutic decisions might be altered based on the results of such tests (Dernell 
et al., 2007). Recently, two bone resorption markers, urine and serum N-
telopeptide, were found to support a diagnosis of OS (Lucas et al., 2008). 
Radiographs of the affected area commonly reveal aggressive lesions (Ling et 
al., 1974). The radiographic appearance of OS varies, as it can range from being 
primarily osteolytic to almost entirely osteoblastic or osteogenic, or it can be a 
mixture consisting of differing proportions (Wrigley 2000) (Figure 1.2). 
Unfortunately a diagnosis of OS cannot be assumed solely on the basis of 
radiographic findings, because the radiographic appearance of OS is similar to 
other bone diseases, including, other primary bone tumours, multiple lymphoma 
of bone, and fungal and bacterial osteomyelitis (Dernell et al., 2007; Ling et al., 
1974; Wrigley 2000). Furthermore, thoracic radiographs only reveal gross 
metastatic disease in less than 15% of dogs at the time of diagnosis, although it 
is well established, that the majority of these dogs will go on to develop 
pulmonary metastatic disease if treated by surgery alone (Brodey & Abt 1976; 
Spodnick et al., 1992). 
Nuclear scintigraphy (survey radiography) can be used to evaluate the degree of 
bone involvement from a primary bone tumour, help to predict time to     Chapter 1 ~ Introduction 
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metastasis in dogs with OS, and to detect secondary skeletal sites of OS (Forrest 
et al., 1992; Janowski et al., 2003; Lamb 1987). However, the specificity of 
nuclear scintigraphy is relatively low for identifying sites of skeletal tumour, so 
any lesions identified by this technique should be verified e.g. regions of 
osteoblastic activity, including osteoarthritis and infection (Berg et al., 1990; 
Chun & de Lorimier 2003; Lamb 1987; Leibman et al., 2001). 
Although current published treatment recommendations and prognoses are 
based on the results of plain radiographs for dogs with OS, the use of advanced 
imaging techniques, in particular, computerized tomography and magnetic 
resonance imaging, are becoming more commonplace for staging dogs with OS 
(Davis et al., 2002; Wallack et al., 2002). 
A presumptive diagnosis of OS can be made based on symptoms, history, physical 
examination and radiographic findings, however, biopsy followed by 
histopathological evaluation remains the definitive diagnostic procedure for OS 
(Dernell et al., 2007; Ling et al., 1974). Although obtaining a bone biopsy is a 
painful procedure, as well as the risk of collecting a non-diagnostic biopsy and 
numerous post-surgical complications (Chun & de Lorimier 2003; Dernell et al., 
2007).  
Ultrasound-guided fine-needle aspiration and cytology of lytic bone lesions are 
gradually being used more frequently in veterinary medicine and may provide a 
more rapid diagnosis and reduce complications because of the minimally invasive 
procedure required to obtain a sample (Barger et al., 2005; Britt et al., 2007). 
However, the cytological information obtained can be limited, in particular, OS 
can appear similar to chondrosarcoma, synovial cell sarcoma and fibrosarcoma 
(Barger et al., 2005). Although, alkaline phosphatase staining of cytological 
samples may help to differentiate OS from other vimentin-positive tumours, 
including other sarcomas affecting bones (Barger et al., 2005; Britt et al., 2007). 
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Figure 1.2: The radiographic appearance of OS in a distal femur of a dog. Areas 
of lucency demonstrate significant bone lysis. OS is typical in the metaphyseal 
area (in-house photograph). 
 
1.1.7 Prognostic factors  
A number of negative prognostic indicators have been identified for canine OS, 
in particular the presence of metastases at the time of diagnosis (Brodey & Abt 
1976; Hammer et al., 1995; Ogilvie et al., 1993), high histological tumour grade 
(Kirpensteijn et al., 2002a; Straw et al., 1996), high tumour microvascular 
density (Coomber et al., 1998), and in dogs with appendicular or axial OS, 
elevated pre- and post-operative alkaline phosphatase levels (Ehrhart et al., 
1998; Fieten et al., 2009; Garzotto et al., 2000). Other factors which have been 
proposed as poor prognostic indicators are large tumour size (Forrest et al., 
1992; Misdorp & Hart 1979), insufficient surgical margins (Hammer et al., 1995; 
Hendrix & Gelatt 2000; Kuntz et al., 1998a), dogs younger than 5 years of age 
and older than 10 years (Spodnick et al., 1992), OS located in the proximal     Chapter 1 ~ Introduction 
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humerus (Bergman et al., 1996; Mehl et al., 2005; Phillips et al., 2009), body 
weight greater than 40kg (Bergman et al., 1996; Hammer et al., 1995; Lascelles 
et al., 2005), and for OS of flat or irregular bones, a telangiectatic (vascular) 
subtype and a rib or scapula location (Hammer et al., 1995).  
However, there are a few factors which are associated with possessing a lower 
metastatic rate and a better prognosis in dogs with OS and these include 
mandibular OS (Kosovsky et al., 1991; Straw et al., 1996), allograft infections 
post limb-sparing surgery (Lascelles et al., 2005), >10% lymphocyte micronuclei 
following chemotherapy (Hahn et al., 1996), and a high percentage of tumour 
necrosis following doxorubicin treatment (Berg et al., 1995).  
  
1.1.7.1 Molecular prognostic factors  
The search continues for reliable prognostic markers in canine OS that can be 
determined at diagnosis. Investigations have been carried out to link the 
expression of various genes or their protein products with response to outcome 
as it is widely recognized that as various tumour suppressor genes (TSG) and 
oncogenes contribute to the tumourigenesis and progression of OS, they may also 
potentially act as negative prognostic indicators.  
The presence of TP53 mutations and protein accumulation, in addition to 
potentially playing a role in the aetiology of canine OS (1.1.5.2.2), have been 
suggested to be suitable poor prognostic indicators for canine OS (Kirpensteijn et 
al., 2008; Loukopoulos et al., 2003). Furthermore, a higher prevalence of TP53 
mutations and accumulation of TP53 are reported in appendicular rather than 
axial sites and multilobular tumours of bone (low-grade malignancies) 
(Loukopoulos et al., 2003; Sagartz et al., 1996). Dogs with OS originating in the 
appendicular skeleton have a poorer prognosis with shorter survival time and 
metastasis occurring earlier than dogs with OS arising in the axial skeleton or 
multilobular tumours of bone (Heyman et al., 1992; Straw et al., 1989). Hence, 
providing evidence for supporting TP53 as a factor in the more aggressive form 
of the disease, i.e. appendicular OS, and as a poor prognostic indicator.      Chapter 1 ~ Introduction 
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The expression of COX2 which may also possess a role in the tumourigenesis of 
canine OS (Table 1.2), has also been demonstrated to be a potential prognostic 
indicator of poor outcome (Mullins et al., 2004). Mullins et al., (2004) reported 
that the majority of canine appendicular OS samples analysed for COX2 
expression were positive and those with strong COX2 expression levels had a 
significantly decreased overall survival compared to those samples with negative 
staining (86 days versus 423 days) (Mullins et al., 2004).  
 An increase in tumour cell proliferation rate, may be an indicator of more 
aggressive tumour cell kinetics (Larue et al., 1994; Ohta et al., 2004). The 
kinetic parameter, Tpot, has been associated with a worse prognosis in dogs with 
OS, in that the samples with the fastest Tpot were highly significant in predicting 
a shorter time to metastasis and reduced survival time (Larue et al., 1994). The 
proliferation marker, Ki-67, was found to be expressed in canine OS samples at a 
significantly higher level than that observed in chondrosarcoma samples (Ohta et 
al., 2004). Furthermore the survival rate of OS cases was significantly lower than 
that of the chondrosarcoma cases, which supports the view that in dogs, OS is 
clinically more aggressive than chondrosarcoma (Ohta et al., 2004).    
Ezrin, as well as possibly functioning in the metastatic disease process in dogs 
with OS (Table 1.2), has been shown to be a prognostic indicator of metastatic 
behaviour and survival in dogs with OS (Khanna et al., 2004). The presence of 
high ezrin staining in the primary tumour was associated with early development 
of metastases and hence, a significantly shorter median disease-free interval 
compared to dogs with low levels of ezrin staining in the primary tumour 
(Khanna et al., 2004).  
 
1.1.8 Therapy 
The current standard treatment for dogs with OS is amputation (Figure 1.3) or 
surgical resection of the primary tumour followed by either a platinum (cisplatin 
or carboplatin)- and/or doxorubicin- based chemotherapy protocol (summarized 
in Table 1.3) (Dernell et al., 2007). In dogs with appendicular or axial OS, this 
treatment results in a median survival time of ~50 weeks and 1-year and 2-year     Chapter 1 ~ Introduction 
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survival rates of ~ 45% and 20%, respectively (Berg et al., 1992; Berg et al., 
1995; Fieten et al., 2009; Kent et al., 2004; Mauldin et al., 1988; Phillips et al., 
2009). In dogs with extraskeletal OS treated with surgery and adjuvant 
chemotherapy, a median survival of 5 months has been reported (Kuntz et al., 
1998b). A systemic therapy is required because if surgery is the sole form of 
treatment, the median survival time in dogs with appendicular or axial OS, is ~17 
weeks with 1-year and 2-year survival rates of ~ 13% and 2%, respectively (Baines 
et al., 2002; Spodnick et al., 1992; Wallace et al., 1992). Dogs with 
extraskeletal OS have a median survival of ~1.6 months (Kuntz et al., 1998b; 
Langenbach et al., 1998). Survival rates are poor because dogs with OS are 
frequently euthanized due to metastatic disease, in particular pulmonary 
metastasis, or refractory pain in untreated dogs (Wilson et al., 2008). Although 
pulmonary (diameter >0.5cm) or osseous metastasis is radiographically 
detectable in less than 15% of dogs at presentation or surgery, microscopic 
metastatic disease is present in ~80-90% of cases, even if there is no evidence 
(Langenbach et al., 1998; Matthiesen et al., 1992; Spodnick et al., 1992; Straw 
et al., 1991). The exception is mandibular OS, as surgery alone has been 
reported to provide a 1-year survival rate of >35%, and chemotherapy has not 
yet demonstrated any survival advantage (Kosovsky et al., 1991; Straw et al., 
1996).   
Metastasectomy may be performed in dogs with solitary bone metastases and no 
evidence of cancer elsewhere, although the subsequent disease-free interval is 
generally short (Dernell et al., 2007). However, pulmonary metastasectomy may 
significantly increase (~50%) median survival time of dogs with appendicular OS 
to nearly 6 months (Brodey & Abt 1976; O'Brien et al., 1993). Treatment with 
various combinations of therapies may increase survival times in dogs with OS 
diagnosed with metastases at time of presentation to that of surgery alone, 
albeit median survival time is only 76 days with a 1 year survival rate of 7% 
(Boston et al., 2006). A couple of pilot studies have also observed partial 
responses in a small number of dogs with metastatic OS following treatment with 
inhalational or intravenous paclitaxel or inhalational doxorubicin for a short 
period of time (Hershey et al., 1999; Khanna & Vail 2003; Poirier et al., 2004).     Chapter 1 ~ Introduction 
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Palliative treatment is provided for dogs with metastatic OS or when owners do 
not want to pursue more aggressive treatment options for primary OS (Mueller et 
al., 2007). Forms of palliative treatment include radiation therapy (Coomer et 
al., 2009), surgery alone (Chun & de Lorimier 2003), nonsteroidal anti-
inflammatory drugs (e.g. piroxicam, carprofen, meloxicam) (Lester & Gaynor 
2000), radiopharmaceuticals, such as samarium (Aas et al., 1999; Lattimer et 
al., 1990), and bisphosphonates (e.g. pamidronate, alendronate) (Fan et al., 
2009; Tomlin et al., 2000). 
Radiation therapy is the main modality of palliative care and in some 
circumstances, amputation may also be required (Dernell et al., 2007). 
Radiotherapy has been reported to improve limb function and quality of life in 
over 70% of patients treated with median duration of response ~10 weeks 
(Knapp-Hoch et al., 2009). After this time, euthanasia often occurs due to 
progressive local disease or the metastatic lesions becoming symptomatic. The 
response rate to radiotherapy may be improved by the addition of chemotherapy 
(Heidner et al., 1991; Ramirez et al., 1999), although, this has unfortunately not 
been found to be the case in other studies (Green et al., 2002; Mueller et al., 
2005; Walter et al., 2005a); albeit in all 5 studies, a relatively small number of 
dogs were treated. Recently, investigations into curative-intent radiation 
therapy protocols were carried out, when limb amputation was not possible in 
dogs with appendicular OS, which demonstrated that they can successfully 
control local disease, while chemotherapy was administered for metastatic 
disease (Coomer et al., 2009). However, curative-intent radiation therapy is 
associated with a high rate of radiation-induced complications and their success 
depends on management of these complications (Coomer et al., 2009). Hence, 
curative-intent radiation therapy protocols, as yet, cannot replace standard of 
care treatments for appendicular OS i.e. amputation and chemotherapy.      Chapter 1 ~ Introduction 
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Figure 1.3: A cross-breed dog after forelimb amputation for OS of the distal 
radius (in-house photograph).  
 
Table 1.3: Commonly used adjuvant chemotherapy agents and the survival outcome for dogs with OS. Abbreviations: Amp, amputation; 
DFI – Disease Free Interval; NA, not applicable; carbo, carboplatin; d, day; DOX, doxorubicin; post-op, post-operative; pre-op, pre-
operative; sx, surgery; NR, not reported; sig. diff., significant difference. Modified from Chun and de Lorimier (2003) (Chun & de 
Lorimier 2003) and Dernell et al., (2007) (Dernell et al., 2007).  
Treatment  OS Site  # chemotherapy 
doses 
# dogs  Median DFI 
(days) 
Median survival (days) 
(1-yr, 2-yr survival) 
Comments  Reference 
Amp/limb-
spare+cisplatin 
Appendicular  1-6  22 (17 - amp,  
5 - limp-spare) 
NR  325 (45.5%, 20.9%)  Increase in treatment failures possibly due to bone 
metastases; survival data not divided for sx types. 
(Berg et al., 1992) 
Amp+cisplatin  
Amp+cisplatin 
Appendicular  2 (post-op) 
2 (1 pre-op;1 post-op) 
17 
19 
226 
177 
262 (38%, 18%) 
282 (43%, 16%) 
No sig. diff. between survival data for dogs given 
cisplatin before amp compared to those after amp. 
(Straw et al., 
1991) 
Surgery+cisplatin  Axial  
(Rib) 
NR  9  225  240 (NR, NR)  Age, weight, sex, number of ribs resected, tumour 
volume, and total cisplatin dose did not influence 
survival or disease-free interval. 
(Pirkey-Ehrhart et 
al., 1995) 
Amp+carboplatin  Appendicular  1-4  48  257  321 (35.4%, NR)  Maximum tolerated cumulative dose has not been 
described for dogs. 
(Bergman et al., 
1996) 
Amp+carboplatin  Appendicular  3-4  155  256  307 (36.8%, 18.7%)  Acceptable alternative to cisplatin  (Phillips et al., 
2009) 
Amp/limb-spare+DOX  Appendicular  5  35 (33 - amp, 
2 - limb-
spare)  
NR  366 (50.5%, 9.7%)  Survival data not divided for sx types; Percentage 
necrosis of tumour predicted survival. 
(Berg et al., 1995) 
Surgery + cisplatin/DOX  Extraskeletal  2-5 
 
5  NR  146 (0%, 0% )  Only factor found to be prognostic for survival was 
use of chemotherapy. 
(Kuntz et al., 
1998b) 
Amp+DOX+cisplatin  Appendicular  3 (starting 2 or 10 d 
post-op) 
102 (53 – 2d; 
49 - 10d) 
NR  2d post-op: 345 (48%, 
28.3%) 
10d post-op: 330 
(46.2%, 27.5%) 
12 dogs died after first cycle; 22 cases of dose 
reduction; no difference in post-op vs. pre-op 
chemotherapy. 
(Berg et al., 1997) 
Amp+DOX+cisplatin  Appendicular 
& axial 
1of each 
 
38 (36 
appendicular, 
2 axial) 
210  300 (37%, 26%)  No sig. diff. between survival data from this study 
and survival data from single agent cisplatin study. 
(Mauldin et al., 
1988) 
Amp+DOX+carboplatin  Appendicular  4 of each  24  195  235 (NR, NR)  Combination at these dosages was well-tolerated in 
most cases. 
(Bailey et al., 
2003) 
Amp+DOX+carboplatin  Appendicular  6 (3 of each)  50  202  258 (NR, NR)  Toxicity reported in 15 (30%) dogs. Survival times 
similar to single-agent protocols. 
(Bacon et al., 
2008) 
Amp/limb-
spare+DOX+carboplatin 
Appendicular  x3 cycles  32  227  320 (48%, 18%)  Minimal toxicity associated with chemotherapy.  (Kent et al., 2004) 
Surgery+/or 
chemotherapy+/or 
radiotherapy 
Axial 
(mandibular) 
2-3  51  285  528 (59.3%, NR)  No apparent difference between various treatment 
modalities.  
(Straw et al., 
1996) 
Surgery+carboplatin+/- 
cisplatin or DOX+/-
cisplatin 
Axial 
(rib+sternum) 
2-8  19  149  290 (32%, NR)  Post-op chemotherapy prolongs survival time.  (Fieten et al., 
2009)     Chapter 1 ~ Introduction 
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1.1.9 Comparative aspects 
Animal models for the study of human diseases are important to our 
understanding of the mechanism and aetiology of disease and for the 
development and refinement of therapeutic strategies (Pang & Argyle 2009). It 
was not until the mid-1970‟s that researchers turned their attention from the 
development of artificial models of OS to OS found spontaneously developing in 
the pet population as a means of not only gaining information regarding OS in 
that particular species, but also into human OS (Brodey 1979).  
Canine OS has many similarities to human OS and can serve well as a valuable 
comparative model for study (Table 1.4) (Argyle 2005; Bronden et al., 2007). For 
example, human OS demonstrates a bimodal age distribution, frequently 
develops in the metaphyses of long bones, and is aggressive with distant 
metastases occurring in more than 80% of patients treated by surgery alone 
(Sandberg & Bridge 2003; Tang et al., 2008). Although there is a difference in 
the main peak of incidence between humans and dogs, i.e. young adults vs 
middle-aged older dogs, this may simply be due to the fact that in young adults 
rapid bone growth is still occurring in the metaphyses of long bones and 
sufficient micro-traumas have already taken place in their earlier years, 
enabling the induction of mitogenic signals. In addition, children with hereditary 
retinoblastoma have a high risk of secondary cancers occurring, particularly in 
their teenage years, 50% of which are OS (Sandberg & Bridge 2003). 
Standard of care treatment for human OS is also similar to that of dogs, in that 
neoadjuvant chemotherapy, followed by amputation or limb-sparing and 
adjuvant chemotherapy are employed (Tang et al., 2008). Negative prognostic 
factors include advanced local or systemic stage, large tumour size and a lower 
percentage of necrosis following neo-adjuvant treatment (Tang et al., 2008). 
Several cases of familial OS in humans have been published e.g. families with 
members suffering from the Li-Fraumeni syndrome possess germ-line TP53 
mutations (Tang et al., 2008). In particular, OS in dogs and humans display 
similar types of DNA ploidy and cytogenetic abnormalities and are clinically and 
histopathologically virtually indistinguishable (Thomas et al., 2009). Of 
considerable relevance to this study, is that human OS, similar to canine OS, 
contain a high prevalence of alterations in TP53 and its protein which are     Chapter 1 ~ Introduction 
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thought to play a significant role in the tumourigenesis of this disease (Pakos et 
al., 2004; Toguchida & Nakayama 2009). Furthermore molecular abnormalities in 
MDM2, PTEN, ERBB2, SIS, MYC, MET, TrkA, GH, IGF-1, IGF-1R, MMP2, MMP9, 
COX1, COX2, VEGF, angiostatin, telomerase reverse transcriptase and ezrin, 
previously described in Table 1.2, have also been reported to be involved in the 
pathogenesis, aggressive tumour growth and the promotion of metastatic 
potential in human OS (Bakhshi et al., 2009; DuBois & Demetri 2007; Freeman et 
al., 2008; Kochevar et al., 1990; Rodriguez et al., 2008; Tang et al., 2008). 
Naturally occurring OS in dogs develops 40-50 times more frequently than in 
humans; therefore, case accrual is more rapid (Withrow et al., 1991). Since 
disease progression is faster in dogs than in humans and responses to treatment 
are similar for the 2 species, results of treatment protocols can be reported 
earlier than would those of similar trials in humans (Dernell et al., 2007). 
Research costs are less for clinical trials in dogs compared to those in humans 
and, from an animal welfare standpoint, no disease is induced and dogs with 
cancer can be helped (Argyle 2005; Mueller et al., 2007). The long-term survival 
rate for human OS is presently 60-70% with the use of established multi-drug 
adjuvant protocols which contrasts to the 20% expected 5-year survival rates of 
the early 1980s (Tang et al., 2008). However, the remaining 30-40% of patients 
with OS develop pulmonary metastases despite the administration of adjuvant 
chemotherapy and the type of surgery (amputation or limb-sparing) does not 
impact outcome, which together support the need for the incorporation of new 
forms of therapy into the adjuvant chemotherapy protocols to impact survival.  
 
1.1.10 Summary 
OS is the most commonly occurring bone cancer in the canine species and is an 
excellent model for human OS. A range of chromosomal aberrations and 
alterations in several TSG, oncogenes, proteinases, growth factors and hormone 
signalling systems have been documented that may be involved in the 
pathogenesis of OS in both species. In particular, TP53 is the most frequently 
altered gene in canine and human neoplasia.       Chapter 1 ~ Introduction 
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Canine OS is biologically aggressive with clinically undetectable micrometastasis 
occurring early on in the course of disease. If amputation of the primary OS is 
the sole form of treatment, the majority of dogs are dead within a year due to 
metastasis. Despite advances in surgical techniques and the tripling of median 
survival times in dogs receiving adequate primary site control, due to the use of 
the platinum class of chemotherapeutics, in terms of actual months, survival 
times have increased from a 4-month median to an 11-month median at best, 
furthermore, ~80% dogs still eventually die because of metastasis (Wilson et al., 
2008).  
In summary, as OS remains a disease of high mortality in both dogs and humans, 
the investigation of alternative treatments is warranted, such as the use of 
targeted gene therapy.   
 
Variable  Dog   Human 
Total # cases diagnosed in United States/year  >8000  1000 
Age (years)  Median 7.5 (early peak @ 1.5 - 2)  Peak incidence @ 15-19 (smaller peak >50)  
Race/breed  Large or giant purebreds  None 
Gender ratio: male: female  1.5: 1.0  1.5: 1.0 
Body weight  90% > 20kg  Heavy 
Site  77% long bones  90% long bones 
   Metaphyseal  Metaphyseal 
   Distal radius > proximal humerus  Distal femur > proximal tibia 
   Distal femur > tibia  Proximal humerus 
Aetiology  Generally unknown  Generally unknown 
Molecular & genetic alterations   Yes  Yes 
% clinically confined to limb at presentation  80 - 90%  80 - 90% 
% histologically high grade   95%  85 - 90% 
% aneuploid  75%  75% 
Prognostic indicators  Alkaline phosphatase  Alkaline phosphatase 
Metastatic rate without chemotherapy  90% before 1 year  80% before 2 years 
Metastatic sites  Lung > bone > soft tissue  Lung > bone > soft tissue 
Improved survival with chemotherapy  Yes  Yes 
Regional lymph node metastasis  <5%, negative prognosis  Poor prognosis 
Radiosensitivity  Generally poor  Generally poor 
Radiographic appearance  Aggressive, osteolytic and osteoblastic  Aggressive, osteolytic and osteoblastic 
   Codman's triangle, sunbursting.  Codman's triangle, sunbursting. 
 
Table 1.4: A comparison of canine and human OS characteristics. Modified from Withrow et al., (1991) (Withrow et al., 1991), Dernell et 
al., (2007) (Dernell et al., 2007), and Sandberg & Bridge (2003) (Sandberg & Bridge 2003). 
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1.2 Gene therapy for cancer  
Gene therapy can be defined as the delivery of genetic information to modify a 
population of target cells for the purpose of treating disease (Argyle 1999). 
Although gene therapy was originally envisioned as a means to treat genetic 
diseases, its potential to play a major role in the development of cancer 
therapeutic agents was quickly recognized. The goal of cancer gene therapy, 
similar to other treatments for cancer, is the elimination of all malignant cells 
whilst minimising damage to normal cells. The first approved gene transfer 
protocol was in human cancer patients (Rosenberg et al., 1990), and the 
dominance of this area in gene therapy has continued, with 65% of all approved 
human gene therapy clinical trials being for cancer (The Journal of Gene 
Medicine Gene Therapy Clinical Trials Worldwide 2009). To date, nearly 1000 
clinical trials for cancer gene therapy have been completed, are ongoing or 
approved in more than 29 countries, using over 100 genes (The Journal of Gene 
Medicine Gene Therapy Clinical Trials Worldwide 2009). However, very few gene 
therapy trials have been undertaken in patients with OS (Dass & Choong 2008).  
Gene therapy has also been on trial in dogs as a method of treatment for a 
number of neoplastic diseases, including OS in which partial and complete 
responses have been observed (Dow et al., 2005; Khanna et al., 1997). 
There is a huge amount of literature regarding cancer gene therapy and as it is 
beyond the scope of this chapter to review it all, that, relevant to this study will 
be described in the following sections. 
 
1.2.1 Gene delivery  
For gene therapy to be successful an efficient vehicle or vector for delivery is 
required, as the gene must be delivered to a sufficient number of target cells in 
the body and the gene must be expressed at an adequate level to provide a 
therapeutic benefit for a duration appropriate to the disease (Argyle 1999). 
Ensuring a sufficient supply is a priority as tumour cells, including those from 
canine OS, typically possess a poor and disorganized blood supply, together with 
a high interstitial pressure (Zachos et al., 2001). The ideal delivery vehicle     Chapter 1 ~ Introduction 
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would be one that could be systemically administered and would selectively 
target tumour cells wherever they occur in the body (Felgner 1997). Above all, 
the process and consequences of gene transfer should be safe. Despite intensive 
efforts and advances being made, the optimal universal vector does not yet 
exist, as many technical hurdles must still be overcome. Gene delivery 
techniques primarily involve viral and non-viral vectors. Viral vectors are 
genetically modified viruses, which are still able to transfer their genetic 
material to a host cell. Most commonly employed viruses include adenovirus, 
retrovirus, vaccinia-virus, poxvirus, adeno-associated virus and herpes simplex 
virus (HSV) (The Journal of Gene Medicine Gene Therapy Clinical Trials 
Worldwide 2009). In addition, oncolytic viruses are frequently used as they 
either possess an inherent trophism for tumour cells or have been engineered 
from viruses such as HSV, vaccinia and adenoviruses (termed conditionally 
replicative adenoviruses, CRAd), to selectively replicate in and destroy cancer 
cells (Arendt et al., 2009; Kumar et al., 2008). Non-viral delivery methods 
frequently utilized are naked/plasmid DNA, lipofection and RNA transfer (The 
Journal of Gene Medicine Gene Therapy Clinical Trials Worldwide 2009). Non-
viral vectors avoid the main problems associated with viral systems, in that they 
possess low host immunogenicity enabling repeat administrations, any size of 
nucleic acid can be inserted and simple large scale production can occur 
(Blagbrough & Zara 2009). In addition, adenoviral vectors may also be restricted 
by their requirement for target cells to express appropriate receptors, such as 
Coxsackie Adenovirus Receptor (CAR) (Yotnda et al., 2002). Although the 
principal disadvantage of non-viral gene transfer methods is that stable long-
term gene expression has, as yet, not been achieved, this may be entirely 
satisfactory for cancer gene therapy, in that permanent gene expression or the 
transmission of transferred genes to daughter cells is not necessarily required 
(Argyle 1999). As clinical trials progress, more data will become available for 
assessing the safety and efficacy of various cancer gene therapy approaches, 
with the vast majority of these trials employing retroviral or adenoviral vectors 
(The Journal of Gene Medicine Gene Therapy Clinical Trials Worldwide 2009). 
Adenoviruses, including CRAd, HSV, retroviruses, lentiviruses and liposomes have 
been used to deliver genes in experimental human OS investigations (Okumura et 
al., 2007; Witlox et al., 2007). In addition, adenoviruses have been employed in     Chapter 1 ~ Introduction 
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Phase I/II trials in patients with refractory OS that possess lung metastases 
(Benjamin et al., 2001). Adenoviruses, also including CRAd, have also been used 
to successfully introduce genes into canine OS cells in vitro and in vivo 
(Hemminki et al., 2003; Kanaya et al., 2005; Le et al., 2006; Yazawa et al., 
2003b). Two separate Phase I studies have obtained effective gene transfer into 
dogs with OS lung metastases using liposome-DNA complexes via intravenous 
gene delivery and aerosol delivery (Dow et al., 2005; Khanna et al., 1997). It 
was also observed in the canine trials that the gene therapy treatments 
employed were well tolerated and produced minimal toxicity, suggesting that 
liposome-DNA complexes may be a relatively safe form of treatment. 
Furthermore, no significant signs of virus-associated toxicity were observed 
following the administration of a canine CRAd into normal dogs, canine 
adenovirus type 2 (CAV-2), which is being developed to transcriptionally target 
canine OS cells (Smith et al., 2006). However, vector-associated toxicities have 
been reported following adenoviral vector-mediated gene therapy in dogs with 
haemophilia, although clinical benefits were observed (Brunetti-Pierri et al., 
2005; McCormack et al., 2006). Thereby highlighting the risk of systemic delivery 
of adenoviral vectors and the importance of preventing immune responses 
against the gene delivery vector. Many publications exist pertaining to these 
different gene delivery systems, of which the ones utilized in OS studies are 
summarized in Table 1.5.  
 
Table 1.5: Summary of gene therapy vector systems employed in OS studies. Adapted from Argyle (2007) (Argyle 2007), Fang and Roth 
 (2001) (Fang & Roth 2001), Witlox et al., (2007) (Witlox et al., 2007), and Okumura et al., (2007) (Okumura et al., 2007). 
Vector  Packaging  Genetic material  Genome  Advantage(s)  Disadvantage(s)  Comments 
   Capacity (kb)     size (kb)          
Adenovirus  8-9  Linear double-stranded   36  Efficiently transduces wide range  Strong immunogenicity  These viruses have become the most popular  
     DNA    of non-dividing and dividing cells.  Transient expression  viral delivery mechanism. Gene is packaged  
          Episomal gene expression    into a replication-incompetent adenovirus  
               (usually E1 deleted). Conditionally replicating  
                adenoviruses are used as oncolytic vectors. 
Retrovirus  8  Linear single-stranded   7-11  Long term expression  Dividing cells only  These viruses were originally the gold standard  
     RNA    Weak immunogenicity  Integration into genome may   vector. Gene is packaged into replication- 
             induce oncogenesis.  defective viral particles using a packaging cell 
                line. 
Lentivirus  8  Linear double-stranded   7-11  Transduces wide range of   Integration into genome may   Subset of retrovirus group; many lentivirus  
     DNA    non-dividing and dividing cells.  induce oncogenesis.  vectors based on HIV-1. Become safer in  
          Long term expression  Inefficient production  recent years with many benefits of  
          Weak immunogenicity    conventional retroviruses. 
Herpes Simplex   30  Linear double-stranded   152  Transduces wide range of   Strong immunogenicity  These viruses, in particular HSV-1, gained  
virus (HSV)    DNA    non-dividing and dividing cells.  Latent infection  attention due to ability to infect neurons and to  
          Large packaging capacity  Difficult to manipulate due to   become latent in some neural cells. Gene is  
          Long term episomal gene   large genome size.  packaged into a replication-defective HSV  
          expression.  Transient expression  (usually deficient for immediate-early gene 3).  
          Ability to grow to high titres       
Liposome/DNA   any size  Linear double-stranded   any size  Delivers DNA to wide range of   Transfection efficiency lower  Naked DNA is surrounded with liposome to  
conjugates    DNA    non-dividing and dividing cells.  than viral vectors.  improve uptake through endocytosis,  
          Episomal gene expression  Rapidly inactivated in serum  enhancing efficiency of gene delivery. 
          Safer to administer than viral       
          vectors.      
            Weak immunogenicity           Chapter 1 ~ Introduction 
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1.2.2 Cancer gene therapy strategies 
A greater understanding of the TSG and oncogenes involved in carcinogenesis, 
along with an expanding knowledge of tumour immunology, have revealed 
potential molecular targets. This has enabled rationally targeted interventions 
at the molecular level to occur, in the development of gene therapy 
technologies for cancer. Essentially, 3 main strategies of cancer gene therapy, 
which are the subject of extensive research and clinical investigation, have been 
reported in OS investigations (Figure 1.4): rescue of the cancer cell through gene 
replacement, antisense, or related therapies which overcome the genetic 
abnormalities associated with the malignant phenotype; destruction of the 
cancer cell through delivery of „suicide genes‟ (pro-drug activating genes i.e. 
gene-directed enzyme prodrug therapy, GDEPT) which result in the death of the 
transduced cell; and introduction of genes, e.g. cytokines, which enhance the 
immune response against the tumour (Witlox et al., 2007).  
True suicide gene therapy involves the expression of a gene whose protein 
product is directly toxic to the cells into which it has been introduced, rather 
than a prodrug activating system approach (Dr. L. Blackwood, University of 
Liverpool; personal communication). Cell death is achieved in GDEPT by the 
protein product converting a prodrug into toxic metabolites. Hence the term 
„suicide gene therapy‟ is often used to described GDEPT, however ideally it 
should be restricted to approaches utilising true suicide gene therapies. 
 
Figure 1.4: Cancer gene therapy strategies: gene replacement, suicide gene 
therapy and immuno-potentiation (Witlox et al., 2007).     Chapter 1 ~ Introduction 
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1.2.2.1 Rescue of the cancer cell through gene replacement  
TSG have been the most attractive targets for developing gene replacement 
strategies thus far. The loss or inactivation of both alleles of a TSG is required to 
eradicate the growth-suppressive function of the gene. Theoretically, then, 
replacement of a functional copy of the TSG in cells having homozygous loss of 
function could restore normal growth and proliferation pathways. Although there 
are concerns with this approach, especially because cancer is not a single gene 
defect, rather it involves multiple genetic abnormalities, and so the correction 
of one alteration may not significantly change the progress of the disease. 
Additionally, there is no technique currently available that can deliver a 
therapeutic gene or its product to all the tumour cells and express the gene at 
the required levels with acceptable levels of toxicity. However, studies 
undertaken by various groups have shown that it may not be necessary to 
reverse all the genetic changes in a cancer cell for a therapeutic effect to be 
observed. Several TSG have been shown to suppress tumour cell growth and 
proliferation and induce apoptosis following delivery into a variety of cell lines 
and preclinical in vivo models (Roth & Grammer 2005). For example, p16INK4A, 
p14ARF, BAX, RB1, and most notably so far, TP53, the most commonly altered 
gene in cancer, have been introduced into human OS cell lines in vitro and in 
vivo (Kim et al., 2004; Okumura et al., 2007; Toyota et al., 2006; Witlox et al., 
2007). In addition, cell proliferation has also been inhibited in canine OS cell 
lines and xenografts following the expression of wild-type TP53 (Kanaya et al., 
2005; Yazawa et al., 2003b). Furthermore, 166 clinical trials involving TSG have 
been approved, including 52 Phase III trials (The Journal of Gene Medicine Gene 
Therapy Clinical Trials Worldwide 2009). Many of these trials involve 
replacement of TP53 (Roth & Grammer 2005) and the replacement of TP53 is 
discussed in further detail in Chapter 4. Results of early clinical trials quickly 
delivered „proof of principle‟ by demonstrating delivery of TSG to tumour cells, 
gene expression in targeted cells, minimal toxic effects, and evidence of 
regression or stabilization of treated tumours. Subsequent trials demonstrated 
that TSG replacement also rendered some tumour cells more sensitive to the 
effects of conventional DNA-damaging therapies, extending the potential 
application of TSG replacement to protocols combining TSG replacement therapy 
with chemotherapy and radiation e.g. introduction of TP53 into patients with     Chapter 1 ~ Introduction 
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non-small cell lung cancer (NSCLC) carcinoma, previously unresponsive to 
platinum treatments, enhanced their chemosensitivity to cisplatin in a Phase I 
trial (Smith et al., 2006). Similarly in human OS cells, improvement in sensitivity 
to cisplatin in combination with adriamycin or doxorubicin, has also been 
reported after the delivery of wild-type TP53 (Witlox et al., 2007). 
In vivo systems have been developed in which genes can be inserted that inhibit 
the production of the abnormal protein product by encoding ribozymes 
(transdominant sequences), short inhibitory RNAs (siRNA; RNA interference 
(RNAi)) or antisense (complementary) mRNA, to that produced by the TSG, 
oncogene or growth factor receptors. Ribozymes that can simultaneously reduce 
mutant TP53 expression and restore wild-type TP53 expression in various human 
cancer cell lines, including OS, have been reported (Watanabe & Sullenger 
2000). The downregulation of IGF-1R and VEGF expression in human OS cells by 
RNAi has been reported to inhibit cell growth and induce apoptosis (Mei et al., 
2008; Wang et al., 2009). Additionally, VEGF-siRNA has recently been reported 
to inhibit OS growth and pulmonary metastasis in vivo (Gao et al., 2009). The 
downregulation of abnormal oncogene expression has also been shown to revert 
the malignant phenotype in OS e.g. antisense gene therapy using a cyclin G1 
construct inhibited the growth of human OS xenografts (Chen et al., 1997). 
Furthermore, a Phase II study for chemotherapy-resistant OS has recently been 
published in which this cyclin G1 construct was reported to aid in controlling 
tumour growth and may improve survival (Chawla et al., 2009). 
 
1.2.2.2 Destruction of cancer cells through delivery of ‘suicide genes’  
The „suicide gene‟ therapy approach has been designed to increase selectivity 
for cancer cells as a strategy towards improving the specificity of chemotherapy, 
reducing resistance and limiting the unwanted side effects of chemotherapy. 
This is achieved in a two-step process, in which the first step involves the 
delivery of a gene („suicide‟ gene), encoding a foreign enzyme (viral, bacterial 
or yeast) not normally expressed by normal cells, to be expressed in cancer 
cells. In the second step, an appropriate non-or mildly toxic prodrug is     Chapter 1 ~ Introduction 
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administered systemically and is converted locally into highly cytotoxic 
metabolites by the expressed foreign enzyme (GDEPT) (Altaner 2008).  
Prodrugs have been used, for more than 30 years, in many areas of medicine and 
there is a considerable level of knowledge and understanding in their application 
and design for differing circumstances (Connors 1995). Prodrugs are defined as 
chemicals, which, even at high dose-levels are pharmacodynamically and 
toxicologically inert, can be converted in vivo to a highly pharmacologically 
active drug (Portsmouth et al., 2007). The active drug can diffuse locally and kill 
even non-transfected neighbouring cells, in a so-called „bystander‟ effect, by 
intercellular (gap junctions) and local extracellular spread (Witlox et al., 2007). 
„Bystander killing‟ of non-transfected tumour cells is actually the main reason 
behind the success of the GDEPT approach, as it overcomes the inability of 
existing gene delivery vectors to transduce all cancer cells, even if only a small 
fraction of the cells express the suicide gene product (Portsmouth et al., 2007). 
The effectiveness of bystander killing also appears to be improved by additional 
mechanisms which include inhibition of angiogenesis, upregulation of various 
immune system components, and secretion of soluble pro-apoptotic proteins 
(Lumniczky & Safrany 2006; Nishizaki et al., 1999).  
More than 20 prodrug metabolising enzyme systems have been described in the 
literature and several have been extensively studied, some of which are 
summarized in Table 1.6 e.g. HSV-thymidine kinase (HSV-TK) phosphorylates 
ganciclovir (GCV) to produce the nucleotide toxin GCV phosphate, cytosine 
deaminase from Escherichia coli (E. coli) converts the antifungal drug 5′-
fluorocytosine (5-FC) into the anticancer drug 5′-fluorouracil (5-FU), and 
nitroreductase (NTR; nfsB), also from E. coli, catalyses the reduction of CB1954, 
to generate a 4-hydroxylamine metabolite which reacts with thioesters, such as 
acetyl coenzyme A, to produce a highly cytotoxic difunctional alkylating agent 
that can be up to 2000-fold more cytotoxic than CB1954 itself, making it an 
attractive prodrug (Anlezark et al., 1992; Portsmouth et al., 2007; Weedon et 
al., 2000). The majority of toxic metabolites produced by the prodrug enzyme 
systems are cell-cycle dependent as they inhibit cellular nucleic acid synthesis 
pathways. This is a disadvantage as only a small percentage of tumour cells are 
proliferating at any one time (Portsmouth et al., 2007). However, the toxicity of     Chapter 1 ~ Introduction 
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the CB1954 activated prodrug is cell-cycle independent as it can be cytotoxic to 
cells not in S-phase, suggesting that this prodrug may potentially be used to 
eliminate non-dividing neoplastic cells. Furthermore, the ideal suicide 
gene/prodrug combination should produce an activated drug that is at least 100-
fold more cytotoxic than the prodrug; possess a sufficiently low molecular 
weight enabling it to diffuse easily to allow the killing of non-transfected 
bystander cells; possess a sufficient half-life to kill non-transfected bystander 
cells; and not be able to diffuse into the bloodstream and cause systemic 
toxicity (Portsmouth et al., 2007). As yet, similar to the search for an optimal 
gene delivery vector, the ideal suicide gene/prodrug combination does not exist, 
but it is the quest of much current research. 
Promising results have been obtained with numerous suicide gene therapy 
systems in vitro and in vivo, in various human cancer cell lines, including OS 
(Witlox et al., 2007). On the basis of these results, over 100 suicide gene 
therapy clinical trials have either been approved, are ongoing or undertaken 
(The Journal of Gene Medicine Gene Therapy Clinical Trials Worldwide 2009). 
However, to the best of my knowledge no clinical trials have yet taken place in 
human OS patients or preclinical investigations into suicide gene therapy for 
canine OS. Suicide gene therapy systems in relation to this study, and in dogs, 
are described in further detail in Chapter 5.   
 
Enzyme  Origin  Prodrug  Active Drug  Comments 
Thymidine kinase   HSV, EHV, VZV  GCG, ACV  Triphosphorylated forms  BEB 
      araM, BVDU  Monophosphorylated forms  BE present 
Cytosine deaminase  E. coli  5-FC  5-FU  BEA 
   S. cerevisiae          
Cytochrome P-450  Rat, human, rabbit  CPA, IFO  4-Hydroxy forms  BEA 
Carboxylesterase  Human, rabbit  Irinotecan  SN-38    
      Capecitabine  5-FU    
      Paclitaxel-2-ethylcarbonate  Paclitaxel    
Nitroreductase  E. coli  CB1954  N-acetoxy derivatives  BEA 
NQO1 (DT diaphorase)  Human, rat  Bioreductive agents e.g. CB1954  Reduced forms    
Carboxypeptidase A1  Human, rat  MTX--peptides  MTX  BEA 
Deoxyribonucleoside kinase  D. melanogaster  BVDU, araT  Monophosphorylated forms  BE present 
-Galactosidase  E. coli  Self-immolative prodrugs from   Anthracycline antibiotics     
      anthracycline antibiotics e.g. daunomycin   e.g. daunorubicin    
-Glucuronidase  E. coli, human,   Self-immolative doxorubicin prodrugs   Doxorubicin  BEA 
   mouse          
-Lactamase  E. coli  Self-immolative prodrugs from cephem  Alkylating agents, vinca alkaloids,    
      prodrugs  anthracycline antibiotics     
Linamarase  Cassava plant  Linamarin  Cyanide  BEA  
 
Table 1.6: Suicide gene/prodrug combinations commonly used in cancer gene therapy studies. ACV, acyclovir; araM, 6-methoxypurine 
arabinoside; araT, 1--D-arabinofuranosylthymine; BEA, bystander effect type A – does not require cell-to-cell contact; BE, bystander 
effect; BEB, bystander effect type B – requires cell-to-cell contact; BVDU, (E)-5-(2-bromovinyl)-2‟-deoxyuridine; CB1954, 5-(Aziridine-1-
yl)-2,4-dinitrobenzamide; CPA, cyclophosphamide; HSV, herpes simplex virus; EHV, equine herpes virus; GCV, ganciclovir; IFO, 
ifosamide; MTX, methotrexate; 5-FU, 5-fluorouracil; 5-FC, 5-fluorocytosine; VZV, varicella zoster virus; SN-38, 7-Ethyl-10-hydroxy-
camptothecin. Modified from Portsmouth et al., (2007) (Portsmouth et al., 2007).     Chapter 1 ~ Introduction 
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1.2.2.3 Gene-directed immunotherapy  
Researchers have achieved some success utilising cytokines and other molecules 
in treating OS via augmentation of immune response (Witlox et al., 2007). 
However, as they tend to be autocrine or paracrine in nature, significant 
problems are associated with the systemic use of these proteins, including short 
half-life, profound toxic side effects, limited dose that can be safely 
administered which may not even have a clinical effect and the inability to 
maintain potentially therapeutic levels at the desired site of action (Fang & Roth 
2001). Hence, the delivery of the actual cytokine gene, e.g. IL-2, IF-, IL-12 or 
IL-18, rather than the protein is a more promising approach. This is because 
tumour immunogenicity is enhanced, either directly by the insertion of cytokine 
or costimulatory molecule encoding genes, or indirectly, by the delivery of an 
immunomodulatory gene, such as an immunogenic antigen or cytokine, that 
activates the immune system to recognize putative tumour antigens, which leads 
to immune-mediated cell killing (Witlox et al., 2007). For example, the delivery 
of IL-2 gene into a primary tumour of a clinically relevant mouse OS model, 
displayed anti-tumoural immunity which not only inhibited primary tumour 
growth but also reduced metastases in distant organs (Nagano et al., 2004). In 
addition, the introduction of the IL-12 gene significantly suppressed the growth 
of OS lung metastases in vivo and in combination with ifosfamide a greater anti-
tumour effect was observed (Duan et al., 2006). Furthermore, B7-1, a well-
characterized co-stimulatory molecule, has also been shown in vivo to induce 
immunity against pre-established primary OS resulting in regression, systemic 
immunity against pre-existing pulmonary metastases and activation of T-cells 
(Tsujii et al., 2002). In conjunction with FAS, B7-1 also induced apoptosis of OS 
cells and had a stronger inhibitory effect on the development of pulmonary 
metastasis compared to B7-1 alone (Tsujii et al., 2003). This gene-directed 
immunotherapy approach also reduces the systemic toxicity previously observed 
with cytokine proteins and in addition, may increase the number of cytokines 
that can be used for anticancer treatment, because many proteins that are 
otherwise intolerable by the host may now be used (Fang & Roth 2001). In 
addition, the combined delivery of cytokine and suicide genes, followed by 
prodrug administration, have been shown to enhance the antitumour response 
and may improve the distant bystander effect against micrometastatic disease     Chapter 1 ~ Introduction 
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(Argyle 1999). This is because the activated prodrug induces the cancer cells to 
undergo necrosis, allowing the exposure of anti-tumour antigens which are 
subsequently recognized by cytokines, thereby promoting the development of a 
cell-mediated immune response which enhances the antitumour response (Argyle 
2007).  
Gene-directed immunotherapy has been investigated in a number of small-scale 
veterinary studies as a potential treatment modality for canine OS. In particular, 
two Phase I studies have been performed in which liposome-DNA complexes 
containing canine IL-2 cDNA have been administered to dogs with OS lung 
metastases (Dow et al., 2005; Khanna et al., 1997). Khanna and colleagues 
(1997) reported that 2 of 4 dogs had complete regression of pulmonary 
metastases for more than 1 year following IL-2 inhalational therapy (Khanna et 
al., 1997). Dow and co-workers (2005) observed that in 3 out of 20 dogs, partial 
or complete regression of lung metastases occurred and overall, survival times 
had significantly increased (Dow et al., 2005). Both studies suggested that the 
tumour regressions observed were due to the activation of a substantial immune 
response and that IL-2 gene therapy is well tolerated as toxicity levels were 
minimal (Dow et al., 2005; Khanna et al., 1997). These investigations in the 
gross disease setting support further development of the gene-directed 
immunotherapy approach, in particular as adjuvants in the micrometastatic 
disease setting and in combination with currently available therapies. 
 
1.2.3 Targeted gene therapy 
In gene therapy, as in all cancer treatments, ensuring that the therapeutic agent 
is selectively delivered and expressed in the targeted tumour cells are not only 
of the highest importance, but are also the primary difficulties to be overcome 
when devising successful gene therapies for cancer. A major barrier to the 
widespread clinical use of gene therapy is the inability to give vectors 
systemically and to ensure that therapeutic genes are not expressed in normal 
cells (Argyle 2007). Whilst a number of vectors have been used for the delivery 
of genes into primary tumours, the larger problem in cancer is treatment of 
disseminated disease, requiring systemic administration of genes. A gene-based     Chapter 1 ~ Introduction 
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drug that kills tumour cells in vitro can be relatively easily designed. However, 
killing only tumour cells in vivo and at the same time sparing normal tissue, 
requires an extremely selective strategy, in particular, in suicide gene therapy 
strategies. Numerous strategies have been attempted to target the effect of a 
gene-based drug, increase transfection efficiency and hence cytotoxicity. These 
strategies can be categorized into two main groups: transductional targeting in 
which gene delivery is restricted to tumour cells; and transcriptional targeting 
which only permits gene expression in tumour cells (Palmer et al., 2006). 
Although, as with other agents in cancer therapy, the heterogeneity of the 
malignant cell population in many tumours, including OS, makes it extremely 
difficult to obtain specific targeting by any one approach, hence methods of 
transductional and transcriptional targeting may also be combined (Fang & Roth 
2001).  
 
1.2.3.1 Transductional targeting  
Transductional targeting can be achieved by the exploitation of specific 
properties of tumour cells by utilising the natural determinants of the virus-host 
cell interactions or the range of cells that the virus can infect and their 
proliferation rate (Fang & Roth 2001). The presence of specific receptors on the 
cell surface contributes to the specific uptake of an agent and its tissue 
distribution. In viral vector-mediated gene delivery, tissue tropisms may be used 
to achieve specific targeting, e.g. adenovirus quite efficiently transduces lung 
epithelium, retroviral vectors are integrated and expressed only in dividing cells 
and HSV can infect many cell types but is most efficient at infecting and then 
mediating prolonged gene expression in neuronal cells (Fang & Roth 2001).  
Viral vectors can also be modified to redirect binding of the vector to molecules 
highly expressed on tumour cell surfaces rather than those it normally interacts 
with e.g. adenovirus fibre can be altered so that it no longer binds with its 
natural receptor, CAR, but instead interacts with tumour-specific receptors 
(Palmer et al., 2006). Viral particles can be altered chemically with an inert 
polymer to inhibit infection or by manipulation of the genes encoding the viral 
capsid (coating proteins). Targeting can then be re-directed by attaching     Chapter 1 ~ Introduction 
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monoclonal antibodies or specific ligands e.g. epidermal growth factor receptor 
(EGFR), which is overexpressed in many tumours including OS, can be targeted 
by adenoviral vectors containing a specifically designed antibody (Witlox et al., 
2007). The use of EGFR targeting has been reported to improve adenoviral gene 
delivery into human OS cells by 10-fold and in combination with suicide gene 
therapy further increased selective cell kill compared to that observed with 
suicide gene/prodrug alone (Witlox et al., 2002). Furthermore, the infectivity of 
a canine conditionally replicative adenovirus has been improved following the 
incorporation of a polylysine peptide onto a native fibre (Le et al., 2006). In 
addition, the use of polymer coats may reduce the immune responses observed 
against viral vectors (Palmer et al., 2006). The identification of a single 
envelope protein variant, EF, screened from a random library has been reported 
to be highly specific for D17 canine OS cells (Bupp & Roth 2002). It was 
suggested that the EF envelope protein would be a useful targeting reagent in 
the study of suicide gene therapy for OS (Bupp & Roth 2002). Non-viral vector 
targeting has been accomplished primarily through the use of molecular 
conjugates and DNA-protein complexes.  
 
1.2.3.2 Transcriptional targeting  
Transcriptional targeting occurs once the vector has entered the cell and 
depends on specific regulatory sequences to direct synthesis of the protein of 
interest only in tissues that are capable of activating the transcriptional 
elements. Although every gene is represented in every cell of the body, 
expression of any one gene requires specific transcription factors that may be 
unique to a particular cell or tissue type. Certain genes have been identified 
that are expressed in cancer cells but not in normal cells, e.g. telomerase, or 
are expressed only in a specific tissue type e.g. osteocalcin (OC), which is 
expressed almost solely in bone tumours and mature calcified tissue (Witlox et 
al., 2007). By using the sequences for promoters, enhancers and/or 5′-UTR that 
are responsive to tumour-specific transcription factors, to drive transgene 
expression, targeted expression can be tumour-specific, e.g. using the 
telomerase promoter, or tissue-specific, e.g. OC promoter in OS. Hence, control     Chapter 1 ~ Introduction 
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of therapeutic gene expression in tumours may be achieved via tumour- or 
tissue-specific regulatory sequences (Palmer et al., 2006).  
The transcriptional targeting approach has been used for targeting gene 
expression to several tumour types including primary OS and OS pulmonary 
metastases, using the OC promoter which resulted in an anti-tumour effect on 
OS cells in vitro and in vivo (Li et al., 2006). In conjunction with suicide gene 
therapy, the OC (Shirakawa et al., 1998) and telomerase reverse transcriptase 
(Majumdar et al., 2001) promoters enhanced the selective cell killing of OS cells 
in vitro and in vivo. Furthermore, in the in vivo experiments, normal tissues 
were seen to be spared (Li et al., 2006; Majumdar et al., 2001; Shirakawa et al., 
1998). The OC promoter has also been used successfully by Hemminki et al., 
(2003) to restrict the replication of a canine oncolytic adenovirus to dog OS 
cells, which resulted in effective cell kill in vitro and yielded a therapeutic 
benefit in vivo (Hemminki et al., 2003). Additionally, a Phase I/II dose study was 
proposed in 2001 by Benjamin and colleagues, to evaluate the OC promoter in 
patients with OS metastatic to the lung (Benjamin et al., 2001); however, no 
results have yet been published. The specificity of tissue-restricted gene therapy 
may be further refined as a 31-amino-acid segment of the haematopoietic and 
osteogenic RUNX2 (CBFA1/AML3) transcription factor has been identified and 
utilized to direct the OC-promoter to sub-nuclear sites that support gene 
expression in bone cells in vivo (Stein et al., 2000).  
A combined transductional and transcriptional targeting approach has been 
described in which an antibody conjugate was used to redirect an adenoviral 
vector to EGFR and the reporter gene was placed under the control of OC 
(Barnett et al., 2002). This dual targeting strategy resulted in a higher level of 
specificity for cancer cells, including OS, being demonstrated than by either 
approach alone (Barnett et al., 2002). 
Hence, the introduction of vectors containing bone tissue specific promoter-
controlled transgenes provides a suitable approach for the delivery and 
expression of therapeutic genes in the treatment of canine and human patients, 
with primary OS and OS metastases. Thus TP53-targeted suicide gene therapy, 
may also have favourable therapeutic implications for canine and human OS.     Chapter 1 ~ Introduction 
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1.2.4 Safety considerations  
Although gene therapy is a highly promising strategy for the treatment of 
numerous diseases, including many different types of cancer, there have 
unfortunately been, a few incidents of serious adverse events, including death, 
which have had a negative impact on progress in this field (Edelstein et al., 
2007). These deaths were as a result of a large inflammatory response to an 
early generation adenoviral vector and retroviral integration near proto-
oncogene promoters (Edelstein et al., 2007). More recently designed viral 
vectors are reported to show an improved safety margin over their predecessors 
after administration to rodents, but their affect on large animal models is less 
well described. The delivery of naked DNA may also offer a safer alternative, 
however, all the potential safety issues with this technology, including 
autoimmunity and actual fate of DNA after delivery into the patient, have not 
yet been fully resolved (Argyle 2007). Nevertheless, in light of over 1500 clinical 
trials currently in place, of which nearly 1000 are Phase I (The Journal of Gene 
Medicine Gene Therapy Clinical Trials Worldwide 2009), there has infact been a 
lack of significant toxicity directly related to gene transfer in these Phase I 
trials. Furthermore, some patients have also been observed to benefit from the 
gene therapy protocol they received (Edelstein et al., 2007). 
Although initially in order to maximize safety, cancer gene therapy protocols 
only involved local, intratumoural delivery e.g. into head and neck cancers, to 
date several additional routes of delivery have been investigated, including 
intraperitoneal, intra-arterial and intravenous (Witlox et al., 2007). This is 
because the efficacy of gene therapy is also affected by the method in which the 
vector is delivered as well as by the vector itself. Furthermore, in the context of 
pulmonary disease, e.g. pulmonary metastases, the use of aerosolized gene 
therapy has been regarded as an attractive route due to it being non-invasive, 
capable of delivering a high dose to the target site and belief that it results in 
fewer adverse effects compared to intravenous delivery (Witlox et al., 2007). 
Indeed, inhalational therapy has been administered to dogs with OS pulmonary 
metastases resulting in clinical responses with minimal toxicity levels (Khanna et 
al., 1997). In addition, systemic delivery may also make gene-based drugs more 
prone to inactivation by the immune system, considerably limiting vector     Chapter 1 ~ Introduction 
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transduction efficiency and the duration of transgene expression, as well as 
inducing an acute inflammatory response (Witlox et al., 2007).  
In view of the known risks of elevated malignancy rates after conventional 
treatment modalities such as radiation therapy, chemotherapy and 
immunosuppression, gene therapy may yet prove to be an acceptable method of 
cancer treatment.  
 
1.2.5 Summary  
One of the most promising approaches to emerge from the improved 
understanding of cancer at the molecular level is the possibility of using gene 
therapy to selectively target and destroy tumour cells, thus improving the 
specificity of the therapy while reducing systemic toxicity. Intuitively, it would 
seem that simple eradication of cells is likely to be the best and safest. The self-
renewing nature of malignant disease dictates that tumour cells should be 
cleared as efficiently as possible rather than genetically corrected. Although, 
the suicide gene therapy strategy seems no more likely to succeed than 
corrective gene therapy, requiring in vivo delivery of the therapeutic gene to 
every tumour cell, the bystander effect can mediate the destruction of 
neighbouring non-transduced tumour cells. Thus, the most frequently used genes 
have been designed to kill cells directly, such as suicide genes, or to induce 
immune-mediated destruction and are likely to provide an all-encompassing 
alternative to the transfer of a single gene implicated in tumourigenesis.  
Many cancer gene therapy clinical trials have now taken place, with different 
strategies, which have confirmed that such treatments are safe and well 
tolerated; however, with a few exceptions, evidence of significant 
improvements in survival over that seen with conventional treatments, has not 
yet been proved. Furthermore, success rates even approaching those routinely 
achieved in preclinical studies, have yet to be obtained in clinical applications, 
including those in which real clinical benefit has been observed. It is likely that 
numerous obstacles are responsible for this discrepancy, including the ability to 
target tumour cells through systemic delivery, gene expression to occur as     Chapter 1 ~ Introduction 
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required, larger size of canine and human malignancies in comparison to in vitro 
and in vivo models and the slower growth rate of spontaneous tumours 
compared to experimental xenografts. Nevertheless, gene therapy remains a 
highly promising strategy for the treatment of many cancers and progress in the 
field is increasing. 
With regard to gene therapy for OS, two main problems exist for OS gene 
therapy to be successful, the eradication of the primary tumour and the 
requirement to inhibit and destroy metastases, particularly pulmonary 
metastases since they are the main cause of death in both canine and human OS 
patients. However, promising results have been obtained following the 
introduction of TP53 into both canine (Kanaya et al., 2005; Yazawa et al., 
2003b) and human (Kim et al., 2004; Okumura et al., 2007; Toyota et al., 2006; 
Witlox et al., 2007) OS cell lines and xenografts and in dogs with OS pulmonary 
metastases after gene-directed immunotherapy treatment utilising cytokine 
genes (Dow et al., 2005; Khanna et al., 1997). Although no preclinical suicide 
gene therapy studies have yet been published in canine OS cells, results 
displaying potential have been reported in in vivo and in vitro investigations of 
human OS cells (Witlox et al., 2007). Therefore, new treatment strategies are 
under investigation for OS; in particular, TP53 is a prime candidate in the 
development of targeted gene therapy systems. 
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1.3 TP53 tumour suppressor gene   
TP53 was discovered in 1979 (Lane & Crawford 1979; Linzer & Levine 1979) and 
subsequently characterized as a tumour suppressor in 1989 (Baker et al., 1989; 
Finlay et al., 1989). Since then it has become the one of the most studied genes 
in cancer biology, as more than 50000 publications have been published due to it 
being the most commonly altered gene in human (Petitjean et al., 2007b) and 
canine cancer (McIntyre et al., 1994; Setoguchi et al., 2001b; Toguchida et al., 
1992; Veldhoen et al., 1999). TP53 has been titled “the guardian of the genome” 
(Lane 1992) and called a “cellular gatekeeper” (Levine 1997), as it possesses a 
central role in regulating the cell cycle and maintaining genomic integrity 
following genotoxic or cellular stress (Vogelstein et al., 2000; Vousden & Lane 
2007). Loss or mutation of TP53 function is highly correlated with an increased 
susceptibility to tumourigenesis (Olivier et al., 2009). Hence, TP53 has been the 
subject of an extensive range of experimental approaches, extending from X-ray 
crystallography to clinical studies, in the pursuit of developing new and more 
effective therapeutic strategies for the treatment of cancer. It is beyond the 
scope of this chapter to describe the vast amount of literature regarding TP53, 
so it will be briefly reviewed and areas of relevance to this study will be 
discussed.  
 
1.3.1 Structure & function of TP53  
The p53 protein, consisting of 393 amino acids () in humans, contains 4 well-
characterized functional domains, each corresponding to specific functions that 
are common to several species, including dogs (Millau et al., 2009; Veldhoen & 
Milner 1998; Zakut-Houri et al., 1985) (Figure 1.5). This is because the primary 
amino acid sequence has been found to be highly conserved during evolution, 
such that five evolutionary conserved domains have been identified in cross-
species comparisons (Soussi & May 1996). The amino-terminus (N-terminus), 
contains two transactivation domains, AD1 (1-42) and AD2 (43-63), and a 
proline-rich domain (64-97) (Millau et al., 2009). The transactivation domains 
regulate transcriptional activity due to the possession of residues which can 
interact with components of the basal transcriptional machinery (Ko & Prives     Chapter 1 ~ Introduction 
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1996). They are also importantly the location for binding with numerous proteins 
that regulate the stability and activity of TP53, in particular, MDM2, and many of 
the post-translational modifications (Alarcon-Vargus & Ronai 2002). The proline-
rich domain, containing 5 „PXXP‟ motifs, is reported to be essential for apoptosis 
as it binds with proteins containing SH3 sites (Walker & Levine 1996). The 
central region (102-292) possesses the sequence-specific DNA-binding domain 
(Bargonetti et al., 1993; El-Deiry et al., 1992), along with four of the five 
evolutionary conserved domains (II-V) (Pavletich et al., 1993). A 21 sequence, 
located between 92-112, in combination with the proline-rich and DNA-binding 
domains, are important for TP53 degradation by both MDM2 and human 
papillomavirus (HPV)-E6 (negative autoregulatory domain) (Gu et al., 2001b; Gu 
et al., 2001a). The carboxy-terminus (C-terminus) possesses an oligomerization 
domain (323-356, which participates in the formation of TP53 tetramers, a 
nuclear export signal and ubiquitination sites for TP53 degradation (Clore et al., 
1994; Lohrum et al., 2001). The last 30 of the C-terminus (363-393), possess 3 
nuclear localization signals (Shaulsky et al., 1990; Stommel et al., 1999), and a 
non-specific DNA binding domain that recognizes structural features of target 
DNA, including damaged DNA (Kruse & Gu 2009).  
TP53 primarily functions as a tetrameric transcription factor by binding to 
specific DNA sequences and transactivating or repressing a large, and increasing, 
group of genes (El-Deiry 1998; Vogelstein et al., 2000). The classical view of 
TP53 function is that TP53 is induced in response to a wide variety of stress 
signals, including DNA damage (e.g. by ultraviolet light, -irradiation and 
genotoxic chemicals), hypoxia, cytokines, DNA/RNA viral infection and activated 
oncogenes (Latonen & Laiho 2005; Ljungman & Lane 2004) (Figure 1.6). 
Following activation, TP53 is believed to initially arrest the cell cycle and based 
on the severity of the genomic damage, determines the fate of the cell. If the 
DNA is repairable, TP53 enables DNA repair to occur and once finished, allows 
completion of the cell cycle. However, if the damage is excessive and 
unrepairable, TP53 irreversibly blocks cell growth and proliferation by inducing 
senescence, differentiation or apoptosis, thereby preventing inappropriate DNA 
synthesis and replication (El-Deiry 1998; Kastan et al., 1991; Lane 1992; Seo & 
Jung 2004). Over the past few years, research suggests that TP53 may also be an 
active mediator of pro-survival signalling pathways due to the identification of a     Chapter 1 ~ Introduction 
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multitude of TP53 targets which may actually oppose apoptosis (Janicke et al., 
2008; Vousden 2006). Furthermore, TP53 may also be involved in the regulation 
of glycolysis, autophagy, oxidative stress, invasion and motility, angiogenesis 
and bone remodelling (Vousden & Lane 2007). An added level of complexity to 
the structure and functions of TP53 now exists following the discovery in 2006 of 
the p53 isoform family (Bourdon et al., 2005), which includes eight p53 variants 
truncated for either one or both of the oligomersation and transactivation 
domains (Murray-Zmijewski et al., 2006). This indicates that the typical view of 
TP53 and its pathways, is based around a central TP53 rather than that of itself 
and its eight variants, which each possess their own characteristics. Hence, TP53 
and its family is involved in many cellular activities and interacts with numerous 
endogenous and exogenous nuclear proteins, to produce a variety of responses 
(Kruse & Gu 2008; Riley et al., 2008). All of these responses can be proposed to 
be essential for the normal development and maintenance of an organism, thus 
protecting the genome from accumulating mutations. Thus, if TP53 becomes 
defective, or the pathways of TP53 possess aberrations, cell growth and 
proliferation fails to be regulated, resulting in tumourigenesis. 
  
 
 
 
 
Figure 1.5: The schematic representation of the structure of the human TP53 protein in its basic form. The functional and conserved 
domains are shown with numbers referring to amino acid residues. Abbreviations: „AD‟, activation domain; „C-Ter‟, carboxy-terminus; 
„N-Ter‟, amino-terminus; „PXXP‟, proline-rich domain containing „PXXP‟ motif. Adapted from Millau et al., (2009) (Millau et al., 2009).    
 
 
 
    
 
Figure 1.6: TP53 is activated in response to a wide variety of stresses and acts as a transcription factor to adapt the expression level of 
many target genes involved in major cellular pathways. Adapted from Millau et al., (2009) (Millau et al., 2009).     Chapter 1 ~ Introduction 
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1.3.1.1 Transcriptional target genes 
TP53 transcriptionally targets and regulates the expression of a multitude and 
constantly growing series of over 125 genes, all of which are the subject of 
extensive investigations (Laptenko & Prives 2006; Riley et al., 2008) (as shown 
previously in Figure 1.6). This occurs via specific DNA binding of TP53 to a TP53 
response element (RE) that is found either in the promoter or first introns of 
target genes (Millau et al., 2009). Several of these genes are critically involved 
in the downstream propagation of growth control signals involved in cell cycle 
arrest, including p21, GADD45 and 14-3-3-sigma, which were some of the first 
TP53 target genes to be identified (Ko & Prives 1996). Canine TP53 has also 
shown to be capable of inducing p21 in response to DNA damage (Zhang et al., 
2009). Additional TP53 transcriptional targets, which may be part of both 
intrinsic and extrinsic pathways of TP53-induced apoptosis, include BAX, and 
PUMA and FAS, respectively (Bossi & Sacchi 2007; Helton & Chen 2007). TP53 
also transactivates another set of genes that mediate cell survival e.g. XPC, 
RAD51, which sense or recognize DNA damage and initiate a repair response for 
the damaged DNA (Helton & Chen 2007; Janicke et al., 2008; Stubbert et al., 
2009). A group of genes that regulate TP53 stabilization, include MDM2 and 
PIRH2, by directly interacting with TP53 to control TP53 degradation and form 
negative regulatory feedback loops (Alarcon-Vargus & Ronai 2002; Leng et al., 
2003). These feedback loops probably act to restrain TP53 activity within cells, 
as well as to terminate TP53-initiated responses once the inducing signal is 
turned off. Further TP53 target genes play a role in anti-angiogenesis, immune 
response, oxidative stress, autophagy and carbon metabolism (Millau et al., 
2009; Vousden & Lane 2007). In addition, the eight p53 isoforms have different 
biochemical transcriptional activities, for example, TP53 binds preferentially to 
the RE for MDM2 and p21 but not the RE for BAX, whereas p53b interacts 
preferentially with the BAX RE, as well as the p21 RE, but not the RE for MDM2 
(Millau et al., 2009). 
 
1.3.2 Regulation of TP53 activity  
The regulation of TP53 is mainly at the protein level (post-translational) by a 
multitude of cellular proteins that have been found to bind to various regions of     Chapter 1 ~ Introduction 
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TP53 in order to regulate the specificity of its activity, including ones that it has 
transcriptionally activated e.g. MDM2 (Kruse & Gu 2009) (Figure 1.7). Although 
there are a large number, it is primarily affected by MDM2 (Jones et al., 1995; 
Montes de Oca et al., 1995).  
In all normal non-stressed cells, the wild-type TP53 is expressed at low or 
undetectable levels, with a half-life of ~10-20 minutes. This is mainly due to the 
down-regulation of TP53, via the ubiquitin-mediated proteasomal degradation 
pathway, involving MDM2, PARC and PIRH2 (Haupt et al., 1997; Leng et al., 
2003). These genes, as previously mentioned, are up-regulated by TP53, 
enabling the negative regulatory feedback loop to maintain TP53 at very low 
levels in normal cells.  
DNA damage, caused by genotoxic or non-genotoxic stresses, is typically thought 
to result in the activation of TP53 through a 3-step process. First of all, TP53 is 
phosphorylated by a wide range of kinases, including ATM/ATR/DNA-PK and 
CHEK1/CHEK2, which inhibit its interaction with MDM2 and the other proteins 
that are involved in the negative feedback loop, resulting in the stabilization and 
accumulation of TP53 levels (Ashcroft & Vousden 1999; Caspari 2000; Shieh et 
al., 1997). Phosphorylation is the most common post-translational modification 
and there are at least 15 phosphorylation sites, of which the majority are in the 
N-terminus (Appella & Anderson 2000; Meek 1998). In conjunction with this step, 
TP53 RNA is overtranslated to ensure the accumulation of TP53 takes place. In 
addition, TP53 is also stabilized by the ARF-MDM2 pathway, as a result of 
oncogenic activation increasing ARF levels, which enables ARF to interact with 
MDM2, releasing TP53 from MDM2 (Kamijo et al., 1998; Lane & Lain 2002). USP7 
(previously known as HAUSP), a deubiquitinating enzyme, acts as a potent TP53 
stabilizer as it prevents ubiquitinated TP53 from degradation, adding further 
complexity to the tight regulation of TP53 stability (Li et al., 2002; Salomoni & 
Pandolfi 2002; Wood 2002). Figure 1.8 summarizes the pathways involved in 
regulating TP53 stability. 
Secondly, sequence-specific DNA binding of the core domain was classically 
thought to be negatively regulated by post-translational modifications of the C-
terminus domain (Chiarugi et al., 1998; Wolkowicz & Rotter 1997). However, 
recently this has been brought into question by studies revealing, for example,     Chapter 1 ~ Introduction 
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that the C-terminus does not interact with the core domain and the core domain 
is already bound to DNA prior to activation of transcription (Kruse & Gu 2009). 
Although, sites of phosphorylation, O-linked glycosylation, ADP-ribosylation and 
acetylation are found in the core domain which may enhance the sequence-
specific DNA binding activity of the core domain with some specific target genes 
(Kruse & Gu 2009).  
The third step of the process is the activation of TP53 transcription via 
interactions with the basal transcriptional machinery, which are aided by several 
post-translational modifications of the C-terminus. These modifications include 
ubiquitination, acetylation, phosphorylation, methylation, sumoylation and 
neddylation (Kruse & Gu 2009). The numerous combinations of these 
modifications and the timing at which they occur, enables different sets of TP53 
target genes to have different requirements for TP53 post-translational 
modifications following stress-induced TP53 activation e.g. acetylation of TP53 is 
required for activation of proapoptotic genes, BAX, PUMA, FAS and NOXA, 
whereas no acetylation is necessary for cell survival by MDM2 and PIRH2 (Kruse & 
Gu 2009). 
Although some aspects of the TP53 post-translational regulatory network appear 
to be redundant, none of the stimuli can induce, for example, all of the 
phosphorylation pathways and the phosphorylation response of TP53 varies to 
each different stimulus. However, findings from a number of studies cannot be 
satisfactorily explained by the classical model of TP53 regulation which have 
recently led Kruse and Gu (2009) to suggest a more sophisticated model for the 
regulation of TP53 activation, in which antirepression, the release of p53 from 
repression by MDM2 and MDM4, is proposed to be central to the regulation of 
TP53 (Kruse & Gu 2009).   
Post-transcriptional modifications of TP53 do exist, and these forms have been 
shown to differ in their response to DNA damage. In particular, an additional 
level in controlling the complexity of TP53 function may occur via the eight 
variants of TP53, all of which generate altered TP53 with either unique N- 
and/or C- termini (Millau et al., 2009).      Chapter 1 ~ Introduction 
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Hence, regardless of the actual mechanism of the regulation of TP53 activation, 
it is clear that the responsiveness of TP53 activity to a wide range of signals is 
tightly and co-ordinately controlled in response to stresses and changes in the 
cellular environment.  
 
 
Figure 1.7: Overview of TP53 post-translational modifications. More than 36 
amino acids of TP53 are reported to be modified. The major sites of TP53 
phosphorylation (P), ubiquitination (Ub), and acetylation (Ac) are shown with 
the corresponding primary modifying enzymes and signals. Furthermore, 
additional phosphorylation and acetylation sites, as well as main sites of 
methylation (Me), sumoylation (S), neddylation (N8), glycosylation (O-Glc), and 
ribosylation (ADP), are indicated (Kruse & Gu 2009).     Chapter 1 ~ Introduction 
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Figure 1.8: Pathways of TP53 stabilization and degradation. MDM2 binds to TP53 
and ubiquitinates TP53 through its RING domain that possesses E3 ligase activity. 
The ubiquitinated TP53 is then degraded by 26S proteasomes or further 
polyubiquitinated by p300 for more efficient degradation. DNA-damage stabilizes 
TP53 by inducing TP53 phosphorylation, which prevents the binding of MDM2. 
The stabilized TP53 in the form of a tetramer transactivates target genes, which 
include MDM2. MDM2 therefore forms a negative feedback loop with TP53 and 
regulates TP53 stabilization. Another feedback loop regulating TP53 stabilization 
is the PIRH2 pathway. Activation of oncogenes stabilizes TP53 by the ARF 
pathway, in which ARF binds to MDM2 and releases TP53 from MDM2-mediated 
degradation. HAUSP (USP7), which contains deubiquitinating enzyme activity, 
acts as a potent TP53 stabilizer, and can rescue TP53 from degradation. PARC, a 
large molecular weight cytosolic protein, also participates in regulating TP53 by 
anchoring TP53 in the cytoplasm. In case of DNA damage, TP53 is heavily 
phosphorylated by ATM/CHEK2 or ATR/CHEK1. Phosphorylation of TP53 at the 
amino-terminus prevents MDM2 binding and TP53 is stabilized (Wang et al., 
2003). 
 
 
1.3.3 Inactivation of TP53 
TP53 fails to function correctly in the majority of human cancers, including OS 
(Petitjean et al., 2007b; Tang et al., 2008). In ~50% of these tumours, the TP53 
is directly inactivated due to mutations in the TP53 and in the remainder, the 
wild-type TP53 can be indirectly inactivated through interactions with viral 
proteins or aberrations in genes whose products are either upstream mediators     Chapter 1 ~ Introduction 
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or downstream events of TP53 (Vogelstein et al., 2000) (Table 1.7). It is 
acknowledged that different forms of mutant TP53 possess different functional 
and biological effects to that of wild-type TP53. Disruption of the TP53 response 
pathway strongly correlates with tumourigenesis. This is clearly demonstrated by 
the predisposition to a wide range of early-onset tumours, including OS, in 
patients who suffer from Li-Fraumeni and related syndromes due to the 
inheritance of TP53 mutations (Kansara & Thomas 2007), and TP53 null mice 
which develop normally, but are prone to the spontaneous development of a 
variety of neoplasms at an early age, thereby mimicking Li-Fraumeni syndrome 
(Donehower et al., 1992). Direct and indirect inactivation of TP53 is also a 
common event in canine malignancies, including OS (Johnson et al., 1998; 
Setoguchi et al., 2001a; Thomas et al., 2009; Van Leeuwen et al., 1997).  
Mechanism of inactivating 
TP53 
Typical tumours  Effect of inactivation 
Amino-acid-changing mutation 
in the DNA-binding domain 
Colon, breast, lung, bladder, 
brain, pancreas, stomach, 
oesophagus and many others 
Prevents TP53 from binding to 
specific DNA sequences and 
activating the adjacent genes 
Deletion of the carboxy-
terminal domain 
Occasional tumours at many 
different sites 
Prevents the formation of 
tetramers of TP53 
Multiplication of the MDM2 
gene in the genome 
Sarcomas, brain  Extra MDM2 stimulates the 
degradation of TP53 
Viral infection e.g. SV40 large 
T antigen, HPV16/18, 
adenovirus E1B 
Cervix, liver, lymphomas  Products of viral oncogenes 
bind to and inactivate TP53 in 
the cell, in some cases 
stimulating TP53 degradation 
Mutations in pathways 
upstream/ downstream of 
TP53 e.g. deletion of p14ARF 
or ATM genes; PI3K/ 
AKT/PTEN 
Breast, brain, lung and others, 
especially when TP53 itself is 
not mutated 
Failure to inhibit MDM2 and 
keep TP53 degradation under 
control 
Mislocalization of TP53 to the 
cytoplasm, outside the 
nucleus 
Breast, neuroblastomas  Lack of TP53 function (TP53 
functions only in the nucleus) 
 
Table 1.7: Mechanisms of TP53 inactivation in cancer (Vogelstein et al., 2000). 
 
 
1.3.3.1 Mutational spectra of TP53  
Over 2000 original publications (published between 1989 and December 2006) 
have described alterations to TP53 in human tumours, totalling 24785 somatic 
and 423 germ-line mutations, of which there at least 1700 different mutations in 
over 230 of the 393 residues (International Association of Cancer Registries 
(IARC) TP53 Mutation Database, R13 release, November 2008, www-p53.iarc.fr) 
(Petitjean et al., 2007b). Several residues have sustained multiple alterations,     Chapter 1 ~ Introduction 
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implying that diverse structural alterations in TP53 can promote carcinogenesis 
(Greenblatt et al., 1994; Petitjean et al., 2007b). It is believed that the main 
reason why TP53 is so frequently mutated is due to the ability of TP53 to 
respond to the many different types of stress stimuli (Appella & Anderson 2000; 
Pluquet & Hainaut 2001).  
Mutations in TP53 include any one or a combination of the following aberrations: 
somatic or germline missense (point), frameshift, nonsense, silent, insertion, 
deletion and splice site mutations (Petitjean et al., 2007b); gene 
rearrangements (Miller et al., 1990; Toguchida et al., 1992); and allelic gains 
and losses (Kansara & Thomas 2007; Kaur et al., 2007; Ozaki et al., 2002; 
Yamaguchi et al., 1992). The most commonly occurring mutation is missense, as 
missense mutations account for 73.4% and 77.3% of the somatic and germline 
mutations in human cancers, respectively (IARC TP53 Mutation Database R13 
release, November 2008) (Petitjean et al., 2007b). Although missense mutations 
are found throughout the open reading frame (ORF), the nature of the mutations 
generally depends on the domain as the mutations mainly observed in the N- and 
C-termini are nonsense (truncation) and frameshift mutations (Hainaut & 
Hollstein 2000).  
Whilst mutations are found throughout the ORF and at splice junctions, over 98% 
are clustered in four of the five evolutionarily conserved domains, located in the 
central region of the TP53, and less than 1% occur in the oligomerization domain 
of the C-terminal domain (Hainaut & Hollstein 2000; Petitjean et al., 2007b). 
The 4 evolutionarily conserved domains lie between codons 110 and 310 and 
cover exons 5 to 8. Within this stretch of amino acids, the majority of mutations 
are missense (84.1%) and the most commonly mutated codons („hotspots‟), are 
located at amino acid residues 175, 245, 248, 249, 273 and 282, which account 
for 50% of mutations within this domain (Petitjean et al., 2007b).  
The most frequently occurring TP53 mutation found in all tumour types is G:C to 
A:T transitions at CpG dinucleotide sites, accounting for 24.7% of the 24785 
somatic mutations analysed in the IARC TP53 Mutation Database R13 release, 
November 2008) (Petitjean et al., 2007b). Furthermore, five of the six 
mutational „hotspots‟ in TP53 are CpG dinucleotide sites (175, 245, 248, 273 and 
282) (Tornaletti & Pfeifer 1995). CpG dinucleotides are estimated to have at     Chapter 1 ~ Introduction 
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least a 10-fold higher mutation rate than that of other dinucleotides, due to 
their preferential methylation to 5-methylcytosine which has the ability to 
spontaneously deaminate (Holliday & Grigg 1993; Rideout, III et al., 1990). It is 
recognized that G:CA:T transitions at CpG sites typically represent endogenous 
DNA damage, whereas G:CT:A transversions are generally associated with 
carcinogen exposure (Greenblatt et al., 1994; Walker et al., 1999). 
The mutational spectra of TP53 in human OS, similar to that for all tumour 
types, indicates that the majority of alterations occur between exons 5 and 8 
and are missense, with mutations being reported at all six „hotspot‟ codons, of 
which 175, 245, 248, 273 and 282, are also found to be frequently mutated (IARC 
TP53 Database R13 release, November 2008), (Figure 1.9) (Petitjean et al., 
2007b). The most commonly occurring mutation in human OS is also G:C to A:T 
transitions at CpG dinucleotide sites (26.7%, n=172) (IARC TP53 Mutation 
Database R13 release, November 2008) (Petitjean et al., 2007b). Thus, from the 
current knowledge of exogenous and endogenous mutation events in TP53, it 
seems likely that mutations in human OS tumours are as a result of endogenous 
factors.  
A similar pattern may exist for TP53 in canine tumours, including OS, as many of 
the aberrations detected, so far, are located in TP53 DNA binding domain and to 
a lesser extent in the transactivation and oligomerization domains (Kirpensteijn 
et al., 2008; Setoguchi et al., 2001b). The majority of mutations in exons 5-8 are 
missense along with the occurrence of a few frameshifts, deletions and 
insertions (McIntyre et al., 1994; Setoguchi et al., 2001b; Toguchida et al., 
1992; Veldhoen et al., 1999). In particular, three studies also reported that 
between 25-50% of the mutations found in canine OS were transitions at CpG 
sites (Johnson et al., 1998; Mendoza et al., 1998; Van Leeuwen et al., 1997).  
These findings therefore indicate the involvement of TP53 in the genesis of 
canine tumours in a way comparable to that of human tumours and mutations in 
the conserved domains of TP53 appear to play a significant role in OS, in both 
species.      Chapter 1 ~ Introduction 
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Figure 1.9: TP53 mutations found in human OS. The green boxes represent 
evolutionarily conserved regions. The length of the black vertical lines above the 
main box represent the frequency at which mutations are found at each 
particular residue and are clustered in conserved regions II-V. Most commonly 
mutated codons are highlighted, of which 175, 245, 248, 273 and 282 are also 
„hotspots‟. The horizontal blue lines represent the locations of exons 5-8 within 
TP53, which contain 4 of the 5 evolutionary conserved domains. Modified from 
IARC TP53 Mutation Database, R13, Release November 2009 (Petitjean et al., 
2007b). 
 
1.3.3.2 Effect on TP53 function 
Cells with TP53 functional deficiencies are unable to respond properly to 
stresses and accumulate DNA damage, while the ability to initiate cell cycle 
arrest and apoptosis are usually lost. These conditions act synergistically to 
promote the transformation of normal cells into malignant cells. Deficiency of 
TP53 function also confers a growth advantage under hypoxic conditions, which 
contributes to tumour progression (Pluquet & Hainaut 2001). In addition, 
conventional cancer treatments are based on genotoxic stresses inducing cell 
death through different pathways e.g. DNA damage, cell cycle inhibition, hence 
the loss of TP53-mediated apoptosis considerably reduces the response to these 
therapies (Lowe et al., 1993).  
Structurally, TP53 mutations can be divided into two classes: class one contains 
alterations in residues regulating sequence-specific binding e.g. arginines 248, 
273 and 282; and class two, aberrations in residues for the global conformation     Chapter 1 ~ Introduction 
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of TP53 structure e.g. arginines 175 and 249 (Cho et al., 1994; Hainaut et al., 
1998). In both cases, mutated TP53 is typically characterized by a prolonged 
half-life and by altered or abolished wild-type RE binding activity (Hainaut & 
Hollstein 2000). Furthermore, TP53 mutations contribute to a broad spectrum of 
TP53 transcriptional activities, which may result in either a loss of function or a 
gain of function (Lin et al., 1995). 
 
1.3.3.2.1 TP53 loss of function 
Many TP53 mutations produce a loss in transcriptional function. A total loss of 
function may occur when mutated TP53 exerts a dominant negative effect within 
TP53 tetramers. This is because mutated TP53 is more abundant in the cell due 
to the possession of a prolonged half-life, resulting in its over-representation in 
tetramers. Hence, even if the remaining wild-type p53 allele is present, TP53 
transcriptional activities are lost (Chene & Bechter 1999). For example, 
transgenic mice expressing p53
+/- or p53
-/- are very prone to both spontaneous 
and induced tumours (Hann & Lane 1995; Harvey et al., 1995). A dominant 
negative effect has been reported to be important for switching off TP53 
transcriptional activity, since 80% of the most common mutants are able to exert 
a dominant negative effect (Petitjean et al., 2007b). However, mutated TP53 
may retain some transcriptional activity, with each one possessing a different 
amount of activity, thereby having a different effect on different target genes 
e.g. p53-175P mutants are correlated with a loss of apoptotic properties but 
retain the ability to induce cell cycle arrest (Rowan et al., 1996). The function 
and structure of all 2314 possible amino acid substitutions caused by a point 
mutation in TP53 showed that 635 mutants exhibited decreased transcriptional 
activities for specific target genes and 361 demonstrated a total loss of 
transcriptional activities (Petitjean et al., 2007b). Furthermore, several TP53 
mutants have been shown to possess some ability to regulate target genes 
similar to that of wild-type TP53, as well as varying their response to different 
stresses. For example, three mutated p53 proteins, each containing a different 
mutation in the DNA-binding domain (p53-143A, p53-273H and p53-175H), were 
exposed to -irradiation, and whilst p53-143A induced G1/S arrest, in the same 
manner as the wild-type protein, p53-273H and p53-175H did not (Pocard et al.,     Chapter 1 ~ Introduction 
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1996). Whereas, following treatment with a mitotic spindle inhibitor, p53-273H 
induced G1/S arrest, but p53-143A and p53-175H did not (Dridi et al., 2003). 
From these findings, it was suggested that mutations in the DNA-binding domain 
may only prevent DNA-binding of the TP53 tetramer to certain target gene RE in 
a stress-dependent manner (Dridi et al., 2003). This could have important 
consequences during cancer treatments since different genotoxic stresses may 
be used, thereby influencing the TP53 response.  
 
1.3.3.2.2 TP53 gain of function 
The discovery that TP53 mutants can regulate new target genes, which are 
normally not regulated by wild-type TP53 e.g. the multi-drug resistance gene, 
led to the TP53 gain of function concept (Dittmer et al., 1993). Gain of function 
switches TP53 from acting as a tumour suppressor to one of an oncogene. It is 
proposed that mutations can alter the sequence-specific DNA-binding activity of 
TP53 to recognize and regulate different target genes, while the activity of the 
target genes normally regulated by wild-type is decreased (O'Farrell et al., 
2004). This provides an explanation as to why TP53 in tumour cells contains 
primarily missense mutations rather than truncation or frameshift mutations, 
which induce total disruption. Also, it has been hypothesized that mutant TP53 
requires the functional integrity of the N- and C-termini to enable it to acquire 
gain of function status (Levine et al., 1995). Hence, in addition to losing tumour-
suppressor activity, mutant TP53 has the potential to be oncogenic, providing a 
proliferative advantage to tumour cells. It was initially thought that RE of new 
target genes recruited TP53 mutants (O'Farrell et al., 2004), however, despite 
several studies, neither TP53 RE, nor any consensus sequences bound by mutated 
TP53 were found in the promoter regions of these genes (Kim & Deppert 2004). 
It has since been shown that most TP53 mutants bind to non-linear DNA 
structures in a highly structure selective manner, but are unable to bind the 
same sequence when presented in linear DNA (Gohler et al., 2005). Hence, 
instead of TP53 mutants recognising new target genes via new RE, they bind to 
DNA secondary structure motifs located in the promoter of these genes (Gohler 
et al., 2005; Walter et al., 2005b). In agreement with this idea of structure-
based binding, another explanation to elucidate the lack of TP53 mutant RE, is     Chapter 1 ~ Introduction 
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that TP53 regulation of new target genes may occur indirectly through other 
DNA-binding factors e.g. involving sequence-specific transactivators ETS1 and 
NF-Y (Gu et al., 2004; Strano et al., 2007). ETS1 plays an important role in cell 
differentiation, cell proliferation, apoptosis and tissue remodelling and NF-Y in 
cell cycle regulation. The transcriptional activities of ETS1 and NF-Y are 
inhibited following binding to wild-type TP53, but are increased by mutant TP53, 
resulting in the up-regulation of the transcription levels of their respective 
target genes (Gu et al., 2004; Strano et al., 2007). 
 
1.3.3.3 Detection of TP53 alterations 
A number of methods have been typically used to detect aberrations in TP53 in 
human OS, including single-strand conformation polymorphism (SSCP) of 
polymerase chain reaction (PCR) products and PCR in conjunction with direct 
DNA sequence analysis (Overholtzer et al., 2003; Toguchida et al., 1992). SSCP 
has also been used to identify TP53 aberrations in several canine tumours, 
including OS (Mendoza et al., 1998; Setoguchi et al., 2001b; Van Leeuwen et al., 
1997). In particular, PCR and direct DNA sequence analysis is one of the most 
precise methods for determining TP53 mutation status (Cheah & Looi 2001; 
Osuna & de Alava 2009; Petitjean et al., 2007b), and has been employed to 
determine the presence of TP53 alterations in various canine tumours (Muto et 
al., 2000; Nasir et al., 2001). More recent methods of detecting TP53 mutations, 
including high-throughput screening techniques, are described in 3.4.2.2.2. 
Mutant TP53 is typically metabolically stable, and possess a 10- to 20-fold longer 
half-life than that of wild-type TP53 (Bartek et al., 1991; Gannon et al., 1990). 
Consequently, transformed cells in culture and in human and canine tumours 
often possess far higher levels of TP53 (5-100 fold) due to the accumulation of 
TP53 in the nucleus (Reich et al., 1983). This enables detection, using antibodies 
specific for TP53 and visualization by immunohistochemistry (IHC) (Bartek et al., 
1991; Gannon et al., 1990; Legros et al., 1994) (Figure 1.10). Since wild-type 
TP53 is rapidly degraded, possesses a short half-life and is present at a level in 
normal cells usually below the amount required for detection using this 
technique (Esrig et al., 1993; Imamura et al., 1994). Many authors have     Chapter 1 ~ Introduction 
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interpreted the detection of nuclear immunopositivity as evidence for mutations 
in TP53, due to the presence of mutant or stabilized forms of TP53, rather than 
the up-regulation of wild-type TP53 due to an increase in the steady-state level 
of TP53 mRNA (Gamblin et al., 1997; Haga et al., 2001; Hall & Lane 1994). 
Although this can be controversial, due to the occurrence of false-positive and 
false-negative results (Wynford-Thomas 1992). Nonetheless, IHC has been 
extensively performed on many human and canine tumours, including OS, and 
has clearly demonstrated that the accumulation of TP53 is a common occurrence 
(Loukopoulos & Robinson 2007; Pakos et al., 2004; Sagartz et al., 1996). 
   
 
 
Figure 1.10: Immunocytochemical detection of accumulated TP53 using CM-1 
polyclonal anti-p53 antibody (Novocastra Laboratories, Newcastle Upon Tyne, 
UK; diluted 1:1000 in 0.1% bovine serum albumin (BSA)) in a canine OS (x100). 
Regions of cells containing accumulated TP53 are stained dark brown, e.g. arrow 
pointing to a cell demonstrates nuclear TP53 expression (in-house photograph). 
Section immunostained using a streptavidin-biotin complex (DakoCytomation, 
UK), and immunoreactivity visualised using diaminobenzidine (DAB) (Sigma, UK) 
and counterstained with haematoxylin. 
 
1.3.3.4 Effect of TP53 mutations on prognosis  
The identification of molecular markers for diagnosis, prognosis and prediction 
of therapy response is of paramount importance in improving the treatment of     Chapter 1 ~ Introduction 
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cancer. Several studies have investigated the possibility of the existence of a 
link between specific TP53 mutations and the prognosis and response to 
treatment. Tumour cells containing wild-type TP53 are usually more sensitive to 
current treatments than those bearing mutant TP53. For a variety of human 
cancers, including breast, colorectal, gastric, poor prognosis and/or poor 
response to treatments have been correlated with TP53 mutational status 
(Petitjean et al., 2007b; Petitjean et al., 2007a). Although TP53 status was 
reported not to be a predictive factor for a histological response to 
chemotherapy in human OS patients, TP53 alterations may be a prognostic factor 
as they were associated with decreased survival (Pakos et al., 2004). 
Importantly, the presence of TP53 mutations and accumulation of TP53 may also 
be suitable poor prognostic indicators for canine OS (Kirpensteijn et al., 2008; 
Loukopoulos et al., 2003), as previously discussed in 1.1.7.1. Additionally, 
different types of TP53 mutations have been related to different outcomes, e.g. 
missense mutations were associated with the poorest outcome in several cohorts 
(Petitjean et al., 2007a; Taubert et al., 1996). Evidence also suggests that 
expression of specific p53 isoforms are associated with the prognostic value of 
TP53 mutations (Olivier et al., 2009). Furthermore, recent findings based on 
computational approaches are able to predict the structural and functional 
effect of TP53 mutations and directly correlate with experimentally validated 
data (Carlsson et al., 2009). This research opens the possibility of classifying 
mutations according to the extent to which they disrupt TP53 structure/function 
and to determine categories of „aggressive‟ or „low-risk‟ mutations. 
Structure/function predictions might therefore be useful when TP53 status is 
used as a molecular prognosis marker and could be an important tool for 
clinicians. However, penetrance of TP53 mutants, may be influenced by various 
factors, such as genetic background, genetic mutations due to carcinogenesis 
and tissue specificity (Soussi 2007). Numerous other studies have been reported, 
including some in human OS, which were unable to demonstrate any correlations 
between either TP53 gene or protein mutational status and poor prognosis 
(Pakos et al., 2004; Petitjean et al., 2007a). In addition, in some human 
tumours, e.g. bladder cancer, TP53 mutations were found to correlate with 
increased drug sensitivity as tumours positive for TP53 responded better to 
chemotherapy than tumours with undetectable TP53 levels (Cote et al., 1997).     Chapter 1 ~ Introduction 
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Similarly, investigations of breast cancer cells possessing wild-type TP53 were 
protected from some forms of cytotoxic chemotherapy and associated with a 
poor response to treatment (Bertheau et al., 2008). It has been suggested that 
these contradictory results could be due to one or a combination of 
methodological and clinical differences, or as TP53 mediates a wide range of 
cellular responses, from cell death to cell survival, the consequences of wild-
type or mutated TP53 activity could thus have a similar spectrum of effects 
(Pakos et al., 2004; Petitjean et al., 2007a). 
 
1.3.4 Summary 
TP53 acts as a tumour suppressor and controls the transcription of many 
different genes in response to a wide variety of stress signals (Riley et al., 2008). 
TP53 truly fulfils in its role as the „guardian of the genome‟, by acting as the 
main co-ordinator of the repair of damaged DNA. The TP53 pathway has been 
divided into five parts: (i), the stress signals that activate the pathway; (ii), the 
upstream mediators that detect and interpret the upstream signals; (iii), the 
core regulation of TP53 through its interaction with several proteins that 
modulate its stability; (iv), the downstream events, mainly transcriptional 
activation or protein-protein interactions; and (v), the final outcome, growth 
arrest, apoptosis or DNA repair (Levine et al., 2006). Post-translational 
modifications of TP53 and specific interactions with distinct cellular proteins, as 
well as the recent discovery of eight p53 isoforms, are the main mechanisms 
responsible for the molecular versatility that enables a single gene to address 
the multiple functions attributed to TP53.  
Inactivation of TP53 is primarily due to either small mutations (missense and 
nonsense mutations or insertions/deletions of several nucleotides), which lead 
to either expression of a mutant protein (90% of cases) or absence of protein 
(10% of cases), or indirectly, for example, by interactions with viral proteins or 
aberrations in genes whose products are either upstream mediators or 
downstream events of TP53 (Vogelstein et al., 2000). Epidemiological data 
reveals that TP53 is the most frequently altered gene in human and canine 
neoplasia, including OS. No inactivation of TP53 expression by hypermethylation     Chapter 1 ~ Introduction 
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of transcription promoters has been demonstrated at the present time, which 
supports the hypothesis of a function for TP53 mutants. Two main problems are 
posed by the loss of gene regulation by TP53, tumourigenesis and insensitivity 
and resistance to cancer treatments.  
The determination of TP53 status is clinically important, since the functional 
status of TP53 has been related to prognosis, progression and therapeutic 
response in a variety of human tumour types (Petitjean et al., 2007a). 
Furthermore, in human OS patients, TP53 alterations may be associated with 
decreased survival (Pakos et al., 2004), and in dogs with OS, the presence of 
TP53 mutations and accumulation of TP53 may be classed as poor prognostic 
factors (Kirpensteijn et al., 2008; Loukopoulos et al., 2003).  
Hence, all these characteristics make TP53 an ideal molecular target for cancer 
therapy, including canine OS.     Chapter 1 ~ Introduction 
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1.4 Summary & overall aim 
OS is the most commonly occurring bone cancer in the canine species. It is an 
excellent model for human OS due to the fact that molecular characteristics 
between the two species are similar, including alterations in TP53. In recent 
years, it has become increasingly clear that the immunocytochemical 
subclassification of OS, as with all cancers, significantly enhances the accuracy 
of pathological diagnosis (Ueda et al., 1993). The determination of TP53 status 
of OS is of the utmost importance, since an accumulation of mutant TP53 in the 
nucleus of neoplastically transformed cells may strongly correlate with the 
genetic instability, proliferative potential and ultimately, survival of the patient. 
Although improvements have been made in the surgical modalities for OS, 
conventional therapies are at best only palliative as survival rates are still poor 
and so OS remains a disease of high mortality in both human and veterinary 
medicine (Ling et al., 1974). In general, patients with OS ultimately die of 
metastatic disease distant to the site of their primary tumour, in that they do 
not die from a lack of adequate surgical therapy for the primary site; rather, 
they die as a result of inadequate adjuvant medical therapy for micro- and 
macro- metastatic disease. However, overall improvements in survival await 
advances in systemic therapy. Hence, in recent years, attention has turned to 
more innovative ideas of combating the problem of metastasis in OS, in both 
dogs and humans. New approaches, based on gene therapy strategies, currently 
showing promise as future methods of adjuvant treatment are the subject of 
intense research. These include modulation of the immune response, novel 
chemotherapeutics incorporating suicide gene/prodrug combinations and 
targeted molecular strategies, in particular, the use of TP53. The latter two 
approaches are of considerable relevance to this study.  
The overall aim of this study, was to perform preliminary investigations into 
TP53-targeted suicide gene therapy as a treatment modality for canine OS by 
constructing and analysing a TP53-targeted suicide gene therapy strategy, which 
could selectively target and initiate the destruction of canine OS cells possessing 
accumulated TP53. This approach could also be easily adapted to target human     Chapter 1 ~ Introduction 
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OS cells accumulating TP53 and furthermore, potentially be modified and 
analysed in any cancer possessing accumulated TP53.  
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2.1 Cell culture 
 
2.1.1 Maintenance of canine cell lines  
Six adherent canine cell lines, with known p53 status (Table 2.1), were used in 
this study. Cells were maintained at 37
oC in a humidified atmosphere of 5% CO2. 
Solutions were pre-warmed (37
oC) before use. D17, MDCK and CML-10 cell lines, 
were maintained in Dulbecco‟s modified eagle medium (DMEM) with GLUTAMAX-
I
TM (L-Ananyl-L-Glutamine), supplemented with 10% (v/v) heat-inactivated foetal 
calf serum (HiFCS; Appendix A), penicillin and streptomycin (both 100 units/ml), 
fungizone (250g/ml; all GIBCO BRL) and ciprofloxacin hydrochloride (10g/ml; 
Bayer Diagnostics). CMT3, CMT7 and CMT8 cell lines, were maintained in RPMI 
1640 medium (GIBCO BRL), containing 10% HiFCS, L-glutamine (0.292mg/ml; 
GIBCO BRL), penicillin (100 units/ml), streptomycin (100 units/ml) and fungizone 
(250 g/ml). Cell culture plastics were purchased from Greiner. 
 
2.1.2 Cell passaging 
Medium was replaced every 3 days and cells routinely passaged when confluent. 
Medium was removed, cells were washed twice with Hanks balanced salt solution 
(HBSS) and incubated in trypsin-ethylene-diamine-tetra-acetic acid (EDTA; both 
GIBCO BRL) at 37
oC/ 5% CO2 until completely detached. To block trypsin, 
detached cells were washed with medium containing 10% HiFCS and pelleted by 
centrifugation at 254 x g for 10 minutes. The cell pellet was resuspended in 
medium and an appropriate volume transferred to a fresh culture vessel and 
placed in an incubator. All experiments were performed within a window of 15 
passages throughout this study. 
 
2.1.2.1 Cell counting  
The cell suspension was introduced to a Neubauer haemocytometer chamber and 
cells counted under an inverted microscope with 10x objective; cells lying on the Chapter 2 ~ Materials and Methods 
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top and right hand perimeter of each large (1mm) square were included, those 
on the bottom or left hand perimeter were excluded. Cell concentration 
(cells/ml) was calculated by multiplying the mean number of cells per large 
square by 10
4 and correcting for the dilution factor. Live cell numbers were 
estimated by adding 0.4% trypan blue (Sigma) to the cell suspension (1:1), 
incubating at room temperature (RT) for 5 minutes prior to counting and 
excluding dead (blue) cells from the count. 
 
2.1.3 Cryopreservation of cells: freezing and recovery  
Cells at 70-80% confluence were detached as above (2.1.2) and cell pellets 
resuspended in freezing medium (Appendix A), at a concentration of ~2x10
6 
cells/ml, and transferred into cryovials in 1ml aliquots. Cryovials were cooled at 
1
oC/min to -70
oC and transferred to a liquid nitrogen tank for permanent 
storage. 
Cells recovered from liquid nitrogen were thawed in a water bath at 37
oC. When 
almost thawed, cells were slowly added to tubes containing 10ml of medium 
with 10% HiFCS, pelleted by centrifugation at 254 x g for 5 minutes, washed with 
10ml of medium containing 10% HiFCS and recentrifuged. The cell pellet was 
resuspended in medium, transferred to a culture flask and placed in an 
incubator at 37
oC/ 5% CO2. The following day, cells were either passaged if 
confluent or medium was replaced.  
 
 
Canine cell line Cell type  Derived from  TP53 status  References 
CML-10  melanoma  primary melanoma  wildtype (exons 5-8)  (Helfand et al., 1996; Sabine et al., 1999; Wolfe et al., 1987) 
CMT3  atypical benign mixed tumour  primary mammary  mutated (exon 5: Cys176Phe) (Hellmen 1992;Van Leeuwen et al., 1996) 
CMT7  osteosarcoma  primary mammary osteosarcoma  mutated (exon 7: Gly245Ala)  (Hellmen 1992;Van Leeuwen et al., 1996) 
CMT8  osteosarcoma  primary mammary osteosarcoma  mutated (exon 7: Tyr236Asn)  (Hellmen 1992;Van Leeuwen et al., 1996) 
D17  osteosarcoma  primary osteosarcoma (metastatic to lung)  wildtype (exons 5-8)  (Riggs et al., 1974;Sabine et al., 1999) 
MDCK   kidney  normal kidney  wildtype (exons 5-8)  (Gaush et al., 1966;Sabine et al., 1999) 
 
Table 2.1: TP53 status of canine cell lines. CMT3, CMT7 and CMT8 cell lines were kindly donated by Dr. E. Hellman, Swedish University 
of Agricultural Sciences, Uppsala, Sweden. D17 and MDCK cell lines were purchased from Health Protection Agency Culture Collections 
(HPACC; Reference numbers, 89090403 and 84121903, respectively). CML-10 cell line was kindly donated by Dr. L. Wolfe, Auburn 
University, Alabama, US. Chapter 2 ~ Materials and Methods 
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2.2 General nucleic acid manipulation & cloning  
 
2.2.1 Polymerase chain reaction 
PCR was used to amplify TP53 exons 5-8 and produce DNA fragments for cloning. 
Both Taq DNA Polymerase kit (QIAGEN) and Ready-To-Go
TM PCR Beads 
(Amersham Pharmacia Biotech) were used according to the manufacturer‟s 
instructions.  
Standard PCR conditions in this study were, depending on the template, 50-
200ng of DNA in a 50l or 25l reaction mixture containing 1.5 units of Taq DNA 
polymerase (0.75l), 10x PCR buffer (5l or 2.5l; including 22.5mM MgCl2 and 
detergents, pH 9.2), 200M of each nucleotide (0.5l), 0.2M of each primer 
(1l) and distilled water to the final volume. A negative control was prepared 
which included all components, but replacing template DNA with distilled water. 
The reaction was gently mixed and aliquoted into 0.2ml thin-walled PCR 
reaction tubes. PCR was performed using a GeneAmp PCR System 2400 
(PerkinElmer Applied Biosystems).  
PCR involved an initial denaturation step at 95
oC for 5 minutes followed by 30 
cycles of: denaturation at 95
oC, annealing and elongation 72
oC each for 1 
minute; after which a final extension step at 72
oC for 30 minutes was 
performed. Annealing temperatures varied depending on the primers used 
(MWG-Biotech) and were optimized for each set of primers used. 
PCR products (5 or 10l) were analysed by agarose gel electrophoresis (2.2.2). If 
a single DNA fragment was present, the PCR product was purified using QIAquick 
PCR Purification Kits (QIAGEN), following the manufacturer‟s guidelines and 
sequenced (2.2.8). If non-specific fragments were present, the product of 
interest was excised and purified (2.2.3). 
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2.2.2 Gel electrophoresis  
Gels containing 0.8-2% agarose (w/v) in 1xTBE (Appendix A) or 1xTAE (Appendix 
A) were used to separate DNA (Sambrook et al., 1989), and to verify the purity 
of PCR fragments of a certain size.  50, 150 or 300 ml gels were poured into 
perspex trays and wells were cast using appropriate combs. Gel loading buffer 
(Appendix A) was added to samples at a final concentration of 1x, samples were 
then loaded into the wells and electrophoresed in 1xTBE or 1xTAE until 
sufficient separation of the DNA had occurred (typically 100V for 30-45 minutes). 
When TAE gels were used, the running buffer was changed frequently to prevent 
buffer exhaustion. Appropriate DNA size markers (Appendix A; GIBCO BRL) were 
included to gauge product size. Gels were stained by adding 0.2 g/ml of 
ethidium bromide (Sigma) to the molten agarose prior to casting, viewed on a 
T2201 UV transilluminator (Sigma) and photographed with a UP-890 CE 
Videographic Printer (Sony). 
 
2.2.3 Purification of DNA from agarose gels  
Following electrophoresis, DNA fragments were excised from gels using a clean 
scalpel. DNA was purified using either QIAEX II Agarose Gel Extraction kit 
(QIAGEN) or JETSORB Gel Extraction kit (GENOMED), as described by the 
manufacturer‟s instructions, quantified (2.2.4) and stored at –20
oC. 
 
2.2.4 DNA quantification 
DNA samples were usually quantified by spectrophotometry (2.2.4.1), however, 
low DNA concentrations were analysed by gel electrophoresis (2.2.4.2). 
 
2.2.4.1 Determination by spectrophotometry 
DNA samples were diluted (usually 1:20) in distilled water. The optical densities 
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to a blank of ddH2O, in a Smartspec 3000 UV spectrophotometer (Bio-Rad). 
Concentrations were calculated, assuming double-stranded DNA has an OD of 1.0 
at 260nm, at a concentration of ~50g/ml. Purity was determined by OD260/OD280 
ratio, with acceptable ratios being between 1.6 – 2.1; lower values suggest 
possible protein or phenol contamination. 
 
2.2.4.2 Determination by gel electrophoresis 
Following DNA electrophoresis alongside low DNA mass ladder (Appendix A), DNA 
concentrations were estimated by comparing the intensity of fluorescence of 
DNA in the sample to that of the DNA in the low DNA mass ladder.   
 
2.2.5 DNA sequence analysis  
Cycle sequencing reactions were carried out using the ABI PRISM Big Dye
TM 
Terminator Cycle Sequencing Ready Reaction Kit (PerkinElmer Applied 
Biosystems), according to the manufacturer‟s recommendations, with 
appropriate primers. Briefly, 200-500ng of plasmid DNA or 20-90ng of PCR 
product, 3.2pmol of primer (MWG-Biotech) and 4l of Terminator Ready reaction 
mix were mixed in a 0.2ml PCR tube and made up to 20l with ddH2O. The 
reaction mixture was then passed through 25 cycles of 96
oC for 10 seconds, 50
oC 
for 5 seconds and 60
oC for 4 minutes.  Data analysis was performed using an ABI 
PRISM 310 DNA Sequencer (PerkinElmer Applied Biosystems). Typically, 400-500 
bp of sequence were obtained from one run. Mrs Elizabeth Gault, Department of 
Veterinary Clinical Science, University of Glasgow, carried out the preparation of 
the sequencing reactions. 
DNA sequences were analysed using Genetics Computer Group (GCG) package 
(Wisconsin Package Version 10.0, Madison, Wisconsin). Database searches were 
carried out by FAST-All (FASTA) searches in GCG or Basic Local Alignment Search 
Tool (BLAST) searches on the National Centre for Biotechnology Information‟s 
(NCBI) website (http://www.ncbi.nlm.nih.gov/BLAST/). 
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2.2.6 Digestion of DNA with restriction endonucleases  
Restriction endonucleases (Promega) were used to linearize plasmids, obtain 
DNA fragments for cloning and for integration of inserts, in accordance with the 
manufacturer‟s guidelines. DNA was mixed with an appropriate amount of 
enzyme and incubated at the recommended temperature, typically 37
oC, for 2-4 
hours. 
 
2.2.7 Cloning of DNA fragments 
2.2.7.1 Ligation reactions  
Vector DNA (typically 1g) was linearized using an appropriate restriction 
enzyme. Re-circularization was prevented by the hydrolysis of 5′-phosphate 
groups, at 37
oC for 30 minutes, with 1 unit of calf intestinal alkaline phosphatase 
(CIAP; Promega). This was followed by the addition of another 1 unit of CIAP and 
the incubation repeated. 
DNA fragments generated by:  
(i), restriction digestion were ligated into a linearized vector overnight at both 
14
oC and 4
oC, using T4 DNA ligase (Promega) at 1:1, 1:3 and 3:1 molar ratios of 
vector:insert DNA using the following formula: 
ng insert required = ng vector x insert size (kb)   x    molar ratio 
                 vector size (kb) 
(ii), PCR products were ligated, following the manufacturer‟s recommendations, 
into either pCR
®2.1-TOPO
® using the TOPO TA Cloning® Kit (Invitrogen; Appendix 
C, Figure C1) or pTargeT
TM Mammalian Expression Vector (Promega; Appendix C, 
Figure C2) via TA cloning. 
 
2.2.7.2 Growth of competent cells 
DH5 (GIBCO BRL; Appendix B) and TOP10 (Invitrogen; Appendix B) cells were 
streaked onto Luria-Bertani (LB) agar (Agar Bacteriological, Oxoid) plates and 
incubated overnight at 37
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supplemented with 1ml/litre of 1M thiamine hydrochloride (GIBCO BRL). 5ml of 
Luria Broth base (LB broth; GIBCO BRL) were inoculated and placed in an orbital 
incubator (200 rpm) at 37
oC overnight. Next morning, a 1:50 dilution was 
prepared in LB broth and grown at 37
oC for 2-4 hours until the OD 650 reached 
approximately 0.6. The culture was then centrifuged at 671 x g for 10 minutes at 
RT. The supernatant was discarded and the cell pellet gently resuspended in 
2.5ml of 0.1M CaCl2 (pre-cooled) and incubated on ice for 20 minutes with 
occasional gentle shaking. The suspension was centrifuged as before and cells 
resuspended in 500l of 0.1M CaCl2. The cells, if immediately required were 
dispensed into 50l aliquots and kept on ice, or, if for later use, 5ml of 50% 
sterile glycerol were added, dispensed into 100l aliquots and frozen at –70
oC. 
 
2.2.7.3 Transformation of bacteria 
DH5, JM109 (Promega; Appendix B) or TOP10 high efficiency competent cells, 
were used for blue/white colour screening and standard ampicillin selection. 
Aliquots containing 25l of competent bacterial cells were removed from -70
oC 
and placed on ice until just thawed. Cells were mixed by gently flicking the 
tubes and ligation mix (~2l) containing 5-25ng of total DNA was added and 
incubated on ice for 30 minutes. Cells were heat shocked at 42
oC for 30 seconds 
and immediately returned to ice for 2 minutes. 250l of SOC medium (GIBCO 
BRL) were added to each tube and cells were incubated with shaking at 200 rpm, 
for 1 hour at 37
oC. 50l and 200l of each transformation culture were spread 
evenly onto LB agar plates containing 100g/ml of ampicillin (filter sterilized; 
GIBCO BRL). For lacZ complementation selection, plates were also treated with 
5-bromo 4-chloro-3-indolyl--D-galactopyranoside (X-gal; Sigma; Appendix B; 
DH5 and TOP10 cells), plus isopropyl--D-thiogalactopyranoside (IPTG; Sigma; 
Appendix B; JM109 cells). Plates were incubated overnight at 37
oC. Positive and 
negative controls in the form of pUC18 DNA (Invitrogen) and ligation mix 
including or excluding insert DNA were used, respectively.  
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2.2.7.4 Identification of recombinants  
Positive (white) colonies were picked, used to inoculate 3-5ml of LB broth 
containing ampicillin (100g/ml) and cultured overnight at 37
oC in an orbital 
shaker (200 rpm), Colonies with appropriate inserts were initially identified by 
small-scale plasmid purification (2.2.8.1) and restriction digestion (2.2.6) and 
later on in the study, by PCR analysis (2.2.1). For PCR analysis, after inoculated 
broth had been shaken for 5 hours, 50l of culture were removed, heated to 
95
oC for 10 minutes, followed by centrifugation at 17900 x g for 5 minutes. 5l 
of supernatant were used in PCR with primers specific to the DNA of interest. 
The PCR product was electrophoresed on agarose stained with ethidium bromide 
(2.2.2) and colonies containing the insert identified.  
 
2.2.7.4.1 Storage of recombinants 
15% glycerol stocks were prepared by the addition of 90l of 50% glycerol to 
210l of culture and stored at -70
oC. For subsequent preparations of DNA, stocks 
were thawed, 5l streaked onto a LB agar plate and incubated overnight at 37
oC. 
Next morning, colonies were picked, used to inoculate 3-5ml of LB broth plus 
ampicillin before DNA isolation (2.2.8). 
 
2.2.8 Isolation of plasmid DNA  
Recombinant plasmid DNA was prepared using 3 different procedures, outlined 
below, depending on the intended use. Unless otherwise stated, a single colony 
was inoculated in LB broth with ampicillin and shaken overnight at 200-300 rpm 
at 37
oC. 
 
2.2.8.1 Small-scale isolation of plasmid DNA  
For sequencing, plasmid DNA was prepared from 3-5ml of an overnight culture, 
using the QIAGEN QIAprep Spin Miniprep kit as described by the manufacturer‟s 
instructions.   Chapter 2 ~ Materials and Methods 
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2.2.8.2 Large-scale isolation of plasmid DNA 
Large quantities of high quality plasmid DNA were produced from 100ml of an 
exponentially growing overnight culture of recombinant bacteria, using the 
QIAGEN Plasmid Purification Maxi kit in accordance with the manufacturer‟s 
guidelines.  
 
2.2.8.3 Large-scale isolation of transfection grade plasmid DNA 
For transfection, plasmid DNA were purified from 100ml of an exponentially 
growing overnight culture of recombinant bacteria, using the QIAGEN Endofree 
Plasmid Purification Maxi kit as described by the manufacturer‟s 
recommendations.  
 
2.2.9 Transfection  
Transfections into cells were carried out using Transfast
TM reagent (Promega), 
following the manufacturer‟s instructions. 
 
2.2.10 Cell survival assay 
Cell survival was measured using the CellTiter 96® AQueous One Solution Cell 
Proliferation Assay (Promega), according to the manufacturer‟s guidelines. 
Assays were incubated at 37
oC, for 1.5 hours, in an atmosphere of 5% CO2. Using 
a 96 well plate reader (Dynex technologies MRX) all assays were read at both 
450nm and 540nm. 
 
2.3 General manipulation of protein 
2.3.1 Preparation of cell lysates   
Cells for protein lysates were prepared by first replacing media with 2ml of fresh 
medium. A sterile pasteur pipette was used to scrape cells from the base of each Chapter 2 ~ Materials and Methods 
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well/flask and each 2ml sample was divided into 1.5ml and 0.5ml aliquots, 
centrifuged for 6 minutes at 17900 x g and the supernatant from each sample 
discarded. 50l of protein treatment sample buffer (2x; Appendix A) were added 
to cell pellets from the 1.5ml samples, heated in a boiling water bath for 10-20 
minutes and allowed to cool to RT, before storing at -20
oC. 50l of PBS (Sigma; 
Appendix A) were added to the cell pellets from the 0.5ml samples and 
sonicated for 3 seconds before storage.  
 
2.3.2 Protein quantification (Bradford assay) 
The Bradford reagent (Sigma) was used to determine the total protein 
concentration for each cell lysate (Bradford 1976). A stock solution of 2 mg/ml 
BSA (Sigma) was serially diluted in ddH2O, 1:1, to provide 7 protein standards 
(1000500, 250, 125, 62.5, 31.3 and 15.6 g/ml). An appropriate volume of each 
sonicated cell lysate was adjusted to 100l with ddH2O. 900l of Bradford 
reagent were added to each of the blanks, standards and samples, followed by 
incubation for 5 minutes at RT to allow the colour to develop. The absorbance at 
595nm was then measured using a spectrophotometer. The absorbance of each 
BSA standard was plotted against its respective protein concentration on a 
calibration curve, from which the concentration of protein in each of the 
samples was determined.  
 
2.3.3 Western blotting 
2.3.3.1 Protein SDS-polyacrylamide gel electrophoresis 
A 7.5% separating gel was prepared by mixing 3ml of 40% (w/v) acrylamide/bis-
acrylamide (Severn Biotech Ltd.), 4.4ml of dH2O, 2.5ml of 1.5M Tris-HCl (pH 
8.8), 100l of 10% SDS, 75l of 10% Ammonium persulphate (BIO-RAD) and 6l of 
TEMED (Sigma). The gel was poured into the casting apparatus using the Mini-
PROTEAN II system (Bio-Rad), the appropriate comb inserted and the gel allowed 
to polymerize. Denatured protein samples were sonicated for 30 seconds – 2 
minutes, centrifuged for 10 minutes at 17900 x g and the supernatant from each 
sample transferred to a fresh tube. An appropriate amount was loaded onto the Chapter 2 ~ Materials and Methods 
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gel and electrophoresed in Laemmli Running Buffer (Appendix A), alongside a 
protein ladder (Bio-Rad; Appendix A), at 60V for 4-5 hours. 
 
2.3.3.2 Protein Transfer 
Proteins were transferred from the gel to Trans-Blot Transfer Medium membrane 
(0.45M; Bio-Rad) using the Mini-PROTEAN II Trans-Blot Cell system (Bio-Rad). 
During the last hour of electrophoresis, nitrocellulose membrane, 2 pieces of 
filter paper and 2 cassettes sponges were equilibrated in transfer buffer 
(Appendix B) for at least 30 minutes. Following SDS-polyacrylamide gel 
electrophoresis (PAGE), a cassette was opened onto which a cassette sponge was 
placed, followed by a piece of filter paper and any bubbles present were 
removed by using a plastic „rolling pin‟. The gel was then lifted from the glass 
plates and placed on top of the filter paper, followed by the nitrocellulose 
membrane, the second piece of filter paper and another sponge. The cassette 
was closed, placed in the Mini-PROTEAN II Trans-Blot Cell system and run in 
transfer buffer at 60V for 2 hours.   
 
2.3.3.3 Blocking, antibody incubations and washes 
The membrane was rinsed in 0.1% (v/v) Tween-20 in PBS (PBS-T) and blocked by 
immersion in 5% (w/v) low fat dried milk (Safeway) in PBS-T (milk/PBS-T) at RT 
on a shaker for 1 hour and then 4
oC overnight. 
Next morning the membrane was rinsed twice with PBS-T, washed in PBS-T for 
15 minutes and finally washed twice in PBS-T for 5 minutes; all washes were 
carried out at RT with shaking. The primary antibody was diluted in 1% milk/PBS-
T (Table 2.2), the membrane placed inside a plastic bag, the diluted antibody 
added and the bag sealed. The bag was incubated on a rotary mixer for 1 hour at 
RT. The membrane was removed from the bag, washed as before in PBS-T and 
placed in a new bag. The secondary donkey anti-rabbit horseradish peroxidase-
conjugated antibody (Amersham Pharmacia Biotech) diluted 1:3000 with 1% 
milk/PBS-T, was added to the membrane, the bag sealed and incubated 1 hour Chapter 2 ~ Materials and Methods 
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at RT as before. The membrane was then removed from the bag, rinsed twice, 
washed once for 15 minutes and 4x for 5 minutes in PBS-T. 
Primary antibody Dilution Source 
Anti-LexA   1:5000  Invitrogen 
CM-1 (anti-p53)  1:500  Novocastra Laboratories 
E.coli NTR   1:500  Donated by Dr. G. Anlezark (Anlezark et al., 1992). 
 
Table 2.2: Primary antibodies (rabbit polyclonal) used in western blotting.  
 
2.3.3.4 Signal detection 
Signals were detected using the ECL
TM system (Amersham Pharmacia Biotech) 
following the manufacturer‟s recommendations. The membrane covered with 
ECL
TM reagent was transferred protein side up to an X-ray film cassette. In a dark 
room, a sheet of Hyperfilm
TM ECL
TM (Amersham Pharmacia Biotech) was placed 
over the membrane for between 10 seconds and 5 minutes before developing in 
a Curix 60 developer (Agfa). 
 
2.4 Statistical analyses 
Statistical analyses were carried out in association with Dr. Mohammed Reza 
Baneshi, Medical Statistics Unit, University of Edinburgh. Background absorbance 
counts (wells containing no cells, only cell culture medium) were removed from 
the data in experiments run over more than 1 time point and where appropriate, 
data were log(x+1), log, sqrt and sqrt/(x+1) transformed. Significant differences 
between the treatment groups were identified by analysis of variance (ANOVA) 
General Linear Model (GLM), followed by Scheffe‟s post hoc pairwise comparison 
of means with Bonferroni‟s adjustment for multiple comparisons. Mean 
significant difference was set at the 0.05 level.  
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Role of TP53 in Canine Osteosarcoma 
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3.1 Introduction 
3.1.1 Canine osteosarcoma  
Over 90% of primary neoplasms found in canine bones are malignant sarcomas, of 
which 65-85% are OS (Jongeward 1985). Approximately 75% of OS occur in the 
appendicular skeleton (Brodey & Riser 1969), with the forelimbs twice as likely 
to be affected as the hind limbs (Ru et al., 1998; Spodnick et al., 1992). Most 
remaining OS arise in the axial skeleton (Brodey & Riser 1969; Loukopoulos & 
Robinson 2007). The most common sites of axial skeleton OS in the dog are skull, 
spine and ribs, particularly at the costochondral junction (Brodey & Riser 1969; 
Egenvall et al., 2007; Heyman et al., 1992; Jongeward 1985). Extraskeletal OS is 
rare (<7% of canine OS) but mostly confined (86%) to visceral organs (Kuntz et 
al., 1998b; Langenbach et al., 1998; Patnaik 1990). Metastases are commonly 
found in the lungs and may also be found in additional bones and/or other soft 
tissue sites e.g. ribs, liver, spleen (Brodey & Riser 1969; Langenbach et al., 
1998; Spodnick et al., 1992). 
 
3.1.2 The canine TP53 gene 
The development of canine and human OS is linked to alterations in a number of 
genes (previously described in 1.1.3.1), with a high prevalence of aberrations in 
TP53 (Johnson et al., 1998; Kirpensteijn et al., 2008; Tang et al., 2008). Canine 
TP53, assigned to chromosome 5 consists of 11 exons and 10 introns, similar to 
human TP53 (Guevara-Fujita et al., 1996; Kraegel et al., 1995; Veldhoen & 
Milner 1998). Several cytogenetic aberrations at the TP53 locus (17p13.1) have 
been reported in human OS samples (Kansara & Thomas 2007). Recently, Thomas 
et al., (2009) observed a range of frequently occurring chromosomal copy 
number imbalances in canine OS, with both gains and losses observed in TP53 
(Thomas et al., 2009). 
The first exon of canine TP53 is untranslated and the first intron is possibly 
large, while exons 2-11 are coding exons. The gene transcript is spliced to 
produce a 2.2-2.5kb mRNA. The full length canine TP53 is 381 in length 
(Veldhoen & Milner 1998) and displays strong sequence homology with TP53 Chapter 3 ~ Role of TP53 in Canine OS 
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identified in other vertebrates, e.g. 78.4% human TP53 (393 ) (Zakut-Houri et 
al., 1985) and 86.3% feline p53 (386 ) (Okuda et al., 1993). Veldhoen and 
Milner (1998) proposed that the difference in length between canine and human 
TP53 might be due to the deletion, during evolution, of amino acid residues 61-
79, located within the proline rich region of canine TP53 (Veldhoen & Milner 
1998). However, they were unable to identify the precise deletion (Veldhoen & 
Milner 1998). Between exons 5 and 8 of TP53, the canine sequence approaches 
100% homology with the human sequence, this region encompassing 4 of the 5 
evolutionary conserved domains II to V (Kraegel et al., 1995; Soussi & May 1996; 
Veldhoen & Milner 1998). This region, includes the majority of mutations 
identified in human (IARC TP53 Mutation Database R13 release, November 2008 
(Petitjean et al., 2007b) and canine neoplasms, including OS (McIntyre et al., 
1994; Setoguchi et al., 2001b; Toguchida et al., 1992; Veldhoen et al., 1999). 
PCR and DNA sequence analysis, is regarded as a robust and precise method for 
mutation detection (Cheah & Looi 2001; Osuna & de Alava 2009; Petitjean et al., 
2007b), and has been employed to determine the presence of TP53 alterations in 
human OS (Overholtzer et al., 2003) and various canine tumours (Muto et al., 
2000; Nasir et al., 2001). 
 
3.1.3 Summary 
The development of OS, in both humans and dogs, is thought to be linked to 
alterations in a number of genes, in particular, TP53. The majority of TP53 
mutations identified in OS samples from human and canine patients are located 
in exons 5-8. Samples, where possible, were taken from the tumour, metastases 
(if detected) and normal tissues of the dogs diagnosed with OS at Glasgow 
University Veterinary School (GUVS), and exons 5-8 of TP53 were analysed by 
PCR and direct DNA sequence analysis. The main aims of this study were to 
analyse the site incidence of canine OS diagnosed at GUVS and to extend data on 
TP53 mutations in canine OS. 
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3.2 Materials & methods  
3.2.1 Canine osteosarcoma at Glasgow University Veterinary School 
The numbers and locations of canine OS, at GUVS either by case referral and/or 
by the histopathology diagnostic service and recorded from January 1986-
September 2001, were retrieved from GUVS histology report database. Tumour 
biopsies were performed on 4 of 8 canine OS cases presented at GUVS from 
September 1998-September 2001, with normal tissue samples also being 
removed from 2 of the 4 dogs. A biopsy of normal lung tissue was obtained from 
a healthy dog as a control. Tissue was cut into approximately 1 cm
3 pieces, 
placed into labelled 5ml bijoux tubes, snap frozen in liquid nitrogen and stored 
at -70
oC. Clinical case records were available for 3/4 dogs with OS (Table 3.1). 
These 3 dogs, 2 female and 1 male, were all large breed dogs (Vizsla Hungarian, 
Rottweiler and German Short-haired Pointer) and weighed over 18kg. The mean 
age of the dogs was 2.7 years (range: 1-6 years). All 3 dogs had primary OS in 
appendicular sites, in 2 the distal radius and the third, the proximal tibia and in 
2 dogs, metastases were found. 
 
3.2.2 Extraction of DNA from frozen tissue samples  
Approximately 50mg of frozen tissue sample were finely minced and 2ml lysis 
buffer (Appendix A) added and mixed using a vortex. The mixture was incubated 
at 55
oC for 2 hours and if sufficient digestion had not occurred, at 37
oC 
overnight. Following incubation, 1ml of each of phenol, chloroform and 
isoamylalcohol were added to the digested material. The mixture was then 
vortexed and centrifuged for 10 minutes at 489 x g. The aqueous layer was 
removed, transferred into a clean tube and 2ml chloroform added. The mixture 
was then vortexed and centrifugation repeated as before. The top aqueous layer 
was again removed, transferred into a fresh tube and 200l 3M sodium acetate 
(pH 5.2) and 4ml cold 100% ethanol added. The mixture was stored at -20
oC for 
at least 1 hour, or overnight, to precipitate DNA. DNA was pelleted by 
centrifugation at 4
oC for 10 minutes at 17900 x g. The supernatant was removed, 
the pellet washed with 1ml 70% ethanol and centrifuged as before. The ethanol 
was then decanted and the DNA air-dried for 10 minutes before dissolving in 50l Chapter 3 ~ Role of TP53 in Canine OS 
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TE buffer (additional TE buffer was used if the DNA did not dissolve after 5 
minutes) at RT for at least 15-20 minutes. The DNA was quantified and its purity 
assessed by spectrophotometry (2.2.4.1) and quality determined by gel 
electrophoresis (2.2.2). DNA was stored at -20
oC and thawed on ice when 
required. 
  
3.2.3 DNA sequence analysis of TP53 in canine osteosarcoma 
PCR (2.2.1) was carried out to enable the DNA sequence analysis of exons 5-8 of 
TP53 from DNA samples prepared from each of the 7 tissue biopsies removed 
from the 4 dogs with OS and the normal tissue biopsy extracted from the healthy 
dog. The PCR products were purified if required (2.2.3), quantified by gel 
electrophoresis (2.2.4.2) and sequenced (2.2.5).   
The oligonucleotide primers used in the PCR and sequencing reactions (Figure 
3.1) were designed from a partial DNA sequence of the canis familiaris TP53 
(GenBank Accession number U62133). Each PCR and sequencing reaction was 
repeated in triplicate. The nucleotide sequences of each PCR product were 
compared, manually and with the GCG package, to 10 complete or partial canine 
wild-type TP53 nucleotide sequences from GenBank for exons 5-8 (Accession 
numbers U62133, U51857, L27630, NC_006587, S77819, L37107, AF159062, 
DN444655, AF060514 and AB020761). Sequence differences between the 7 DNA 
samples, control DNA sample and exons 5-8 in the 10 published wild-type TP53 
sequences were recorded.  
 
 
Dog  Case no.  Clinical details  Date first presented  Treatment  Outcome  Biopsy  Sample no. 
      @ GUVS         
1  136964  18.5kg 1 year old female Vizsla Hungarian   01/05/1999  Amputation  Euthanized 2 weeks  Lung metastasis  1 
    Primary appendicular OS affecting proximal tibia of    and cisplatin after limb amputation Lymph node metastasis  2 
    right hindlimb. Radiological evidence of pulmonary     therapy        
    and lymph node metastases.              
2  Unknown Unknown - Primary OS  07/08/2000  Unknown  Unknown  Primary OS  3 
3  138398  56kg 6 year old female neutered Rottweiler   04/11/1999  None  Euthanatized  Primary OS  4 
    Primary appendicular OS affecting distal radius of left          Normal kidney  5 
    forelimb. No radiological evidence of metastasis,             
    however post-mortem report indicated metastases in              
    lungs, nodular hyperplasia of liver and spleen and a              
    hyperplastic draining lymph node.              
4  141572  28.3kg 1 year old male German Short-haired Pointer   17/01/2001  Amputation  Still alive 1 yr later  Primary OS  6 
      Primary appendicular OS affecting distal radius of     and cisplatin   Normal muscle  7 
      right forelimb (25.5kg after amputation). No    therapy         
      radiological evidence of pulmonary metastasis.                
 
Table 3.1: Clinical case details of dogs with OS presented at Glasgow University Veterinary School (GUVS), from which biopsies were 
obtained, DNA extracted and TP53 sequence analysed.  
 
 
Primer  Primer Sequence (5′ --> 3′ orientation)  Tm  Location (nts)  Reaction 
P53 704u  tga cct gtc cat ctg tcc tt  57  714-733  PCR & Seq 
P53 941u  gct aca gat ggg aca agg ct  59  941-960  Seq 
P53 1272u  act gag gct gat aga cta ca  55  1272-1291  Seq 
P53 1920r  atc atg cct gat gct caa cc  57  1901-1920  PCR & Seq 
 
Figure 3.1: Details of the oligonucleotide primers used in the PCR and Sequencing (Seq) reactions designed from a partial canine TP53 
DNA sequence (GenBank Accession number U62133): A, region of canine TP53 DNA sequence able to be analysed with each of the 4 
sequencing primers. Red arrows indicate forward primers and green arrow indicates a reverse primer. Size, in base pairs (bp), and 
location of exons 5,6 7 and 8 within the nucleotide sequence of GenBank Accession number U62133 are displayed (location in 
parentheses); B, Sequence of each primer, annealing temperature (Tm) and nucleotide (nts) location within the sequence of GenBank 
Accession number U62133 are tabulated. Forward primers are indicated by „u‟ at end of primer name and reverse primer by „r‟.  
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3.3 Results 
3.3.1 Incidence of canine osteosarcoma by site  
132 OS cases, obtained from the GUVS histology report database, were grouped 
into 26 defined and 8 non-defined sites. Defined sites were separated into 3 
main locations, appendicular, axial and extraskeletal (Table 3.2); unfortunately 
sites of metastatic OS could not be identified in this database. The number of OS 
situated in the appendicular locations (n=51, 38.7%) is slightly greater than those 
in the axial sites (n=48, 36.4%). The extraskeletal locations (n=25, 19.15%) 
represent the lowest proportion of OS cases. The non-defined sites account for 8 
(6.1%) of the 132 cases.       
Of the 51 appendicular tumours, approximately twice as many OS were 
diagnosed in the forelimbs (n=27) than the hindlimbs (n=13). The 4 major 
weight-bearing bones, radius (plus ulna), humerus, tibia and femur, accounted 
for 51% (n=26) of the OS originating in the appendicular sites (19.7% of the 132 
cases). Of the 48 OS diagnosed in 12 axial sites, 52.1% (n=25) were located in the 
maxilla & mandible. The remaining 23 OS were distributed between 11 other 
sites. Of the 25 OS diagnosed in 11 extraskeletal sites, 56% (n=14) were located 
in the mammary glands. Overall, the site in dogs most commonly diagnosed with 
OS at GUVS was the maxilla & mandible (n=25, 18.9%), followed by the 
mammary glands (n=14, 10.6%), radius & ulna (n=11, 8.3%) and the scapula (n=7, 
5.3%). 
 
3.3.2 DNA sequence analysis of TP53 in canine osteosarcoma 
All samples generated PCR products of the expected size, ~1140 bp, revealing the 
absence of major gene deletions/insertions. DNA sequence analysis indicated that 
there were no disparities in the nucleotide sequences for TP53 exons 5-8 between 
each of the 5 tumour DNA samples and the 3 normal tissue DNA samples. 
The alignment of the control DNA sequence with exons 5-8 of the 10 nucleotide 
sequences accessible in Genbank are summarized in Table 3.3 and displayed in 
Appendix D. The control DNA sequence is most similar to the sequences in 
GenBank Accession numbers U51857 and NC_006587, as it only had 1 sequence Chapter 3 ~ Role of TP53 in Canine OS 
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difference with each of these Genbank sequences. In contrast, the control DNA 
sequence was most different to GenBank Accession number U62133 as 6 
sequence differences were found. A total of 11 nucleotide sequence differences 
were observed between exons 5-8 of the published sequences, 5 in exons and 6 
in intronic sequences. 6 of the 11 differences, (located in exon 5, intron 7 and 
exon 8 (canine codons 294-295)), are between the sequence of GenBank 
Accession number U62133 and the sequences of the remaining 9 GenBank 
Accession numbers. No differences were identified between the sequences of 
exons 5-8 in GenBank Accession numbers NC_006587, S77819, L37107, AF159062, 
AF060514 and AB020761. Chapter 3 ~ Role of TP53 in Canine OS 
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Appendicular Site  No. cases  % Appendicular cases   % Total cases  
Scapula  7  13.73  5.3 
Humerus  6  11.76  4.55 
Radius & Ulna  11  21.57  8.33 
Carpus  3  5.88  2.27 
Hock  3  5.88  2.27 
Femur  4  7.84  3.03 
Stifle  1  1.96  0.78 
Tibia  5  9.8  3.79 
Foot  4  7.84  3.03 
Leg (not defined)  7  13.73  5.3 
Sub-total  51  99.99  38.65 
Axial Site  No. cases  % Axial cases   % Total cases 
Sternum  3  6.25  2.27 
Ribs  5  10.42  3.79 
Spine  6  12.5  4.55 
Pelvis  1  2.08  0.78 
Skull  4  8.33  3.03 
Maxilla & Mandible  25  52.08  18.94 
Nasal Cavity & Sinus  4  8.33  3.03 
Sub-total  48  99.99  36.39 
Extraskeletal Site  No. cases  % Extraskeletal cases   % Total cases  
Trachea  1  4  0.78 
Axilla  2  8  1.52 
Lung  1  4  0.78 
Lymph node  1  4  0.78 
Pancreas  1  4  0.78 
Mammary gland  14  56  10.61 
Gastric  1  4  0.78 
Soft tissue (subcutaneous, perianal) 3  4  2.27 
Muscle  1  4  0.78 
Sub-total  25  100  19.15 
Non-defined site  8  -  6.06 
Total  132  -  100.25 
 
Table 3.2: Incidence of OS cases at Glasgow University Veterinary School, from 
January 1986 - September 2001, categorized into appendicular, axial and 
extraskeletal sites. N.B. Sites of metastatic OS could not be identified. 
  
 
                       Nucleotide Sequence Differences             
Location     Exon 5  Intron 5  Exon 6  Intron 6  Exon 7  Intron 7  Intron 7  Intron 7  Intron 7  Exon 8  Exon 8 
Canine Codon   113-114  -  198  -  215  -  -  -  -  259  294-295 
Equivalent to Human Codon  126-127  -  210  -  227  -  -  -  -  271  306-307 
Nucleotide alteration  3bp del  1bp del  AAC --> TAC  1bp sub  TCT --> TTT  1bp del  1bp ins  1bp ins  2bp RA  GAG --> GAA  2bp del 
      ACT  G pres/abs  A:T --> T:A  A/G  G:C --> A:T  A  G  G  GA --> AG  G:C --> A:T  AG 
Amino acid substitution  FS  -  Asn --> Tyr  -  Ser --> Phe  -  -  -  -  Glu --> Glu (sil)  FS 
          TV    TS          TS   
Control DNA Sequence  X  G pres  A  A  C  No del  No ins  No ins  No RA  G  AG del 
        229bp  332bp  464bp  606bp  749bp  814-815bp  824-825bp  846-847bp  1002bp  1106-1107bp 
   U62133  ACT del  G abs  A  G  C  A del  G ins  G ins  AG  G  AG del 
      743-744bp  972-973bp  1075bp  1207bp  1349bp  1491-1492bp  1555bp  1566bp  1588-1589bp  1744bp  1848-1849bp 
   U51857  X  G pres  A  A  C  No del  No ins  No ins  No RA  A  X 
        204bp  307bp  439bp  581bp  724bp  787-788bp  797-798bp  819-820bp  975bp   
   L27630  X  G abs  T  G  T  X  X  X  X  X  X 
        117-118bp  220bp  352bp  494bp             
   NC_006587  No del  G pres  A  A  C  No del  No ins  No ins  No RA  G  No del 
      1099-1101bp  1331bp  1434bp  1566bp  1708bp  1851bp  1914-1915bp  1924-1925bp 1946-1947bp  2102bp  2207-2208bp 
GenBank   S77819  No del  X  A  X  C  X  X  X  X  G  No del 
Accession     266-268bp    520bp    572bp          705bp  810-811bp 
Number  L37107  No del  X  A  X  C  X  X  X  X  G  No del 
      54-56bp    308bp    360bp          493bp  598-599bp 
   AF159062  No del  X  A  X  C  X  X  X  X  G  No del 
      24-26bp    278bp    330bp          463bp  568-569bp 
   DN444655  No del  X  X  X  X  X  X  X  X  X  X 
      472-474bp                     
   AF060514  No del  X  A  X  C  X  X  X  X  G  No del 
      354-356bp    608bp    660bp          793bp  898-899bp 
   AB020761  No del  X  A  X  C  X  X  X  X  G  No del 
      384-386bp    638bp    690bp          823bp  928-929bp 
Table 3.3: Summary of the nucleotide sequence differences between the control TP53 DNA sequence (normal canine lung tissue) with exons 5-8 in the 10 canine wild-type TP53 
sequences accessible in GenBank (U62133, U51857, L27630, NC_006587, S77819, L37107, AF159062, DN444655, AF060514, AB020761). „Equivalent to Human Codon‟, according to 
GenBank Accession number X54156; 'X', difference is not able to be analysed; „del‟, deletion; „ins‟, insertion; „sub‟, substitution; „pres‟, present; „abs‟, absent; „sil‟, silent; „RA‟, 
rearrangement; „FS‟, frameshift; „TS‟, transition; „TV‟, transversion. Chapter 3 ~ Role of TP53 in Canine OS 
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3.4 Discussion 
3.4.1 Locations of canine osteosarcoma 
The locations of 132 cases of canine OS, retrieved from the GUVS histology 
report database, were categorized into appendicular, axial and extraskeletal 
regions. Overall, it was determined that the most commonly affected region was 
the appendicular area, of which, the majority originated in the forelimbs 
followed by similar numbers occurring in the hindlimbs and non-defined regions 
of the leg or foot, then axial sites and the least affected, extraskeletal 
locations. In general, these findings are in agreement with those previously 
published (Brodey & Riser 1969; Langenbach et al., 1998; Loukopoulos & 
Robinson 2007; Ru et al., 1998; Spodnick et al., 1992). It was observed that 
approximately twice as many OS were diagnosed in radius/ulna and humerus of 
the forelimbs to the femur and tibia of the hindlimbs. It is generally accepted 
that OS occur most frequently in these forelimb and hindlimb bones as they are 
the 4 major weight-bearing bones, with forelimbs being twice as affected as 
hindlimbs (Brodey 1979). Hence, multiple episodes of minor trauma and injury to 
these bones whilst they are growing may result in DNA damage, which could 
subsequently lead to the development of OS (Dernell et al., 2007; Tjalma 1966). 
It was also seen that the axial sites most often diagnosed with OS were the 
maxilla & mandible followed by ribs and in the extraskeletal sites, OS were 
primarily found in the mammary glands. This concords with the locations 
previously described in the literature (Brodey & Riser 1969; Heyman et al., 1992; 
Jongeward 1985; Langenbach et al., 1998).  
One main distinction found between this study and those previously published 
was that the total percentages of OS diagnosed in the appendicular, axial and 
extraskeletal regions were different. In this study, the OS located in 
appendicular regions are ~50% lower, whereas the incidence of axial and 
extraskeletal OS are ~2 and 3-fold higher. This is likely to be due to GUVS 
possessing a biased population as a result of its key role as a referral/diagnostic 
centre. Veterinarians at local practices are more likely to biopsy a tumour at an 
axial/extraskeletal site than one at an appendicular location due to the greater 
uncertainty of the clinical diagnosis. In addition, the GUVS histology report Chapter 3 ~ Role of TP53 in Canine OS 
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database grouped together all diagnosed OS, so that sites of primary OS could 
not be distinguished from metastatic sites. For example, metastases to the lungs 
are more frequently reported than primary extraskeletal OS in the lung (Brodey 
& Riser 1969; Kuntz et al., 1998b; Langenbach et al., 1998). 
To the best of my knowledge, the only publication reporting the site incidence 
of canine OS in the UK across all breeds is by Dobson et al., 2002 (Dobson et al., 
2002) at 57 cases/100000 dogs/year (confidence interval range: 44-70). The 
majority of studies described in the literature were carried out in the U.S.A., 
Netherlands, Australia and New Zealand. However, the study by Dobson and 
colleagues, utilizes incidence rates from an insured dog population (Dobson et 
al., 2002). Therefore, to gain a more accurate representation of the site 
incidence of OS in the UK canine population as a whole, attempts should be 
made in future studies to obtain information from numerous veterinary practices 
and the remaining 5 university veterinary hospitals in the UK. 
 
3.4.2 Analysis of TP53 in canine osteosarcoma  
3.4.2.1 Case studies 
Only 8 of the 132 cases of canine OS diagnosed at GUVS between January 1986 – 
September 2001, were case referrals, as the majority were diagnosed by the 
histopathology diagnostic service.  Of these 8, samples were only obtained from 
4 dogs, due to weekend admissions and owner permission. Unfortunately, the 
complete case records (including age, sex, breed, weight, site of primary OS and 
presence and site of metastases) for the remaining 124 cases were not accessible 
from the histology report database used to retrieve the OS sites of these cases. 
Thus, comparisons to previously published reports are limited due to the small 
sample size in this study. Any future investigations would require the complete 
case details for each dog to be recorded to enable more detailed comparisons to 
occur. 
However, a number of observations can be made between this study and those 
previously published. Clinical case records were available for 3 of 4 dogs from 
which samples were taken. All 3 were large-breed dogs (Rottweiler, German 
Short-haired Pointer and Vizsla Hungarian) which agree with the findings that Chapter 3 ~ Role of TP53 in Canine OS 
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large/giant breeds are more likely to be affected by OS than small breed dogs 
(Ru et al., 1998; Tjalma 1966). The sites of OS diagnosed in the 3 dogs were in 
the radius and tibia, 2 of the 4 major-weight bearing bones, which is in 
agreement with previous studies, as described in 3.4.1. Metastases were found 
in lungs and lymph nodes, which have also been previously reported (Brodey & 
Riser 1969; Hillers et al., 2005; Langenbach et al., 1998; Spodnick et al., 1992). 
Appendicular OS have also been previously reported in Rottweilers and Pointers 
(Jongeward 1985; Rosenberger et al., 2007). In addition, these 3 dogs each 
weighed over 18kg which correlates with the observations that the risk of OS 
increases as weight increases (Ru et al., 1998; Tjalma 1966). In this study, 2 
dogs were females and 1 was male. There is disagreement between published 
literature as to whether males are more affected than females or vice versa or 
no sex-related differences exist (Egenvall et al., 2007; Jongeward 1985; Merlo et 
al., 2008; Priester & McKay 1980; Ru et al., 1998). In addition, conflicting 
evidence exists regarding neutering increasing or decreasing the risk of OS and 
the age at which the dog is neutered due to hormonal changes altering skeletal 
homeostasis (Cooley et al., 2002; Priester & McKay 1980; Ru et al., 1998). Thus 
in future studies, information should be recorded regarding neutering status and 
if so, at what age the dog was neutered. In this study, 1 dog is 6 years old and 2 
dogs are 1 year old, and although in the literature, generally middle-aged to 
older dogs are reported to be afflicted (Langenbach et al., 1998), there is a 
small peak in age incidence at 12-24 months (Jongeward 1985). Owen and Steel 
(1969) have also reported that the significance of age statistics is doubtful in a 
series in which there are many breeds of dogs with widely differing life 
expectancies and so age incidence figures may also be probably more significant 
when each breed is considered separately (Owen & Steel 1969).  
 
3.4.2.2 DNA sequence analysis of TP53  
DNA sequence analysis revealed that there were no differences in the nucleotide 
sequences for TP53 exons 5-8 between the 7 DNA samples (3 primary OS, 2 
metastases and 2 normal tissues) with the control sample. This is probably as a 
result of a small sample number. However, several studies in the literature have 
reported the detection of TP53 mutations in exons 5-8 in 23-100% canine OS Chapter 3 ~ Role of TP53 in Canine OS 
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studied (Johnson et al., 1998; Mendoza et al., 1998; Setoguchi et al., 2001b; 
Van Leeuwen et al., 1997). Hence, the absence of TP53 mutations in the 5 OS 
samples analysed in this study is well within statistical probability. The majority 
of the reported mutations are not only missense mutations, the most commonly 
occurring type of mutation in human TP53, but also located in evolutionary 
conserved domains (II, IV, and V) (Petitjean et al., 2007b). In particular, 4 of the 
codons affected (248*, 249, 273* and 282*), of which 3 contain CpG dinucleotide 
sites (*) belong to the 6 most commonly mutated codons in human TP53 
(„hotspots‟) for somatic single base substitutions (IARC TP53 Database, R13 
release, November 2008 (Petitjean et al., 2007b)). The effects of TP53 
mutations on p53 protein function p53 are previously described in 1.3.3.2.  
The frequency of TP53 mutations detected in the published canine OS studies, is 
comparable to 18-100% found in human OS and some of the mutations reported 
in canine OS have also been reported to be altered in human OS e.g. „hotspot‟ 
codons 273 and 282 (Iavarone et al., 1992; McIntyre et al., 1994; Miller et al., 
1996; Overholtzer et al., 2003; Toguchida et al., 1992).  
11 nucleotide sequence differences were noted between the 7 GenBank 
sequences, NC_006587, S77819, L37107, AF159062, DN444655, AF060514 and 
AB020761, with GenBank sequences, U62133, U51857 and L27630. These 
differences are probably due to the replication error rate of Taq DNA 
polymerase, although some may be polymorphisms or even mutations (Chu et 
al., 1998). Indeed, the codons involved in 3 of these differences, canine 113-
114, 215 and 259 (equivalent to codon‟s 126-127, 227 and 271 in human TP53, 
respectively (GenBank Accession number X54156)), have been found to be 
altered in canine and/or human OS samples (McIntyre et al., 1994; Setoguchi et 
al., 2001b; Toguchida et al., 1992). In particular, canine codon‟s 113 and 259 
are located in evolutionary conserved domains, II and V, respectively.  
These findings indicate the involvement of TP53 in the tumourigenesis of canine 
OS in a manner comparable to that of human OS, as there are many sites within 
TP53 that are susceptible to alterations and that in both species, mutations in 
the conserved domains of TP53 appear to play a significant role in OS. Although 
no TP53 mutations were detected in the canine OS investigated in this study, Chapter 3 ~ Role of TP53 in Canine OS 
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this study fits within the range of published data given only 5 samples were 
analysed from 4 dogs.  
 
3.4.2.2.1 Mutations outside of TP53 exons 5-8  
Although the small sample size is likely to be the main reason for the lack of 
TP53 aberrations detected in this study, another potential cause could be that 
mutations were present but located outside of exons 5-8. Even though it is 
generally accepted that very few alterations in TP53 occur outside of these 4 
exons, over 80% of TP53 mutational studies have limited their investigations to 
the analysis of only exons 5-8 (Soussi & Beroud 2001). In addition, the small 
number of studies published regarding TP53 mutations in canine OS, also 
possessed small sample sizes. In particular, two studies which have examined 
the entire TP53 coding region found that of the mutations identified, 42-56% 
were located in exons 5-8, whilst the remaining were located outside this region 
(Kirpensteijn et al., 2008; Setoguchi et al., 2001b). Additionally, numerous 
research groups have reported that between 4-33% of mutations in TP53 they 
found in human OS were situated outside of exons 5-9 (Toguchida et al., 1992; 
Overholtzer et al., 2003). Thus a future improvement to this study, as the canine 
genome sequence has now been published (GenBank Accession Number 
NC_006587; (Lindblad-Toh et al., 2005)), would be to screen, at minimum, exons 
4-10, including the splice junctions, as recommended by the IARC TP53 Mutation 
Database R13 release November 2008, to reduce the number of missed mutations 
to an acceptable level (Petitjean et al., 2007b).  
 
3.4.2.2.2 Methods of mutational analysis  
Another explanation for the difference in the frequency of TP53 mutations 
observed in this study to that of previous studies might be due to the use of 
different methodologies.  
Wedge sections of tissue were removed from the OS analysed in this study by a 
pathologist, from which, DNA was extracted from the wedge tip. False negative Chapter 3 ~ Role of TP53 in Canine OS 
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results may still have arisen from tumour heterogeneity and/or sampling error, 
e.g. normal stromal contamination (Thomas et al., 2006). 
The PCR and sequencing primers employed in this study were designed using the 
GenBank sequence U62133. This partial canine TP53 DNA sequence has also been 
used for the design of primers in several published TP53 mutational 
investigations (Chu et al., 1998; Muto et al., 2000; Nasir & Argyle 1999; Stoica et 
al., 2004). It has also been used as the reference TP53 sequence in the study by 
Stoica et al., (2004), for comparison of sequences from tumour samples.  
PCR and DNA sequence analysis is the gold standard for the detection of 
mutations in genes (Osuna & de Alava 2009), especially when performed in 
triplicate as in this study, and has been used to successfully identify TP53 
mutations in human OS (Overholtzer et al., 2003) and various canine tumours 
(Muto et al., 2000; Nasir et al., 2001). Unfortunately its main limitation is that it 
can only detect mutations when the fraction of mutated alleles is greater than 
~20% (Collins et al., 1989; van Ommen et al., 1999). Hence, in future TP53 
mutational studies, microscopic assessment of each tumour sample should be 
performed by a pathologist and if necessary, manual/laser microdissection 
carried out prior to PCR and DNA sequence analysis (Takahashi et al., 1995). IHC 
should also be carried out as post-translational aberrations may occur to TP53, 
resulting in TP53 accumulation in the absence of sequence mutations (Sjogren et 
al., 1996). IHC is the most extensively reported method for determining the 
presence of TP53 accumulation in a wide variety of canine and human tumour 
samples, including OS (Loukopoulos & Robinson 2007; Pakos et al., 2004; Sagartz 
et al., 1996). 
High through-put TP53 mutational screening including large population-based 
studies, can now be performed using DNA microarrays and single-nucleotide 
polymorphism (SNP) assays, and more recently high-resolution melting assays 
(Garritano et al., 2009; Tennis et al., 2006). Kits are also commercially available 
designed specifically to examine the entire TP53 coding sequence in human 
tumours. For example, the „GeneChip p53 Assay‟ (Affymetrix), consists of more 
than 50000 unique probes to analyse TP53 exons 2-11, includes more than 400 
mutations (Affymetrix 2001), and has been successfully used to analyse human 
tumours from a variety of tissue types e.g. breast (Tennis et al., 2006), bladder Chapter 3 ~ Role of TP53 in Canine OS 
 
96 
(Wikman et al., 2000), and OS (Chen et al., 2004). Wikman et al., (2000) also 
found that the „GeneChip p53 assay‟ could detect as little as 1% mutated DNA 
(Wikman et al., 2000). Hence, similar studies in canine OS warrant investigation.  
 
3.4.2.2.3 Non-TP53 alterations in osteosarcoma 
Another putative reason for the lack of mutations detected in TP53 in the OS 
analysed in this study may be due to the presence of non-TP53 aberrations. 
Alternative mechanisms for the inactivation of TP53 are described in 1.3.3, 
which were identified after a number of tumours were reported to no longer 
possess wild-type TP53 function, even though no mutations in TP53 could be 
observed (Leach et al., 1993; Thomas et al., 1999). Frequent chromosomal 
aberrations have been observed on numerous loci, besides TP53 locus, in canine 
and human OS samples (Tang et al., 2008; Thomas et al., 2009), thereby 
indicating that more than 1 gene is altered in OS. Indeed, 14 loci found to 
contain either copy number gain or loss in >30% canine OS studied were located 
in 8 different chromosomes which included sites for 5 major cancer-related 
genes, PTEN, MYC, HRAS, WT1 and KIT (Thomas et al., 2009). Alterations in 
several TSG, oncogenes, proteinases, growth factors and hormone signalling 
systems have also been documented, as previously described in 1.1.5.2, in 
addition to TP53 that may also be involved in the pathogenesis of canine OS. In 
particular, amplification of the MDM2 gene or overexpression of the MDM2 
protein can be detected, whilst TP53 remains wild-type. It is generally accepted 
that MDM2 and TP53 mutations are mutually exclusive, suggesting that either of 
these 2 mechanisms may inactivate TP53 (Tang et al., 2008).  
It would therefore be worthwhile in any future canine OS mutational studies, to 
analyse, in addition to TP53, chromosomal aberrations and expression of these 
other genes. This could be achieved using aCGH, cDNA microarrays and next-
generation sequencing. For example, canine gene expression microarrays are 
now commercially available (Affymetrix 2005; Agilent Technologies 2006; 
Holzwarth et al., 2005) and integrated molecular profiling using whole-genome 
analysis of DNA copy number and gene expression analysis of human OS 
(Sadikovic et al., 2008) has been reported. Thomas et al., (2008) have recently Chapter 3 ~ Role of TP53 in Canine OS 
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published the development of a comprehensive 1-Mb resolution BAC microarray 
which also enables the direct translation of dog tumour-associated copy numbers 
into DNA sequence, revealing the consequences of genomic aneuploidy on gene 
dosage (Thomas et al., 2008). This array has yet to be used to analyse canine OS 
and will no doubt provide valuable information once this has been performed.  
Breed agencies and support organizations are presently involved in tissue 
archiving with a goal of genetic screening for susceptibility prediction to OS as a 
tendency for familial predisposition may exist in some pure-breeds (Lord et al., 
2007; Phillips et al., 2007; Urfer et al., 2007). Whether these are true „cancer 
families‟ due to a genetic defect, for example, the Li-Fraumeni syndrome in 
humans which has a known aberration in TP53 (Kansara & Thomas 2007), has still 
to be determined.  
Hence, molecular events involved in canine OS tumourigenesis can be elucidated 
more quickly with the increasing widespread use of molecular-based 
technologies and the publication of the entire canine genome sequence. The 
frequency and distribution of such molecular changes are essential to establish 
not only the molecular aetiology of the disease, but also improve understanding 
of the basic biology of the tumour, such that management and treatment may be 
improved. 
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4.1 Introduction 
TP53 is functionally involved in tumour suppression, cell cycle control and 
apoptosis and is mutated in 40-80% of human and canine cancers, making it the 
most frequently altered and studied gene in canine and human neoplasia. In 
particular, aberrations in TP53 are a common occurrence in canine OS (Johnson 
et al., 1998; Mendoza et al., 1998; Setoguchi et al., 2001b; Van Leeuwen et al., 
1997). It is anticipated that a better understanding of the biology of TP53 can be 
exploited to develop new and more effective therapeutic strategies for treating 
cancer, as well as better diagnostic and prognostic tools. Hence, TP53 is an 
attractive candidate in the development of a targeted suicide gene therapy 
strategy for OS. 
 
4.1.1 TP53 gene therapy strategies  
A number of TP53 gene therapy approaches have addressed the problem of 
overcoming the vast number of TP53 mutations or inactivation of wild-type TP53 
present in cancer. These approaches include, introducing an exogenous wild-
type TP53 to replace the defective TP53, which can also be carried out in 
combination with conventional DNA-damaging agents or other gene therapy 
strategies e.g. expression of p14ARF, p33ING1, p16, IL-2 and GMCSF or inhibition 
of telomerase, cyclin D1, PCNA and clusterin genes (Almazov et al., 2007); TP53 
antisense, ribozymes and RNAi that reduce mutant TP53 expression and restore 
wild-type TP53 expression (Watanabe & Sullenger 2000); enhancing or 
reactivating transcriptional function to mutant TP53 by small synthetic 
molecules e.g. PRIMA-1, C-terminal peptides, antibodies against the C-terminus, 
and single-chain Fv antibody fragments corresponding to defined TP53 domains 
e.g. CDB3 (Bassett et al., 2008); activation of wild-type TP53 by the inhibition of 
MDM2 with Nutlin-3 (Vassilev et al., 2004); and selective killing of TP53 mutant 
tumours, which includes suicide gene therapy strategies and a TP53-targeting 
oncolytic adenovirus, ONYX-015 (Bischoff et al., 1996; Nemunaitis et al., 2001). 
Although several of these approaches e.g. ONYX-015, are not classed as a gene 
therapy strategy per se, they do utilize the genetic aberrations of tumour cells. 
It is beyond the scope of this introduction to discuss all these approaches, as Chapter 4 ~ TP53 as a Target for Canine OS Gene Therapy 
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there is an extensive amount of literature available, however the aim for all of 
them, is to eliminate tumour cells through the induction of apoptosis. Hence, 
the strategies that will be discussed here are the approaches that have 
undergone the most investigation in canine or human OS, being the delivery of 
wild-type TP53 and its delivery in combination with conventional therapies, and 
those that are also of particular relevance to this study i.e. suicide gene therapy 
systems utilising TP53. 
 
4.1.1.1 Introduction of exogenous wild-type TP53  
The restoration of TP53 function in tumours has been pursued as a promising 
strategy for cancer therapy as its inactivation is advantageous for tumour 
survival. One of the main approaches employed to achieve this purpose, is the 
delivery and expression of exogenous wild-type TP53 in cancer cells and studies 
on more than 100 cell lines derived from many different tumour types have been 
published, using viral and non-viral vectors. The common theme throughout the 
literature is that expression of wild-type TP53 effectively restores suppression of 
growth and proliferation and induction of apoptosis in most cancer cells in vitro 
and in vivo, albeit with reduced efficacy in tumour cells containing wild-type 
TP53 (Tang et al., 2004; Tsuchiya et al., 2000). Additionally, minimal levels of 
toxicity are observed in animal models (Kastan 2007). In particular, cell 
proliferation has been inhibited and apoptosis induced in canine OS cell lines and 
xenografts (Kanaya et al., 2005; Yazawa et al., 2003b). Similar observations 
were also reported in human OS cells in vitro and in vivo (Densmore et al., 2001; 
Hellwinkel et al., 2005; Nakase et al., 2005a).  
Several pre-clinical studies have also importantly shown that normal non-
transformed cells from different tissue types with functional endogenous TP53, 
e.g. fibroblasts, bone marrow cells, and astrocytes, may tolerate the presence 
and expression of low to moderate levels of exogenous wild-type TP53 as their 
levels of proliferation were at most, only minimally affected (Harris et al., 1996; 
Seth et al., 1996). 
Numerous TP53 gene therapy clinical trials have been completed, are ongoing or 
approved in humans with a variety of different cancers, although none as yet Chapter 4 ~ TP53 as a Target for Canine OS Gene Therapy 
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with patients suffering from OS (US National Institutes of Health 2009). 
Encouraging results have been reported in several Phase I and Phase II clinical 
trials carried out in patients with unresectable NSCLC and head and neck 
squamous cell carcinoma (HNSCC), which had failed to respond to conventional 
treatments (Clayman et al., 1998; Swisher et al., 1999). As successful gene 
transfer, low toxicity (<5% incidence of serious adverse advents), evidence of 
apoptosis, reduction in tumour size, disease stabilization and partial and 
complete responses were observed to have occurred in some patients (Clayman 
et al., 1998; Swisher et al., 1999). Furthermore, Phase III clinical trials are 
currently underway with replication-deficient recombinant adenoviral-mediated 
p53 (Ad-p53) gene therapy products, Advexin and SCH 585500, and under more 
intensive investigation in China, is Gendicine (Vazquez et al., 2008) (Table 4.1). 
However, the efficacy of TP53 therapy has been brought into question, as 
clinical studies carried out in lung, bladder, breast and ovarian carcinoma 
resulted in the absence of additional beneficial effects in comparison to 
conventional treatments (Vecil & Lang 2003; Zeimet & Marth 2003). In addition, 
the therapeutic effect of TP53 delivery may be limited due to the majority of 
cancers containing mutant TP53, which possess a dominant negative activity that 
can inactivate the function of exogenous wild-type TP53 (Watanabe & Sullenger 
2000). 
Various methods of TP53 delivery have been used in both experimental cancer 
models and clinical trials. Among them, the use of Ad-p53 is a common 
approach, due to its ability to generate a large viral titre and target a broad 
spectrum of cells (Fujiwara et al., 2000; Wilson 2002). Although, the efficient 
induction of apoptosis in OS cells, following delivery of wild-type TP53, using an 
Ad5-based adenoviral vector, can only be achieved if OS cells express high levels 
of Ad5 receptors (Hellwinkel et al., 2005). Intratumoural and intraperitoneal 
administrations of high titre Ad-p53 have generally proved to be safe and 
efficient with no significant toxicity observed even in repeated subsequent 
injections (Merritt et al., 2001; Wadler et al., 2002; Wen et al., 2003). Induction 
of immune responses by the virus infection may also contribute to the tumour 
shrinkage by Ad-p53 delivery (Carroll et al., 2001). In addition, exogenous TP53 
expression and TP53 target gene activation were detected in clinical trials even 
in the presence of a high titre of anti-adenovirus antibodies in the circulation. Chapter 4 ~ TP53 as a Target for Canine OS Gene Therapy 
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However, the endogenous TP53 status, whether wild-type or mutant, appears to 
be critically decisive to the response of Ad-p53 therapy, where endogenous wild-
type TP53 is associated with reversible cell growth arrest and mutant TP53 with 
apoptosis. Thus ironically, a poorer response and greater resistance to Ad-p53 
therapy is observed in the wild-type TP53 context, due to DNA repair and 
recovery from cell cycle arrest.  
 
Agent 
Stage of 
development  Types of cancers in trials 
Gendicine  Approval in China  Head and neck 
Advexin  Phase I-III  Head and neck, NSCLC, breast, oesophageal, prostate,  
      ovarian, bladder, bronchoalveolar and glioblastoma 
SCH 58500  Phase I-III  Ovarian, lung, bladder and liver 
 
Table 4.1: Clinical trials of recombinant adenoviral-mediated p53 gene therapy 
agents that restore wild-type TP53 function. NSCLC, non-small-cell lung cancer 
(Vazquez et al., 2008). 
 
4.1.1.2 Introduction of exogenous TP53 in combination with standard 
therapeutic modalities  
Inactivation of TP53 is not only involved in tumourigenesis but also in conferring 
resistance to chemo- and radiotherapy and consequently a poor prognosis as 
most of these treatments elicit DNA damage and induce TP53-dependent 
apoptosis in cells (Lowe et al., 1993; Petitjean et al., 2007a). For example, the 
presence of TP53 mutations and accumulation of TP53 may be poor prognostic 
indicators for canine OS (Kirpensteijn et al., 2008; Loukopoulos et al., 2003), as 
previously discussed in 1.1.7.1 and 1.3.3.4. In addition, TP53 gene alterations 
may be associated with decreased survival in human OS patients (Pakos et al., 
2004). Hence, the therapeutic replacement of the wild-type TP53 in combination 
with these conventional modalities has been investigated.  
Preclinical studies have demonstrated that delivery of wild-type TP53 
significantly increases the therapeutic effects of chemotherapy and radiotherapy 
in several different tumour types (Fujiwara et al., 1994; Gallardo et al., 1996; 
Spitz et al., 1996; Xu et al., 2001a). In particular, restoring wild-type TP53 has Chapter 4 ~ TP53 as a Target for Canine OS Gene Therapy 
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been shown to increase sensitivity of human OS cells (Saos-2, p53 null) to 
chemotherapeutic agents, cisplatin (Tsuchiya et al., 2000) and adriamycin (Song 
& Boyce 2001). In addition, after delivery of Ad-p53, the viability of 4 different 
human OS cell lines (3 p53 mutants, 1 p53 null) was reported to decrease with 
an increase in sensitivity to cisplatin and doxorubicin (Ganjavi et al., 2006). 
Furthermore, it has recently been published that upregulating the expression of 
wild-type TP53 in canine OS cells, already possessing wild-type TP53, enhanced 
their sensitivity to radiation at clinically relevant doses and significantly 
decreased their survival in comparison to cells in which TP53 was not 
upregulated (Shiomitsu et al., 2008). However, results reported by Hellwinkel et 
al., (2005), who found that Ad-p53 treatment with cisplatin or doxorubicin, 
increased sensitivity in 2 human OS cell lines, U2OS and Saos-2 cells but not in 3 
other human cell lines studied, K-HOS, MG-63 and SJSA (Hellwinkel et al., 2005).  
In clinical trials, similar to those of wild-type TP53 administered alone, 
conflicting results have been observed with the delivery of wild-type TP53 in 
conjunction with conventional treatments. For example, treatment of Ad-p53 
plus chemotherapy in patients with ovarian cancer and NSCLC was found to 
provide no additional survival benefit over that of chemotherapy alone, although 
NSCLC tumours had significantly decreased in size (Buller et al., 2002; Schuler et 
al., 2001; Wen et al., 2003). In comparison, randomized Phase II trials of 
intratumoural Ad-p53 followed by radiotherapy in patients with HNSCC, 
nasopharyngeal carcinoma and NSCLC, reported significantly improved response 
rates compared to radiotherapy alone (Chen et al., 2003; Swisher et al., 2003; 
Zhang et al., 2003). Phase II and III clinical trials on 135 patients with late-stage 
HNSCC, treated with Gendicine and radiotherapy, showed complete regression in 
64% patients and partial regression in 32%, with no serious side effects observed 
(unknown 2007). Clinical benefit has also been observed in NSCLC patients, 
previously unresponsive to conventional treatments, after Ad-p53 administration 
in combination with cisplatin (Fujiwara et al., 2006; Nemunaitis et al., 2000). 
Advexin, as well as demonstrating a consistent safety profile and clinical 
efficacy as a monotherapy, has also shown additive or synergistic effects in a 
variety of tumour types in combined modality regimens with chemotherapy 
and/or radiotherapy (Senzer & Nemunaitis 2009; unknown 2007).  Chapter 4 ~ TP53 as a Target for Canine OS Gene Therapy 
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Hence, findings from studies in which TP53 therapy has been combined with 
DNA-damaging agents appear encouraging as additional efficacy has been 
observed over TP53 therapy alone and together may interact in synergistic or 
additive ways. Furthermore, no observations of antagonistic interactions 
between TP53 therapy and standard cancer treatments have been reported.  
 
4.1.1.3 Selective killing of TP53 mutant tumours 
Although the restoration of TP53 function has shown promise, there are inherent 
problems, in that TP53 plays a pivotal role in tumour progression and 
tumourigenesis is a multi-step process. Most tumour cells already contain a 
broad spectrum of genetic abnormalities before they become clinically 
apparent; thus it seems likely that corrective gene therapy will not realistically 
be able to produce the required clinical benefit in all tumour types. Hence, gene 
therapy protocols for cancer using non-corrective genes to enhance tumour cell 
killing have occurred, including many suicide gene therapy preclinical and 
clinical studies.  
Surprisingly though, at present, only 2 preclinical studies have been published 
that involve TP53 directly in a suicide gene therapy system. Firstly, Da Costa et 
al., (1996) devised a novel strategy, in which the human TP53 C-terminus, 
employed as a TP53 binding domain, can bind to intact TP53, recruiting the N-
terminus transactivation domain (Da Costa et al., 1996). This can occur, even in 
accumulated TP53, resulting in the transcriptional activation of a toxic gene, 
because in most TP53 mutants, as previously described in 1.3.3.1, only a small 
percentage of mutations are located in the N- and C-termini as the majority are 
found in the central DNA-binding domain (Petitjean et al., 2007b; Zambetti & 
Levine 1993). Thereby, the transactivation domain is generally preserved in TP53 
mutants, enabling the wild-type TP53 C-terminus to be utilized in a gene 
therapy approach that can specifically kill tumour cells possessing accumulated 
TP53. Secondly, Mizumoto and colleagues (2002) published a TP53-mutated 
cancer cell-specific suicide gene therapy strategy using TP53 as a transcriptional 
activating factor (Mizumoto et al., 2002). This strategy used the HSV-TK 
expression system containing the wild-type TP53-specific promoter (p53-SP) and Chapter 4 ~ TP53 as a Target for Canine OS Gene Therapy 
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the Cre/loxP exchange system to specifically induce expression of the HSV-TK 
gene in TP53-mutated cells, whilst in the cells containing wild-type TP53, to 
reduce HSV-TK expression. On addition of GCV, growth inhibition occurred in the 
TP53-mutated cells but not in the wild-type TP53 cells. Thus, enabling the 
selective growth inhibition of cells possessing mutated TP53.  
Two other suicide gene therapy studies have been published, which indirectly 
target TP53 to inhibit the growth of tumour cells possessing mutant TP53 
(Lipinski et al., 2001; Zhu et al., 2000). This was achieved through the 
expression of a suicide gene being placed under the control of heat shock 
protein (HSP) 70 promoter and similar to the study by Mizumoto et al., (2002), 
suicide gene expression was able to be minimized in cells containing wild-type 
TP53, as wild-type TP53 is able to repress HSP70. 
It is the study by Da Costa and colleagues (1996) (Da Costa et al., 1996), which is 
of specific relevance to this study, in that a similar strategy was to be 
investigated as a treatment modality for canine OS, as the canine TP53 C-
terminus was to be utilized instead of the human TP53 C-terminus. Importantly, 
Veldhoen and Milner (1998) had previously shown that the canine TP53 produced 
in vitro recognizes and binds TP53-specific DNA targets derived from p21 and 
GADD45 promoters and to a consensus TP53 binding site (Veldhoen & Milner 
1998). They also reported that canine TP53 associates with oligonucleotides 
representing damaged DNA sites and undergoes proteolytic cleavage similar to 
that described for murine and human TP53; as well as demonstrating that the 
canine TP53 is able to transcriptionally activate a TP53-dependent reporter gene 
in vivo. These results add further evidence to the likelihood that canine TP53 is 
similar, in function as well as structure, to human TP53 and that canine cancer 
may provide a useful model for human TP53 therapy approaches. 
 
4.1.2 Summary  
Since TP53 mutation, as well as wild-type TP53 impairment, is observed in most 
canine and human malignancies, restoring TP53 function by TP53 delivery in 
tumours was the initial approach pursued as a strategy for cancer therapy. TP53 Chapter 4 ~ TP53 as a Target for Canine OS Gene Therapy 
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is also an attractive candidate for gene therapy protocols because it can directly 
elicit apoptosis in cancer cells, possessing both wild-type and mutant TP53, 
without apparent toxicity to normal cells and enhances the therapeutic efficacy 
of conventional therapies. Previously published findings in canine and human OS 
cells suggest that their proliferative ability can be suppressed in vitro and in 
vivo by the restoration of normal TP53 function (Densmore et al., 2001; Kanaya 
et al., 2005; Nakase et al., 2005a; Oshima et al., 2007; Yazawa et al., 2003b). 
However the usefulness of this approach continues to be debated in light of the 
wide range of aberrations found in cancer cells, in that restoring just one gene, 
is unlikely to produce the desired clinical effect. This led to the development of 
several alternative TP53 therapy strategies, including the use of TP53 in a 
suicide gene therapy approach to selectively target and destroy tumour cells. 
However, to the best of my knowledge, none of the clinical trials reported so 
far, involve TP53 in a suicide gene therapy system or have studied the effects of 
TP53 delivery in canine or human OS patients. In addition, none of the cell lines 
utilized in the preclinical TP53 suicide gene therapy studies by Da Costa et al., 
(1996) and Mizumoto et al., (2002), in which growth was inhibited in TP53-
mutated cancer cells, but not in wild-type TP53-producing, were OS (Da Costa et 
al., 1996; Mizumoto et al., 2002).  
The aims of this chapter were two-fold. Firstly, to investigate the effects of 
introducing exogenous wild-type TP53 into 4 canine OS cell lines, D17, CMT3, 
CMT7 and CMT8. This was carried out because the delivery of wild-type TP53 has 
not been previously reported in the CMT3, CMT7 and CMT8 cell lines, only one 
publication to date has reported TP53 gene delivery in D17 cells (Shiomitsu et 
al., 2008), and only 3 other canine OS cell lines have been investigated to date 
(Kanaya et al., 2005; Yazawa et al., 2003b). Thereby, extending data on TP53 
restoration gene therapy in canine OS cells.  
Secondly, and more importantly, to design, construct and analyse the vectors 
required for a TP53-targeted suicide gene therapy strategy, in which the canine 
TP53 C-terminus domain (294-382) was to be utilized. This was performed to 
determine if the transactivation domain of accumulated canine TP53 can be 
recruited to drive, the expression of a luciferase reporter gene in this study and 
ultimately a suicide gene (as described in Chapter 5), via the use of a Lex-DNA Chapter 4 ~ TP53 as a Target for Canine OS Gene Therapy 
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binding domain interacting with its operator site acting as an upstream 
activating sequence, as highlighted in Figure 4.1. Hence, enabling the selective 
targeting of canine OS cells possessing accumulated TP53. The analysis of this 
transcriptional targeting approach was the primary aim of the entire thesis. 
 
 
Figure 4.1: Transcriptional targeting using canine TP53 to initiate tumour cell destruction: (A), LexA DNA Binding Domain (DBD) is fused 
in frame to p53-binding domain (BD) of canine TP53 (C-terminal domain); (B), Production of LexA-p53 protein; (C), LexA-p53 protein 
binds to both accumulated TP53 to recruit its transactivation domain and the LexA operator site (acting as an upstream activating 
sequence, UAS) to be able to drive the expression of the suicide gene. The suicide gene converts the inactive prodrug to the active 
drug, thereby causing cell death. Chapter 4 ~ TP53 as a Target for Canine OS Gene Therapy 
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4.2 Materials & methods 
4.2.1 Optimization Assays  
4.2.1.1 Cell number  
Cells were approximately 80% confluent on the day of transfection (2.2.9), as 
recommended by the manufacturer‟s instructions. For all of the transfections 
performed in this study, the cells were transfected 16-24 hours after placement 
into 96-well plates or 25cm
2 flasks. The canine OS cell lines utilized in this study 
were D17, CMT3, CMT7 and CMT8 and were each cultured and maintained as 
described in 2.1.1.  
The concentration of cells required to achieve 80% confluence for each of the 
four cell lines, was determined by plating out a range of cell concentrations into 
96-well plates in quadruplicate per cell concentration (200 l/well): 
(i), D17: 35000-100000 cells/ml at increments of 5000 cells/ml (35000, 40000, 
45000, 50000, 55000, 60000, 65000, 70000, 75000, 80000, 85000, 90000, 95000 
and 100000); 
(ii), CMT 3: 25000-80000 cells/ml at increments of 5000 cells/ml (25000, 30000, 
35000, 40000, 45000, 50000, 55000, 60000, 65000, 70000, 75000 and 80000);  
(iii), CMT7: 15000-65000 cells/ml at increments of 10000 cells/ml (15000, 25000, 
35000, 45000, 55000, 65000); 
(iv), CMT8: 30000-85000 cells/ml at increments of 5000 cells/ml (30000, 35000, 
40000, 45000, 50000, 55000, 60000, 65000, 70000, 75000, 80000 and 85000). 
   
The percentage of cells confluent at each cell concentration was estimated by 
eye after 24 hours, enabling the concentration of cells required to achieve 80% 
confluence for the D17, CMT3, CMT7 and CMT8 cell lines to be determined. 
 
4.2.1.2 Transfection efficiency 
The „In situ Staining of Cells for -galactosidase (-gal) Activity‟ of the „-
Galactosidase Enzyme Assay System‟ (Promega) protocol was used to determine 
the: optimal amount of plasmid DNA to be transfected; and charge ratio of Chapter 4 ~ TP53 as a Target for Canine OS Gene Therapy 
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transfection reagent (Transfast
TM, Promega) to DNA, for the subsequent 
experimental assays utilising D17, CMT3, CMT7 and CMT8 cells.  
The four cell lines were each cultured and maintained (2.1.1), and 16-24 hours 
prior to transfection occurring, seeded at the appropriate density (as 
determined in 4.3.1.1) per well of a 96-well plate. 50, 100, 150 and 200 ng of 
pSV--Galactosidase control vector (pSV--gal) DNA were each transfected into 
D17, CMT3, CMT7 and CMT8 cells, in quadruplicate. Two charge ratios of 
Transfast
TM to DNA were used: 1:1; and 2:1. 48 hours later the cells were fixed, 
as directed by the manufacturer‟s instructions, using a 0.25% glutaraldehyde 
solution and incubated with the substrate X-gal, at 37
oC for 2-4 hours, until the 
cells were visibly stained blue. The cells were viewed with a light microscope 
(10x magnification) and if the cells retained a normal visual appearance, the 
number of blue stained (transfected) and total number of cells were recorded 
per well. This enabled the transfection efficiency (%) to be calculated, hence 
the amounts of plasmid DNA to be transfected and the charge ratio of 
Transfast
TM to DNA in the subsequent experimental assays, employing D17, 
CMT3, CMT7 and CMT8 cells, to be determined.  
 
4.2.2 Construction of expression vectors  
The methods involved in constructing the vectors in this study are previously 
described in Chapter 2. Methods included DNA purification (2.2.3), restriction 
digestion (2.2.6), PCR (2.2.1), cloning (2.2.7) and DNA sequence analysis (2.2.5). 
PCR conditions are as previously described in 2.2.1 and details of primers used 
for PCR and DNA sequence analysis are displayed in Table 4.2. 
 
4.2.2.1 pTargeT-p53-full-length construct 
The construction of the pTargeT-p53-full-length expression vector (pTargeT-
p53FL) was carried out by designing 2 PCR primers, „p53FLF‟ and „p53FLR‟, 
which allowed the amplification of the full-length (FL) canine TP53 cDNA 
sequence from the pK9 vector (kindly donated by Dr. N. Veldhoen (Veldhoen & 
Milner 1998); Figure 4.2). The p53FL fragment was directly ligated, at 4
oC for 20 Chapter 4 ~ TP53 as a Target for Canine OS Gene Therapy 
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hours, into the pTargeT mammalian expression vector system of TA cloning 
(Promega), and cloned using JM109 competent cells (Promega), to produce the 
pTargeT-p53FL expression vector. DNA sequence analysis, using the sequencing 
primers „T7 Promoter‟, „p531006F‟ and „pTargeT1358R‟, was carried out to 
confirm that the p53FL fragment had been correctly ligated into the pTargeT
TM 
Mammalian Expression Vector (Figure 4.3).  
  
 
Expression Vector(s)  Primer  Forward (F) /  Primer Sequence  Tm  Location  Vector(s) 
     Reverse (R)  (5′ --> 3′ orientation)    (nts)   
A, Construction             
pTargeT-p53FL  p53FLF  F  cgt aat acg act cac tag tgg gta  61  2447-2470  pK9 
   p53FLR  R  gga att cct gca gga tat cgt gga  62.7  3620-3643  pK9 
pTargeT-LexDBD  LexF358  F  gcc gct gca caa tat ttc aag cta t  61.3  358-378  pHybLex/Zeo 
   LexR1052  R  ctg aga tct gag ctc aag ctt  57.9  1032-1052  pHybLex/Zeo 
pTargeT-Lexp53  XhoIp53F  F  gcc tcg agc tcg aga att tcc aca aga ag  68.1  3297-3311  pK9 
   p53XhoIR  R  gcc tcg agc tcg aga tac gac tca ctt aa  68.1  3697-3710  pK9 
   pRcLexXbaIF  F  gcc tct aga tct aga ata cgg cct tcc ttc  68.1  221-233  pHybLex/Zeo-p53 
   pRcp53XbaIR  R  gcc tct aga tct aga gaa att cgc ccg ga  68.1  1515-1528  pHybLex/Zeo-p53 
pGL3B8LA, pGL3E8LA & pGL3P8LA  2KpnIpGL3F  F  ggt acc ggt acc ggc att acc acc ata tac  69.5  227-244  pSH18-34 
   NheIpGL3FR  R  gct agc gct agc tac ccc aga aat aag gct  69.6  463-480  pSH18-34 
B, DNA Sequence Analysis             
pTargeT-p53FL, pTargeT-LexDBD &  T7 Promoter  R  taa tac gac tca cta tag ggc ga  58.9  1229-1252  pTargeT 
pTargeT-Lexp53  pTargeT1358R  R  aga tat gac cat gat tac gcc aag  59.3  1358-1381  pTargeT 
pTargeT-p53FL & pTargeT-Lexp53  p531006F  F  ttg gag ctg aag gat gcc cag agt  64.4  3477-3500  pK9 
pTargeT-LexDBD & pTargeT-Lexp53  Lex735F  F  aag ccg aat gct gat ttc ctg ctg  62.7  735-758  pHybLex/Zeo 
pGL3B8LA, pGL3E8LA & pGL3P8LA  RV3primer  F  cta gca aaa tag gct gtc cc  57.3  4760-4779; 5006-5025; 4952-4971  pGL3B, pGL3E & pGL3P 
   GL2primer  R  gga aga cgc caa aaa cat aaa g  57.1  111-89; 111-89; 303-281  pGL3B, pGL3E & pGL3P 
 
 
Table 4.2: Details of the oligonucleotide primers used in the overall process of constructing each expression vector by: (A), PCR; and (B), DNA 
sequence analysis. For each primer the following information is provided: the sequence, acting as a forward (F) or a reverse (R) primer, 
annealing temperature (Tm) and nucleotide (nts) location on the particular vector undergoing PCR/DNA sequence analysis. (pGL3B, pGL3-
Basic; pGL3E, pGL3-Enhancer; pGL3P, pGL3-Promoter; 8LA, 8 LexA operator). Chapter 4 ~ TP53 as a Target for Canine OS Gene Therapy 
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Figure 4.2: Flow-diagram indicating the processes involved in the construction of 
the pTargeT-p53FL expression vector. The PCR primers, „p53FLF‟ & „p53FLR,‟ 
were used to amplify the full-length (FL) canine TP53 cDNA sequence from the 
pK9 vector.  Chapter 4 ~ TP53 as a Target for Canine OS Gene Therapy 
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Figure 4.3: Confirmation by DNA sequence analysis that the pTargeT-p53FL 
expression vector contains the full-length (FL) canine TP53 cDNA sequence from 
the pK9 vector. The sequences of the PCR primers, „p53FLF‟ and „p53FLR‟, are 
indicated. (XXX, represents start and stop codons).  
 
 
4.2.2.2 pTargeT-LexA DNA Binding Domain construct 
The pTargeT-LexA DNA Binding Domain expression vector (pTargeT-LexDBD) was 
constructed by designing the 2 PCR primers, „LexF358‟ and „LexR1052‟, which 
enabled the amplification of the LexDBD ORF from pHybLex/Zeo (Invitrogen; 
Appendix C, Figure C3) (Figure 4.4). The LexDBD was directly ligated, at 4
oC for 
20 hours, into the pTargeT
TM Mammalian Expression Vector (Promega) and cloned 
using JM109 competent cells (Promega), to produce the pTargeT-LexDBD 
expression vector. DNA sequence analysis was employed to confirm that the 
LexDBD fragment had been correctly ligated into the pTargeT
TM Mammalian 
Expression Vector, using the sequencing primers, „T7 Promoter‟, „Lex735F‟ and 
„pTargeT1358R‟ (Figure 4.5). 
 
pTargeT vector p53FLF
1252 ATTCGGATCC TTGCTAGCCT CGAGACGCGT GATTCGTAAT ACGACTCACT 
pK9 full length p53
1302 AGTGGGTACC GGTGACTGCA ATG GAG GAG TCG CAG TCA GAG CTC 
1346 AAT ATC GAC CCC CCT CTG AGC…(1077bp)…AGA GAA GGG CTT
  pK9    p53FLR
2456 GAC TCA GAC TGA GGTTAAGGAT CCACGATATC CTGCAGGAAT 
pTargeT vector
2498 TCAATCTTTC CCGGGGGTAC CGTCGACTGC GGCCGCGAAT TCCAAGCTTGChapter 4 ~ TP53 as a Target for Canine OS Gene Therapy 
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Figure 4.4: Flow-diagram indicating the processes involved in the construction of 
the pTargeT-LexDBD expression vector. The PCR primers, „LexF358‟ and 
„LexR1052‟, were used to amplify the LexA DNA-binding domain (LexDBD) from the 
pHybLex/Zeo vector.  
 Chapter 4 ~ TP53 as a Target for Canine OS Gene Therapy 
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Figure 4.5: Confirmation by DNA sequence analysis that the pTargeT-LexDBD 
expression vector contains the LexA DNA-binding domain (LexDBD) open reading 
frame (ORF) from the pHybLex/Zeo vector. The sequences of the PCR primers, 
„LexF358‟ and „LexR1052‟, are shown. (XXX, represents start and stop codons).  
 
 
4.2.2.3 pTargeT-Lexp53 construct 
The pTargeT-Lexp53 expression vector, containing the LexDBD and canine TP53 
C-terminus, was constructed in 3 main stages (Figure 4.6). The first stage 
involved the design of 2 PCR primers, „XhoIp53F‟ and „p53XhoIR‟, enabling the 
amplification of the C-terminus of canine TP53 cDNA (826-1146bp) from the pK9 
vector. These 2 PCR primers had been constructed with XhoI restriction enzyme 
sites to allow the incorporation of XhoI sites at the 5′ and 3′ -ends of the TP53 C-
terminus PCR products. The TP53 C-terminus PCR products were electrophoresed 
on an agarose gel, extracted, purified and ligated into the pCR
®2.1-TOPO
® 
cloning vector (Invitrogen) using the TOPO TA Cloning® Kit. The pCR
®2.1-TOPO
® 
vector was subsequently digested with the XhoI restriction enzyme to create 
TP53 C-terminus fragments with XhoI digested 5′ and 3′ -ends. 
The second stage focussed on the preparation of the „Lexp53‟ fragment. The 
LexDBD in the pHybLex/Zeo vector (Invitrogen) is located upstream of a multiple 
cloning site, containing a XhoI site. pHybLex/Zeo was digested using the XhoI 
restriction enzyme, dephosphorylated and purified. The XhoI digested TP53 C-
terminal fragments were ligated into the purified XhoI digested pHybLex/Zeo 
pTargeT vector LexF358
1252 CTTGCTAGCC TCGAGACGCG TGATTGCCGC TGCACAATAT TTCAAGCTAT
pHybLex/Zeo
1302 ACCAAGCATA CAATCAACTC CAAGCTTTAA TTCCGGGCGG A ATG AAA
LexA ORF
1349 GCG TTA ACG GCC AGG CAA CAA GAG GTG …(558bp)…AAC GGC 
         pHybLex/Zeo LexR1052
1940 GAC TGG CTG GAATTCAAGC TTGAGCTCAG ATCTCAGAAT CTTTCCCGGG
pTargeT vector
1989 GGTACCGTCG ACTGCGGCCG CGAATTCCAA GCTTGAGTATChapter 4 ~ TP53 as a Target for Canine OS Gene Therapy 
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vector in frame with the LexA ORF, at 4
oC for 20 hours, and cloned using Max 
Efficiency DH5 competent cells (GIBCO BRL). The fused in frame LexA DBD and 
TP53 C-terminus sequence was amplified by PCR, in which the primers 
„pRcLexXbaIF‟ and „pRcp53XbaIR‟ were utilized, to produce „Lexp53‟ PCR 
products.   
The third and final stage involved the direct ligation of these „Lexp53‟ PCR 
products into the pTargeT
TM Mammalian Expression Vector System of TA cloning 
(Promega), at 4
oC for 20 hours, and cloned using JM109 competent cells 
(Promega), to produce the pTargeT-Lexp53 expression vector. DNA sequence 
analysis was subsequently performed, using the „T7 Promoter‟, „Lex735F‟, 
„p531006F‟ and „pTargeT1358R‟ sequencing primers, to confirm that the LexA 
DBD and TP53 C-terminus sequence had been correctly ligated into the 
pTargeT
TM Mammalian Expression Vector (Figure 4.7). 
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Figure 4.6: continued on next page. Chapter 4 ~ TP53 as a Target for Canine OS Gene Therapy 
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Figure 4.6: Flow-diagram indicating the processes involved in the construction of 
the pTargeT-Lexp53 expression vector. The PCR primers, „XhoIp53F‟ & 
„p53XhoIR‟ and „pRcLexXbaIF‟ and „pRcp53XbaIR‟, were used to amplify the 
canine TP53 C-terminus from the pK9 vector and the Lexp53 fragment from the 
pHybLex/Zeo-p53 vector, respectively. Chapter 4 ~ TP53 as a Target for Canine OS Gene Therapy 
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Figure 4.7: Confirmation by DNA sequence analysis that the pTargeT-Lexp53 
expression vector contains the canine TP53 C-terminus (826-1146 bp), from the 
pK9 vector, fused in frame with the LexA open reading frame (ORF), from the 
pHybLex/Zeo vector. The sequences of the PCR primers, „pRcLexXbaIF‟ and 
„pRcp53XbaIR‟, and the XhoI restriction enzyme site, are shown. (XXX, 
represents start and stop codons). 
 
4.2.2.4 pGL3-Basic 8LexA Operator, pGL3- Enhancer 8LexA Operator & pGL3-
Promoter 8LexA Operator constructs  
The construction of the pGL3-Basic 8LexA Operator (pGL3B8LA), pGL3-Enhancer 
8LexA Operator (pGL3E8LA) and pGL3-Promoter 8LexA Operator (pGL3P8LA) 
vectors involved the insertion of the 8 LexA operator site from the pSH18-34 
vector (Invitrogen; Appendix C, Figure C4), into the pGL3-Basic (pGL3B), pGL3-
Enhancer (pGL3E) and pGL3-Promoter (pGL3P) firefly luciferase reporter vectors 
(all Promega; Appendix C, Figure C5), respectively (Figure 4.8). This was carried 
out in 2 stages.  
pTargeT vector pRcLexXbaIF
1252 ATTCGGATCC TTGCTAGCCT CGAGACGCGT GATTGCCTCT AGATCTAGAA 
pHybLex/Zeo
1302 TACGGCCTTC CTTCCAGTTA CTTGAATTTG A…(160bp)…CCGGGCGGA 
LexA ORF
1502 ATG AAA GCG TTA ACG GCC AGG CAA CAA GAG GTG
1536 …(558bp)...AAC GGC GAC TGG CTG GAA TTC AAG  
2119 CTT GAG CTC AGA TCT CAG CTG GGC CCG GTA CCH 
XhoI p53 C-terminus (826-1146bp)
2152 CGG CCG CTC GAG AAT TTC CAC AAG AAG GGG GAG CCT TGT  
2191 GAG CCA CCC CCC GGG AGT ACC AAG…(243bp)…AGA GAA GGG CTT 
pK9 
2470 CCT GAC TCA GAC TGA GGTTAAGGAT CCACGATATC CTGCAGGAAT 
   XhoI      pHybLex/Zeo       pRcp53XbaIR
2515 TCCTCGAGTC GACCTGCAGC CAAGCTAATT CCGGGCGAAT TTCTCTAGAT 
pTargeT vector
2565 CTAGAGGCAA TCTTTCCCGG GGGTACCGTC GACTGCGGCC GCGAATTCCA Chapter 4 ~ TP53 as a Target for Canine OS Gene Therapy 
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The first stage involved the use of the PCR primers, „2KpnIpGL3F‟ and 
„NheIpGL3R‟, to amplify the 8LexA operator site from pSH18-34. The 
„2KpnIpGL3F‟ and „NheIpGL3R‟ primers had been designed with KpnI and NheI 
restriction sites, respectively, to enable the incorporation of KpnI and NheI sites 
at the 5′- and 3′ -ends of the 8LexA operator site PCR products, respectively. The 
8LexA operator site PCR products were electrophoresed on an agarose gel, 
extracted and purified. 
The second stage consisted of the ligation of the purified 8LexA operator site 
PCR products into the pGL3B, pGL3E and pGL3P firefly luciferase reporter 
vectors, to create pGL3B8LA, pGL3E8LA and pGL3P8LA. This was achieved by 
digesting the 3 pGL3 vectors, each possessing KpnI and NheI restriction enzyme 
sites in their multiple cloning sites, with the KpnI and NheI restriction enzymes. 
The digested pGL3 vectors were subsequently electrophoresed on an agarose 
gel, extracted and purified. The purified 8LexA operator site PCR products were 
ligated into each of the purified pGL3 vectors, at 4
oC for 20 hours, and cloned 
using JM109 competent cells (Promega). DNA sequence analysis was performed, 
using the „RV3primer‟ and „GL2primer‟ sequencing primers, to confirm that the 
8LexA operator site sequence had been correctly ligated into the pGL3B, pGL3E 
and pGL3P firefly luciferase reporter vectors (Figure 4.9). 
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Figure 4.8: Flow-diagram indicating the processes involved in the construction of 
the pGL3-8LexA Operator (Op) firefly luciferase reporter vectors, pGL3-Basic 
8LexA Op (lacks the SV40 Promoter and Enhancer sequences), pGL3-Enhancer 
8LexA Op (pGL3-Basic 8LexA Op plus the SV40 Enhancer sequence) and pGL3-
Promoter 8LexA Op (pGL3-Basic 8LexA Op plus the SV40 Promoter sequence). 
The PCR primers „2KpnIpGL3F‟ and „NheIpGL3R‟ were used to amplify the 8LexA 
Op site from the pSH18-34 vector. Chapter 4 ~ TP53 as a Target for Canine OS Gene Therapy 
 
123 
 
Figure 4.9: Confirmation by DNA sequence analysis that the pGL3-8LA Operator 
firefly luciferase (lUC) reporter vectors, pGL3-Basic 8LexA Operator (B), pGL3-
Enhancer 8LexA Operator (E) and pGL3-Promoter 8LexA Operator (P) contain the 
8LexA operator site. The sequences of the PCR primers „2KpnIpGL3F‟ and 
„NheIpGL3R‟ and the KpnI, NheI, NcoI and XbaI restriction enzyme sites, are 
shown. The locations at which the SV40 promoter and enhancer sequences are 
positioned in the pGL3-Promoter 8LexA Operator (P) and pGL3-Enhancer 8LexA 
Operator (E) vectors, respectively, are also indicated. (ATG represents start 
codon). 
B5060  pGL3 vector        1 KpnI
E5310 TGCAAGTGCA GGTGCCAGAA CATTTCTCTA TCGATAGGTA CCCATGGCAT
P5250
 KpnIPGL3F
51 TACCACCATA TACATATCCA TATACATATC CATATCTAAT CTTACCTCGA
101 CTGCTGTATA TAAAACCAGT GGTTATATGT ACAGTACTGC TGTATATAAA
8 Lex A Operator
151 ACCAGTGGTT ATATGTACAG TACGTCGACT GCTGTATATA AAACCAGTGG
201 TTATATGTAC AGTACTGCTG TATATAAAAC CAGTGGTTAT ATGTACAGTA
       NheIPGL3R
251 CGTCGAGGGA TGATAATGCG ATTAGTTTTT TAGCCTTATT TCTGGGGTAG
 NheI         SV40 promoter 
301 CTAGCCCGGG CTCGAGATCT GCGATCTAAG TAAGCTTGGC ATTCCGGTAC
  NcoI lUC
351 (P546) TGTTGGTAAA GCCACCATG G AAGACGCCA AAAACATAAA 
401 (P596) GAAAGGCCCG GCGCCATTCT ATCCGCTGGA AGATGGAACC
451 (P646) GCTGGAGAGC AACTGCATAA…(1490bp)… GTCTTACCGG
1971 (P2166) AAAACTCGAC GCAAGAAAAA TCAGAGAGAT CCTCATAAAG
    XbaI
2011 (P2206) GCCAAGAAGG GCGGAAAGAT CGCCGTGTAA TCTAGA GTCG
pGL3 vector
2051 (P2246) GGGCGGCCGG CCGCTTCGAG CAGACATGAT AAGATACATT GATGAGTTTG
2101 (P2296) GACAAACCAC AACTAGAATG CAGTGAAAAA AATGCTTTAT TTGTGAAATT
2151 (P2346) TGTGATGCTA TTGCTTTATT TGTAACCATT ATAAGCTGCA ATAAACAAGT 
2201 (P2396) TAACAACAAC AATTGCATTC ATTTTATGTT TCAGGTTCAG GGGGAGGTGT 
2251 (P2446) GGGAGGTTTT TTAAAGCAAG TAAAACCTCT ACAAATGTGG TAAAATCGAT
SV40 enhancer
2301 (P2496) AAGGATCCGT CGACCGATGC CCTTGAGAGC CTTCAACCCA GTCAGCTCCTChapter 4 ~ TP53 as a Target for Canine OS Gene Therapy 
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4.2.3 Detection of endogenous TP53 and proteins expressed by pTargeT-
Lexp53, pTargeT-p53FL & pTargeT-LexDBD  
4.2.3.1 Transfection of DNA & preparation of cell lysates for western blotting 
The pTargeT-Lexp53, pTargeT-p53FL and pTargeT-LexDBD expression vectors 
were prepared using the QIAGEN EndoFree Plasmid Purification Maxi kit 
(2.2.8.3). Each vector was transfected, in duplicate, into each of the D17, CMT3, 
CMT7 and CMT8 cell lines using the Transfast
TM reagent (Promega) (2.2.9).  
These four cell lines were each cultured and maintained (2.1.1) and 16-24 hours 
prior to transfection occurring, seeded at the appropriate density (as 
determined in 4.3.1.1) per 25cm
2 flask. 3.25g and 6.5g of construct were 
transfected per flask (as determined in 4.3.1.2) of D17 cells and CMT3, CMT7 
and CMT8 cells, respectively. One pair of flasks for each cell line was not 
transfected to act as negative controls and also enable the endogenous levels of 
TP53 to be determined. 48 hours after transfection, the cells in each pair of 
flasks were harvested in protein treatment sample buffer (2.3.1) and the protein 
concentration determined (2.3.2). 
 
4.2.3.2 SDS-polyacrylamide gel electrophoresis & western blotting 
Following protein concentration determination, SDS-PAGE was performed, in 
which 100g of each protein sample were loaded per lane (2.3.3.1). Western 
blotting was subsequently carried out, using primary antibodies of rabbit 
antiserum raised against TP53 on the pTargeT-Lexp53, pTargeT-p53FL and non-
transfected control samples and LexA on the pTargeT-Lexp53, pTargeT-LexDBD 
and non-transfected control samples (2.3.3).  
 
4.2.4 Analysis of exogenous wild-type TP53 delivery  
The pTargeT-p53FL and pTargeT-LexDBD expression vectors were used to 
investigate the effects of delivering the exogenous wild-type TP53 into the 4 
canine OS cell lines, D17, CMT3, CMT7 and CMT8. The 2 vectors were prepared 
using the QIAGEN EndoFree Plasmid Purification Maxi kit (2.2.8.3). Each vector Chapter 4 ~ TP53 as a Target for Canine OS Gene Therapy 
 
125 
was transfected into the D17, CMT3, CMT7 and CMT8 cell lines using the 
Transfast
TM reagent (Promega), in quadruplicate per time point (2.2.9). The 
CellTiter 96® AQueous One Solution Cell Proliferation Assay (Promega; 2.2.10) was 
employed to determine cell numbers immediately before transfection (0 hour 
time point), and 12, 24, 48, 96 hours post-transfection for all four cell lines and 
at 144 hours for only D17 and CMT7 cells. This experiment was carried out in 
triplicate.   
The four cell lines were each cultured and maintained (2.1.1) and 16-24 hours 
prior to transfection occurring, seeded at the appropriate density (as 
determined in 4.3.1.1) per well of a 96-well plate. 50ng and 100ng of construct 
were transfected per well (as determined in 4.3.1.2) of D17 cells and CMT3, 
CMT7 and CMT8 cells, respectively. 4 wells remained untransfected for each cell 
line (NTC – non-transfected cells) and 4 wells containing no cells for each cell 
culture medium (background) were used at each time point to act as negative 
controls. The cell culture medium was replaced after 72 hours with fresh 
medium. 
The mean absorbance reading for each set of 4 wells was determined. The 
background readings were removed and the percentages of cell survival (+/- 
standard error (SE)), compared to the 0 hour time point for the NTC (100%), 
calculated. 
 
4.2.5 Analysis of vectors required for TP53-targeted suicide gene therapy 
strategy using Dual-Luciferase® Reporter Assay System   
The vectors used in the following Dual-Luciferase® Reporter Assay System (DLR) 
experiments were prepared using the QIAGEN EndoFree Plasmid Purification Maxi 
kit (2.2.8.3). They were transfected, in quadruplicate, into the D17, CMT3, 
CMT7 and CMT8 cell lines using the Transfast
TM reagent (Promega; 2.2.9). The 
DLR experiments were performed 48 hours post-transfection, as directed by the 
manufacturer‟s instructions, except for the use of 50l of each of the Luciferase 
Assay Reagent (LAR) II and Stop & Glo Reagent, instead of the indicated 100l. Chapter 4 ~ TP53 as a Target for Canine OS Gene Therapy 
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This was because no difference was observed in the production of luciferase 
activity by these 2 volumes, thereby increasing the cost efficiency of a DLR kit. 
The four cell lines were each cultured and maintained (2.1.1) and 16-24 hours 
prior to transfection occurring, seeded at the appropriate density (as 
determined in 4.3.1.1) per well of a 96-well plate. 4 wells remained 
untransfected for each cell line (NTC – non-transfected cells) at each time point 
to act as negative controls.  
The firefly luciferase (FFluc) and Renilla luciferase (Rluc) activities for each well 
were separately measured on a Dynex plate-reading luminometer. This enabled 
the mean FFluc activity (+/-SE), normalized for Rluc activity, to be determined 
for each set of 4 wells. 
 
4.2.5.1 Optimization of Dual-Luciferase® Reporter Assay System 
Preliminary experiments were performed in D17, CMT3, CMT7 and CMT8 cell 
lines, using the pGL3-Control vector (Promega; Appendix C, Figure C5) to assess 
which of the: two Rluc co-reporter vectors (both Promega; Appendix C, Figure 
C6), pRL-TK or pRL-cytomegalovirus (CMV); and at which of the 3 charge ratios, 
5:1, 10:1 and 25:1, of pGL3-Control to co-reporter vector, were optimal for use 
in the DLR experiments, to enable transfection efficiency to be accounted for, 
allowing normalization of FFluc activity. The amounts of DNA of each vector 
transfected, per ratio, are displayed in Table 4.3A. The DLR optimization 
experiment was performed once.  
  
4.2.5.2 Dual-Luciferase® Reporter Assay System experiments  
Three DLR experiments were carried out, and each in duplicate, to analyse the 
vectors required for the TP53-targeted suicide gene therapy strategy: 
(i), pTargeT-Lexp53 and pGL3-P8LA with pRL-CMV as co-reporter vector (ratio 
5:1); 
(ii), pTargeT-Lexp53 and pGL3-P8LA with pRL-TK as co-reporter vector (ratio 
25:1); Chapter 4 ~ TP53 as a Target for Canine OS Gene Therapy 
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(iii), pTargeT-Lexp53 and pGL3-B8LA, pGL3-E8LA and pGL3-P8LA with pRL-TK as 
co-reporter vector (ratio 25:1). 
The following vectors were required in some or all of the 3 DLR experiments: 
pRL-TK, pRL-CMV; pGL3-Control; pGL3-B8LA, pGL3-E8LA pGL3-P8LA; pTargeT-
Lexp53; pTargeT-p53FL (as a means for producing a cellular environment 
possessing increased levels of TP53 – positive control); and pBLCAT6 (contains 
chloramphenicol acetyl transferase (CAT) gene and utilized as „carrier DNA‟ due 
to its lack of promoter sequences, ensuring all wells were transfected with 
similar amounts of DNA, regardless of number of vectors transfected; Appendix 
C, Figure C7).  
The vectors transfected into each set of wells for each DLR experiment were 
labelled as: 
(i), Carrier DNA - comprising pBLCAT6 and pRL-CMV or pRL-TK; 
(ii), Control - containing pGL3-Control, pBLCAT6 and pRL-CMV or pRL-TK; 
(iii), 8LA – comprising pBLCAT6, pGL3-8LA (B, E, or P) and pRL-CMV or pRL-TK 
(carried out due to the expectation of background FFluc activity as a result of 
basal promoter activity by pGL3-P8LA); 
(iv), p53-FL - containing pTargeT-Lex-p53, pTargeT-p53FL, pGL3-P8LA and pRL-
CMV or pRL-TK 
(v), Lex-p53 - comprising pTargeT-Lex-p53, pGL3-8LA (B, E or P) and pRL-CMV or 
pRL-TK. 
The amounts of DNA transfected at a ratio of experimental DNA: co-reporter 
vector of 25:1, per combination of vectors, are displayed in Table 4.3B.   
 
 
A, Optimization of DLR   Positive Control     Ratio     
co-reporter vectors        5:1  10:1  25:1 
Cell Line     D17  CMT3,7 & 8  D17  CMT3,7 & 8  D17  CMT3,7 & 8  D17  CMT3,7 & 8 
Vector DNA  pGL3-Control  50  100  45  83  50  91  50  96 
(ng)  pRL-CMV or pRL-TK  -  -  9  17  5  9  2  4 
Total amount of DNA transfected (ng)  50  100  54  100  55  100  52  100 
 
B, DLR experiments  Carrier  Control  8LA  p53-FL  Lex-p53 
Cell Line     D17  CMT3,7 & 8  D17  CMT3,7 & 8  D17  CMT3,7 & 8  D17  CMT3,7 & 8  D17  CMT3,7 & 8 
   pBLCAT6  50  100  40  80  40  80  -  -  -  - 
   pTargeT-Lex-p53  -  -  -  -  -  -  20  40  40  80 
Vector DNA  pTargeT-p53FL  -  -  -  -  -  -  20  40  -  - 
(ng)  pGL3-8LA (B, E or P)  -  -  -  -  10  20  10  20  10  20 
   pGL3-Control  -  -  10  20  -  -  -  -  -  - 
   pRL-CMV or pRL-TK  2  4  2  4  2  4  2  4  2  4 
Total amount of DNA transfected (ng)  52  104  52  104  52  104  52  104  52  104 
 
Table 4.3: The amounts of DNA (in ng) and combinations of vectors transfected into D17, CMT3, CMT7 and CMT8 cells to enable the 
analysis of vectors required for TP53-targeted suicide gene therapy strategy using the Dual-Luciferase® Reporter Assay System (DLR): 
(A), Optimization of DLR co-reporter vectors, pRL-TK and pRL-CMV, in combination with pGL3-Control; (B), DLR experiments, in which 
sets of wells were labelled as „Carrier‟, „Control‟, „8LA‟, „p53-FL‟ and „Lex-p53‟, and ratio of experimental DNA: co-reporter vector of 
25:1, per combination of vectors, was utilized. Chapter 4 ~ TP53 as a Target for Canine OS Gene Therapy 
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4.3 Results 
4.3.1. Optimization assays 
4.3.1.1 Cell number  
The concentrations of cells required for the D17, CMT3, CMT7 and CMT8 cell 
lines to obtain 80% confluence were:  D17 - 90000 cells/ml; CMT3 - 75000 
cells/ml; CMT7 - 35000 cells/ml; and CMT8 - 75000 cells/ml. This enabled the 
same number of cells to be transfected for each cell line, in all the subsequent 
assays performed in this study, without any toxicity occurring due to the 
transfection of low cell densities (200l/well of a 96-well plate; 13ml per 25cm
2 
flask). 
 
4.3.1.2 Transfection efficiency  
The D17, CMT3, CMT7 and CMT8 cell lines appeared normal following the 
transfection of 50ng pSV--gal DNA, at the charge ratio of 1:1, for which the 
transfection efficiencies were calculated as: 18.1% D17 cells; 2.75% CMT3 cells; 
1% CMT7 cells; and 0.5% CMT8 cells (Table 4.4). A greater percentage of cells 
were transfected using 100ng pSV--gal DNA at the ratio of 1:1: D17 cells, 27.9%; 
CMT3 cells, 19.7%; CMT7 cells, 10.0%; and CMT8 cells, 4.75%. However, a small 
number of the D17 cells were observed to have an abnormal visual appearance, 
in contrast all the CMT3, CMT7 and CMT8 cells appeared normal. Following the 
transfection of 150 and 200ng pSV--gal DNA into the four cell lines, at the 
charge ratio of 1:1, all the cells possessed an abnormal visual appearance. 100% 
cytotoxicity was observed in the D17, CMT3, CMT7 and CMT8 cells after the 
transfection of 50, 100, 150 and 200ng pSV--gal DNA at the ratio of 2:1, 
Transfast
TM reagent to DNA.  
Therefore, the amounts of plasmid DNA to be transfected and the ratio of 
Transfast
TM to DNA in the subsequent experimental assays employing these four 
cell lines, were determined to be 50ng DNA per well (or 3.25g per 25cm
2 flask) 
of D17 cells and 100ng DNA per well (or 6.5g per 25cm
2 flask) of CMT3, CMT7 
and CMT8 cells, at a ratio of 1:1 Transfast
TM: DNA. These amounts enabled an 
acceptable level of transfection efficiency to be achieved for each cell line, Chapter 4 ~ TP53 as a Target for Canine OS Gene Therapy 
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without appearing to compromise the normal visual appearance of these cells. 
Hence, any cytotoxicity induced in the experimental assays could be deemed to 
be as a result of the active construct/prodrug and not the components involved 
in the transfection protocol. 
 
 
 
Table 4.4: The transfection efficiency (%) and the effect on the normal visual 
appearance of D17, CMT3, CMT7 and CMT8 cells following the transfection of 50, 
100, 150 and 200 ng pSV--galactosidase control vector (pSV--gal) DNA at the 
charge ratios of transfection reagent (Transfast
TM) to DNA, 1:1 and 2:1 (* - small 
number of D17 cells possessed an abnormal visual appearance). 
 
4.3.2 Detection of endogenous TP53 and expression of proteins by pTargeT-
Lexp53, pTargeT-p53FL & pTargeT-LexDBD  
Endogenous TP53 was detected, using the CM-1 antibody (anti-p53), in the NTC 
lysates of CMT7 and CMT8 cells and possibly in CMT3 cells but not in D17 cells 
(Figure 4.10A). LexA immunopositivity was not detected, using the anti-LexA 
antibody, in the NTC lysates of all four cell lines (Figure 4.10B). 
Immunopositivities of the full-length p53 and LexA DNA binding domain proteins 
employing the CM-1 (Figure 4.10C) and anti-LexA (Figure 4.10D) antibodies, 
respectively, were detected in the D17, CMT3, CMT7 and CMT8 cell lysates, after 
transfection of the pTargeT-p53FL and pTargeT-LexDBD constructs, respectively. 
Immunopositivity of the Lexp53 protein, following the transfection of the 
pTargeT-Lexp53 construct, was detected with both antibodies in the cell lysates 
from all four cell lines (Figure 4.10 E & F). Faint bands indicated the possible 
detection of immunopositivity of the Lexp53 protein bound to endogenous TP53 
in CMT3, CMT7 and CMT8 cell lysates, using the anti-LexA antibody (Figure 
4.10E); however, no bands were visible employing the CM-1 antibody (Figure Chapter 4 ~ TP53 as a Target for Canine OS Gene Therapy 
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4.10F). The Lexp53 protein was not detected bound to endogenous TP53, using 
either antibody, in the lysate from D17 cells (Figure 4.10 E & F). 
These results demonstrate that the pTargeT-Lexp53, pTargeT-p53FL and 
pTargeT-LexDBD constructs can be successfully transfected into the D17, CMT3, 
CMT7 and CMT8 cell lines and the Lexp53, full-length TP53 and LexA DNA binding 
domain proteins expressed, respectively. The NTC lysates of CMT7 and CMT8 
cells, and possibly CMT3 cells, are shown to possess endogenous TP53, whereas 
no endogenous TP53 is evident in the D17 cell lysate. There is also evidence that 
the Lexp53 protein can bind to the endogenous TP53 in the CMT3, CMT7 and 
CMT8 cell lines.  
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Figure 4.10: The chemiluminescent immunoblots obtained using anti-p53 (CM1) 
and anti-LexA primary antibodies, in cell lysates prepared from D17, CMT3, 
CMT7 and CMT8 cells, to detect the expression of: endogenous levels of TP53 (A) 
and LexA DNA binding domain (B) proteins in non-transfected cells (NTC); full-
length p53 (53kDa) and LexA DNA binding domain (36kDa) proteins following the 
transfection of the pTargeT-p53FL construct (C) and the pTargeT-LexDBD 
construct (D), respectively; Lexp53 protein (56kDa) following the transfection of 
the pTargeT-Lexp53 construct (E & F; 97kDa indicates the possible detection of 
the Lexp53 protein bound to endogenous TP53). (100g protein loaded per lane; 
black arrows indicate the position of the relevant protein).  
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4.3.3 Analysis of exogenous wild-type TP53 delivery 
The survival curves of the pTargeT-p53FL and pTarget-LexDBD transfected and 
NTC for each of the four cell lines are displayed in Figure 4.11. It can be 
observed that the expression of the full-length TP53 and the negative control 
protein, LexA DNA binding domain by pTarget-p53FL and pTargeT-LexDBD, 
respectively, did not appear to reduce cell survival. Indeed, there are no 
statistically significant differences between the survival curves for the pTargeT-
p53FL and pTargeT-LexDBD transfected cells and NTC for each cell line (Table 
4.5).  
Increases in cell survival seen at the 96-hour time point, were probably due to 
the cell culture medium being replaced with fresh medium at 72 hours. 
Thus as the expression of the full-length TP53 by pTargeT-p53FL was not 
observed to decrease the survival of D17, CMT3, CMT7 and CMT8 cells, a 
requirement was demonstrated for the investigation of a TP53-targeted suicide 
gene therapy strategy in these canine OS cell lines. 
 
Treatment Comparison  D17  CMT3  CMT7  CMT8 
NTC vs.  LexDBD  0.998  0.161  0.82  0.713 
   p53FL  0.954  0.98  0.954  0.064 
LexDBD vs.  p53FL  0.918  0.11  0.948  0.296 
 
Table 4.5: p-values of post hoc pairwise comparisons of treatment groups in 
Figure 4.11, which were not significantly different, for the D17, CMT3, CMT7 and 
CMT8 cell lines (significance was set at p = 0.05). 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.11: The effect of the expression of the full-length p53 and LexA DNA binding domain proteins following the transfection of the 
pTargeT-p53FL (p53FL) and the pTargeT-LexDBD (lexDBD) constructs, respectively, over a 96/144 hour time course on the D17 (A), 
CMT3 (B), CMT7 (C) and CMT8 (D) cell lines. („NTC‟, non-transfected cells; each assay was repeated in triplicate and each time point in 
quadruplicate; bars represent +/-SE). Please note different scales on Y-axes.  
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4.3.4 Analysis of vectors required for TP53-targeted suicide gene therapy 
strategy using Dual-Luciferase® Reporter Assay System   
4.3.4.1 Optimization of Dual-Luciferase® Reporter Assay System 
The data from the D17, CMT3, CMT7 and CMT8 optimization experiments are 
summarized in Figure 4.12 A, B, C and D, respectively. The post hoc pairwise 
comparison results of FFluc values are displayed in Table 4.6. There were, 
unexpectedly, no statistically significant differences between the FFluc 
activities of the NTC and pGL3-Control transfected cells in any of the cell lines. 
However, as expected, the background Rluc activities of the NTC and pGL3-
Control transfected cells were similar to each other. Although, there does 
appear to be two anomalous results in CMT3 cells: firstly, the FFluc activities of 
the NTC and cells transfected with pGL3-Control are greater than those cells 
transfected with pGL3-Control in combination with pRL-TK or pRL-CMV; and 
secondly, the Rluc activities of the NTC and cells transfected with pGL3-Control 
are higher than the activities produced by the cells transfected with pRL-TK, 
even though no co-reporter vector was transfected. It was realized at a later 
date that 50ng of pGL3-Control, instead of 100ng, and half the required amount 
of co-reporter vector, had accidentally been transfected into each of the six 
charge ratio experiments. In comparison, 100ng of pGL3-Control had been 
transfected into the cells with no co-reporter vector. Even though the incorrect 
amounts of pGL3-Control plus pRL-TK or pRL-CMV had been transfected, the 
charge ratios of pGL3-Control to pRL-TK/ pRL-CMV were correct. Hence, these 
anomalies can probably be explained, but the experiment should have been 
repeated, to confirm these explanations. In addition, the background FFluc and 
Rluc activities of CMT3 cells appear to be much higher than those of D17, CMT7 
and CMT8 cells, and this should be investigated further. 
The observed Rluc activities are greater, as expected, following transfection of 
pRL-CMV than pRL-TK in all four cell lines. This is due to pRL-CMV containing the 
CMV enhancer and early promoter elements, which are stronger than the TK 
promoter in pRL-TK and able to provide a higher-level expression of Rluc in co-
transfected cells. However, anomalous results were observed in the CMT7 and 
CMT8 cells, as similar Rluc readings were observed for each pRL-TK ratio, 
suggesting that comparable amounts of pRL-TK had been transfected into these Chapter 4 ~ TP53 as a Target for Canine OS Gene Therapy 
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cells. Furthermore, the activities of Rluc in the CMT8 cells appear to be lower 
than the Rluc reading for NTC indicating that pRL-TK might not have actually 
been transfected into these cells. These two experiments should have been 
repeated, to validate the Rluc activities obtained. 
It can also be seen that, as expected, the activity of Rluc decreases as the ratio 
of pGL3-Control to pRL-TK/ pRL-CMV increases i.e. reduction in amount of co-
reporter vector transfected resulted in a lower Rluc measurement, in the D17, 
CMT3, CMT7 and CMT8 cells, except for CMT7 and CMT8 cells transfected with 
pRL-TK (as previously described). 
There was a statistically significant difference between FFluc activities of D17 
cells transfected with pGL3-Control on their own to those co-transfected with 
pRL-TK or pRL-CMV at 5:1, 10:1 and 25:1, even though similar amounts of pGL3-
Control vector had been transfected in all cells. Although theoretically this 
should not occur, one of the primary objectives for carrying out this 
optimization assay was to ensure that independent genetic expression of the 
experimental and control reporter genes occurs, due to the reported possibility 
of a trans effect occurring with the use of a strong promoter, such as CMV (Farr 
& Roman 1992). Significant differences were also found in the CMT7 cells, 
between those cells transfected with pGL3-Control and those co-transfected 
with pRL-CMV at 5:1 and 10:1. In addition, a significant difference was observed 
between the CMT8 cells transfected with pGL3-Control and those co-transfected 
with pRL-CMV at 5:1. The likely reason for significant differences not being 
found between CMT7 and CMT8 cells transfected with pGL3-Control on their own 
to those co-transfected with pRL-CMV at 25:1 and 10:1 and 25:1, respectively, is 
also due to the error in which only 50ng of pGL3-Control, instead of 100ng, and 
half the required amount of co-reporter vector, albeit at the correct ratio, had 
been transfected. In addition, statistically significant differences cannot be 
assessed in the CMT3 cells and CMT7 and CMT8 cells between the cells only 
transfected with pGL3-Control to those co-transfected with pRL-TK, due to the 
discrepancies previously described. 
It was observed that within the six charge ratio experiments of the D17 cells, the 
FFluc activity of the cells transfected with pGL3-Control in combination with 
pRL-TK at 5:1 ratio were higher and statistically significantly different from all Chapter 4 ~ TP53 as a Target for Canine OS Gene Therapy 
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the other ratios of pRL-TK and pRL-CMV, except pRL-CMV at 10:1. This was not 
expected as TK is a weaker promoter than CMV and theoretically, a stronger 
trans effect is more likely to occur with pRL-CMV than pRL-TK, due to CMV being 
the stronger promoter. The FFluc activity of the cells transfected with pGL3-
Control in combination with pRL-CMV at 10:1 was also higher and significantly 
different to those transfected with pRL-CMV at 5:1 and 25:1. The higher FFluc 
activity of cells transfected with pRL-CMV at 10:1 to those at 5:1 is also 
unexpected, as theoretically lower readings should be obtained with weaker 
ratios in comparison to stronger ratios. In the CMT3 cells, there were no 
statistically significant differences between the CMT3 cells transfected with 
pGL3-Control in combination with pRL-TK or pRL-CMV at 5:1, 10:1 or 25:1. This 
shows that in the CMT3 cells, the FFluc activity produced by pGL3-Control is 
affected equally by pRL-TK and pRL-CMV and the ratio at which they are 
utilized. In the CMT7 cells transfected with pGL3-Control in combination with 
pRL-CMV, there was a statistically significant difference between FFluc activities 
of the cells transfected with pRL-CMV at 10:1 to those transfected with pRL:CMV 
at 25:1. This indicates that in the CMT7 cells, higher levels of CMV, may interact 
with the pGL3-Control vector to increase FFluc expression, due to the reported 
trans effect of the CMV reporter. In the CMT 8 cells transfected with pGL3-
Control in combination with pRL-CMV, there were also no significant differences 
at 5:1, 10:1 or 25:1. Showing that the ratios of pRL-CMV in combination with 
pGL3-Control possess a similar effect on FFluc activity.  
A second primary objective of this optimization assay was to determine relative 
light units produced by each co-reporter to enable reliable quantification. 
Although, it can be observed that the readings of FFLuc activities in CMT3, CMT7 
and CMT8 transfected with pGL3-Control in combination with pRL-CMV or pRL-TK 
are much lower than the equivalent D17 transfected cells, this is likely to be due 
to the transfection of 50ng of pGL3-Control instead of 100ng. It could be 
hypothesized that as ~ 7-, 10- and 9.5- fold increases in transfection efficiency 
were observed between 50ng and 100ng in CMT3, CMT7 and CMT8 cells, 
respectively, in 4.4.1, similar increases in FFluc activity would also be observed. 
Overall, these results show, that even in light of the identified discrepancies, 
similar FFluc activities were generally observed between the cells transfected Chapter 4 ~ TP53 as a Target for Canine OS Gene Therapy 
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with pGL3-Control in combination with pRL-CMV or pRL-TK at 5:1, 10:1 and 25:1. 
Hence, pRL-CMV could be used initially in the subsequent assay for normalising 
FFluc activity, and at a ratio of 5:1, as CMV is the stronger promoter and to 
ensure adequate levels of Rluc expression occur in all four cell lines.  
 
Group  Treatment  D17  CMT3  CMT7  CMT8 
1  NTC  All except 2  All except 2  6, 7  6 
2  pGL3-Control  All except 1  All except 1  6, 7  6 
3  5:1 TK  All except 7  1, 2    6 
4  10:1 TK  1, 2, 3  1, 2      
5  25:1 TK  1, 2, 3  1, 2      
6  5:1 CMV  1, 2, 3, 7  1, 2  1, 2  1, 2, 3 
7  10:1 CMV  1, 2, 6, 8  1, 2  1, 2, 8    
8  25:1 CMV  1, 2, 3, 7  1, 2  7    
 
Table 4.6: Post hoc pairwise comparisons of FFluc activites for the treatment 
groups in Figure 4.12, listing the treatment groups which were significantly 
different from each group for the D17, CMT3, CMT7 and CMT8 cell lines 
(significance was set at p = 0.05). 
  
 
 
Figure 4.12: Optimization of Dual-Luciferase® Reporter Assay System to determine which of the two Renilla luciferase co-reporter 
vectors, pRL-TK or pRL-CMV, and ratio of experimental vector (in this assay pGL3-Control) to Renilla vector, 5:1, 10:1 and 25:1, were to 
be used in the Dual-Luciferase® Reporter Assay System experiments for the D17 (A), CMT3 (B), CMT7 (C) and CMT8 (D) cell lines. „NTC‟ – 
non-transfected cells in which cells were only treated with cell culture medium. Each transfection was repeated in quadruplicate; bars 
represent +/-SE (Rluc mean and SE values are displayed at the bottom of each graph). Please note different scales on Y-axes. Chapter 4 ~ TP53 as a Target for Canine OS Gene Therapy 
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4.3.4.2 Dual-Luciferase® Reporter Assay System experiments 
4.3.4.2.1 Analysis of pTargeT-Lexp53 and pGL3-Promoter 8LexA Operator with 
pRL-CMV as co-reporter vector  
In this DLR assay, pTargeT-Lexp53 in combination with pGL3-Promoter 8LexA Op 
(pGL3-P8LA) was assessed, using pRL-CMV as the co-reporter vector, in the D17, 
CMT3, CMT7 and CMT8 cell lines. The data from this experiment are summarized 
in Figure 4.13 and the post hoc pairwise comparison results of FFluc values are 
displayed in Table 4.7. It was observed in all four cell lines that the NTC had 
very low FFluc and Rluc (D17, 6.6 +/- 2.2 relative light units (RLU); CMT3, 3.0 
+/- 0.2 RLU; CMT7, 3.9 +/- 0.4 RLU; CMT8, 5.6 +/- 0.5 RLU (+/-SE)) activities; of 
which the FFluc values were statistically significantly different to all the other 
treatments except for the D17 and CMT3 cells in the „Carrier‟ experiment. FFluc 
values were measured in all the cells transfected with carrier DNA, although only 
pRL-CMV and pBLCAT6 had been transfected into them, however the FFluc 
readings were statistically significantly different to all the other treatments 
except for the D17 cells in „Lex-p53‟ experiment. Variable Rluc activity was 
observed in all four cell lines (D17, 69693 +/- 7263 RLU; CMT3, 6620 +/- 1285 
RLU; CMT7, 24974 +/- 3353 RLU; CMT8, 25744 +/- 2990 RLU (+/-SE)), 
demonstrating that normalization of FFluc activity was required. The cells 
treated in the „Control‟ experiment produced relatively high FFluc readings, 
indicating that an acceptable percentage of the cells had been transfected and 
the assay was functioning correctly. The cells treated in the „P8LA‟ experiment 
produced FFluc readings not statistically significantly different to those cells 
treated with „Control‟, except for CMT7 cells, which is generally as anticipated 
due to pGL3-P8LA also possessing the strong SV40 promoter (only difference 
being that pGL3-Control also contains the SV40 enhancer). Finally, the „p53FL‟ 
cells which had been transfected with pGL3-P8LA, pTargeT-p53FL and pTargeT-
Lexp53, produced the highest FFluc readings, statistically significant different to 
all other treatments except for „Lex-p53‟ in CMT7 cells, indicating that pTargeT-
p53FL was acting as required, as a positive control to show that the designed 
system could function correctly in the presence of increased levels of TP53 i.e. 
exogenous wild-type TP53 expressed by pTargeT-p53FL was able to bind to 
Lexp53 protein expressed by pTargeT-Lexp53 and in turn, the Lexp53 protein 
was able to bind to 8LexA operator site in pGL3-P8LA, thereby driving the Chapter 4 ~ TP53 as a Target for Canine OS Gene Therapy 
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expression of FFluc. Hence, cells treated with „p53FL‟ were suitable as a model 
for cells possessing accumulated TP53. 
The cells treated with „Lex-p53‟, to produce FFluc activity from pGL3-P8LA, 
would have to utilize the endogenous TP53 present in each cell line. It can be 
seen in D17, CMT3 and CMT8 cells that „Lex-p53‟ FFluc activities in these cell 
lines are statistically significantly lower than those of „p53-FL‟ treated cells. In 
addition the FFluc values of the „Lex-p53‟ treated cells in the D17, CMT3 and 
CMT8 cells were not statistically significantly different to the cells treated with 
„8LA‟. It could be proposed that as pGL3-P8LA is a component of the „Lex-p53‟ 
treatment, the FFluc activities measured were mainly due to pGL3-P8LA. In 
contrast in the CMT7 cells, there is no statistically significant difference 
between the cells treated with „Lex-p53‟ and „p53FL‟ but there is a difference 
between „Lexp53‟ and „P8LA‟. These results indicate that generally the 
endogenous TP53 levels within each cell line are able to control the amount of 
FFluc expressed by this TP53-targeted gene therapy system. This is because D17 
cells possess wild-type TP53 and CMT3 cells although containing mutated TP53 
(Table 2.1), both display none or very low levels of endogenous TP53, as 
previously shown in Figure 4.10. In comparison, CMT7 cells, contain mutated 
TP53 and express higher levels of endogenous TP53. However, the CMT8 cells 
although possessing mutated TP53 and demonstrating equivalent endogenous 
TP53 levels as that of CMT7 cells in Figure 4.10, did not appear to upregulate 
FFluc expression. Hence, the low levels of TP53 present in the D17, and CMT3 
cells, provide little or nothing for the Lex-p53 protein to bind with, resulting in 
lower expression levels of FFluc. In comparison, the higher levels of endogenous 
TP53 in the CMT7 cells interact with the Lexp53 protein, producing increased 
levels of FFluc expression from pGL3-P8LA.  
Thus, as pRL-CMV produced high levels of Rluc expression in this experiment, the 
possibility of reducing the occurrence of any trans effect, particularly in the 
CMT7 cells, was able to be investigated in the next experiment, in which pRL-TK 
was employed instead of pRL-CMV, and at a ratio of 25:1 (vector DNA:pRL-TK).   
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Group Treatment  D17  CMT3  CMT7  CMT8 
1  NTC  All except 2  All except 2  All other treatments  All other treatments  
2  Carrier  1, 3, 4, 5  All except 1  All other treatments  All other treatments 
3  Control  1, 2, 5  1, 2, 5  All except 4  All except 4 
4  P8LA  1, 2, 5  1, 2, 5  All except 3  1, 2, 5 
5  p53FL  All other treatments  All other treatments   All except 6  All other treatments 
6  Lexp53  1, 5  1, 2, 5  All except 5  All except 4 
 
Table 4.7: Post hoc pairwise comparisons of treatment groups in Figure 4.13, 
listing the treatment groups which were significantly different from each group 
for the D17, CMT3, CMT7 and CMT8 cell lines (significance was set at p = 0.05).  
 
 
Figure 4.13: Dual-Luciferase® Reporter analysis of pTargeT-Lexp53 (Lexp53) and pGL3-Promoter 8LexA Op (P8LA) with pRL-CMV as co-
reporter vector in the D17 (A), CMT3 (B), CMT7 (C) and CMT8 (D) cell lines.  („NTC‟ – non-transfected cells; „Carrier DNA‟ - pBLCAT6 and 
pRL-CMV; „Control‟ - pGL3-Control, pBLCAT6 and pRL-CMV; „P8LA‟ – pBLCAT6, pGL3-P8LA and pRL-CMV; „p53-FL‟ - pTargeT-Lex-p53, 
pTargeT-p53FL, pGL3-P8LA and pRL-CMV; „Lex-p53‟ - pTargeT-Lex-p53, pGL3-P8LA and pRL-CMV). Firefly luciferase activity was 
normalized using pRL-CMV. Each assay (4 replicates/transfection) was repeated in duplicate; bars represent +/-SE. Please note different 
scales on Y-axes. Chapter 4 ~ TP53 as a Target for Canine OS Gene Therapy 
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4.3.4.2.2 Analysis of pTargeT-Lexp53 and pGL3-Promoter 8LexA Op with pRL-TK 
as co-reporter vector 
In this DLR assay, pTargeT-Lexp53 in combination with pGL3-Promoter 8LexA Op 
(pGL3-P8LA) was assessed, using pRL-TK as the co-reporter vector, in the D17, 
CMT3, CMT7 and CMT8 cell lines. The data from this experiment are summarized 
in Figure 4.14 and the post hoc pairwise comparison results of FFluc values are 
displayed in Table 4.8. It was observed in all four cell lines that the NTC had 
extremely low FFluc and Rluc (D17, 2.5 +/- 0.1 RLU; CMT3, 2.8 +/- 0.1 RLU; 
CMT7, 2.6 +/- 0.1 RLU; CMT8, 3.0 +/- 0.2 RLU (+/-SE)) activities; of which the 
FFluc values were statistically significantly different to all the other treatments 
except for the cells treated with „Carrier‟. FFluc was measured in all the cells 
transfected with „Carrier‟, although only Rluc had been transfected into them, 
however the FFluc readings were statistically significantly different to all the 
other treatments except for the CMT3 cells in „p53FL‟ and „Lex-p53‟ 
experiments. The cells treated in the „Control‟ experiment had high FFluc 
values, indicating that an acceptable percentage of the cells had been 
transfected and the assay was functioning correctly. Finally, in comparison to 
the previous DLR assay (4.3.4.2.1) in which the „p53FL‟ cells had produced the 
highest FFluc readings, in this assay the „p53FL‟ transfected cells produced FFluc 
values statistically significantly lower than cells treated with „P8LA‟ in D17, 
CMT7 and CMT8 experiments. As pGL3-P8LA is a component of the „p53FL‟ 
treatment it could be suggested that the FFluc activities measured were mainly 
due to pGL3-P8LA. This implies that pTargeT-p53FL may not have been 
expressing TP53 as required to increase levels of TP53 present or the use of pRL-
TK affected the expression of FFluc. It was also observed that the expression of 
Rluc was, as expected, much lower from pRL-TK (D17, 314 +/- 21 RLU; CMT3, 
116 +/- 18 RLU; CMT7, 134 +/- 18 RLU; CMT8, 137 +/- 11 RLU (+/-SE)), than the 
expression previously observed using pRL-CMV, as TK is a weaker promoter than 
CMV. In addition, TK was likely to have a reduced effect on the promoters in the 
other transfected constructs, in comparison to CMV, including those in the 
„pTargeT-p53FL‟ vector, which contains both the CMV and SV40 enhancers and 
promoters. Chapter 4 ~ TP53 as a Target for Canine OS Gene Therapy 
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Similar to the previous DLR assay (4.3.4.2.1), the cells treated with „Lex-p53‟ 
would have to utilize the endogenous TP53 levels present in each cell line to 
produce FFluc activity from pGL3-P8LA. It can be seen in D17 cells that „Lex-
p53‟ FFluc activity is not statistically significantly different than „p53FL‟ treated 
cells but is significantly lower than „P8LA‟ treated cells. In the CMT3 and CMT8 
cells, the „Lex-p53‟ FFluc activities are not statistically significantly different to 
those of „p53-FL‟ and „P8LA‟ treated cells. In comparison, in the CMT7 cells, the 
„Lex-p53‟ FFluc activities are statistically significantly higher to those of „p53-
FL‟ and „P8LA‟ treated cells. The lower FFluc expression levels observed in the 
D17 and CMT3 cells are as a result of these cells possessing low levels of 
endogenous TP53 and the higher FFLuc expression levels in the CMT7 cells, due 
to the possession of higher levels of endogenous TP53. Again, the CMT8 cells did 
not appear to increase FFluc expression levels. These results are generally in 
agreement with the findings made in the previous assay using pRL-CMV 
(4.3.4.2.1.2). 
The aim of decreasing the expression of Rluc to lower levels was achieved using 
the pRL-TK vector and, it was hoped that any trans effect would also be 
reduced. It was also noted that the FFluc expression levels obtained in each cell 
line were much lower than that observed in the previous assay, however similar 
overall findings were obtained. Hence, the pRL-TK co-reporter could be used in 
the subsequent DLR experiment, in which the possibility of reducing the 
background FFluc expression by „P8LA‟ was investigated using the pGL3-
Enhancer 8LexA Op and pGL3-Basic 8LexA Op constructs. 
Group  Treatment  D17  CMT3  CMT7  CMT8 
1  NTC  All except 2  All except 2  All except 2  All except 2 
2  Carrier  All except 1  3, 4  All except 1  All except 1 
3  Control  All other treatments 1, 2, 5  All except 5  1, 2 
4  P8LA  All other treatments 1, 2  All other treatments  1, 2, 5 
5  p53FL  All except 6  1, 3  All except 3  1, 2, 4 
6  Lexp53  All except 5  1  All other treatments  1, 2 
 
Table 4.8: Post hoc pairwise comparisons of treatment groups in Figure 4.14, 
listing the treatment groups which were significantly different from each group 
for the D17, CMT3, CMT7 and CMT8 cell lines (significance was set at p = 0.05). 
  
 
 
Figure 4.14: Dual-Luciferase® Reporter analysis of pTargeT-Lexp53 (Lexp53) and pGL3-Promoter 8LexA Op (P8LA) with pRL-TK as co-
reporter vector in the D17 (A), CMT3 (B), CMT7 (C) and CMT8 (D) cell lines. („NTC‟ – non-transfected cells; „Carrier DNA‟ - pBLCAT6 
and pRL-TK; „Control‟ - pGL3-Control, pBLCAT6 and pRL-TK; „P8LA‟ – pBLCAT6, pGL3-P8LA and pRL-TK; „p53-FL‟ - pTargeT-Lex-p53, 
pTargeT-p53FL, pGL3-P8LA and pRL-TK; „Lex-p53‟ - pTargeT-Lex-p53, pGL3-P8LA and pRL-TK). Firefly luciferase activity was 
normalized using pRL-TK. Each assay (4 replicates/transfection) repeated in duplicate; bars represent +/-SE. Please note different 
scales on Y-axes. Chapter 4 ~ TP53 as a Target for Canine OS Gene Therapy 
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4.3.4.2.3 Analysis of pTargeT-Lexp53 and pGL3-Basic 8LexA Op, pGL3-Enhancer 
8LexA Op and pGL3-Promoter 8LexA Op with pRL-TK as co-reporter vector 
The data from this experiment are summarized in Figure 4.15 and the post hoc 
pairwise comparison results of FFluc values are displayed in Table 4.9. It was 
observed in the D17, CMT3, CMT7 and CMT8 cell lines that the NTC had minimal 
FFluc and Rluc (D17, 6.5 +/- 0.5 RLU; CMT3, 6.5 +/- 0.2 RLU; CMT7, 10.0 +/- 2.4 
RLU; CMT8, 8.8 +/- 1.3 RLU (+/-SE)); activities; of which the FFluc values were 
statistically significantly different to all the other treatments except for the 
CMT7 cells treated with „Carrier‟. FFluc was measured in all the cells 
transfected with „Carrier‟, although only Rluc had been transfected into them, 
however the FFluc readings were statistically significantly different to all the 
other treatments except for the D17 cells treated with „B8LA‟. It was also 
observed that the expression of Rluc from pRL-TK in this experiment (D17, 349 
+/- 62 RLU; CMT3, 268 +/- 47 RLU; CMT7, 190 +/- 34 RLU; CMT8, 180 +/- 32 RLU 
(+/-SE)), was similar to that in the previous assay using pRL-TK as the co-
reporter. High FFluc values were obtained in the cells treated in the „Control‟ 
experiment, indicating that an acceptable percentage of the cells had been 
transfected and the assay was functioning correctly. The cells treated with 
„B8LA‟ produced statistically significantly lower FFluc values than cells treated 
with „E8LA‟ or „P8LA‟ except for „E8LA‟ treated cells in CMT3 cells. Similarly 
„E8LA‟ treated cells gave statistically significantly lower FFluc readings than 
„P8LA‟ treated cells. Thereby demonstrating that the background FFluc activity 
of pGL3-P8LA can be reduced, although it is at the expense of an overall 
reduction in the level of FFluc expressed. There were no statistically significant 
differences between the cells treated with „B8LA+Lexp53‟ and „E8LA+Lexp53‟, 
showing that in the „Lexp53 setting‟ pGL3-B8LA and pGL3-E8LA constructs 
behave similarly. However there are statistically significant differences between 
the cells treated with „P8LA+Lexp53‟ and those with „B8LA+Lexp53‟ and 
„E8LA+Lexp53‟, except in CMT3 cells between „P8LA+Lexp53‟ and 
„E8LA+Lexp53‟, showing that greater activity is achieved with a construct 
containing a promoter sequence. 
The D17 and CMT3 cells treated with „B8LA+Lexp53‟, „E8LA+Lexp53‟ or 
„P8LA+Lexp53‟ did not produce statistically significantly higher FFluc readings Chapter 4 ~ TP53 as a Target for Canine OS Gene Therapy 
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than their respective counterparts treated without „Lexp53‟, except in the 
„B8LA‟ treated D17 cells. Whereas there is a statistically significant difference 
between the CMT7 cells treated with „B8LA+Lexp53‟, „E8LA+Lexp53‟ or 
„P8LA+Lexp53‟ and those without „Lexp53‟. In the CMT8 cells, there is also a 
statistically significant difference between the cells treated with „B8LA+Lexp53‟ 
or „E8LA+Lexp53‟ and those without „Lexp53‟ but not between those treated 
with „P8LA+Lexp53‟. This indicates that in the D17 and CMT3 cell lines, as they 
possess low levels of TP53, FFluc expression is unable to be increased, whereas 
the CMT7 cells containing high levels of accumulated TP53 are able to increase 
FFluc expression. These findings are in agreement with the previous DLR 
experiments. However, there is evidence in this experiment that, in the absence 
of the SV40 promoter in the pGL3-B8LA and pGL3-E8LA constructs, the levels of 
TP53 present in CMT8 cells may be able to significantly increase the expression 
of FFluc. But in the presence of SV40 promoter, this significance is lost in the 
CMT8 cells regardless of endogenous TP53 levels, probably due to the inherent 
strength of the SV40 promoter in pGL3-P8LA to drive FFluc expression.  
 
Group Treatment  D17  CMT3  CMT7  CMT8 
1  NTC  All other treatments  All other treatments  All except 2  All other treatments 
2  Carrier  All except 4  All other treatments  All except 1  All other treatments 
3  Control  1, 2, 4, 5, 7, 8  1, 2, 4, 5, 7, 8  All except 6  1, 2, 4, 5, 7, 8 
4  B8LA  All except 2  1, 2, 3, 6, 8, 9  All other treatments  All other treatments 
5  E8LA  1, 2, 3, 4, 6, 9  1, 2, 3, 6, 9  All other treatments  All except 7 
6  P8LA  1, 2, 4, 5, 7, 8  1, 2, 4, 5, 7, 8  All except 3  1, 2, 4, 5, 7, 8 
7  B8LA+Lexp53  1, 2, 3, 4, 6, 9  1, 2, 3, 6, 9  All except 8  1, 2, 3, 4, 6, 9 
8  E8LA+Lexp53  1, 2, 3, 4, 6, 9  1, 2, 3, 4, 6  All except 7  All except 7 
9  P8LA+Lexp53  1, 2, 4, 5, 7, 8  1, 2, 4, 5, 7  All other treatments  1, 2, 4, 5, 7, 8 
 
Table 4.9: Post hoc pairwise comparisons of treatment groups in Figure 4.15, 
listing the treatment groups which were significantly different from each group 
for each of the D17, CMT3, CMT7 and CMT8 cell lines (significance was set at p = 
0.05).  
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Figure 4.15: Dual-Luciferase® Reporter analysis of pTargeT-Lexp53 (Lexp53) in combination with either pGL3-Basic 8LexA Op (B8LA), pGL3-Enhancer 8LexA Op 
(E8LA), or pGL3-Promoter 8LexA Op (P8LA), and pRL-TK as the co-reporter in the D17 (A), CMT3 (B), CMT7 (C) and CMT8 (D) cell lines. („NTC‟ – non-transfected 
cells; „Carrier DNA‟ - pBLCAT6 and pRL-TK; „Control‟ - pGL3-Control, pBLCAT6 and pRL-TK; „B8LA‟ – pBLCAT6, pGL3-B8LA and pRL-TK; „E8LA‟ – pBLCAT6, pGL3-
E8LA and pRL-TK; „P8LA‟ – pBLCAT6, pGL3-P8LA and pRL-TK; „B8LA+Lex-p53‟ - pGL3-B8LA, pTargeT-Lex-p53 and pRL-TK; „E8LA+Lex-p53‟ - pGL3-E8LA, pTargeT-
Lex-p53 and pRL-TK; „P8LA+Lex-p53‟ - pGL3-P8LA, pTargeT-Lex-p53 and pRL-TK). Firefly luciferase activity was normalized using pRL-TK. Each assay (4 
replicates/transfection) repeated in duplicate; bars represent +/-SE. Please note different scales on Y-axes. 
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4.4 Discussion 
4.4.1 Detection of endogenous TP53 and expression of proteins by pTargeT-
Lexp53, pTargeT-p53FL & pTargeT-LexDBD  
The CM-1 rabbit-origin polyclonal antibody is raised against recombinant human 
wild-type TP53 produced in a bacterial expression system (Bartek et al., 1991). 
CM-1 recognizes, in humans, a range of TP53 epitopes, including those present in 
wild-type and several forms of mutant TP53 (Aprikian et al., 1994; Auvinen et 
al., 1994). The CM-1 antibody has been used previously to successfully detect 
both wild-type and accumulated canine TP53 in a number of different types of 
neoplasms, including OS (Gamblin et al., 1997; Sagartz et al., 1996). It was 
demonstrated in this study that it is also able to recognize the canine wild-type 
TP53 expressed by pTargeT-p53FL and detect the presence of endogenous TP53 
in the NTC lysates of CMT7 cells, CMT8 cells and possibly in CMT3 cells; 
endogenous TP53 was not detected in D17 cells. Since the half-life of mutant 
TP53 is long (up to 12 hours) and wild-type TP53 half-life is comparatively short 
(30 minutes), it is assumed that the amount of wild-type TP53 stained by CM-1 is 
negligible (Jaffe et al., 2000). Immunopositivity is often accepted as evidence of 
an underlying TP53 abnormality, because there is a strong positive correlation 
between immunopositivity and the possession of missense base substitutions in 
TP53 as previously discussed in 1.3.3.3 (Gamblin et al., 1997; Haga et al., 2001; 
Hall & Lane 1994). Hence, it can be proposed that CMT7 and CMT8 cells, and 
maybe CMT3 cells, possess accumulated TP53, and D17 cells do not. These 
results are in agreement with a number of studies. DNA sequence analyses of 
TP53 from each of the cell lines CMT7, CMT8 and CMT3 have been shown to 
contain missense mutations (Hellmen 1992; Van Leeuwen et al., 1996), and the 
sequence in D17 cells found to be that of wild-type TP53 (Sabine et al., 1999).  
The transfected pTargeT-Lexp53 construct was detected, with both CM-1 and 
anti-LexA antibodies, in the cell lysates from the four cell lines, which indicates 
that CM-1 is able to bind to the C-terminal domain of TP53 present in pTargeT-
Lexp53. Although no bands were visible using the CM-1 antibody to detect 
pTargeT-Lexp53 binding to accumulated endogenous TP53 in CMT3, CMT7 and 
CMT8 cells. There is possible evidence that this interaction can be detected as 
faint bands were detected in the immunoblot, in the expected region of 97kDa, Chapter 4 ~ TP53 as a Target for Canine OS Gene Therapy 
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using the anti-LexA antibody. This result may be due to the length of time the 
endogenous TP53 is bound to the C-terminal domain of TP53 in pTargeT-Lexp53 
as the on/off rate of TP53 DNA binding is in the order of seconds (Bargonetti et 
al., 1992). At any one point in time only a percentage will be bound and the 
level of detection will depend on the number bound.  Hence, the number of 
bound molecules was probably below the detection limit of the ECL
TM western 
blotting analysis system (Amersham Pharmacia Biotech). No binding was 
detected in the D17 cell lysates, as expected, as these cells contain wild-type 
TP53, which has a short half-life.  
An improvement in further studies would be to determine if binding could be 
detected by using a more sensitive chemiluminescent method. Although, the 
ECL
TM western blotting analysis system is well-publicized and can detect down to 
low-picogram (10
-12) quantities, kits are commercially available that possess 
detection limits of zeptomole amounts (10
-20) e.g. ECL Advance Western Blotting 
Detection Kit (Amersham Biosciences), and SuperSignal® West Femto Maximum 
Sensitivity Substrate Kit (PIERCE). In addition, the cell lysates in this study were 
prepared using a standard protocol, which may be suitable for enabling the 
detection of stable protein expression but not necessarily for transient binding. 
Thus, this method should be optimized for the detection of p53-p53 protein 
interactions. Furthermore, the expression of Lexp53, full-length TP53, and LexA 
DNA binding domain proteins were determined after a single time point (48 
hours post-transfection), hence, it would be worthwhile investigating the 
expression levels of these proteins over a time course. 
 
4.4.2 Analysis of exogenous wild-type TP53 delivery  
The expression of full-length p53 by pTargeT-p53FL did not reduce the survival 
of the D17, CMT3, CMT7 and CMT8 cells employed in this study. Acceptable 
levels of transfection efficiency were deemed to be achieved for each cell line 
(D17 cells, 18.1%; CMT3 cells, 19.7%; CMT7 cells, 10.0%; and CMT8 cells, 4.75%). 
These percentages are comparable to those previously reported using cationic 
liposomes to deliver -gal expression plasmid into human OS cells (11.5-17%) 
(Nakase et al., 2005b), and wild-type TP53 into human HNSCC (5-20%) (Xu et al., Chapter 4 ~ TP53 as a Target for Canine OS Gene Therapy 
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1997). These 4 cell lines were used in this study as they were the only canine OS 
cell lines available in-house at the time of the study. To the best of my 
knowledge, the introduction of exogenous wild-type TP53 has only been 
previously reported in D17 cells, in one publication, in which D17 cells were 
stably transfected with wild-type TP53 and decreases in cell survival were 
achieved above radiation doses of 1 Gy (Shiomitsu et al., 2008). Hence, it 
appears that in this study by Shiomitsu et al., (2008), the upregulation of TP53 
expression also had no inhibitory effect, by itself, on the growth of D17 cells. 
The results obtained in this study and by Shiomitsu et al., (2008), are in contrast 
to two other studies investigating the delivery of wild-type TP53 in canine OS 
cells, in which cell proliferation was found to be inhibited and apoptosis induced 
in vitro (Yazawa et al., 2003b) and in vivo (Kanaya et al., 2005). However, a 
total of 3 different canine OS cell lines were utilized in these 2 studies and the 2 
cell lines in the in vitro studies were TP53 null (in vivo study contained a mutant 
TP53 cell line). Contrasting results have also been demonstrated in human OS in 
vitro and in vivo studies, in which the restoration of wild-type TP53 has proved 
to be both ineffective in some cells lines, possessing wild-type and mutant TP53, 
but in others, either TP53 null or containing wild-type or mutant TP53, cell 
proliferation was reduced and apoptosis induced (Densmore et al., 2001; Endo et 
al., 2001; Nakase et al., 2005a; Oshima et al., 2007). Hence, showing that the 
differences in the results obtained in canine OS cell lines, including those in this 
study, are in agreement with those previously published in human OS in vitro 
studies. Furthermore, the delivery of wild-type TP53 into human OS cells only 
inhibited cell proliferation and induced apoptosis in some studies, if it was 
introduced in combination with chemotherapy (Endo et al., 2001; Ganjavi et al., 
2006).  
Several explanations have been proposed for these varying results. Firstly, 
differences observed may be due to the small number of OS cell lines studied, 
particularly canine cell lines. Secondly, variations in experimental conditions 
employed. For example, previous studies using adenoviral constructs have 
reported dose-dependent, p53-specific effects as higher levels of TP53 transfer 
and expression correlated with a greater efficiency in inhibiting DNA synthesis of 
infected cells (Harris et al., 1996; Hellwinkel et al., 2005; Wills et al., 1994). 
Additionally, the cellular level of transduced wild-type TP53 dictates the Chapter 4 ~ TP53 as a Target for Canine OS Gene Therapy 
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response of the cell because in vitro, p53-induced apoptosis seems to occur only 
above a certain percentage of transfected cells (Gomez-Manzano et al., 1996). 
Thus, the amount of pTargeT-p53FL introduced and/or wild-type TP53 
expressed, following delivery of pTargeT-p53FL into D17, CMT3, CMT7 and CMT8 
cells, may not have been sufficient to have an inhibitory effect on cell 
proliferation. In addition, the half-life of full-length TP53 expressed by pTargeT-
p53FL was unknown, thereby requires investigation. Although the optimal 
amount of pTargeT-p53FL was delivered into the four cell lines using the 
Transfast
TM transfection reagent, a cationic liposomal based method, 
improvements in further studies would be to investigate alternative methods of 
gene delivery or increase the transfection efficiency gained using this method. 
This could be achieved with regard to the next explanation. The presence of 
specific cell surface receptors, can increase the uptake of gene delivery vectors 
e.g. targeting of EGFR improves adenoviral gene delivery into human OS cells by 
10-fold (previously described in 1.2.3.1) (Witlox et al., 2002), and efficient 
induction of apoptosis in OS cells, following delivery of wild-type TP53, using an 
Ad5-based adenoviral vector, can only be achieved if OS cells express high levels 
of Ad5 receptors (Hellwinkel et al., 2005). Furthermore, the transfection 
efficiency of cationic liposomes in human OS cells has been improved with the 
use of magnetic cationic liposomes, which subsequently increased the level of 
apoptosis (Hirao et al., 2003), and the presence of transferrin receptor ligand on 
the liposomes, enabling receptor-mediated endocytosis to occur (Nakase et al., 
2005a; Pirollo et al., 2000). Transferrin receptors (TfR) levels are elevated in 
various types of cancer cells, including OS and correlate with the aggressive or 
proliferative ability of tumour cells (Cheng 1996; Thorstensen & Romslo 1993). 
Finally, generally only the TP53 status of the cell lines are known, while 
knowledge of the abnormalities in the TP53 signalling networks are limited, 
differences in individual molecular pathologies of different cancer lines do vary, 
each having a different impact on TP53 function, even if TP53 is wild-type 
(Momand et al., 1998; Ternovoi et al., 2006; Trotman & Pandolfi 2003). For 
example, elevated MDM2 protein levels may enhance the degradation of TP53, 
particularly in tumour cells, including OS, possessing endogenous wild-type TP53 
(Ternovoi et al., 2006), and other genetic alterations may impair the ability of 
TP53 to trigger
 an apoptotic response (Atencio et al., 2001; Fulci et al., 2000; Chapter 4 ~ TP53 as a Target for Canine OS Gene Therapy 
 
154 
Ternovoi et al., 2006). Although D17 cells possess endogenous wild-type TP53 
(Sabine et al., 1999; Shiomitsu et al., 2008), and it is accepted that the efficacy 
of exogenous wild-type TP53 in human tumour cells, containing wild-type TP53, 
including OS, is likely to be less than that observed in tumour cells possessing 
null or mutant TP53 (Harris et al., 1996; Tang et al., 2004; Tsuchiya et al., 
2000). Mutant TP53 whilst retaining certain functions of the wild-type molecule, 
react very differently to the introduction of TP53 than a straightforward TP53 
inactivation (TP53 somatic deletion and knockout cells) (Cimoli et al., 2004). In 
addition, different mutant TP53 may vary in their individual mechanism of 
response to the introduction of wild-type TP53, because of the diverse 
mechanism of action of different TP53 mutants (Cimoli et al., 2004). Hence, the 
effects of the introduction of wild-type TP53 on cell growth, including D17, 
CMT3, CMT7 and CMT8 cells, are likely to be different than that hypothesized or 
demonstrated in other cell lines, regardless of the known endogenous status of 
TP53. Furthermore, the transcriptional regulation of expression of exogenous 
TP53 in different cell lines may be affected differently by the same promoter-
enhancer (Lu et al., 2002).  
These explanations, particularly the latter two, bear important potential 
consequences for the clinical use of the restoration of TP53 approach. The 
extrapolation of these findings on cell lines to that of a patient‟s tumour, 
indicate that knowledge of the TP53 status alone will be highly unlikely to 
succeed in trying to determine the response of a patient to this strategy. Indeed, 
the therapeutic benefit observed in clinical trials, carried out following 
preclinical studies that reported successful results, were lower than expected. 
Therefore, even though suggestions have been made to modify and improve the 
methodology employed in this study, in an attempt to determine if cell survival 
can be reduced following expression of wild-type TP53 in D17, CMT3, CMT7 and 
CMT8 cells, it is doubtful if these results would be translated positively in an in 
vivo setting. Hence, investigations into the effects of the TP53-targeted suicide 
gene therapy strategy are warranted on the D17, CMT3, CMT7 and CMT8 cell 
lines. 
 Chapter 4 ~ TP53 as a Target for Canine OS Gene Therapy 
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4.4.3 Analysis of vectors required for TP53-targeted suicide gene therapy 
strategy using Dual-Luciferase® Reporter Assay System 
4.4.3.1 Optimization of Dual-Luciferase® Reporter Assay System co-reporter 
vectors  
pGL3-Control was utilized in this experiment, due to the information provided by 
the manufacturer protocol, stating that pGL3-Control provides an indicator to 
the efficacy of the assay itself as it can produce strong expression of FFluc in 
many mammalian cell types due to the possession of SV40 promoter and 
enhancer sequences. Although, to the best of my knowledge, the use of pGL3-
Control has not been previously reported in the D17, CMT3, CMT7 and CMT8 
canine cell lines, it has been used in MDCK cells (Campbell et al., 2001; Yoshida 
et al., 2002). Hence, the expression of FFluc from pGL3-Control observed 
following transfection in the cell lines in this study, appears to be remarkably 
low for that expected from a positive control, as a statistically significant 
difference was expected with the NTC. As significant differences were not 
observed, this entire assay should have been repeated twice more, as is standard 
practice, and because of the anomalous results observed in the CMT3, CMT7 and 
CMT8 experiments. 
It was observed in this experiment that generally low levels of background firefly 
and Renilla luminescence were recorded in the NTC. In addition, reduced levels 
of background Renilla luminescence were usually determined in the cells only 
transfected with pGL3-Control. It has been reported that as the FFluc and Rluc 
enzymes are not endogenously expressed in mammalian cells, all background 
measurements, typically arise from the instrumentation and/or the sample 
plates (Promega Corporation 1999). In addition, some of the background Renilla 
luminescence activity can be attributed to Rluc substrate, coelenterazine. It has 
been documented that the primary limitation of Rluc assay chemistry is the 
emission of a low level non-enzymatic background luminescence, termed „auto-
luminescence‟ as a result of coelenterazine rapidly undergoing non-enzymatic 
oxidation as a result of being unstable in cell culture media (Hawkins et al., 
2005; Promega Corporation 2003; Wood 1998). Furthermore, the level of auto-
luminescence can be increased by the presence of lipids and proteins found in 
cell lysates and detergents used in cell lysis buffers to protect the luminescent Chapter 4 ~ TP53 as a Target for Canine OS Gene Therapy 
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excited state from quenching by water (Promega Corporation 2003; Wood 1998). 
Although the reagents in the DLR Assay System are formulated to minimize the 
level of coelenterazine auto-oxidation, they are not 100% effective because the 
presence of small amounts of detergents are still required to enable cell lysis to 
occur (Sherf et al., 1996).  
Similar FFluc activities were generally observed between the cells transfected 
with pGL3-Control in combination with pRL-CMV or pRL-TK at 5:1, 10:1 and 25:1. 
The only probable indication of a trans effect by the CMV promoter was 
observed in the CMT7 cells, as the FFluc activities of the cells transfected with 
pGL3-Control in combination with pRL-CMV at 10:1 were statistically significant 
higher than those cells transfected with pGL3-Control in combination with 
pRL:CMV at 25:1.  
It was apparent however, that statistically significantly differences occurred 
between the FFluc activities produced in the cells only transfected with the 
pGL3-Control vector to those co-transfected with either of the pRL-reporter 
vectors. One of the main requirements of the experimental and control reporters 
is that they should both be devoid of undesirable regulatory sites in the gene 
sequence so that their expression should not interfere significantly with the 
expression of the other. However, these findings suggest that a regulatory 
sequence(s) may exist within the backbone of the pRL- and/or pGL3- vector, 
which is interacting with the presence of an unknown transcription factor, to 
artificially increase the activities of FFluc and Rluc. This would result in the 
normalization of FFluc activity, in the subsequent DLR experiments, to be 
inaccurately calculated. 
Indeed, since the DLR experiments were performed in this study, the presence 
of ~300 consensus sequences for binding mammalian transcription factors have 
been identified in Rluc (Zhuang et al., 2001), and also a large number in both 
the FFluc gene, luc+ and the pGL3 Vector backbone (Bert et al., 2000; Paguio et 
al., 2005). These may yield high backgrounds and anomalous transcriptional 
behaviour in mammalian cells under certain experimental conditions, thereby 
compromising the gene‟s reliability as a reporter molecule (Bert et al., 2000; 
Thirunavukkarasu et al., 2000). For example, several of the consensus binding 
sites are for the GATA transcription factors and Ho and colleagues (2004), have Chapter 4 ~ TP53 as a Target for Canine OS Gene Therapy 
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reported that Rluc expression, by the pRL-TK and pRL-SV40 vectors, increased 2 
- 8 -fold following the co-transfection of plasmids expressing members of the 
GATA transcription factor family (Ho & Strauss 2004). Furthermore, several other 
research groups have also reported experimental evidence in which the co-
transfection of different pRL plasmids influenced the expression of the 
experimental vector and as a consequence, limited the evaluation of their 
results (Matuszyk et al., 2002; Mulholland et al., 2004). The DLR manual now 
recommends a charge ratio of experimental vector to pRL-vector from 10:1 to 
50:1; the optimization assay employed ratios of 5:1 – 25:1, the first DLR 
experiment, a ratio of 5:1, and the subsequent two experiments, 25:1. 
These studies highlight the need to be aware of potential artefacts when using 
reporter gene plasmids and assessing the results obtained, as well as ensuring 
suitable controls are included, as it is apparent that there may be major 
contributions to reporter gene expression from the vectors themselves. Thus, 
the presence of an unidentified transcription factor(s) in the solutions used in 
the co-reporter optimization assays was likely to have interacted with its 
respective binding site either in Rluc, FFluc gene, luc+ and/or pGL3 Vector 
backbone to result in the overall increased expression of FFluc.   
Zhuang and co-workers (2001) and Paguio and colleagues (2005), as a result of 
identifying the transcription factor binding sites in the native Rluc gene and 
luc+, developed synthetic Rluc, hRluc, and FFluc, luc2, genes and reporter gene 
vectors, the pGL4 Luciferase Reporter Vectors, respectively (Paguio et al., 2005; 
Zhuang et al., 2001). The number of mammalian transcription factor binding 
sites were reduced to an absolute minimum, thereby decreasing the risk of 
anomalous transcription behaviour and improving expression levels, sensitivity 
and reliability over the native Rluc and luc+ genes and pGL3 vector backbone in 
mammalian cells (Bhaumik et al., 2004; Paguio et al., 2005; Zhuang et al., 
2001). Additionally, the resultant increase in Rluc expression enables the risk of 
trans effect to be reduced because instead of strong promoters being used in the 
control reporters, weaker ones can be employed (Zhuang et al., 2001). 
Furthermore, both hRluc and luc2 were cloned into the pGL4 Luciferase Reporter 
Vectors, obviously creating a greater structural similarity between a pGL4 
control reporter and a pGL4 experimental reporter than that of a pGL3 Vector to Chapter 4 ~ TP53 as a Target for Canine OS Gene Therapy 
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a pRL Vector. This structural similarity may enable the pGL4 Vectors to respond 
similarly to any biochemical changes that might occur, thereby resulting in the 
accuracy of normalization potentially being greater than that previously 
obtained with a pGL3 experimental reporter and a pRL control reporter. 
Thus it would certainly be worthwhile analysing pGL4.13[luc2/SV40] instead of 
pGL3-Control as the experimental reporter and pGL4.74[hRluc/TK] and 
pGL4.75[hRluc/CMV] instead of pRL-TK and pRL-CMV, respectively, as the 
control reporters, in future DLR assays, as a means for improving independent 
genetic expression from the reporter vectors. This would also hopefully reduce 
the difference in FFluc expression observed between pGL4.13[luc2/SV40] alone 
with that of pGL4.13[luc2/SV40] in combination with either pGL4.74[hRluc/TK] 
or pGL4.75[hRluc/CMV]. In addition, a further control that could be employed in 
future studies, is the transfection of pGL4.74[hRluc/TK] and 
pGL4.75[hRluc/CMV] alone as the transfection of the pRL vectors alone was not 
carried out in the co-reporter optimization assays. This would be used to confirm 
that pGL4.74[hRluc/TK] and pGL4.75[hRluc/CMV] are themselves not 
contributing directly to FFluc2 activity expressed from pGL4.13[luc2/SV40]. Any 
abnormal expression that did occur was again possibly due to the presence of 
the unknown transcription factors being able to bind to regulatory sequences. 
These control transfections could also be used to determine the level of hRluc 
expression from pGL4.74[hRluc/TK] and pGL4.75[hRluc/CMV], in the absence of 
an experimental reporter, as a means for comparing to the hRluc activity gained 
following co-transfection with pGL4.13[luc2/SV40].   
 
4.4.3.2 Dual-Luciferase® Reporter Assay System experiments  
In the first DLR experiment, although pRL-CMV was used and at a ratio that 
would have permitted a trans effect to occur, this experiment did demonstrate 
promising initial results, as the p53-targeted gene therapy system appeared to 
function as designed. In that not only were high levels of FFluc expression 
observed with the introduction of pTargeT-p53FL (positive control), in 
combination with pTargeT-Lexp53 and pGL3-P8LA, into D17, CMT3, CMT7 and 
CMT8 cells, but also, after the transfection of pTargeT-Lexp53 in combination Chapter 4 ~ TP53 as a Target for Canine OS Gene Therapy 
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with pGL3-P8LA in the CMT7 cells. These observations were generally confirmed 
in the subsequent two DLR experiments. In addition, in the third DLR 
experiment, a significant difference was also observed between the CMT7 cells 
treated with „B8LA+Lexp53‟ and „E8LA+Lexp53‟ to those treated without 
„Lexp53‟. These results indicate that the canine TP53 C-terminus of the Lexp53 
protein expressed by pTargeT-Lexp53 is able to recruit the transactivation 
domain of the accumulated TP53 present in the CMT7 cells and bind to the 8 
LexA Op in pGL3-8LA, to significantly increase FFluc expression. In comparison, 
in the D17 and CMT3 cells, possessing none and low levels of accumulated TP53, 
non-significant levels of FFluc expression were found. Thereby, indicating that 
the presence of accumulated TP53 is able to drive the expression of FFluc, which 
is in agreement with the results previously published by Da Costa et al, (1996) 
(Da Costa et al., 1996). Also providing further evidence that canine TP53 C-
terminus is similar in function, as well as structure, to human TP53 C-terminus. 
It was observed however, that although CMT8 cells were proposed to contain 
accumulated TP53 (as previously described in 4.4.1), no significant increase in 
FFluc expression occurred in the first two DLR experiments. This could possibly 
be due to either the mutation already known to be present in CMT8 TP53 
inhibiting the interaction between the transactivation domain and Lexp53 
protein, or, an unknown mutation is located in the transactivation domain as 
TP53 mutational analysis of the first 108 codons has not yet been reported in the 
CMT8 cell line (Van Leeuwen et al., 1996). Although both explanations are not 
commonly reported (as previously described in 1.3.3.1 and 4.1.1.3), they are 
still likely to occur. In addition, as mentioned in 4.4.2, the differences in 
individual molecular pathologies and differentiations of different cancer lines, 
does not enable knowledge of the endogenous TP53 status to be entirely 
predictive for a response to a TP53-based gene therapy. However, in the third 
DLR experiment utilising pGL3-B8LA and pGL3-E8LA in addition to pGL3-P8LA, 
there is evidence that the lack of a significant increase in FFluc expression may 
be due to the ability of SV40 promoter in pGL3-P8LA to drive FFluc expression to 
such an extent that it „swamps‟ the effect of the endogenous TP53 present, as a 
significant difference is observed in the absence of the SV40 promoter. Hence, 
further investigations are warranted to study these different explanations. 
Additionally, the reduction in the number of LexA operator sites upstream of the Chapter 4 ~ TP53 as a Target for Canine OS Gene Therapy 
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luciferase gene should be analysed. This is because the greater the number of 
LexA sites, the weaker the interaction that can be detected, however, the 
number of false positives measured may increase. In contrast, using a smaller 
number of upstream sites would reduce the number of false positives and 
increase the stringency of the protein-protein interactions detected. 
Furthermore, optimizations into the amounts of different constructs transfected 
into the cells treated with „Control‟, „8LA‟, and „Lex-p53‟ should be performed, 
as this was not done.  
Although a trans effect was only apparent in the optimization assay employing 
CMT7 cells, there did appear to be one between the DLR experiments as there 
was an overall reduction in FFluc expression between the first DLR experiment 
using pRL-CMV as the co-reporter, at a ratio of 5:1, and the second and third 
DLR experiment, using pRL-TK at a ratio of 25:1. In addition to this trans effect, 
it has also been reported that pRL-TK is unresponsive to human TP53 (Thavathiru 
& Das 2001). In the first DLR experiment, the D17, CMT3, CMT7 and CMT8 cells 
treated with „p53FL‟ all produced FFluc expression levels significantly greater 
than the cells treated with „P8LA‟. In comparison, in the second experiment, 
significantly lower FFluc expression levels were observed (except for CMT3 
cells). Hence, not only indicating that pRL-TK may also be unresponsive to 
canine TP53, but also that pRL-CMV is affected by TP53. Although the possibility 
exists that pTargeT-p53FL may not have been expressing TP53 as required to 
increase levels of TP53 present. However, the overall indication that pTargeT-
Lexp53 in combination with pGL3-P8LA was able to utilize accumulated TP53 
present in canine OS cells to drive FFluc expression did not appear to be 
affected by the use of either co-reporter, as similar results were obtained in all 
3 DLR experiments. 
Therefore, these DLR assays demonstrated the TP53-targeted suicide gene 
therapy strategy shows promise, enabling further investigations to take place, 
which are described in the next chapter. Briefly, the luciferase gene was 
replaced with a suicide gene to determine if, in combination with a prodrug, the 
significant differences observed in FFLuc activity with pTargeT-Lexp53 in 
combination with pGL3-P8LA, pGL3-E8LA and pGL3-B8LA resulted in significant 
reductions in survival of canine OS cells possessing accumulated TP53. 
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5.1 Introduction 
5.1.1 Suicide gene therapy in dogs 
A small number of suicide gene therapy studies, using HSV-TK/GCV or ACV and 
linamarase/linamarin, have been carried out in canine cell lines and Beagles, to 
investigate their potential as treatments for cancer (Garcia-Escudero et al., 
2008; Matsukura et al., 1999; Park et al., 2003; Rainov et al., 2000). 
Additionally, two Phase I/II canine clinical trials have been reported, one a 
clinical protocol for dogs with mammary tumours using cytochrome 
P450/cyclophosphamide (Winiarczyk et al., 2002), and the second, in dogs with 
melanoma using HSV-TK/GCV (Finocchiaro et al., 2008). In the study by 
Finocchiaro et al., (2008), survival was demonstrated to be significantly 
extended and toxicity levels observed were minimal (Finocchiaro et al., 2008). 
GCV treatment has also been reported to be well tolerated in healthy dogs with 
no significant toxicities occurring (Appelbaum et al., 1988; Link Jr et al., 2000). 
The canine herpesvirus TK has been cloned and characterized, but as yet has not 
been utilized in a suicide gene therapy study (Solaroli et al., 2006). As far as I 
am aware, there is no literature evaluating the use of suicide gene therapy in 
canine OS cell lines; hence, this study is likely to be the first. Studies have been 
performed investigating the use of suicide gene therapy in human OS in vitro and 
in vivo, including HSV-TK/GCV (Charissoux et al., 1999; Ketola et al., 2004), 
varicella-zoster virus (VZV)-TK/(E)-5-(2-bromovinyl)-2‟-deoxyuridine (BVDU) 
(Degreve et al., 1997), carboxylesterase-2/CPT-11 (Oosterhoff et al., 2003), and 
cytosine deaminase/5-FC (Ramnaraine et al., 2003). These studies demonstrated 
inhibition of tumour growth and induction of cytotoxicity and a proximal 
bystander effect was also observed following treatment with HSV-TK/GCV 
(Charissoux et al., 1999; Ketola et al., 2004) and cytosine deaminase/5-FC 
(Ramnaraine et al., 2003). Furthermore, Charissoux et al., (1999) reported that 
the HSV-TK/GCV prodrug system may have the potential to suppress pulmonary 
metastasis (Charissoux et al., 1999). As yet, no suicide gene therapy clinical 
trials have been performed in human OS patients. Although, a Phase II clinical 
study reported that after chemotherapy with 5-FU (active drug) in human OS 
patients, in addition to no objective responses, numerous grade 3/4 toxicities 
were observed (Pratt et al., 1994). Pratt and colleagues (1994) concluded no Chapter 5 ~ Suicide Gene Therapy for Canine OS 
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further evaluation of 5-FU would occur in patients with malignant solid tumours, 
including OS (Pratt et al., 1994). In addition, the use of 5-FU in the treatment of 
dogs with carcinomas of the mammary gland, gastro-intestinal tract, liver and 
lung, is at best palliative (Bishop 1996; Karayannopoulou et al., 2001; Yamashita 
et al., 2001). 5-FC is regarded not to be suitable as a prodrug in dogs, 
particularly those with cancer, as serious side-effects of 5-FU are well-
documented and which can be fatal after exposure to high levels (Davis et al., 
1994; Dorman et al., 1990; Hammer et al., 1994). However, S-1, a relatively new 
oral formulation of 5-FU, has been reported to have a low level of toxicity in 
Beagles (Kato et al., 2001), and human Phase II clinical trials (Saif et al., 2009). 
Furthermore, as therapeutic benefits were observed in patients with several 
different types of cancer, S-1 is currently being tested in a Phase III trial (Saif et 
al., 2009). 
Hence, investigations into additional suicide gene/prodrug systems, including 
E.coli NTR/CB1954, are warranted for canine cancers, in particular OS, to 
extend the publications currently available. In addition, all of the original 
toxicological work on CB1954 was performed in dogs (Workman et al., 1986b), 
and other aromatic nitrogen mustard alkylating agents, such as 
cyclophosphamide and chlorambucil are used therapeutically to treat a variety 
of different tumours in dogs (Ahrens, 1996). 
 
5.1.2 E.coli NTR/CB1954 system  
The E.coli NTR/CB1954 system is now established as a successful pre-clinical 
prodrug activating system. NTR is an enzyme (24kDa), encoded by the nfsB gene 
of E. coli, which contains flavin mononucleotide (FMN) cofactors and was 
originally identified through its involvement in bacterial sensitivity to nitrofuran 
antibiotics e.g. nitrofurazone (NFZ, 5-nitro-2-furaldehyde semicarbazone) 
(Searle et al., 2004). It is also oxygen-insensitive, enabling it to function even 
within hypoxic cells present in large solid tumours (Lemmon et al., 1997), and 
can be successfully introduced into a broad range of mammalian species 
(Blackwood et al., 2001; Denny 2003). NTR functions as a monomer, thus 
minimising the requirement for post-translational modifications and can reduce Chapter 5 ~ Suicide Gene Therapy for Canine OS 
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a variety of quinone and nitroaromatic substrates including non-toxic prodrugs, 
such as CB1954 (5(-aziridine-1-yl)-2,4-dinitrobenzamide)) into toxic metabolites. 
Its use however, is limited to the activation of intracellular prodrugs as it acts 
via a substituted enzyme („ping-pong‟) mechanism, which requires either 
reduced nicotinamide adenine dinucleotide (NADH) or reduced nicotinamide 
adenine dinucleotide phosphate (NADPH) cofactors to first reduce the tightly 
bound FMN molecule (Searle et al., 2004). In the second step, the substrates are 
then able to bind to NTR, which enables their reduction by FMN (Friedlos et al., 
1992a). Four broad classes of prodrugs for NTR have been described: 
dinitroaziridinylbenzamides, which includes CB1954; dinitrobenzamide mustards; 
4-nitrobenzylcarbamates; and nitroindolines; but the majority of current 
research to date has focussed primarily on CB1954 (Denny 2003).  
Although CB1954 is now regarded as a non-toxic prodrug, it was initially 
developed as a chemotherapeutic agent, which was found to be extremely 
selective and toxic against the rat Walker carcinoma 256 in vitro and in vivo 
(Cobb et al., 1969). Based on these results, in early 1970‟s CB1954 was entered 
into human clinical trials, but no anti-tumour effects were observed (Knox et 
al., 1993). In addition, CB1954 was found to possess no significant toxicity on 
several other animal or human tumours in vitro or in vivo (Connors & Melzack 
1971; Workman et al., 1986a). The sensitivity of the Walker tumour towards 
CB1954 was subsequently attributed to the rat NQO1 (DT diaphorase) enzyme, 
and that the human equivalent of this enzyme was far less efficient at reducing 
CB1954 to its cytotoxic metabolite (4-(N-acetoxy)-5-(aziridin-1-yl)-2-
nitrobenzamide) (Boland et al., 1991; Knox et al., 1991). The addition of this 
enzyme alone to cells normally insensitive to CB1954 resulted in a large increase 
in their sensitivity towards CB1954 (Knox et al., 1988). It was later determined 
that E. coli NTR could also reduce CB1954, increase sensitivity to CB1954 by 770-
fold compared to untransfected controls and is ~90-fold more efficient than rat 
NQO1 (Anlezark et al., 1992; Bailey et al., 1996; Knox et al., 1992). NTR 
converts CB1954 from a weak, monofunctional alkylating agent into a toxic 
bifunctional alkylating agent that can be upto 2000-fold more cytotoxic than 
CB1954 itself in human cancer cell lines (Green et al., 1997; Knox et al., 1988; 
Weedon et al., 2000). This is because activated CB1954 is capable of reacting 
with DNA to form a large number of interstrand DNA crosslinks, which are poorly Chapter 5 ~ Suicide Gene Therapy for Canine OS 
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repaired by the cell inducing p53-independent apoptosis (Cui et al., 1999; 
Friedlos et al., 1992c). Thus, activated CB1954 is independent of ongoing 
cellular DNA replication for its cytotoxicity and can kill both proliferating and 
non-proliferating cells (Bridgewater et al., 1995; Weedon et al., 2000). This is 
an advantage over, for example, activated GCV or 5-FU, as they are cell-cycle 
dependent and their toxicity is mainly restricted to cells in S-phase, which is 
further limited by there only being a small percentage of tumour cells 
proliferating at any one time (Bridgewater et al., 1995). As with the other 
enzyme/prodrug combinations, bystander cell killing has been observed with 
NTR/CB1954 due to local spread of the activated prodrug (Bridgewater et al., 
1997; Green et al., 1997; McNeish et al., 1998b). This enabled an antitumour 
effect to be achieved in vivo even when a minimal number of cells expressed 
NTR (Djeha et al., 2000). Furthermore, as the conversion of a prodrug by NTR to 
its active species relies on the presence of NADH, an intracellular co-factor, an 
element of safety is introduced, since no extracellular activation can occur 
(Palmer et al., 2004). Additionally, NADH is not a cofactor for human NQO1, 
hence it does not potentiate any unwanted CB1954 cytotoxicity (Friedlos et al., 
1992b). CB1954 is also toxic to tumours, which have acquired resistance to other 
chemotherapeutic agents e.g. cisplatin (McNeish et al., 1998b; Weedon et al., 
2000). 
The E. coli NTR/CB1954 system has shown high levels of selectivity (100-2000 
fold) in several pre-clinical studies, using a wide variety of human cancer cell 
lines in vitro (Bridgewater et al., 1995; Green et al., 1997; McNeish et al., 
1998a), and in tumour xenografts (Djeha et al., 2000; McNeish et al., 1998a; 
Weedon et al., 2000). In addition, this system has been used to indirectly inhibit 
the growth of tumour cells possessing mutant TP53, in which NTR expression was 
placed under the control of the HSP70 promoter (Lipinski et al., 2001). Following 
systematic treatment with CB1954, toxicity was achieved in the required 
cells/tissue, reducing tumour volume, whilst healthy cells containing wild-type 
TP53 remained unaffected. Furthermore, clinical trials have been carried out 
separately with NTR and CB1954 in human cancer patients, which demonstrated 
that they were well tolerated at doses required for use in combination with each 
other (Chung-Faye et al., 2001; Palmer et al., 2004). Recently, results from the 
first Phase I/II clinical trial of NTR in combination with CB1954, carried out in Chapter 5 ~ Suicide Gene Therapy for Canine OS 
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prostate cancer patients, were reported (Patel et al., 2009). Minimal levels of 
toxicity were observed and there was evidence of a time-delay in progression of 
prostate specific antigen.  
 
5.1.3 Nitrofurazone 
Several alternative prodrugs have been investigated as to their efficacy with 
NTR, in the hope of revealing more potent and selective killing of cells and/or 
superior bystander effect than that obtained with CB1954. In particular, Bailey 
et al., (1996) reported that NTR reduced NFZ more actively than CB1954 (Bailey 
et al., 1996). NFZ has a wide range of antimicrobial effects, and is used in both 
human and veterinary medicine (Hiraku et al., 2004; Kobierska-Szeliga & 
Czeczot 1994). Although, cytotoxic analyses of Chinese hamster lung V79 cells 
revealed that CB1954 was actually more cytotoxic than NFZ to NTR-expressing 
cells than non-expressing cells by ~8-fold, NFZ still exhibited 97-fold differential 
cytotoxicity between NTR- and non- expressing cells (Bailey et al., 1996).  
 
5.1.4 Summary  
The E.coli NTR/CB1954 system possesses several intrinsic advantages that are of 
potential value for its use as a treatment for canine OS. Firstly, NTR is oxygen-
insensitive, enabling it to function even within hypoxic cells present in large 
solid tumours (Lemmon et al., 1997), and it can be introduced into a wide range 
of mammalian species (Blackwood et al., 2001; Denny 2003). Secondly, CB1954 
is not dependent on a cell cycle phase (Bailey & Hart 1997), and all the original 
toxicological work on CB1954 was performed in dogs (Workman et al., 1986b). 
Finally, NTR-mediated cell death by CB1954 is very rapid and of particular 
importance to this study is that it is by a TP53-independent apoptotic pathway 
(Cui et al., 1999). In addition, NFZ is a well-known veterinary antimicrobial drug 
accepted for use in dogs (Hiraku et al., 2004).  
Hence, the aims of this chapter were two-fold. Firstly, to perform preliminary in 
vitro suicide gene/prodrug assays, using NTR in combination with CB1954 or NFZ, Chapter 5 ~ Suicide Gene Therapy for Canine OS 
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to assess the suitability of CB1954 and NFZ as prodrugs for use with NTR in 
several canine cell lines, primarily OS; thereby extending in vitro data on the 
effects of suicide gene therapy in canine cancer cells.  
Secondly, to replace the luciferase gene in the constructed vectors, belonging to 
the TP53-targeted suicide gene therapy strategy, with the NTR gene, to 
determine if the TP53-targeted suicide gene therapy strategy in combination 
with CB1954, translates the promising results obtained in the DLR experiments 
(Chapter 4), into significant reductions in survival of canine OS cells possessing 
accumulated TP53.  
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5.2 Materials & methods 
5.2.1 Optimization assays  
5.2.1.1 Cell number 
Cells were approximately 80% confluent on the day of transfection (2.2.9), as 
recommended by the manufacturer‟s instructions. For all of the transfections 
performed in this study, the day of transfection was 24 hours after the cells had 
been placed into the 96-well plates or 25cm
2 flasks. The canine cell lines 
employed in the NFZ (Sigma; Appendix A) assays were D17, CMT3, CMT7, CMT8, 
MDCK and CML-10 and in the CB1954 assays, D17 and CMT7 were used.   
The concentration of cells required to obtain 80% confluence for the D17, CMT3, 
CMT7 and CMT8 cells had been previously determined in 4.3.1.1. The MDCK and 
CML-10 cells were each cultured and maintained as described in 2.1.1. The 
determination of the concentration of cells required to obtain 80% confluence 
for the MDCK and CML-10 cell lines was carried out by plating the following cell 
concentrations into a 96-well plate, in quadruplicate per cell concentration (200 
l/well): MDCK - 50000 cells/ml (E. Gault, Department of Veterinary Clinical 
Studies, University of Glasgow; personal communication); and CML-10 - 75000 
cells/ml, due to the observation that these cells showed a similar growth rate to 
CMT3 and CMT8 cells.  
The percentage of cells confluent at each cell concentration was estimated by 
eye after 24 hours, enabling the concentration of cells required to achieve 80% 
confluence for the MDCK and CML-10 cell lines to be confirmed. 
 
5.2.1.2 DMSO 
Dimethyl sulphoxide (DMSO; Sigma) was used as the solvent for NFZ and CB1954 
(kindly donated by Dr. N. Keith, University of Glasgow; Appendix A). DMSO was 
applied at 0, 0.125, 0.25, 0.5, 1 and 2% to D17, CMT3, CMT7 and CMT8 cells, in 
quadruplicate, to determine the optimal percentage of DMSO that could be used 
in the final volume of prodrug for the subsequent assays. 
The D17, CMT3, CMT7 and CMT8 cell lines were each cultured and maintained 
(2.1.1), and 16-24 hours prior to DMSO treatment, seeded at the appropriate Chapter 5 ~ Suicide Gene Therapy for Canine OS 
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density (as determined in 4.3.1.1), per well of a 96-well plate. MDCK and CML-10 
cell lines were not available at the time of this optimization assay. 
Following 24 hours of DMSO treatment, the CellTiter 96® AQueous One Solution 
Cell Proliferation Assay (Promega; 2.2.10) was employed to determine cell 
numbers.  
The mean absorbance reading for each set of 4 wells was determined and the 
percentages of cell survival (+/-SE), compared to the cells treated with 0% DMSO 
(100%), were calculated. 
 
5.2.2 Construction of nitroreductase expression vectors 
The methods involved in constructing the NTR expression vectors are previously 
described in Chapter 2. Methods included DNA purification (2.2.3), restriction 
digestion (2.2.6), PCR (2.2.1), cloning (2.2.7) and DNA sequence analysis (2.2.5). 
PCR conditions are as previously described in 2.2.1 and details of primers used 
for PCR and DNA sequence analysis are displayed in Table 5.1.  
The construction of the NTR expression vectors, pGL3-Basic 8LexA Operator NTR 
(pGL3B8LA-NTR), pGL3-Enhancer 8LexA Operator NTR (pGL3E8LA-NTR) and 
pGL3-Promoter 8LexA Operator NTR (pGL3P8LA-NTR) involved the replacement 
of the luciferase gene in pGL3-B8LA, pGL3-E8LA and pGL3-P8LA vectors, 
respectively, with the NTR gene (Figure 5.1). This was carried out in 2 stages. 
The first stage involved the use of the PCR primers, „2NcoIpNTRF‟ and 
„XbaIpNTRR‟, to amplify the full-length NTR gene from the pCMVNTR expression 
vector (kindly donated by Dr. L. Blackwood, (Blackwood et al., 2001); Appendix 
C, Figure C8). The „2NcoIpNTRF‟ and „XbaIpNTRR‟ primers had been designed 
with NcoI and XbaI restriction enzyme sites, respectively, to enable the 
incorporation of NcoI and XbaI sites at the 5′ and 3′ -ends of the NTR PCR 
product, respectively. The NTR PCR product was electrophoresed on an agarose 
gel, extracted and purified.  
The second stage consisted of the excision of the luciferase gene and the 
ligation of the purified NTR PCR product into the pGL3-B8LA, pGL3-E8LA and Chapter 5 ~ Suicide Gene Therapy for Canine OS 
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pGL3-P8LA vectors, to create the NTR expression vectors, pGL3B8LA-NTR, 
pGL3E8LA-NTR and pGL3P8LA-NTR. This was achieved by digesting the pGL3-
B8LA, pGL3-E8LA and pGL3-P8LA vectors, each possessing NcoI and XbaI 
restriction enzyme sites at the 5′ and 3′ -ends of the luciferase gene, 
respectively, with the NcoI and XbaI restriction enzymes. The digested pGL3-8LA 
vectors were subsequently electrophoresed on an agarose gel, extracted and 
purified. The purified NTR PCR product was ligated into each of the purified 
pGL3-8LA vectors, at 4
oC for 20 hours, and cloned using JM109 competent cells 
(Promega). DNA sequence analysis was performed, using the „RV3primer‟ and 
„RV4primer‟ sequencing primers, to confirm that the NTR gene sequence had 
been correctly ligated into pGL3-B8LA, pGL3-E8LA and pGL3-P8LA (Figure 5.2).  
 
 
Primer  Reaction  Forward (F) /  Primer Sequence  Tm  Location (nts)  Vector(s) 
      Reverse (R)  (5′ --> 3′ orientation)          
2NcoIpNTRF  PCR  F  cca tgg cca tgg ata tca ttt ctg tcg  65  820-838  pCMVNTR 
XbaIpNTRR  PCR  R  tct aga tct aga tta cac ttc ggt taa gg  62.4  1458-1474  pCMVNTR 
RV3primer  Sequencing  F  cta gca aaa tag gct gtc cc  57.3  4760-4779; 5006-5025; 4952-4971  pGL3-B8LA; pGL3-E8LA; pGL3-P8LA 
RV4primer  Sequencing  R  gcg cgg ggc atg act atc gtc  61  2080-2061; 2326-2307; 2272-2253  pGL3-B8LA; pGL3-E8LA; pGL3-P8LA 
 
Table 5.1: Details of the oligonucleotide primers involved in the construction and DNA sequence analysis of the nitroreductase 
expression vectors, pGL3B8LA-NTR, pGL3E8LA-NTR and pGL3P8LA-NTR, from pGL3-B8LA, pGL3-E8LA and pGL3P8LA firefly luciferase 
reporter vectors, respectively, and pCMVNTR expression vector. For each primer the following information is provided: the sequence, 
acting as a forward (F) or a reverse (R) primer, annealing temperature (Tm) and nucleotide (nts) location on the particular vector 
undergoing PCR/DNA sequence analysis. Chapter 5 ~ Suicide Gene Therapy for Canine OS 
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Figure 5.1: Flow-diagram indicating the processes involved in the construction of 
the pGL3-8LexA Operator NTR expression vectors, pGL3-Basic 8Lex A Op NTR 
(lacks the SV40 Promoter and Enhancer sequences), pGL3-Enhancer 8LexA Op 
NTR (pGL3-Basic 8LexA Op NTR plus the SV40 Enhancer sequence) and pGL3-
Promoter 8LexA Op NTR (pGL3-Basic 8Lex A Op NTR plus the SV40 Promoter). 
The PCR primers, „2NcoIpNTRF‟ and „XbaIpNTRR‟ were used to amplify the NTR 
gene from the pCMVNTR vector.  Chapter 5 ~ Suicide Gene Therapy for Canine OS 
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Figure 5.2: Confirmation by DNA sequence analysis that the pGL3-8LexA 
Operator NTR expression vectors, pGL3-Basic 8LexA Op NTR (B), pGL3-Enhancer 
8LexA Op NTR (E) and pGL3-Promoter 8LexA Op NTR (P), contain the NTR gene. 
The sequences of the PCR primers „2KpnIpGL3F‟, „NheIpGL3R‟, „2NcoIpNTRF‟ and 
„XbaIpNTRR‟ and the KpnI, NheI, NcoI and XbaI restriction enzyme sites are 
shown.  The locations at which the SV40 promoter and enhancer sequences are 
positioned in the pGL3-Promoter 8LexA Op NTR (P) and pGL3-Enhancer 8LexA 
Operator (E) vectors, respectively, are also indicated. Chapter 5 ~ Suicide Gene Therapy for Canine OS 
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5.2.3 Detection of nitroreductase protein expression by pCMVNTR and 
pGL3B8LA-NTR, pGL3E8LA-NTR and pGL3P8LA-NTR, in combination with 
pTargeT-Lexp53 or pCMVCAT6  
5.2.3.1 Transfection of DNA & preparation of cell lysates for western blotting 
The 3 NTR constructs, pGL3B8LA-NTR, pGL3E8LA-NTR and pGL3P8LA-NTR, and 
the pTargeT-Lexp53, pCMVNTR and pCMVCAT6 (kindly donated by Dr. L. 
Blackwood; Appendix C, Figure C9) vectors were prepared using the QIAGEN 
EndoFree Plasmid Purification Maxi kit (2.2.8.3). All transfections were carried 
out, in duplicate, using the Transfast
TM reagent (Promega; 2.2.9). The pCMVNTR 
construct (positive control) was transfected into the D17, CMT3, CMT7, CMT8 
and MDCK cell lines and pGL3B8LA-NTR, pGL3E8LA-NTR and pGL3P8LA-NTR, with 
and without pTargeT-Lexp53, were transfected into D17 and CMT7 cells. The 
pCMVCAT6 vector was used as the carrier DNA to ensure all wells were 
transfected with similar amounts of DNA. The amounts of DNA of each vector 
transfected per combination per cell line are displayed in Table 5.2. CML-10 
cells were not used in this experiment as they had previously been shown to be 
difficult to transfect (E. Gault, Department of Veterinary Clinical Studies, 
University of Glasgow; personal communication).  
These 5 cell lines were each cultured and maintained (2.1.1) and 16-24 hours 
prior to transfection occurring, seeded at the appropriate density (as 
determined in 4.3.1.1 and 5.3.1.1) per 25cm
2 flask. A total of 3.25g and 6.5g 
of vector DNA were transfected per flask (as determined in 4.3.1.2) of D17 cells 
and CMT3, CMT7 and CMT8 cells, respectively. 6.5g of vector DNA were 
transfected per flask of MDCK cells (E. Gault, Department of Veterinary Clinical 
Studies, University of Glasgow; personal communication). One pair of flasks 
remained untransfected for each cell line to act as negative controls and enable 
the endogenous levels of NTR protein to be determined. 48 hours after 
transfection, the cells in each pair of flasks were harvested in protein treatment 
sample buffer (2.3.3.1) and the protein concentration determined (2.3.3). 
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5.2.3.2 SDS-PAGE and western blotting 
Following protein concentration determination, SDS-PAGE (2.3.3.1) was 
performed, in which 3 separate gels were used. The first gel was loaded, per 
lane, with 50g protein sample from each of the D17, CMT3, CMT7, CMT8 and 
MDCK cell lines transfected with pCMVNTR in combination with pCMVCAT6 and 
NTC lysates. 5ng purified E. coli NTR enzyme were also loaded as a positive 
control. In the second and third gels, 25g protein sample from each of the D17 
and CMT7 cells, respectively, transfected with pCMVCAT6 alone, pCMVNTR in 
combination with pCMVCAT6, pGL3B8LA-NTR, pGL3E8LA-NTR and pGL3P8LA-NTR 
in combination with pCMVCAT6 or pTargeT-Lexp53 and NTC lysates, were loaded 
per lane. Western blotting was subsequently carried out using a primary 
antibody of rabbit antiserum raised against E.coli NTR, kindly provided by Dr. G. 
Anlezark (Centre for Applied Microbiology and Research, Porton Down, Salisbury) 
(Anlezark et al., 1995) (2.3.3). The primary antibody was detected by a 
secondary anti-rabbit horseradish peroxidase conjugated antibody.   
 
 
   NTR  CAT  B/E/P  B/E/P+Lp 
Cell Line  D17  CMT3, CMT7, CMT8 & MDCK  D17  CMT 7  D17  CMT7  D17  CMT7 
 
  pCMVCAT6  2.6  5.2  3.25  6.5  2.6  5.2  -  - 
Vector DNA  pTargeTLex-p53  -  -  -  -  -  -  2.6  5.2 
(g)  PGL3-8LANTR (B, E or P)  -  -  -  -  0.65  1.3  0.65  1.3 
 
  pCMVNTR  0.65  1.3  -  -  -  -  -  - 
Total amount of DNA transfected (g)  3.25  6.5  3.25  6.5  3.25  6.5  3.25  6.5 
 
Table 5.2: The amounts of DNA (in g) and combinations of vectors transfected, to enable the detection of NTR expression by:  
pCMVNTR in combination with pCMVCAT6 (NTR) in D17, CMT3, CMT7, CMT8 and MDCK cells; and pCMVCAT6 (CAT), and pGL3B8LA-NTR, 
pGL3E8LA-NTR and pGL3P8LA-NTR, in combination with pCMVCAT6 (B/E/P, respectively), or pTargeT-Lexp53 (B/E/P+Lp, respectively), 
in D17 and CMT7 cells. Chapter 5 ~ Suicide Gene Therapy for Canine OS 
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5.2.4 Analysis of pCMVNTR in combination with nitrofurazone  
The pCMVNTR and pCMVCAT6 vectors were used to investigate the effects of 
NFZ, following the transfection of pCMVNTR, on the survival of D17, CMT3, 
CMT7, CMT8, MDCK and CML-10 cells. 3 main assays were performed: 
(i), D17 assays consisting of 2 preliminary experiments and 1 „proper‟ 
experiment; 
(ii), CMT3, CMT7 and CMT8 assays composed of 4 preliminary experiments and 1 
„proper‟ experiment; 
(iii), non-OS cell line assays in which experiments on MDCK and CML-10 cells 
were performed. 
All the experiments assessed the transfection of pCMVNTR in combination with 
pCMVCAT6 (acting as carrier DNA) and NTC, except for the CML-10 cells in which 
only NTC were studied. The D17 „proper‟ experiment also examined the 
transfection of pCMVCAT6 alone. The preliminary experiments were each 
performed once and the „proper‟ experiments in triplicate, unless otherwise 
stated.  
The pCMVNTR and pCMVCAT6 vectors were prepared using the QIAGEN EndoFree 
Plasmid Purification Maxi kit (2.2.8.3). Each vector was transfected into the cell 
lines using the Transfast
TM reagent (Promega; 2.2.9), in quadruplicate per time 
point. The CellTiter 96® AQueous One Solution Cell Proliferation Assay (Promega; 
2.2.10) was employed to determine cell numbers immediately before the 
addition of NFZ (0 hour time point) and after cells had been treated for the 
required amount of time, typically 12, 24, 48, 96 and 144 hours (2.2.10), unless 
otherwise stated.  
The 6 cell lines were each cultured and maintained (2.1.1), and 16-24 hours 
prior to transfection occurring, seeded at the appropriate density (as 
determined in 4.3.1.1 and 5.3.1.1) per well of a 96-well plate. A total of 50ng 
and 100ng of vector DNA were transfected per well (as determined in 4.3.1.2 
and 5.2.3.1) of D17 cells and CMT3, CMT7, CMT8 and MDCK cells, respectively. 
The amounts of DNA of each vector transfected per cell line are displayed in 
Table 5.3. 4 wells remained untransfected for each cell line (NTC) and 4 wells 
containing no cells for each cell culture medium (background) were used at each 
time point to act as negative controls. 24 hours after transfection, NFZ was Chapter 5 ~ Suicide Gene Therapy for Canine OS 
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added to the cells. The appropriate amount of freshly made NFZ stock solution 
in DMSO was added to each cell culture medium and DMSO added, to adjust the 
final DMSO concentration to 0.5% (5.3.1.2). The cell culture medium was 
replaced after 72 hours with fresh medium. 
The mean absorbance reading for each set of 4 wells was determined. The 
background readings were removed and the percentages of cell survival (+/-SE), 
compared to the 0 hour time point for the NTC (100%), calculated. 
    NTR  CAT 
Cell Line    D17  CMT3, CMT7, 
CMT8 & MDCK 
D17  CMT3, CMT7, 
CMT8 & MDCK 
Vector DNA 
(ng) 
pCMVCAT6 
pCMVNTR 
40 
10 
80 
20 
50 
- 
100 
- 
Total amount of DNA 
transfected (ng) 
50  100  50  100 
 
Table 5.3: The amounts of pCMVNTR and pBLCAT6 (in ng) transfected into D17, 
CMT3, CMT7, CMT8 and MDCK cell lines to enable the analysis of the effects of 
NFZ, following transfection of pCMVNTR, on cell survival. 
 
5.2.4.1 D17 assays 
In the first preliminary experiment, D17 cells were treated with 1M and 5M 
NFZ and cell numbers determined after 12 and 24 hours. The second preliminary 
experiment was carried out to determine the concentration at which NFZ 
reduces the survival of pCMVNTR-transfected cells by ~50%, but NTC remain 
unaffected. A range of concentrations from 0.002 - 1M (0.002, 0.004, 0.008, 
0.016, 0.031, 0.063 0.125, 0.25, 0.5 and 1M) NFZ were applied to D17 cells for 
144 hours.  
The „proper‟ experiment consisted of treating D17 cells with 0.125M and 
0.25M NFZ for 96 hours and cell numbers determined at 0, 12, 24, 48 and 96 
hours. This experiment was repeated 4 times.   
5.2.4.2 CMT3, CMT7 and CMT8 assays 
Concentrations below 0.125M NFZ were observed to not reduce cell survival in 
the second D17 preliminary experiment. The first two preliminary experiments 
were carried out on CMT3 cells, using a range of concentrations from 0.0625 - 
0.5M (0.0625, 0.125, 0.25 and 0.5M) NFZ in the first and 0.5 – 4M (0.5, 1, 2 Chapter 5 ~ Suicide Gene Therapy for Canine OS 
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and 4M) in the second, to obtain 2 concentrations at which NFZ reduces the 
survival of pCMVNTR-transfected cells by ~ 50% and 100%. The CMT3 cells in both 
experiments were treated with the various concentrations of NFZ for 96 hours 
and cell numbers determined at 0, 12, 24, 48 and 96 hours.  
The next preliminary experiment involved the treatment of CMT7 cells with 
0.0625, 0.125, 0.25 and 0.5M NFZ, over 144 hours. The fourth consisted of 
treating CMT8 cells with 0.0625, 0.125, 0.25 and 0.5M NFZ over 96 hours and 
cell numbers determined at 0, 12, 24, 48 and 96 hours.  
In the „proper‟ experiment, CMT3 cells were treated with 0.5M and 1M NFZ 
and CMT7 and CMT8 cells with 0.25M and 0.5M NFZ, over 144 hour time 
period.  
 
5.2.4.3 Non-osteosarcoma cell line assays 
MDCK and CML-10 cells were treated with 0.25M and 0.5M NFZ, over 144 hour 
time period.   
 
5.2.5 Analysis of pCMVNTR and TP53-targeted suicide gene therapy strategy 
in combination with CB1954  
The pCMVNTR, pCMVCAT6, pTargeT-Lexp53, pGL3B8LA-NTR, pGL3E8LA-NTR and 
pGL3P8LA-NTR vectors were used to investigate the effects of CB1954 on the 
survival of D17 and CMT7 cells. 3 experiments were carried out, each only 
performed once, 1 preliminary experiment repeated in quadruplicate per time 
point, followed by 2 „proper‟ experiments, in triplicate per time point. All the 
experiments assessed the transfection of pCMVNTR in combination with 
pCMVCAT6 and NTC. The 2 „proper‟ experiments also examined the transfection 
of pCMVCAT6 alone, and pGL3B8LA-NTR, pGL3E8LA-NTR and pGL3P8LA-NTR in 
combination with pCMVCAT6 or pTargeTLex-p53. The vectors were prepared 
using the QIAGEN EndoFree Plasmid Purification Maxi kit (2.2.8.3). Each vector 
was transfected into the cell lines using the Transfast
TM reagent (Promega; 
2.2.9). The CellTiter 96® AQueous One Solution Cell Proliferation Assay (Promega; Chapter 5 ~ Suicide Gene Therapy for Canine OS 
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2.2.10) was employed to determine cell numbers immediately before the 
addition of CB1954 (0 hour time point) and after cells had been treated for the 
required amount of time. 
In the preliminary experiment, D17 and CMT7 cells were treated with 0.15, 0.3, 
0.625, 1.25, 2.5, 5, 10, 20, 40, 80 and 160M CB1954 for 48 hours and cell 
numbers determined at 0, 12, 24 and 48 hours. This was performed to obtain 2 
concentrations at which CB1954 reduces the survival of pCMVNTR-transfected 
cells, particularly CMT7 cells, by ~ 50 and 100%.  
The 2 „proper‟ experiments were similar in that D17 and CMT7 cells were 
treated with 5M and 20M CB1954, and cell numbers determined at 0, 12, 24, 
48, 96 and 144 hours. The cell culture medium was replaced after 72 hours with 
fresh medium. The exception was that the first was carried out one in the 
absence of NADH and the second in the presence of NADH (Sigma; Appendix A). 
In this second experiment, NADH was applied at the same time as CB1954, at a 
final concentration of 100M.  
The 2 cell lines were each cultured and maintained (2.1.1) and 16-24 hours prior 
to transfection occurring, seeded at the appropriate density (as determined in 
4.3.1.1) per well of a 96-well plate. A total of 50ng and 100ng of vector DNA 
were transfected per well (as determined in 4.3.1.2 and 5.2.3.1) of D17 and 
CMT7 cells, respectively. The amounts of DNA of each vector transfected per cell 
line are displayed in Table 5.4. 4 wells remained untransfected for each cell line 
(NTC) and 4 wells containing no cells for each cell culture medium (background) 
were used at each time point to act as negative controls. 24 hours after 
transfection, CB1954 was added to the cells. The appropriate amount of freshly 
made CB1954 stock solution in DMSO was added to each cell culture medium and 
DMSO added, to adjust the final DMSO concentration to 0.5% (5.3.1.2).  
The mean absorbance reading for each set of 4 wells was determined. The 
background readings were removed and the percentages of cell survival (+/-SE), 
compared to the 0 hour time point for the NTC (100%), calculated.  
 
 
 
 
  NTR  CAT  B/E/P -8LA  B/E/P -8LA+p53 
Cell Line  D17  CMT7  D17  CMT7  D17  CMT7  D17  CMT7 
 
  pCMVCAT6  40  80  50  100  40  80  -  - 
Vector DNA pTargeTLex-p53  -  -  -  -  -  -  40  80 
(ng)  PGL3-8LANTR (B, E or P)  -  -  -  -  10  20  10  20 
 
  pCMVNTR  10  20  -  -  -  -  -  - 
Total amount of DNA transfected (ng)  50  100  50  100  50  100  50  100 
 
Table 5.4: The amounts of DNA (in ng) and combinations of vectors transfected into D17 and CMT7 cell lines to enable the analysis of 
pCMVNTR and TP53-targeted suicide gene therapy strategy, in combination with CB1954, on cell survival. Abbreviations: „NTR‟, 
pCMVNTR in combination with pCMVCAT6; „CAT‟, pCMVCAT6; „B/E/P –8LA‟, pGL3B8LA-NTR, pGL3E8LA-NTR or pGL3P8LA-NTR, in 
combination with pCMVCAT6, respectively; „B/E/P –8LA+p53‟, pGL3B8LA-NTR, pGL3E8LA-NTR or pGL3P8LA-NTR, in combination with 
pTargeT-Lexp53, respectively. .  
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5.3 Results 
5.3.1 Optimization assays  
5.3.1.1 Cell number 
The concentrations of MDCK and CML-10 cells proposed to obtain 80% 
confluence, 50000 cells/ml and 75000 cells/ml, respectively, were correct. This 
enabled the same number of cells to be transfected for each cell line, in all the 
subsequent assays performed in this study, without any toxicity incurring due to 
the transfection of low cell densities (200l/well of a 96-well plate; 13ml per 
25cm
2 flask). 
 
5.3.1.2 DMSO 
The survival curves for the D17, CMT3, CMT7 and CMT8 cell lines treated with 0, 
0.125, 0.25, 0.5, 1 and 2% of DMSO for 24 hours are displayed in Figure 5.3. The 
post hoc pairwise comparison results are shown in Table 5.5. There were no 
statistically significant differences between the untreated (0%) cells to those 
treated with 0.125, 0.25, 0.5, 1 and 2% DMSO. However, the appearance of the 
cells treated with 1% DMSO for all four cell lines was not normal and in the 
presence of 2% DMSO clear signs of cytotoxicity were apparent. Therefore it was 
determined that DMSO would contribute 0.5% to the final volume of NFZ and 
CB1954 in solution. 
The maximum percentage of DMSO that could be used, in the final volume, to 
dissolve NFZ and CB1954 without having a cytotoxic effect on D17, CMT3, CMT7 
and CMT8 cells was determined to be 0.5%. In all NFZ and CB1954 experiments, 
the NTC were cultured in medium containing 0.5% DMSO and appeared to grow 
normally.  Chapter 5 ~ Suicide Gene Therapy for Canine OS 
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Group  Treatment  D17  CMT3  CMT7  CMT8 
  (% DMSO)         
1  0         
2  0.125      6   
3  0.25  6    6   
4  0.5  6    6   
5  1         
6  2  3, 4    2, 3, 4   
 
Table 5.5: Post hoc pairwise comparisons of treatment groups in Figure 5.3, 
listing the treatment groups which were significantly different from each group 
for the D17, CMT3, CMT7 and CMT8 cell lines (significance was set at p = 0.05).  
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Figure 5.3: The effect of DMSO, at 0, 0.5, 1 and 2%, for 24 hours on the survival 
of D17, CMT3, CMT7 and CMT8 cells. (Each data point represents the mean of 4 
values; bars represent +/-SE).  
 
5.3.2 Detection of nitroreductase protein expression by pCMVNTR and 
pGL3B8LA-NTR, pGL3E8LA-NTR and pGL3P8LA-NTR, in combination with 
pTargeT-Lexp53 or pCMVCAT6  
NTR immunopositivity was detected, using the anti-NTR antibody, in the positive 
control, purified E. coli NTR enzyme and the cell lysates of D17, CMT3, CMT7, Chapter 5 ~ Suicide Gene Therapy for Canine OS 
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CMT8 and MDCK cells transfected with pCMVNTR, in combination with pCMVCAT6 
(Figure 5.4). NTR was not detected in the NTC lysates of any of the 5 cell lines. 
There was no evidence of immunopositivity in the: D17 and CMT7 cell lysates 
only transfected with pCMVCAT6; D17 cells transfected with pGL3B8LA-NTR, 
pGL3E8LA-NTR and pGL3P8LA-NTR, in combination with pTargeT-Lexp53 or 
pCMVCAT6 (Figure 5.4B); and CMT7 cell lysates transfected with pGL3B8LA-NTR, 
pGL3E8LA-NTR and pGL3P8LA-NTR, in combination with pCMVCAT6 (Figure 
5.4C). However, NTR is detected in the CMT7 cell lysates transfected with 
pGL3P8LA-NTR in combination with pTargeT-Lex53; although expression was not 
as strong as that detected in the pCMVNTR transfected cell lysates. 
Unfortunately no evidence was provided of NTR immunopositivity following 
transfection of pGL3B8LA-NTR and pGL3E8LA-NTR in combination with pTargeT-
Lexp53.   
These results indicate that the D17, CMT3, CMT7, CMT8, and MDCK NTC lysates 
do not appear to endogenously express NTR. pCMVNTR can be successfully 
transfected into these 5 cell lines and expression of NTR detected. NTR 
expression was only detected in the CMT7 cells transfected with pGL3P8LA-NTR 
in combination with pTargeT-Lexp53. These results are in agreement with those 
obtained using the DLR, previously described in 4.3.4. Hence, the TP53-targeted 
suicide gene therapy system was then able to be tested in cell survival assays. Chapter 5 ~ Suicide Gene Therapy for Canine OS 
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Figure 5.4: Chemiluminescent immunoblots of NTR (24kDa) detected using anti-NTR 
primary antibody in lysates prepared from: (A) D17, CMT3, CMT7, CMT8 and MDCK cells 
transfected with pCMVNTR (NTR), in combination with pCMVCAT6 (50g protein loaded 
per lane; +ve - positive control, 5ng purified E. coli nitroreductase enzyme); D17 (B) and 
(C) CMT7 cells, transfected with pCMVCAT6 (CAT), pCMVNTR in combination with 
pCMVCAT6 (NTR), and pGL3B8LA-NTR pGL3E8LA-NTR and pGL3B8LA-NTR in combination 
with pCMVCAT6 (B, E and P, respectively) or pTargeTLex-p53 (B+lp, E+lp and P+lp, 
respectively) (25g protein loaded per lane). (NTC – non-transfected cell lysates; arrow 
indicates position of NTR protein). 
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5.3.3 Analysis of pCMVNTR in combination with nitrofurazone  
5.3.3.1. D17 assays 
5.3.3.1.1 Preliminary experiment 1  
The data from this experiment are summarized in Figure 5.5 and the post hoc 
pairwise comparison results are displayed in Table 5.6. In the absence of NFZ 
treatment, it was observed that the NTC, appeared to grow normally during the 
24 hour treatment period, whereas, the cells transfected with pCMVNTR 
suffered a statistically significant decrease in cell survival, probably due to 
toxicity from transfection. In the presence of 1M and 5M NFZ treatment, the 
survival of NTC was statistically significantly reduced in comparison to those not 
treated and after 24 hours ~10% cells remained in both sets of treated cells. 
There was also a statistically significant difference between the cells 
transfected with pCMVNTR and those transfected with pCMVNTR and treated 
with 1M and 5M NFZ. After 12 hours of 5M NFZ treatment, none of the 
pCMVNTR transfected cells were alive and with 1M NFZ treatment, only ~10% 
had survived. After 24 hours, none of the NTR-transfected cells treated with 1M 
NFZ were alive. There were no statistically significant differences between NTC 
and pCMVNTR transfected cells treated with 1M or 5M NFZ. 
Hence, 1M and 5M NFZ results in statistically significant decreases in survival 
of both NTC and pCMVNTR transfected D17 cells.  
 
Group  Treatment  D17 
1  NTC  All other treatments 
2  NTC + 1M NFZ  1, 4 
3  NTC + 5M NFZ  1, 4 
4  NTR  All other treatments 
5  NTR + 1M NFZ  1, 4 
6  NTR + 5M NFZ  1, 4 
 
Table 5.6: Post hoc pairwise comparisons of treatment groups in Figure 5.5, 
listing the treatment groups which were significantly different from each group 
for the D17 cell line over the 24-hour treatment period (significance was set at p 
= 0.05).  
 
 Chapter 5 ~ Suicide Gene Therapy for Canine OS 
 
187 
0
20
40
60
80
100
120
140
0 12 24
Length of NFZ treatment (hours)
M
e
a
n
 
C
e
l
l
 
S
u
r
v
i
v
a
l
 
(
%
)
NTC
NTC 1uM NFZ
NTC 5uM NFZ
pCMVNTR
pCMVNTR 1uM NF
pCMVNTR 5uM NF
 
 
Figure 5.5: The effect of 1M and 5M nitrofurazone (NFZ) on survival of D17 
cells, following the transfection of pCMVNTR (NTR), over 24 hours. („NTC‟, non-
transfected cells; each time point was repeated in quadruplicate; bars represent 
+/- SE).  
 
 
5.3.3.1.2 Preliminary experiment 2  
The data from this experiment are summarized in Figure 5.6 and the post hoc 
pairwise comparison results are displayed in Table 5.7. There were no 
statistically significant differences in mean cell survival percentages after 144 
hours between the NTC, cells transfected with pCMVNTR and the NTC and 
pCMVNTR-transfected cells treated with 0.002 – 0.0625M NFZ. There were also 
no statistically significant decreases between the NTC and cells transfected with 
pCMVNTR, with NTC treated with 0.125M and 0.5M NFZ. Statistically 
significant reductions in cell survival were observed between the NTC and cells 
transfected with pCMVNTR, with NTC treated with 0.5M and 1M NFZ and 
pCMVNTR-transfected cells treated with 0.125 - 1M NFZ. The NTC treated with 
0.5M and 1M NFZ were not statistically different to each other and nor were 
the pCMVNTR-transfected cells treated with 0.125 - 1M NFZ. The pCMVNTR-
transfected cells treated with 0.25 - 1M NFZ were significantly different to NTC 
treated with 0.5M NFZ but not to NTC treated with 1M NFZ. Chapter 5 ~ Suicide Gene Therapy for Canine OS 
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Hence, it appears that 0.125M NFZ was the only concentration to cause a large 
decrease in survival of pCMVNTR-transfected cells and a minimal amount in NTC 
after 144 hours treatment. Treatment of pCMVNTR-transfected cells with 0.25, 
0.5 and 1M NFZ induced >85% reduction in cell survival after 12 hours and 
~100% by 24 hours. In comparison, the NTC treated with 0.25M NFZ remained 
largely viable for 48 hours and by 144 hours, ~60% were still alive. The NTC 
treated with 0.5M and 1M NFZ after 12 hours were reduced to ~80% and 50% 
after 12 hours, and ~15% and 0% after 144 hours, respectively. Therefore, 
0.125M and 0.25M NFZ concentrations were to be used in the subsequent D17 
NFZ experiments.  
 
Group  Treatment  D17 
1  NTC  10, 11, 19, 20, 21, 22 
2  NTC + 0.002M NFZ  10, 11, 19, 20, 21, 22 
3  NTC + 0.004M NFZ  10, 11, 19, 20, 21, 22 
4  NTC + 0.008M NFZ  10, 11, 19, 20, 21, 22 
5  NTC + 0.016M NFZ  10, 11, 19, 20, 21, 22 
6  NTC + 0.031M NFZ  9, 10, 11, 19, 20, 21, 22 
7  NTC + 0.0625M NFZ  10, 11, 19, 20, 21, 22 
8  NTC + 0.125M NFZ  10, 11, 19, 20, 21, 22 
9  NTC + 0.25M NFZ  6, 11, 19, 20, 21, 22 
10  NTC + 0.5M NFZ  1, 2, 3, 4, 5, 6, 7, 8, 12, 13, 14, 15, 16, 17, 20, 21, 22 
11  NTC + 1M NFZ  1, 2, 3, 4, 5, 6, 7, 8, 9, 12, 13, 14, 15, 16, 17, 18 
12  NTR  10, 11, 19, 20, 21, 22 
13  NTR + 0.002M NFZ  10, 11, 19, 20, 21, 22 
14  NTR + 0.004M NFZ  10, 11, 19, 20, 21, 22 
15  NTR + 0.008M NFZ  10, 11, 19, 20, 21, 22 
16  NTR + 0.016M NFZ  10, 11, 19, 20, 21, 22 
17  NTR + 0.031M NFZ  10, 11, 19, 20, 21, 22 
18  NTR + 0.0625M NFZ  11, 19, 20, 21, 22 
19  NTR + 0.125M NFZ  1, 2, 3, 4, 5, 6, 7, 8, 9, 12, 13, 14, 15, 16, 17, 18 
20  NTR + 0.25M NFZ  1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 13, 14, 15, 16, 17, 18 
21  NTR + 0.5M NFZ  1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 13, 14, 15, 16, 17, 18 
22  NTR + 1M NFZ  1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 13, 14, 15, 16, 17, 18 
 
Table 5.7: Post hoc pairwise comparisons of treatment groups in Figure 5.6 
(A&B), listing the treatment groups which were significantly different from each 
group over the 144hour treatment period (significance was set at p = 0.05).  Chapter 5 ~ Suicide Gene Therapy for Canine OS 
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Figure 5.6: The effect of 0.002 - 1M nitrofurazone (NFZ) on survival of D17 
cells, following the transfection of pCMVNTR (NTR), over 144 hours: (A) 0.002, 
0.004, 0.008, 0.016 and 0.031M NFZ; (B) 0.063 0.125, 0.25, 0.5 and 1M NFZ. 
(„NTC‟, non-transfected cells; each time point was repeated in quadruplicate; 
bars represent +/- SE). 
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5.3.3.1.3 D17 experiment 
The data from this experiment are summarized in Figure 5.7 and the post hoc 
pairwise comparison results are displayed in Table 5.8. There were no 
statistically significant differences in mean cell survival percentages after 96 
hours between the NTC, pCMVNTR- and pCMVCAT-transfected cells without NFZ 
treatment. Hence, cell growth was not affected by the transfection of pCMVNTR 
and pCMVCAT. However there were statistically significant decreases between 
the untreated NTC, pCMVNTR- and pCMVCAT-transfected cells with the NTC, 
pCMVNTR- and pCMVCAT-transfected cells treated with 0.125M and 0.5M NFZ. 
There were no statistical differences between the NTC and pCMVCAT-
transfected cells, following treatment with 0.125M and 0.25M NFZ, showing 
that the observed decrease in cell survival was due to NFZ treatment. However 
there were statistical differences between the NTC and pCMVNTR-transfected 
cells treated with 0.125M and 0.25M NFZ. There were also statistical 
differences between the NTC and pCMVNTR-transfected cells treated with 
0.125M to those treated with 0.25M but not between these treatments in 
pCMVCAT-transfected cells. 
The largest reduction in cell survival was observed in the pCMVNTR-transfected 
cells treated with 0.25M NFZ. After 12 hours, <20% cells had survived, and by 
96 hours, only a small percentage remained. ~40% of the pCMVNTR-transfected 
cells treated with 0.125M NFZ and the NTC and pCMVCAT-transfected cells 
treated with 0.25M NFZ, survived 24hours, but after 96 hours, cell survival was 
reduced to <10%. The smallest decrease in cell survival following NFZ treatment, 
was observed in the NTC treated with 0.125M NFZ, in which ~70% were alive 
after 24 hours and ~35% after 96 hours. 
Hence, NFZ was seen to reduce survival in pCMVNTR-transfected D17 cells and to 
a slightly lesser extent in NTC and pCMVCAT-transfected D17 cells. This suggests 
that NFZ is activated by endogenous enzymes in these canine cells. 
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Group  Treatment  D17 
1  NTC  2, 3, 5, 6, 8, 9 
2  NTC + 0.125M NFZ  All except 5 
3  NTC + 0.25M NFZ  1, 2, 4, 7, 9 
4  CAT  2, 3, 5, 6, 8, 9 
5  CAT + 0.125M NFZ  1, 4, 7, 9 
6  CAT + 0.25M NFZ  1, 2, 4, 7, 9 
7  NTR  2, 3, 5, 6, 8, 9 
8  NTR + 0.125M NFZ  1, 2, 4, 7, 9 
9  NTR + 0.25M NFZ  All other treatments 
 
Table 5.8: Post hoc pairwise comparisons of treatment groups in Figure 5.7, 
listing the treatment groups which were significantly different from each group 
over the 96hour treatment period (significance was set at p = 0.05).  
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Figure 5.7: The effect of 0.125M and 0.25M nitrofurazone (NFZ) on survival of 
D17 cells, following the transfection of pCMVNTR (NTR), and pCMVCAT6, over 96 
hours.  („NTC‟, non-transfected cells; this assay and each time point was 
repeated in quadruplicate; bars represent +/- SE). 
 
5.3.3.2 CMT3, CMT7 and CMT8 assays 
5.3.3.2.1 Preliminary experiments  
5.3.3.2.1.1 CMT3 experiment 1 
The data from this experiment are summarized in Figure 5.8. There were no 
significant interactions found between post hoc pairwise comparisons of 
treatment groups shown in Figure 5.8. Cell survival was observed to increase Chapter 5 ~ Suicide Gene Therapy for Canine OS 
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after 96 hours in untreated NTC and pCMVNTR-transfected cells and NTC and 
pCMVNTR-transfected cells treated with 0.062, 0.125 and 0.25M NFZ. 
Treatment with 0.5M NFZ achieved ~40% reduction in cell survival in NTC and 
pCMVNTR-transfected cells after 96 hours.  
Hence, it appears that CMT3 cells are not as sensitive to NFZ as D17 cells and so 
a second preliminary assay was performed using higher concentrations of NFZ. 
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Figure 5.8: The effect of 0.0625 - 0.5M nitrofurazone (NFZ) on survival of CMT3 
cells, following the transfection of pCMVNTR (NTR), over 96 hours. („NTC‟, non-
transfected cells; each time point was repeated in quadruplicate; bars represent 
+/- SE). 
 
5.3.3.2.1.2 CMT3 experiment 2 
The data from this experiment are summarized in Figure 5.9 and the post hoc 
pairwise comparison results are displayed in Table 5.9. There were no 
statistically significant differences in mean cell survival percentages after 96 
hours between the NTC and pCMVNTR-transfected cells without NFZ treatment. 
Hence, cell growth was not affected by the transfection procedure. There were 
also no significant differences between untreated NTC and pCMVNTR-transfected 
cells and those treated with 0.5M and 1M NFZ. Chapter 5 ~ Suicide Gene Therapy for Canine OS 
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Statistically significant decreases were found between the untreated NTC 
following treatment with 2M and 4M NFZ, in both the NTC and pCMVNTR-
transfected cells. The cells treated with 4M NFZ were significantly different to 
those treated with 0.5, 1M and 2M NFZ. However, there were no statistical 
differences between the 2M NFZ treated cells and those treated with 0.5M 
and 1M NFZ. In addition, there were no significant differences between any of 
the NFZ treatments in the NTC with the equivalent treatment in the pCMVNTR-
transfected cells as the NTC cells had similar growth patterns to the transfected 
cells. 
Following treatment with 1,2 and 4M NFZ, NTC and NTR-transfected cells, 
~100% reduction in cell survival was observed after 96 hours. 0.5M NFZ 
produced similar effects on cell survival to that observed in the previous 
preliminary assay with pCMVNTR-transfected cells and NTC displaying ~60% cell 
survival after 96 hours. However due to the similar cell survival curves observed 
between the NTC and NTR-transfected cells for the 4 different NFZ treatments, 
this suggests that either the transfection of pCMVNTR in CMT3 cells does not 
increase predisposition to larger decreases in cell survival following NFZ 
treatment, than in their non-transfected counterparts, or an experimental error 
occurred. This assay should have been repeated as it was only performed once.  
Group  Treatment  CMT3 
1  NTC  4, 5, 9, 10 
2  NTC + 0.5M NFZ  5, 10 
3  NTC + 1M NFZ  5, 10 
4  NTC + 2M NFZ  1, 5, 10 
5  NTC + 4M NFZ  All except 10 
6  NTR  5, 10 
7  NTR + 0.5M NFZ  5, 10 
8  NTR + 1M NFZ  5, 10 
9  NTR + 2M NFZ  1, 5, 10 
10  NTR + 4M NFZ  All except 5 
 
Table 5.9: Post hoc pairwise comparisons of treatment groups in Figure 5.9, 
listing the treatment groups which were significantly different from each group 
over the 96 hour treatment period (significance was set at p = 0.05).  Chapter 5 ~ Suicide Gene Therapy for Canine OS 
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Figure 5.9: The effect of 0.5 - 4M nitrofurazone (NFZ) on survival of CMT3 cells, 
following the transfection of pCMVNTR (NTR), over 96 hours. („NTC‟, non-
transfected cells; each time point was repeated in quadruplicate; bars represent 
+/- SE). 
 
5.3.3.2.1.3 CMT7 experiment  
The data from this experiment are summarized in Figure 5.10 and the post hoc 
pairwise comparison results are displayed in Table 5.10. There were no 
statistically significant differences in mean cell survival percentages after 144 
hours between the NTC and pCMVNTR-transfected cells without NFZ treatment. 
Hence, cell growth was not affected by the transfection procedure. There were 
also no significant differences between untreated NTC and pCMVNTR-transfected 
cells and NTC treated with 0.0625, 0.125 and 0.25M NFZ and pCMVNTR-
transfected cells treated with 0.0625M and 0.125M NFZ. 
Statistically significant decreases were found between the untreated NTC and 
pCMVNTR-transfected cells with NTC treated with 0.5M NFZ and pCMVNTR-
transfected cells treated with 0.25M and 0.5M NFZ. There were also 
significant differences between the NTC treated with 0.25M and 0.5M NFZ Chapter 5 ~ Suicide Gene Therapy for Canine OS 
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with the equivalent treatment in the pCMVNTR-transfected cells. The NTC 
treated with 0.5M were not statistically different to pCMVNTR-transfected cells 
treated with 0.25M NFZ, which indicates that the expression of NTR in CMT7 
cells decreases the amount of NFZ required to reduce cell survival. 
After 96 hours of 0.25M NFZ treatment, the survival of pCMVNTR-transfected 
cells was ~60%, whereas no decrease in survival was observed in NTC. Treatment 
with 0.5M NFZ resulted in ~50% reduction in cell survival occurring after 12 
hours in the pCMVNTR-transfected cells and nearly 100% at 96 hours. In the NTC, 
0.5M NFZ treatment decreased cell survival by ~20% and ~75% after 48 and 96 
hours, respectively.  
Thus as 0.25M and 0.5M NFZ induced ~ 60% and 100% reductions in cell 
survival, respectively, in the pCMVNTR-transfected cells, after 96 hours, these 2 
concentrations were used in the subsequent CMT 7 experiment (5.3.3.1.2.2). 
Group  Treatment  CMT7 
1  NTC  5, 9, 10 
2  NTC + 0.0625M NFZ  5, 8, 9, 10 
3  NTC + 0.125M NFZ  5, 9, 10 
4  NTC + 0.25M NFZ  9, 10 
5  NTC + 0.5M NFZ  1, 2, 3, 6, 7, 10 
6  NTR  5, 9, 10 
7  NTR + 0.0625M NFZ  5, 9, 10 
8  NTR + 0.125M NFZ  2, 9, 10 
9  NTR + 0.25M NFZ  All except 5 
10  NTR + 0.5M NFZ  All other treatments 
 
Table 5.10: Post hoc pairwise comparisons of treatment groups in Figure 5.10, 
listing the treatment groups which were significantly different from each group 
over the 144 hour treatment period (significance was set at p = 0.05).  Chapter 5 ~ Suicide Gene Therapy for Canine OS 
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Figure 5.10: The effect of 0.0625 - 0.5M nitrofurazone (NFZ) on survival of 
CMT7 cells, following the transfection of pCMVNTR (NTR), over 96 hours. („NTC‟, 
non-transfected cells; each time point was repeated in quadruplicate; bars 
represent +/- SE). 
 
5.3.3.2.1.4 CMT8 experiment  
The data from this experiment are summarized in Figure 5.11 and the post hoc 
pairwise comparison results are displayed in Table 5.11. There were no 
statistically significant differences in mean cell survival percentages after 96 
hours between the NTC and pCMVNTR-transfected cells without NFZ treatment. 
Hence, cell growth was not affected by the transfection procedure. There were 
also no significant differences between untreated NTC and pCMVNTR-transfected 
cells and NTC and pCMVNTR-transfected cells treated with 0.0625M and 
0.125M NFZ. 
Statistically significant decreases were found between the untreated NTC and 
pCMVNTR-transfected cells with NTC and pCMVNTR-transfected cells treated 
with 0.25M and 0.5M NFZ. There were however no significant differences 
between the NTC treated with 0.25M and 0.5M NFZ with the equivalent 
treatment in the pCMVNTR-transfected cells. The survival of pCMVNTR-Chapter 5 ~ Suicide Gene Therapy for Canine OS 
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transfected cells treated with 0.5M NFZ was statistically lower than NTC 
treated with 0.25M NFZ.  
Following 96 hours of 0.25M NFZ treatment, ~75% NTC and pCMVNTR-
transfected cells survived. Treatment with 0.5M NFZ, resulted in ~25% survival 
in the pCMVNTR-transfected cells after 48 hours, compared to ~50% in the NTC. 
After 96 hours 0.5M NFZ treatment, no NTC and pCMVNTR-transfected cells 
survived. 
Thus, as demonstrated previously in the other cell lines, a decrease in survival of 
CMT8 cells does not appear to exclusively occur in the pCMVNTR-transfected 
cells treated with NFZ, as similar reductions also occur in the NFZ treated NTC. 
0.25M and 0.5M NFZ were used in the subsequent CMT8 experiment as a 
means of validating the results from this experiment. 
Group  Treatment  CMT8 
1  NTC  4, 5, 9, 10 
2  NTC + 0.0625M NFZ  4, 5, 9, 10 
3  NTC + 0.125M NFZ  5, 10 
4  NTC + 0.25M NFZ  1, 2, 6, 10 
5  NTC + 0.5M NFZ  1, 2, 3, 6, 7, 8 
6  NTR  4, 5, 9, 10 
7  NTR + 0.0625M NFZ  5, 9, 10 
8  NTR + 0.125M NFZ  5, 10 
9  NTR + 0.25M NFZ  1, 2, 6, 7 
10  NTR + 0.5M NFZ  1, 2, 3, 4, 6, 7, 8 
 
Table 5.11: Post hoc pairwise comparisons of treatment groups in Figure 5.11, 
listing the treatment groups which were significantly different from each group 
over the 96 hour treatment period (significance was set at p = 0.05).  Chapter 5 ~ Suicide Gene Therapy for Canine OS 
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Figure 5.11: The effect of 0.0625 - 0.5M nitrofurazone (NFZ) on survival of 
CMT8 cells, following the transfection of pCMVNTR (NTR), over 96 hours. („NTC‟, 
non-transfected cells; each time point was repeated in quadruplicate; bars 
represent +/- SE). 
 
5.3.3.2.2 CMT3, CMT7 and CMT8 experiments 
The data from this experiment are summarized in Figure 5.12 and the post hoc 
pairwise comparison results are displayed in Table 5.12. There were no 
statistically significant differences in mean cell survival percentages after 144 
hours between the NTC and pCMVNTR-transfected cells without NFZ treatment. 
Hence, cell growth in all 3 cell lines was not affected by the transfection 
procedure.  
Statistically significant decreases were found between the untreated NTC and 
pCMVNTR-transfected cells with NTC and pCMVNTR-transfected cells treated 
with 0.5M and 1M NFZ in the CMT3 cells and 0.25M and 0.5M NFZ in the 
CMT7 and CMT8 cells. There were however no significant differences between 
the NTC treated with 0.5M and 1M NFZ in the CMT3 cells and 0.25M and 
0.5M NFZ in the CMT7 and CMT8 cells with the equivalent treatment in the 
pCMVNTR-transfected cells. There were statistical differences between the NTC 
or pCMVNTR-transfected cells treated with 0.25M NFZ and those treated with Chapter 5 ~ Suicide Gene Therapy for Canine OS 
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0.5M in the CMT3 cells, and 0.25M and 0.5M NFZ in the CMT7 and CMT8 cells, 
except between the pCMVNTR-transfected CMT8 cells treated with 0.25M and 
0.5M NFZ. The NTC treated with 0.5M in CMT3 cells and 0.25M in CMT7 and 
CMT8 cells were statistically different to pCMVNTR-transfected cells treated 
with 1M and 0.5M NFZ, respectively. This indicates that in these 3 cell lines, 
to induce statistically increased reductions in cell survival, a larger amount of 
NFZ has to be applied to the pCMVNTR-transfected cells than the NTC, which is 
practically impossible. 
Following 96 hours of 0.5M NFZ treatment in the CMT3 cells, ~75% NTC and 
pCMVNTR-transfected cells survived. Treatment with 1M NFZ, resulted in ~35% 
cells surviving in the pCMVNTR-transfected cells, compared to ~45% in the NTC. 
In the CMT7 cells, after the NTC and pCMVNTR-transfected cells had been 
treated with 0.25M and 0.5M NFZ for 96 hours, ~20% and no cells survived, 
respectively. Treatment with 0.25M and 0.5M NFZ treatment in the CMT8 cells 
resulted in 100% decrease in survival after 96 hours. 
The increases in cell survival observed at 96 hours were likely due to the 
removal of NFZ and replacement with fresh medium at 72 hours. Thus showing 
that these cells are able to recover and increase in number once NFZ is 
removed. 
These results suggest that the expression of NTR in CMT3, CMT7 and CMT8 cells 
does not effectively predispose them to selective cell kill by NFZ, also indicating 
that endogenous enzymes are present in these canine cells, as in D17 cells, 
capable of activating NFZ. Chapter 5 ~ Suicide Gene Therapy for Canine OS 
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Group  Treatment  CMT3  CMT7  CMT8 
1  NTC  2, 3, 5, 6  2, 5, 7, 8  2, 5, 7, 8 
2  NTC + 0.5M NFZ  1, 3, 4, 6  1, 4, 7  1, 4, 7 
3  NTC + 1M NFZ  1, 2, 4  NA  NA 
4  NTR  2, 3, 5, 6  2, 5, 7, 8  2, 5, 7, 8 
5  NTR + 0.5M NFZ  1, 4, 6  1, 4, 7, 8  1, 4, 7 
6  NTR + 1M NFZ  1, 2, 4, 5  NA  NA 
7  NTC + 0.25M NFZ  NA  1, 2, 4, 5  1, 2, 4, 5 
8  NTR + 0.25M NFZ  NA  1, 4, 5  1, 4 
 
Table 5.12: Post hoc pairwise comparisons of treatment groups in Figure 5.12, 
listing the treatment groups which were significantly different from each group 
over the 144 hour treatment period (significance was set at p = 0.05).  
  
 
         
 
 
 
Figure 5.12: The effect of nitrofurazone (NFZ) over 144 hours, following 
the transfection of pCMVNTR (NTR), on survival of CMT3 cells (A) 
treated with 0.5M and 1M NFZ, and CMT7 (B) and CMT8 (C) cells 
treated with 0.25Mand 0.5M NFZ. („NTC‟, non-transfected cells; 
each assay was repeated in triplicate and each time point in 
quadruplicate; bars represent +/- SE). Please note different scales on 
Y-axes. 
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5.3.3.3 Non-osteosarcoma cell line assays 
The findings from the NFZ assays suggest that NFZ reduces the survival of canine 
OS cells regardless of NTR expression. This raised the question as to whether this 
effect is cell type specific and NFZ was subsequently analysed in 2 non-OS cell 
lines, MDCK and CML-10. 
 
5.3.3.3.1 MDCK experiment 
The data from this experiment are summarized in Figure 5.13 and the post hoc 
pairwise comparison results are displayed in Table 5.13. There were no 
statistically significant differences in mean cell survival percentages after 144 
hours between the NTC and pCMVNTR-transfected cells without NFZ treatment. 
Hence, cell growth was not affected by the transfection procedure.  
Statistically significant decreases were found between the untreated NTC and 
pCMVNTR-transfected cells with NTC and pCMVNTR-transfected cells treated 
with 0.25M and 0.5M NFZ. There was also a significant difference between the 
NTC treated with 0.5M NFZ with the equivalent treatment in the pCMVNTR-
transfected cells, but no difference between the 0.25M NFZ treated cells. 
There was a statistical difference between the NTC or pCMVNTR-transfected 
cells treated with 0.25M NFZ and those treated with 0.5M. These results 
indicate that the expression of NTR in MDCK cells reduces cell survival following 
0.5M NFZ treatment. 
Following 24 hours treatment with 0.5M NFZ, <20% pCMVNTR-transfected cells 
survived, compared to ~35% in the NTC. However by 96 hours, ~100% decrease in 
survival was observed in both sets of cells. In the cells treated with 0.25M NFZ, 
~95% NTC and ~65% pCMVNTR-transfected cells survived after 24 hours, which 
was reduced to ~15%, for both sets of cells, after 144 hours. 
Hence, this shows that MDCK cells behave similarly, following treatment with 
NFZ, to the responses previously seen in the canine OS cell lines. 
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Group  Treatment  MDCK 
1  NTC  All except 4 
2  NTC + 0.25M NFZ  All except 5 
3  NTC + 0.5M NFZ  All other treatments 
4  NTR  All except 1 
5  NTR + 0.25M NFZ  All except 2 
6  NTR + 0.5M NFZ  All other treatments 
 
Table 5.13: Post hoc pairwise comparisons of treatment groups in Figure 5.13, 
listing the treatment groups which were significantly different from each group 
over the 144 hour treatment period (significance was set at p = 0.05).  
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Figure 5.13: The effect of 0.25M and 0.5M nitrofurazone (NFZ), on survival of 
MDCK cells, following the transfection of pCMVNTR (NTR), over 144 hours. 
(„NTC‟, non-transfected cells; each time point was repeated in quadruplicate; 
bars represent +/- SE). 
 
5.3.3.3.2 CML-10 experiment 
Although the CML-10 cells were not transfected, it was still considered 
worthwhile to determine the effect of NFZ on NTC. The data from this 
experiment are summarized in Figure 5.14 and the post hoc pairwise comparison 
results are displayed in Table 5.14. There were statistically significant Chapter 5 ~ Suicide Gene Therapy for Canine OS 
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differences in mean cell survival percentages after 144 hours between the NTC 
without NFZ treatment and those treated with 0.5M and 0.25M NFZ. There 
was not a significant difference between the cells treated with 0.5M and 
0.25M NFZ.  
After only 12 hours, both 0.5M and 0.25M NFZ treatments induced ~100% 
reductions in cell survival. Thus in the absence of NTR transfection, NFZ is highly 
cytotoxic to the CML-10 cell line. It is unlikely that a difference in amounts of 
cell survival would be observed between NTC and pCMVNTR-transfected cells if 
lower concentrations of NFZ were used.   
Group  Treatment  CML-10 
1  NTC  All other treatments 
2  NTC + 0.25M NFZ  All except 3 
3  NTC + 0.5M NFZ  All except 3 
 
Table 5.14: Post hoc pairwise comparisons of treatment groups in Figure 5.14, 
listing the treatment groups which were significantly different from each group 
over the 96 hour treatment period (significance was set at p = 0.05).  
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Figure 5.14: The effect of 0.25M and 0.5M nitrofurazone (NFZ), on survival of 
non-transfected (NTC) CML-10 cells, over 96 hours. (Each time point was 
repeated in quadruplicate; bars represent +/- SE). 
 Chapter 5 ~ Suicide Gene Therapy for Canine OS 
 
205 
5.3.4 Analysis of pCMVNTR and TP53-targeted suicide gene therapy strategy 
in combination with CB1954  
Due to the limited amount of CB1954 available, the D17 and CMT7 cells were 
chosen to be used in the CB1954 assays as a result of the findings from the DLR 
experiments. 
 
5.3.4.1 Preliminary experiment 
The data from this experiment are summarized in Figure 5.15 and the post hoc 
pairwise comparison results are displayed in Table 5.15. There were no 
statistically significant differences in mean cell survival percentages after 48 
hours between the NTC and pCMVNTR-transfected cells without CB1954 
treatment, in D17 cell line but there was a difference in the CMT7 cell line. 
Hence, cell growth was not affected by the transfection procedure in D17 cells 
but may have been in CMT7 cells.  
No statistically significant decreases were found between the untreated NTC 
with any of the NTC treated with CB1954 in both cell lines. There were 
statistical differences in the D17 and CMT7 cells between the untreated NTC and 
all the CB1954 treated NTC, with the pCMVNTR-transfected D17 cells treated 
with 2.5 - 160M CB1954 and all the CB1954 treated pCMVNTR-transfected CMT7 
cells. Significant differences were present between the untreated pCMVNTR-
transfected D17 and CMT7 cells, pCMVNTR-transfected D17 cells treated with 
0.15 - 1.25M CB1954 and pCMVNTR-transfected CMT7 cells treated with 0.15 - 
0.625M CB1954 with pCMVNTR-transfected D17 and CMT7 cells treated with 40, 
80 and 160M CB1954. However there were no significant differences between 
the pCMVNTR-transfected D17 cells treated with 2.5 - 160M CB1954 and the 
pCMVNTR-transfected CMT7 cells treated with 1.25 - 160M CB1954, 
demonstrating no clear dose effect at these concentrations. There were 
significant differences between the D17 NTC treated with 2.5 - 160M CB1954 
and all the CMT7 NTC treated with CB1954 with the equivalent treatment in the 
pCMVNTR-transfected D17 and CMT7 cells. A statistical difference was found 
between D17 NTC treated with 2.5M CB1954 with pCMVNTR-transfected D17 Chapter 5 ~ Suicide Gene Therapy for Canine OS 
 
206 
cells treated with 1.25M CB1954. This shows that the expression of NTR in D17 
cells decreases the amount of CB1954 required to significantly reduce cell 
numbers. Although, this was not able to be demonstrated in the CMT7 cells due 
to the untreated pCMVNTR-transfected cells being significantly different to 
untreated NTC and all the treated NTC. 
After 48 hours CB1954 treatment, ~60% of the pCMVNTR-transfected D17 cells 
treated with 2.5 - 20M CB1954 survived and with increasing CB1954 
concentration, survival was reduced to 20% with 160M CB1954. In the CMT7 
cells after 48 hours treatment with CB1954, ~60% of the pCMVNTR-transfected 
cells treated with 2.5M CB1954 survived, which also, with increasing CB1954 
concentrations, was reduced to ~10% with 160M CB1954. 
The subsequent assays were to be performed over 144 hours. CB1954 
concentrations of 5M and 20M were chosen to be used, because after 48 
hours, both D17 and CMT7 NTC treated with 5M and 20M CB1954 possessed 
similar survival curves to the untreated NTC, ~60% pCMVNTR-transfected D17 
cells survived 5M and 20M CB1954 treatment and 50% and 10% of pCMVNTR-
transfected CMT7 cells survived 5M and 20M CB1954 treatment, respectively. 
Hence by 144 hours, it was assumed that very few of the pCMVNTR-transfected 
cells, in particular CMT7 cells, treated with 5M and 20M CB1954 would 
survive. 
Thus, the results from this preliminary experiment show that pCMVNTR encodes 
a functional NTR, which can be expressed in canine cells and is capable of 
activating CB1954 to its cytotoxic metabolite. In addition, it appears that there 
is no activation of CB1954 by endogenous enzymes, unlike that observed in the 
NFZ assays.  
  
 
Group  Treatment  D17  CMT7 
1  NTC  12, 19, 20, 21, 22, 23, 24  7, 8, 9, 10, 11, 12, 19, 20, 21, 22, 23, 24 
2  NTC + 0.15M CB  12, 19, 20, 21, 22, 23, 24  7, 8, 9, 10, 11, 12, 19, 20, 21, 22, 23, 24 
3  NTC + 0.3M CB  12, 19, 20, 21, 22, 23, 24  7, 8, 9, 10, 11, 12, 19, 20, 21, 22, 23, 24 
4  NTC + 0.625M CB  12, 19, 20, 21, 22, 23, 24  7, 8, 9, 10, 11, 12, 19, 20, 21, 22, 23, 24 
5  NTC + 1.25M CB  12, 19, 20, 21, 22, 23, 24  7, 8, 9, 10, 11, 12, 19, 20, 21, 22, 23, 24 
6  NTC + 2.5M CB  7, 11, 12, 19, 20, 21, 22, 23, 24  7, 8, 9, 10, 11, 12, 19, 20, 21, 22, 23, 24 
7  NTR  6, 22, 23, 24  1, 2, 3, 4, 5, 6, 12, 13, 14, 15, 16, 17, 18, 20, 21, 22, 23, 24 
8  NTR + 0.15M CB  19, 21, 22, 23, 24  1, 2, 3, 4, 5, 6, 13, 14, 15, 16, 17, 18, 21, 22, 23, 24 
9  NTR + 0.3M CB  19, 21, 22, 23, 24  1, 2, 3, 4, 5, 6, 13, 14, 15, 16, 17, 18, 21, 22, 23, 24 
10  NTR + 0.625M CB  22, 23, 24  1, 2, 3, 4, 5, 6, 13, 14, 15, 16, 17, 18, 22, 23, 24 
11  NTR + 1.25M CB  6, 22, 23, 24  1, 2, 3, 4, 5, 6, 13, 14, 15, 16, 17, 18 
12  NTR + 2.5M CB  1, 2, 3, 4, 5, 6, 13, 14, 15, 16, 17, 18  1, 2, 3, 4, 5, 6, 7, 13, 14, 15, 16, 17, 18 
13  NTC + 5M CB  12, 19, 20, 21, 22, 23, 24  7, 8, 9, 10, 11, 12, 19, 20, 21, 22, 23, 24 
14  NTC + 10M CB  12, 19, 20, 21, 22, 23, 24  7, 8, 9, 10, 11, 12, 19, 20, 21, 22, 23, 24 
15  NTC + 20M CB  12, 19, 20, 21, 22, 23, 24  7, 8, 9, 10, 11, 12, 19, 20, 21, 22, 23, 24 
16  NTC + 40M CB  12, 19, 20, 21, 22, 23, 24  7, 8, 9, 10, 11, 12, 19, 20, 21, 22, 23, 24 
17  NTC + 80M CB  12, 19, 20, 21, 22, 23, 24  7, 8, 9, 10, 11, 12, 19, 20, 21, 22, 23, 24 
18  NTC + 160M CB  12, 19, 20, 21, 22, 23, 24  7, 8, 9, 10, 11, 12, 19, 20, 21, 22, 23, 24 
19  NTR + 5M CB  1, 2, 3, 4, 5, 6, 8, 9, 13, 14, 15, 16, 17, 18  1, 2, 3, 4, 5, 6, 13, 14, 15, 16, 17, 18 
20  NTR + 10M CB  1, 2, 3, 4, 5, 6, 13, 14, 15, 16, 17, 18  1, 2, 3, 4, 5, 6, 7, 13, 14, 15, 16, 17, 18 
21  NTR + 20M CB  1, 2, 3, 4, 5, 6, 8, 9, 13, 14, 15, 16, 17, 18  1, 2, 3, 4, 5, 6, 7, 8, 9, 13, 14, 15, 16, 17, 18 
22  NTR + 40M CB  1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 13, 14, 15, 16, 17, 18 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 13, 14, 15, 16, 17, 18 
23  NTR + 80M CB  1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 13, 14, 15, 16, 17, 18 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 13, 14, 15, 16, 17, 18 
24  NTR + 160M CB  1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 13, 14, 15, 16, 17, 18 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 13, 14, 15, 16, 17, 18 
 
Table 5.15: Post hoc pairwise comparisons of treatment groups in Figure 5.15, listing the treatment groups which were significantly 
different from each group over the 48 hour treatment period (significance was set at p = 0.05; CB1954 – „CB‟).   
 
 
     
Figure 5.15: The effect of 0.15 - 160M CB1954 (CB) over 48 hours, following the transfection of pCMVNTR (NTR) on survival of D17 (A) 
and CMT7 (B) cells treated with 0.15 - 2.5M CB1954, and D17 (C) and CMT7 (D) cells treated with 5 - 160M CB1954. („NTC‟, non-
transfected cells; each time point was repeated in triplicate; bars represent +/- SE). Please note different scales on Y-axes. 
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5.3.4.2 In the absence and presence of NADH 
For ease of displaying the effects of CB1954, on the survival of D17 and CMT7 
cells using pGL3B8LA-NTR, pGL3E8LA-NTR and pGL3P8LA-NTR in combination 
with pCMVCAT6 or pTargeTLex-p53, the data from the experiment in the: 
(i), absence of NADH are summarized in Figures 5.16, 5.17 and 5.18 
(respectively) and the post hoc pairwise comparison results are displayed in 
Tables 5.16, 5.17 and 5.18 (respectively); 
(ii), presence of NADH are summarized in Figures 5.19, 5.20 and 5.21 
(respectively) and the post hoc pairwise comparison results are displayed in 
Tables 5.19, 5.20 and 5.21 (respectively).  
In both experiments, there were no statistically significant differences in mean 
cell survival percentages after 144 hours, in both D17 and CMT7 cell lines, 
between the NTC and cells transfected with pCMVNTR-, pCMVCAT6-, and 
pGL3B8LA-NTR, pGL3E8LA-NTR and pGL3P8LA-NTR in combination with 
pCMVCAT6 or pTargeTLex-p53, without CB1954 treatment. Hence, cell growth 
was not affected by the transfection procedure in both cell lines.  
In the absence and presence of NADH, there was a statistically significant 
difference in survival between the D17 cells transfected with pCMVNTR and 
treated with 20M CB1954, to the D17 cells transfected with all the other 
constructs and treated with 5M and 20M CB1954. In addition, in the absence 
of NADH, there was also a statistically significant difference in survival between 
the D17 cells transfected with pCMVNTR and treated with 5 M CB1954, to the 
D17 cells transfected with all the other constructs and treated with 5M and 
20M CB1954. There was however no difference between the pCMVNTR-
transfected D17 cells treated with 5M and 20M CB1954 in the absence of 
NADH. Hence, survival in the absence of NADH, was reduced in D17 cells 
transfected with pCMVNTR and treated with 5M and 20M CB1954 and in the 
presence of NADH, was only significantly reduced in D17 cells transfected with 
pCMVNTR and treated with 20M CB1954. 
In the absence and presence of NADH, there was a statistically significant 
decrease between the pCMVNTR-transfected CMT7 cells treated with 20M 
CB1954 with all the other treatment groups. Except for, in the „absence of Chapter 5 ~ Suicide Gene Therapy for Canine OS 
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NADH‟ experiment, CMT7 cells treated with 20M CB1954 and transfected with 
pGL3-P8LA-NTR alone, and pGL3B8LA-NTR and pGL3-P8LA-NTR, in combination 
with pTargeT-Lexp53. However, a 90% difference in cell survival existed 
between the pGL3B8LA-NTR- and pCMVNTR- transfected cells treated with 20M 
CB1954 after 144 hours. This result was probably due to survival of pGL3B8LA-
NTR+pTargeT-Lexp53 transfected cells being lower at 12 and 24 hour time points 
than for pCMVNTR-transfected cells as the statistical tests employed compared 
overall cell numbers. Additionally, except for, in the „presence of NADH‟ 
experiment, pCMVNTR-transfected CMT7 cells treated with 5M CB1954 and 
pGL3P8LA-NTR transfected cells, in combination with pTargeTLex-p53, treated 
with 20M CB1954. There was also a significant difference between pCMVNTR-
transfected CMT7 cells treated with 5M CB1954 with untreated NTC and 
pCMVNTR-transfected cells, NTC treated with 5M and 20M CB1954, and 
pGL3B8LA-NTR treated with 5M CB1954.  
These results show that in the absence or presence of NADH, transfection of 
pGL3B8LA-NTR or pGL3E8LA-NTR in combination with pTargeTLex-p53, does not 
appear to reduce survival of D17 and CMT7 cells following treatment with 
CB1954. In addition, pGL3P8LA-NTR in combination with pTargeTLex-p53, does 
not appear to reduce survival of D17 cells, with CB1954 treatment. 
In the absence of NADH, the survival of pCMVNTR-transfected D17 and CMT7 
cells after 144 hours 5M CB1954 treatment was ~25% and ~50%, respectively. 
20M CB1954 treatment in the pCMVNTR-transfected D17 cells after 96 hours, 
resulted in <10% survival and in the pCMVNTR-transfected CMT7 cells after 144 
hours, ~15% survival. In the presence of NADH, after 5M CB1954 treatment for 
144 hours, ~80% and 35% pCMVNTR-transfected D17 and CMT7 cells survived, 
respectively. 20M CB1954 treatment, almost reduced cell survival to 0% in both 
the pCMVNTR-transfected D17 and CMT7 cells. These results suggest that NADH 
may reduce the survival of pCMVNTR-transfected CMT7 cells treated with 
CB1954. However, in the D17 cells, an experimental error may have occurred, 
which would have been repeated if more CB1954 was available, hence requires 
further investigation.  Chapter 5 ~ Suicide Gene Therapy for Canine OS 
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In the absence of NADH, there was also a significant difference between CMT7 
cells treated with 20M CB1954 and transfected with pGL3P8LA-NTR in 
combination with pTargeTLex-p53 to the untreated CMT7 cells transfected with 
pGL3P8LA-NTR alone or in combination with pTargeTLex-p53. This shows that 
overall, similar levels of reduction in cell survival were achieved in the 
pGL3P8LA-NTR transfected cells treated with 20M CB1954 alone or in 
combination with pTargeTLex-p53 to those of pCMVNTR-transfected cells. 
Although no significant difference existed between the pGL3P8LA-NTR 
transfected cells alone or in combination with pTargeTLex-p53, survival was 
~20% less in those transfected with pTargeTLex-p53 (~30% survival vs. ~50% 
survival) after 144 hours. Similarly, in the presence of NADH, there was also a 
significant difference between CMT7 cells treated with 20M CB1954 and 
transfected with pGL3P8LA-NTR in combination with pTargeTLex-p53 to the 
untreated NTC and NTC treated with 5M and 20M CB1954. This also shows that 
overall, similar levels of reduction in cell survival were achieved in the 
pGL3P8LA-NTR transfected cells in combination with pTargeTLex-p53 and 
treated with 20M CB1954 to those of pCMVNTR-transfected cells. Although no 
significant difference existed between the pGL3P8LA-NTR transfected cells alone 
or in combination with pTargeTLex-p53, survival was ~30% less in those 
transfected with pTargeTLex-p53 (~50% survival vs. ~80% survival). 
This suggests that in both the absence and presence of NADH, a decrease in 
survival of CMT7 cells may occur by pGL3P8LA-NTR in combination with 
pTargeTLex-p53 following treatment with 20M CB1954 after 144 hours. Cell 
survival also appears to be higher in the presence of NADH (50%) than in the 
absence of NADH (30%).  Chapter 5 ~ Suicide Gene Therapy for Canine OS 
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Group  Treatment  D17  CMT7 
1  NTC  6, 13  13 
2  NTC + 5M  6, 13  13 
3  CAT  6, 13  13 
4  CAT + 5M  6, 13  13 
5  NTR  6, 13  13 
6  NTR + 5M  All except 13  13 
7  B8LA  6, 13  13 
8  B8LA + 5M  6, 13  13 
9  B8LA + Lexp53  6, 13  13 
10  B8LA + Lexp53 + 5M  6, 13  13 
11  NTC + 20M  6, 13  13 
12  CAT + 20M  6, 13  13 
13  NTR + 20M  All except 6  1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14 
14  B8LA + 20M  6, 13  13 
15  B8LA + Lexp53 + 20M  6, 13    
 
Table 5.16: Post hoc pairwise comparisons of treatment groups in Figure 5.16, 
listing the treatment groups which were significantly different from each group 
over the 144 hour treatment period (significance was set at p = 0.05).  
 
 
Group  Treatment  D17  CMT7 
1  NTC  6, 13  13 
2  NTC + 5M  6, 13  13 
3  CAT  6, 13  13 
4  CAT + 5M  6, 13  13 
5  NTR  6, 13  13 
6  NTR + 5M  All except 13  13 
7  E8LA  6, 13  13 
8  E8LA + 5M  6, 13  13 
9  E8LA + Lexp53  6, 13  13 
10  E8LA + Lexp53 + 5M  6, 13  13 
11  NTC + 20M  6, 13  13 
12  CAT + 20M  6, 13  13 
13  NTR + 20M  All except 6  All other treatments 
14  E8LA + 20M  6, 13  13 
15  E8LA + Lexp53 + 20M  6, 13  13 
 
Table 5.17: Post hoc pairwise comparisons of treatment groups in Figure 5.17, 
listing the treatment groups which were significantly different from each group 
over the 144 hour treatment period (significance was set at p = 0.05).  Chapter 5 ~ Suicide Gene Therapy for Canine OS 
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Group  Treatment  D17  CMT7 
1  NTC  6, 13  13 
2  NTC + 5M  6, 13  13 
3  CAT  6, 13  13 
4  CAT + 5M  6, 13  13, 15 
5  NTR  6, 13  13, 15 
6  NTR + 5M  All except 13  13 
7  P8LA  6, 13  13, 15 
8  P8LA + 5M  6, 13  13 
9  P8LA + Lexp53  6, 13  13, 15 
10  P8LA + Lexp53 + 5M  6, 13  13 
11  NTC + 20M  6, 13  13 
12  CAT + 20M  6, 13  13 
13  NTR + 20M  All except 6  1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 
14  P8LA + 20M  6, 13    
15  P8LA + Lexp53 + 20M 6, 13  4, 5, 7, 9 
 
Table 5.18: Post hoc pairwise comparisons of treatment groups in Figure 5.18, 
listing the treatment groups which were significantly different from each group 
over the 144 hour treatment period (significance was set at p = 0.05).   
 
 
 
 
 
Figure 5.16: The effect of 5M (A & B) and 20M (C & D) CB1954 (CB), in the absence of NADH over 144 hours, on survival of D17 (A & C) 
and CMT7 (B & D) cells transfected with: pCMVCAT6 (CAT); pCMVNTR in combination with pCMVCAT6 (NTR); and pGL3B8LA-NTR, in 
combination with pCMVCAT6 (B8LA), or pTargeT-Lexp53 (B8LA+p53). (NTC, non-transfected cells; each time point was repeated in 
triplicate; bars represent +/- SE). Please note different scales on Y-axes. 
A  B 
C  D  
 
 
 
 
Figure 5.17: The effect of 5M (A & B) and 20M (C & D) CB1954 (CB), in the absence of NADH over 144 hours, on survival of D17 (A & C) 
and CMT7 (B & D) cells transfected with: pCMVCAT6 (CAT); pCMVNTR in combination with pCMVCAT6 (NTR); and pGL3E8LA-NTR, in 
combination with pCMVCAT6 (E8LA), or pTargeT-Lexp53 (E8LA+p53). (NTC, non-transfected cells; each time point was repeated in 
triplicate; bars represent +/- SE). Please note different scales on Y-axes. 
A  B 
C  D  
 
 
 
 
 
 
Figure 5.18: The effect of 5M (A & B) and 20M (C & D) CB1954 (CB), in the absence of NADH over 144 hours, on survival of D17 (A & C) 
and CMT7 (B & D) cells transfected with: pCMVCAT6 (CAT); pCMVNTR in combination with pCMVCAT6 (NTR); and pGL3P8LA-NTR, in 
combination with pCMVCAT6 (P8LA), or pTargeT-Lexp53 (P8LA+p53). (NTC, non-transfected cells; each time point was repeated in 
triplicate; bars represent +/- SE). Please note different scales on Y-axes. 
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Group  Treatment  D17  CMT7 
1  NTC  13  6, 13 
2  NTC + 5M  13  6, 13 
3  CAT  13  13 
4  CAT + 5M  13  13 
5  NTR  13  6, 13 
6  NTR + 5M  13  1, 2, 5, 8, 11 
7  B8LA  13  13 
8  B8LA + 5M  13  6, 13 
9  B8LA + Lexp53  13  13 
10  B8LA + Lexp53 + 5M  13  13 
11  NTC + 20M  13  6, 13 
12  CAT + 20M  13  13 
13  NTR + 20M  All other treatments All except 6 
14  B8LA + 20M  13  13 
15  B8LA + Lexp53 + 20M  13  13 
 
Table 5.19: Post hoc pairwise comparisons of treatment groups in Figure 5.19, 
listing the treatment groups which were significantly different from each group 
over the 144 hour treatment period (significance was set at p = 0.05).  
 
 
Group  Treatment  D17  CMT7 
1  NTC  13  6, 13 
2  NTC + 5M  13  6, 13 
3  CAT  13  13 
4  CAT + 5M  13  13 
5  NTR  13  6, 13 
6  NTR + 5M  13  1, 2, 5, 11 
7  E8LA  13  13 
8  E8LA + 5M  13  13 
9  E8LA + Lexp53  13  13 
10  E8LA + Lexp53 + 5M  13  13 
11  NTC + 20M  13  6, 13 
12  CAT + 20M  13  13 
13  NTR + 20M  All other treatments All except 6 
14  E8LA + 20M  13  13 
15  E8LA + Lexp53 + 20M  13  13 
 
Table 5.20: Post hoc pairwise comparisons of treatment groups in Figure 5.20, 
listing the treatment groups which were significantly different from each group 
over the 144 hour treatment period (significance was set at p = 0.05).  Chapter 5 ~ Suicide Gene Therapy for Canine OS 
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Group  Treatment  D17  CMT7 
1  NTC  13  6, 13, 15 
2  NTC + 5M  13  6, 13, 15 
3  CAT  13  13 
4  CAT + 5M  13  13 
5  NTR  13  6, 13 
6  NTR + 5M  13  1, 2, 5, 11 
7  P8LA  13  13 
8  P8LA + 5M  13  13 
9  P8LA + Lexp53  13  13 
10  P8LA + Lexp53 + 5M  13  13 
11  NTC + 20M  13  6, 13, 15 
12  CAT + 20M  13  13 
13  NTR + 20M  All other treatments  1, 2, 3, 4, 5, 7, 8, 9, 10, 11, 12, 14 
14  P8LA + 20M  13  13 
15  P8LA + Lexp53 + 20M 13  1, 2, 11 
 
Table 5.21: Post hoc pairwise comparisons of treatment groups in Figure 5.21, 
listing the treatment groups which were significantly different from each group 
over the 144 hour treatment period (significance was set at p = 0.05).  
  
 
      
 
 
       
 
Figure 5.19: The effect of 5M (A & B) and 20M (C & D) CB1954 (CB), in the presence of NADH over 144 hours, on survival of D17 (A & 
C) and CMT7 (B & D) cells transfected with: pCMVCAT6 (CAT); pCMVNTR in combination with pCMVCAT6 (NTR); and pGL3B8LA-NTR, in 
combination with pCMVCAT6 (B8LA), or pTargeT-Lexp53 (B8LA+p53). (NTC, non-transfected cells; each time point was repeated in 
triplicate; bars represent +/- SE). Please note different scales on Y-axes. 
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Figure 5.20: The effect of 5M (A & B) and 20M (C & D) CB1954 (CB), in the presence of NADH over 144 hours, on survival of D17 (A & 
C) and CMT7 (B & D) cells transfected with: pCMVCAT6 (CAT); pCMVNTR in combination with pCMVCAT6 (NTR); and pGL3E8LA-NTR, in 
combination with pCMVCAT6 (E8LA), or pTargeT-Lexp53 (E8LA+p53). (NTC, non-transfected cells; each time point was repeated in 
triplicate; bars represent +/- SE). Please note different scales on Y-axes. 
A  B 
C  D  
 
 
 
 
 
 
 
Figure 5.21: The effect of 5M (A & B) and 20M (C & D) CB1954 (CB), in the presence of NADH over 144 hours, on survival of D17 (A & 
C) and CMT7 (B & D) cells transfected with: pCMVCAT6 (CAT); pCMVNTR in combination with pCMVCAT6 (NTR); and pGL3P8LA-NTR, in 
combination with pCMVCAT6 (P8LA), or pTargeT-Lexp53 (P8LA+p53). (NTC, non-transfected cells; each time point was repeated in 
triplicate; bars represent +/- SE). Please note different scales on Y-axes.  
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5.4 Discussion 
5.4.1 Detection of nitroreductase protein expression by pCMVNTR and 
pGL3B8LA-NTR, pGL3E8LA-NTR and pGL3P8LA-NTR, in combination with 
pTargeT-Lexp53 or pCMVCAT6 
The results observed in this study are in agreement with those obtained in the 
DLR experiments (previously described in 4.3.4), as expression of NTR was 
detected following transfection of pGL3P8LA-NTR in combination with pTargeT-
Lex53 in CMT7 cells possessing accumulated TP53, but not in D17 cells containing 
wild-type TP53. Thus, further confirming that the TP53-targeted suicide gene 
therapy system is able to recruit the transactivation domain of the accumulated 
TP53 present in CMT7 cells to drive the expression of the gene downstream of 
the upstream activating sequence (i.e. LexA operator site), whether it is a gene 
for FFluc or NTR.  
The lack of detection of NTR expression following transfection of pGL3B8LA-NTR 
and pGL3E8LA-NTR, in combination with pTargeT-Lexp53, in CMT7 cells, could 
be due to, as previously described in 4.4.1, the sensitivity of the ECL
TM western 
blotting analysis system (Amersham Pharmacia Biotech). The amount of NTR 
expressed, as a result of pGL3B8LA-NTR and pGL3E8LA-NTR lacking a promoter, 
may be below the detection limit of this kit. The ECL
TM Plus Western Blotting 
System was previously used by Blackwood et al., (2001), to detect expression of 
NTR following transfection of pCMVNTR into feline cells (Blackwood et al., 
2001). The ECL
TM Plus system is 4- to 20-fold more sensitive than the standard 
kit. Hence, the use of a more sensitive chemiluminescent method (as previously 
described in 4.4.1), is warranted in subsequent studies. 
Although the expression of NTR was only detected after a single time point in 
this study (48 hours post-transfection), NTR expression by pCMVNTR has been 
previously shown by Blackwood et al., (2001), to be expressed in feline cells 
from 24 hours after transfection upto at least 72 hours. Hence, in future studies, 
the expression of NTR by all the vectors containing NTR, following transfection 
in the relevant cell lines, should be confirmed over the period of time utilized in 
the cell survival assays. 
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5.4.2 Analysis of pCMVNTR in combination with nitrofurazone  
Preliminary prodrug activating system cell survival assays were performed in the 
4 OS cell lines, D17, CMT3, CMT7 and CMT8, and 2 additional canine cell lines, 
MDCK and CML-10, using pCMVNTR and the prodrug, NFZ. These assays represent 
the first demonstration of the activities of the E.coli NTR/NFZ system in canine 
cells. Overall, the reductions in cell survival after treatment with NFZ were 
similar between the NTC and cells transfected with pCMVNTR, as few significant 
differences were found. Hence, selective cell kill could not be achieved using 
NTR in combination with NFZ in these 6 cell lines. Additionally, NTR has 
demonstrated an apparent Km value for NFZ at 64M (Roldan et al., 2008), which 
is at least 10-fold greater than the maximum concentration employed in this 
study. 
These results suggest that there may be endogenous activation of NFZ under the 
conditions of the experiments carried out. Mammalian cells, including canine, 
contain for example, NQO1 and xanthine oxidase, which can also reduce NFZ 
(Roldan et al., 2008). NQO1 is known to be present in a variety of tumours, 
including OS (Belinsky & Jaiswal 1993; Friedlos et al., 1992a; Hussein et al., 
2009; Kumaraguruparan et al., 2006), and normal tissues (Jaiswal 1994; Li et al., 
2001), in both dogs and humans. In addition, NQO1 present in breast cancer cells 
is capable of resulting in high levels of cytotoxicity following exposure to 5M 
CB1954 for 20 hours (Friedlos et al., 1992a). Furthermore, xanthine oxidase, is 
thought to play a pivotal role in the bone microenvironment (Kanczler et al., 
2003). Thus, it is realistic to expect that D17, CMT3, CMT7, CMT8, MDCK and 
CML-10 cells also contain endogenous enzymes, such as NQO1, that possess 
nitroreductase activity. Hence, further studies are warranted to identify the 
nitroreductases present in these 6 canine cell lines. However, an alternative 
explanation for the activation of NFZ in canine cells also exists, in that toxicity 
may occur via another, as yet, unknown pathway. 
The concentrations of NFZ employed in this study were based on those 
previously published by Bailey and colleagues (1996), in which 1M NFZ achieved 
100% cell kill in NTR-transfected hamster lung fibroblasts, whereas 100M NFZ 
was required in NTC (Bailey et al., 1996). Hence, the findings from this study are Chapter 5 ~ Suicide Gene Therapy for Canine OS 
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in contrast to those obtained by Bailey and co-workers (1996), as no endogenous 
activation of NFZ was observed in hamster lung fibroblasts (Bailey et al., 1996). 
As far as I am aware, no other mammalian in vitro studies have been reported 
investigating either the use of E.coli NTR/NFZ system or the endogenous 
activation of NFZ.  
Additionally, Bailey et al., (1996) employed the MTT dye reduction assay to 
determine levels of cell survival (Bailey et al., 1996); the CellTiter 96® AQueous 
One Solution Cell Proliferation Assay utilized in this study is the improved 
version of the MTT assay.  
Thus, NFZ does not appear to be suitable as a prodrug for NTR in these canine 
cells. Although NFZ is used in human and veterinary medicine primarily to treat 
surface infections that have become resistant to antibiotics, the National 
Toxicology Program has provided clear evidence of carcinogenic activity of NFZ 
for female rats and mice (National Toxicology Program 1988), its use is 
prohibited in medicinal products for food-producing species in the UK (EEC 
1995), and the International Agency for Research on Cancer (IARC) suspected 
that NFZ was carcinogenic to humans (Bartsch & Malaveille 1990; Bartsch & 
Tomatis 1983; Hiraku et al., 2004; Marselos & Vainio 1991); suspected levels are 
similar to the concentrations used in this study and by Bailey et al., (1996) 
(Bailey et al., 1996). Hence, the use of a carcinogenic substance should not be 
used without much consideration in the treatment of tumours. 
 
5.4.3 Analysis of pCMVNTR and TP53-targeted suicide gene therapy strategy 
in combination with CB1954  
Preliminary prodrug activating system cell survival assays were also carried out 
in the D17 and CMT7 cell lines, using pCMVNTR and TP53-targeted suicide gene 
therapy strategy, both in combination with the prodrug, CB1954. These assays 
represent the first demonstration of the activities of the E.coli NTR/CB1954 
system in canine cells.  
The results from the preliminary experiment show that functional NTR can be 
expressed from the bacterial gene by canine OS cells in vitro, which is capable Chapter 5 ~ Suicide Gene Therapy for Canine OS 
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of activating CB1954 to its cytotoxic metabolite, resulting in significant 
reductions in cell survival after only 12 hours. This also suggests that the D17 
and CMT7 cells are capable of carrying out the final step required to activate 
CB1954, which requires thioesters endogenously present to react with the 
reduced CB1954 metabolite, to produce the cytotoxic difunctional alkylating 
agent. The rapid activation of CB1954 by NTR has been previously reported in 
vitro in a variety of human cancer cells (Bridgewater et al., 1995; Green et al., 
1997; McNeish et al., 1998a), and in feline cells using pCMVNTR in vitro 
(Blackwood et al., 2001). In addition, histological changes in vivo, have been 
observed in mammary gland of transgenic mice as soon as 7 hours after 
treatment with CB1954, and severe pathological changes after 24 hours (Cui et 
al., 1999). Furthermore, in vivo studies have shown the expression of NTR in 
combination with CB1954 results in significant decreases in survival of human 
tumour cells (Djeha et al., 2000; McNeish et al., 1998a; Weedon et al., 2000). 
CB1954 itself, appeared to be entirely non-toxic to the D17 and CMT7 cells at 
the concentrations used in the preliminary pCMVNTR experiment, indicating that 
any endogenous enzymes present are unable to significantly activate CB1954, 
even after prolonged exposure. This finding is in contrast to the results of the 
NFZ assays (5.4.2), in which endogenous nitroreductases, such as NQO1, were 
suggested to be responsible for the lack of a significant difference between 
pCMVNTR-transfected cells and NTC. The ability of the endogenous 
nitroreductases to reduce NFZ but not CB1954 is likely to be due to the lower 
sensitivity of these enzymes to reduce CB1954 to its cytotoxic metabolite 
(Boland et al., 1991). For example, Boland et al., (1991) reported that in human 
cells possessing relatively high levels of NQO1, a higher dose of CB1954 (100 to 
5000 times, representing concentrations of 100M to 10000M) was required to 
produce responses comparable to those produced in CB1954-sensitive rat cells 
(Boland et al., 1991). Additionally, Drabek et al., (1997) reported that 
concentrations greater than 500M were required to induce toxicity in cells not 
transfected with NTR, compared to 10M in NTR expressing cells (Drabek et al., 
1997). Hence, canine NQO1 may be similar to human NQO1 in that they both 
poorly reduce CB1954. In addition, the dose required to induce a significant 
decrease in cell survival by cells not expressing NTR, was not investigated in this Chapter 5 ~ Suicide Gene Therapy for Canine OS 
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study, as it would have rapidly used up the limited stock of CB1954 available. 
Therefore, these should be analysed in future studies.  
In cells that produce endogenous enzymes capable of CB1954 activation (as 
previously described in 5.4.2), and exposed to concentrations of CB1954 similar 
to that used in this study, appreciable levels of cytotoxicity have been reported 
to occur in less than 24 hours (Friedlos et al., 1992a; Sunters et al., 1991). Thus 
it would be expected that, if the enzymes present in canine OS cells were able 
to activate CB1954, as observed with NFZ, some reductions in cell survival would 
have occurred after maintenance of the cells in the CB1954 treatment medium 
for up to 72 hours. In all experiments, numbers of NTC treated with CB1954 were 
not significantly different from untreated NTC.  
The concentrations of CB1954 chosen to be used in this study were based on 
published in vitro data, in which 5, 10 and 40M CB1954 were previously 
employed by Blackwood et al., (Blackwood et al., 2001). The concentrations in 
the preliminary experiment, except for 160M CB1954, are also below the peak 
plasma concentrations that can be achieved in dogs and mice in vivo (100M and 
400M CB1954 following intravenous injection of 25mg/kg in dogs and 50mg/kg 
in mice, respectively), which do not produce toxicity (Workman et al., 1986b). 
Concentrations of ~50 - 60% of the plasma levels have been reported in tumours 
in mice, so the concentrations used in vitro are theoretically obtainable in vivo 
(Workman et al., 1986b). Indeed, doses of 20mg/kg (Drabek et al., 1997) and 
50mg/kg (Clark et al., 1997) have been successfully used in GDEPT in mice. 
Furthermore, concentrations of 1 - 100M (Bridgewater et al., 1995) and 
140M (Clark et al., 1997) have been employed in vitro, to selectively induce 
cytotoxicity following expression of NTR. 
No significant dose effects were demonstrated in NTR-expressing D17 and CMT7 
cells following treatment with 2.5 – 160M and 1.25 – 160M, respectively. This 
is likely to be due to the final step of converting the reduced CB1954 metabolite 
into the difunctional alkylating agent, also being the rate-limiting step, rather 
than an insufficient amount of NTR being available, due to the efficiency of 
transfection. This is because Blackwood et al., (2001), previously reported a 
dose response to increasing concentrations of CB1954 at a relatively low Chapter 5 ~ Suicide Gene Therapy for Canine OS 
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transfection efficiency of 5%, which was absent at a higher transfection 
efficiency of 28% (Blackwood et al., 2001). The transfection efficiencies for 
these NTR/CB1954 assays were deemed to be similar to those previously 
determined in 4.3.1.2, of 18.1% for D17 cells and 10% for CMT7. Hence, a 
threshold was reached whereby increases in the amount of CB1954 administered 
did not result in correlating reductions in cell survival. A plateau effect with 
increasing CB1954 concentrations has been previously reported (Blackwood et 
al., 2001; Knox et al., 1988). Hence, additional investigations are warranted.  
A bystander effect was also observed in this preliminary experiment, as the 
percentages of surviving cells following transfection of pCMVNTR in combination 
with 5M and 20M CB1954 after 48 hours were 50% and 10% in CMT7 cells, 
respectively, and ~60% in D17 cells for both concentrations. The set up of the 
experiment enabled the cells expressing NTR to be exposed to CB1954 for 72 
hours, maximising prodrug activation. Activated CB1954 rapidly diffuses into the 
cell culture medium, conferring cytotoxicity to cells not expressing NTR. 
However, the half-life of the diffusible active metabolite is short, hence, build 
up in the medium will be limited (Knox et al., 1988). The bystander effect and 
transfection efficiency seen in this study are comparable to that published in an 
in vitro study, in which NTR expressing cells were treated with 10M CB1954 and 
a 50% cell kill was demonstrated after 72 hours when only 10% of cells expressed 
NTR (McNeish et al., 1998a).  
The effect of NADH, a cofactor for NTR, was also investigated on NTR-expressing 
D17 and CMT7 cells, in combination with CB1954. It was expected that larger 
decreases in cell survival would be observed in the presence of NADH, as had 
previously been reported by Blackwood et al., 2001 (Blackwood et al., 2001). 
This was observed in the pCMVNTR-transfected CMT7 cells, but not in the D17 
cells. This difference may be because of an experimental error occurring in the 
D17 cells, but may also partly be due to the stability of NADH. NADH is a 
relatively unstable compound that is metabolized by serum components and at 
the cell surface (Friedlos & Knox 1992). Friedlos et al., (1992) reported that 
metabolism of NADH is rapid because they observed that ~50% of NADH (500M) 
in DMEM medium containing 10% FCS and PBS had disappeared within 6 hours 
(Friedlos & Knox 1992). Thus, it can be suggested that NADH is more stable in Chapter 5 ~ Suicide Gene Therapy for Canine OS 
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RPMI 1640 medium containing FCS, used for culturing CMT7 cells, than DMEM, 
which was employed for D17 cells. Unfortunately, due to the limited availability 
of CB1954, this experiment could only be performed once, hence, should be 
repeated in future studies.  
No significant toxicity of NADH was observed in this study on the NTC cells, 
which is in agreement with similar previously published studies (Anlezark et al., 
1995; Blackwood et al., 2001). Although nicotinamide riboside (reduced) (NRH) 
can be generated from the metabolism of NADH, in the presence of FCS in 
culture medium (Friedlos & Knox 1992), which is more stable than NADH and is a 
very poor cofactor for NTR, it can act as a cofactor for endogenous NQO1 (Knox 
et al., 1995). No reductions in cell survival were apparent in NTC treated with 
20M CB1954 and NADH. This finding agrees with the preliminary experiment 
results in which no decreases in cell survival were observed in NTC even treated 
with 160M CB1954. Hence, the endogenous enzymes present in D17 and CMT7 
cells are poor at activating CB1954, but not NFZ, under the conditions of this 
experiment, even in the presence of a cofactor. This provides a promising basis, 
on which these experiments may be performed in vivo, as NADH is an 
intracellular factor that does not appear to be a cofactor for endogenous canine 
nitroreductases. Thus, NTR and CB1954 can be exogenously introduced to 
selectively kill tumour cells, with hopefully, minimal unwanted toxicity 
occurring.  
The ultimate aim of this study was to use the TP53-targeted suicide gene 
therapy strategy, using NTR as the suicide gene and CB1954 as the prodrug, to 
selectively target and reduce cell numbers in canine OS cells possessing 
accumulated TP53. The results obtained in this experiment, in the presence and 
absence of NADH, were generally in agreement with the findings of the DLR 
experiments. Although no significant decreases in survival of CMT7 cells, 
containing accumulated TP53, occurred following the transfection of pGL3P8LA-
NTR in combination with pTargeTLex-p53 after CB1954 treatment, to that of 
pGL3P8LA-NTR transfected alone and treated with CB1954, the percentages of 
cells surviving were, both in the presence and absence of NADH, 20-30% lower. 
This non-significant result may be due to the statistical analyses employed, 
which analysed all the time points together, as it can be seen in Figures 5.18 and Chapter 5 ~ Suicide Gene Therapy for Canine OS 
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5.21 that the cell survival curves began to separate after 96 hours treatment. 
Hence, further statistical analysis is warranted. Unfortunately, the significant 
differences observed in the DLR experiments in the CMT7 cells treated with 
„B8LA+Lexp53‟ and „E8LA+Lexp53‟ to those treated with „Lexp53‟ did not 
translate into any significant or apparent decreases in cell survival. Importantly 
however, no significant reductions in survival of D17 cells, possessing 
accumulated TP53, occurred following transfection of pGL3P8LA-NTR, 
pGL3B8LA-NTR or pGL3E8LA-NTR in combination with pTargeTLex-p53, after 
CB1954 treatment. Significant decreases in survival of D17 cells were only 
observed following transfection with pCMVNTR and CB1954 treatment. Hence, 
the results demonstrated in this study are encouraging, because the TP53-
targeted suicide gene therapy strategy does appear to selectively target and 
reduce cell numbers in canine OS cells possessing accumulated TP53. 
Furthermore, similar levels of reductions in survival of CMT7 cells were achieved 
following transfection with pGL3P8LA-NTR in combination with pTargeTLex-p53, 
to CMT7 cells transfected with pCMVNTR, when treated with 20M CB9154. 
Additionally, in the absence of CB1954 treatment, the survival of CMT7 cells 
transfected with pGL3P8LA-NTR in combination with pTargeTLexp53 is not 
statistically different to that of the non-transfected CMT7 cells.  
The results obtained in this study are in agreement with those previously 
published by Costa et al., (1996) (Da Costa et al., 1996). In addition, several in 
vitro and in vivo transcriptional targeting studies utilising NTR/CB1954 system 
have been reported, in which the number of targeted tumour cells were 
significantly reduced following CB1954 treatment, whilst non-targeted cells 
remained unaffected (Blackwood et al., 2001). 
The effect of NADH had similar effects on D17 and CMT7 cells transfected with 
pGL3P8LA-NTR, pGL3B8LA-NTR and pGL3E8LA-NTR in combination with and 
without pTargeTLex-p53, to those in pCMVNTR-transfected cells, after CB1954 
treatment. No increases in reductions in cell survival were seen in presence of 
NADH, infact cell survival appeared to be lower in absence of NADH. This is 
probably due to the stability of NADH, as previously described, or an anomalous 
result as this experiment was only performed once. Chapter 5 ~ Suicide Gene Therapy for Canine OS 
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Improvements for modifying the constructs employed in the TP53-targeted 
suicide gene therapy strategy have been previously described in 4.4.3, which will 
enable a reduction in the expression of luciferase/NTR gene, in the absence of 
pTargeT-Lexp53, to occur. In particular, the use of pGL4 vectors to reduce the 
occurrence of any trans effects, optimizations into the amounts of different 
constructs transfected and the number of LexA operator sites employed 
upstream of the luciferase/NTR gene. Additionally, verification of these results 
at a future time will be necessary as the assays utilising CB1954 were only 
performed once. 
CB1954 certainly warrants further investigation as the prodrug of choice for the 
TP53-targeted suicide gene therapy strategy, whereas NFZ does not. Prior to any 
in vivo evaluation of the TP53-targeted suicide gene therapy strategy, a range of 
canine cell lines possessing wild-type and accumulated TP53, from different 
types of tissue should be tested, to determine whether activation by endogenous 
enzymes might occur in other tissues. In particular, hepatotoxicity has been 
reported as the dose-limiting toxicity of CB1954 administered alone in humans 
(Chung-Faye et al., 2001), hence, the possibility exists that this may also occur 
in dogs. However, the dose of CB1954 required for use in combination with NTR 
was well-tolerated and no dose-limiting toxicities have been reported for NTR 
given on its own (Chung-Faye et al., 2001; Palmer et al., 2004). Furthermore, 
minimal levels of toxicity were observed in the recently reported first clinical 
trial in human prostate cancer patients analysing NTR in combination with 
CB1954 (Patel et al., 2009). Hence the NTR/CB1954 system may be suitable for 
use in dogs.  
Furthermore, the TP53-targeted suicide gene therapy strategy, in conjunction 
with the selective bioactivation of CB1954 by NTR, offers the potential of a 
strategy that can be targeted towards any canine tumour cell, or human cell, 
possessing accumulated TP53. In recent years, the NTR/CB1954 system has been 
extensively optimized to increase efficacy. Mutants of NTR have been 
developed, which include double and triple mutants and unnatural amino acids, 
that are at least 7-fold more efficient at activating CB1954 than NTR itself 
(Jackson et al., 2006; Jarrom et al., 2009; Searle et al., 2004). Additionally, 
different nitroreductases have been evaluated, including nfsA, the primary E. Chapter 5 ~ Suicide Gene Therapy for Canine OS 
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coli nitroreductase, which has shown a greater sensitivity to CB1954 as well as a 
greater bystander effect in human cells, than nfsB (Emptage et al., 2009; Vass 
et al., 2009). NTR has also been analysed with a variety of different substrates 
to enable new prodrugs to be synthesized, e.g. the 3,5-dinitrobenzamide-2-
bromomustard, SN27686, that are more potent at selectively killing cells in vitro 
and/or possess a greater bystander effect than CB1954 (Atwell et al., 2007; 
Denny 2003; Jiang et al., 2006; Singleton et al., 2007). Furthermore, the actual 
mechanism of action of CB1954 has recently been elucidated (Christofferson & 
Wilkie 2009), so it is hoped that together, all this information will enable further 
progress to be made in developing optimal suicide gene therapy strategies for 
cancers in both dogs and humans.   
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TP53, the most commonly altered and studied gene in canine and human 
cancers, has also been demonstrated in this study to be important in canine OS. 
In particular, the canine TP53 C-terminus domain was shown to be able to 
recruit the transactivation domain present in canine OS cells possessing 
accumulated TP53, to drive the expression of NTR, acting as a suicide gene, via 
the use of a Lex-DNA binding domain interacting with its operator site acting as 
an upstream activating sequence. Thus enabling, following the administration of 
the prodrug CB1954, the selective targeting and killing of canine OS cells 
possessing accumulated TP53. Importantly, cells possessing wild-type TP53 did 
not show any reductions in cell survival. 
Hence, a TP53-targeting gene therapy suicide strategy has been designed and 
constructed which has been shown to be functional in vitro, which warrants 
further investigation as a treatment modality for OS, in both dogs and humans. 
In addition, this system could be used to selectively target and initiate the 
destruction of any tumour containing cells possessing accumulated TP53.  
Few suicide gene therapy studies have been published in canine tumour cells in 
vitro or in vivo and none as yet in canine OS, or with the E.coli NTR/CB1954 
system. This study demonstrates, for the first time, that the prodrug CB1954 is 
non-toxic to canine OS cells „in vitro’, and that E.coli NTR can be expressed in 
its biologically active form in these cells, resulting in activation of CB1954 to 
significantly reduce survival of canine OS cells. A marked bystander effect was 
also observed.  
Veterinary treatment for canine cancer, in terms of suicide gene therapy, is well 
behind the progress that has been made in the treatments for humans, 
particularly in the number of suicide gene therapy trials that have been 
performed in cancer patients. Dogs with cancer are gaining acceptance as 
excellent comparative models for human neoplasia, due to the identification of 
similarities in the histological types, tumour genetics, molecular targets e.g. 
TP53, response to conventional therapies and biological behaviour of tumours. It 
is therefore hoped that with the formation of the Canine Comparative Oncology 
and Genomics Consortium in 2003 (http://ccr.cancer.gov/resources/cop/), an 
increase in the number of clinical trials performed in dogs will occur. Thereby Chapter 6 ~ Conclusions & Future Directions 
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providing useful information for assessing the efficacy and optimal therapeutic 
regimens of anti-cancer agents (Figure 6.1).  
  
Figure 6.1: Integrated approach. An optimal drug development path would 
integrate both preclinical and clinical components of drug development so that 
questions that emerge in the human clinic could be answered in animals. 
Translational drug development studies in the pet dog with cancer are optimal 
for such an approach, being an intermediary between conventional preclinical 
models (mouse, research-bred dog and non-human primate) and the human 
clinical trial (Paoloni & Khanna 2008). 
 
A major area of gene therapy research is the development of effective gene 
delivery vectors because for GDEPT to be successful at treating cancers in the 
clinic, they must exist. Advances in vector technology are progressing at a rapid 
rate and there is a tremendous effort to increase the ability to express the 
therapeutic gene of interest at high levels, deliver selectively and efficiently to 
tumour cells, to reduce levels of toxicity and to increase applicability for 
systemic administration, enabling the treatment of metastatic disease. Synthetic 
systems have been designed that combine positive elements from various 
sources, for example, dioleoyl trimethylammonium propane: Cholesterol Chapter 6 ~ Conclusions & Future Directions 
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(DOTAP:Chol) liposomes encapsulate adenovectors, thereby possessing the 
targeting potential of natural receptor ligands, viral ability to enter cells, viral 
nuclear localization signals and packaging of liposomal envelopes. In preclinical 
studies, DOTAP:Chol liposomes were demonstrated to efficiently deliver TSG to 
disseminated lung tumours in vitro and in vivo (Ramesh et al., 2001; Ramesh et 
al., 2004). Although, the systemic administration of DNA- DOTAP:Chol liposomes 
induced multiple signalling molecules associated with inflammation, both in 
vitro and in vivo, small molecule inhibitors against these signalling molecules 
have been successfully used, resulting in their suppression and thus the 
reduction of inflammation (Gopalan et al., 2004). Thus, if the TP53-targeted 
suicide gene therapy system continued to produce successful results in future 
studies, the current method of using cationic liposomes would need to be 
improved, as well as alternative methods of delivery investigated, in particular 
for administration systemically. Numerous studies have also demonstrated that 
gene therapy transfer protocols, optimized for use in vitro, including liposome 
formulations, may not predict the optimal formulation that can be used in vivo, 
hence, optimizations must also be carried in vivo, prior to in vivo analyses being 
performed (Danthinne & Imperiale 2000; Egilmez et al., 1996; Nishikawa & 
Huang 2001; Xu et al., 2001b). However, the use of liposomes has already shown 
promise as a gene delivery system for dogs with OS, as two separate Phase I 
studies demonstrated that liposomes are well-tolerated and produce minimal 
toxicity in dogs with OS lung metastases (Dow et al., 2005; Khanna et al., 1997).  
Since factors that influence the efficacy of cancer therapy remain poorly 
understood, a molecular understanding of neoplasia will certainly improve 
cancer diagnosis and treatment. However, attempts to translate basic biology to 
clinically useful information have encountered many pitfalls. While TP53 clearly 
has an important role in tumourigenesis, it does not function in isolation. To 
date, many studies attempting to correlate findings to TP53 status have failed to 
account for other members of the TP53 pathway and hence, interpretations are 
incomplete. Indeed, tumours containing wild-type TP53, typically possess 
defects in the TP53-mediated apoptotic pathway. In the past few years, better 
methods to assess both TP53 status and the TP53 pathway have been developed 
and are being used to further increase our knowledge of TP53 biology and 
understand the clinical behaviour of TP53 mutant and wild-type tumours. Chapter 6 ~ Conclusions & Future Directions 
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However, the preliminary success of approaches, that specifically address TP53 
status in tumours, underscores the notion that a molecular understanding of 
cancer will have a positive impact on treatment. 
Cancer, even of a single cell type in a single organ, is a molecularly 
heterogeneous disease. Although a single therapeutic approach alone, including 
a fully optimized suicide gene therapy strategy, can induce a tumour response, 
it is unlikely to be curative and induce cell death in all tumour cells. Instead, it 
is believed that several different therapeutic methods will need to be combined 
to enhance efficacy, reduce toxicity, alleviate associated pain, slow the 
development of metastasis and prevent or delay drug resistance. Multimodality 
therapy using combinations of conventional therapies are already in use for 
treating cancer and has, unfortunately, shown that intolerably high levels of 
toxicity occur in most cancer patients because of the small difference in 
biochemical signals between normal and malignant cells. 
Gene therapies however, in comparison to current cancer therapies, have the 
great advantage of non-cross-resistance to most conventional treatments, a 
much lower systemic toxicity and the potential to selectively target 
micrometastatic deposits that are currently difficult to detect or treat, 
particularly so in OS. Efforts to combine gene therapies with conventional 
modalities are proceeding, as are efforts to combine different types of gene 
therapies themselves. For example, if TK gene transfer (followed by GCV) is 
combined with cytokine gene transfer, the patient may benefit from both a 
direct cytotoxic and an immune-mediated antitumour effect. NTR has been 
inserted into oncolytic viruses, which has been demonstrated to further enhance 
levels of cell kill and increase survival in vitro and in vivo, following 
administration of CB1954 and SN27686 (Braidwood et al., 2009; Singleton et al., 
2007). The E. coli NTR/CB1954 system has also been demonstrated to improve 
the effect of radiotherapy in vitro and in vivo (White et al., 2008). Hence, at 
the current rate of biotechnological development, it is only a matter of time 
until the development of more efficient vectors and combined modality 
approaches overcome technical limitations that currently prevent the 
widespread application of gene therapy to cancer (Roth & Grammer 2004). Chapter 6 ~ Conclusions & Future Directions 
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In addition to this study, there is a growing body of investigation into molecular 
targeted therapies for the treatment of canine OS. Several studies have shown 
that proliferation can be reduced and apoptosis induced in canine OS cell lines in 
vitro, including, multikinase inhibitor, sorafenib (Wolfesberger et al., 2009), 
small molecule MET inhibitor, PF2362376 (Liao et al., 2007), histone deacetylase 
(HDAC) inhibitors, OSU-HDAC42  (S(+)-N-hydroxy-4-(3-methyl-2-phenyl-
butyrylamino)benzamide) and SAHA (suberoylanilide hydroxamic acid) 
(Kisseberth et al., 2008), HSP90 inhibitor, STA-1474 (McCleese et al., 2009), 
mammalian target of rapamycin (mTOR) inhibitor, rapamycin (Gordon et al., 
2008), and in vivo, thalidomide, a drug that is gaining a modest resurgence in 
oncology as a potential anti-angiogenesis agent (Farese et al., 2004). These have 
all been suggested to represent potential therapeutic agents that may be used 
as adjuvant treatments to conventional therapies. However, they all require 
further investigation to determine if preclinical activity translates into 
antitumour activity in dogs with OS. Two Phase I clinical trials have been 
performed in dogs with OS, investigating an IGF-1 suppressant, OncoLAR 
(octreotide pamoate), in combination with carboplatin following amputation 
(Khanna et al., 2002), and a protein-kinase C inhibitor, dexniguldipine (Hahn et 
al., 1997). A third is currently in progress evaluating rapamycin (Paoloni & 
Khanna 2007). Although the two completed trials reported encouraging results, 
they did not produce the desired therapeutic benefit. OncoLAR suppressed IGF-1 
levels by 43% and minimal levels of toxicity were observed, however survival 
times were not enhanced when compared to carboplatin treatment alone 
(Khanna et al., 2002). Dexniguldipine- and cisplatin- treated dogs had longer 
median remission duration and survival time than untreated dogs; however, 
dexniguldipine-treated dogs had a shorter survival time than cisplatin-treated 
dogs (Hahn et al., 1997). Hence, clinical studies investigating alternative 
molecular targets are still necessary. Furthermore, understanding the 
mechanisms and interactions of various molecular pathways in OS will hopefully 
help to identify new targets for therapy that may prove more effective and/or 
less toxic, especially for the tumours that respond poorly to conventional 
treatments. 
It is hoped therefore, that with future research, a targeted suicide gene therapy 
approach in combination with other molecular-based treatments will be Chapter 6 ~ Conclusions & Future Directions 
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developed that is able to successfully treat OS and combat the problem of 
micro- and macro- metastatic disease, thereby increasing survival rates in both 
dogs and humans.  
Overall, this thesis demonstrates that a TP53-targeted suicide gene therapy 
strategy may play a role as a treatment modality for OS and other canine and 
human cancers possessing accumulated TP53.  
 
239 
 
 
References  
 
 References 
 
240 
    1.   Aas, M., Moe, L., Gamlem, H., Skretting, A., Ottesen, N., & Bruland, O. S. 1999, 
"Internal radionuclide therapy of primary osteosarcoma in dogs, using 153Sm-ethylene-
diamino-tetramethylene-phosphonate (EDTMP)”, Clin Cancer Res., vol. 5, no. 10S, pp. 
3148s-3152s. 
  2.   Affymetrix 2001, "GeneChip(R) p53 Assay", www.Affymetrix.com. 
  3.   Affymetrix 2005, "GeneChip(R) Canine Genome 2.0 Array", www.Affymetrix.com. 
  4.   Agilent Technologies 2006, "Agilent Canine Oligo Microarray", www.chem.agilent.com. 
  5.   Ahrens, F. A. 1996, “Antineoplastic diseases.,” in The National Veterinary Medical 
Series: Pharmacology, J. P. Kluge, ed., Williams & Wilkins, Baltimore, pp. 229-241. 
  6.  Alarcon-Vargus, D. & Ronai, Z. 2002, "p53-Mdm2 - the affair that never ends", 
Carcinogenesis, vol. 23, no. 4, pp. 541-547. 
  7.   Almazov, V. P., Kochetkov, D. V., & Chumakov, P. M. 2007, "The use of p53 as a tool 
for human cancer therapy", Mol Biol (Mosk)., vol. 41, no. 6, pp. 947-963. 
  8.   Altaner, C. 2008, "Prodrug cancer gene therapy”, Cancer Lett., vol. 270, no. 2, pp. 
191-201. 
  9.   Anderson, T. J. 1996, "Primary bone sarcomas of the dog and cat - diagnosis and 
management options", Unknown. 
  10.   Anlezark, G. M., Melton, R. G., Sherwood, R. F., Coles, B., Friedlos, F., & Knox, R. J. 
1992, "The bioactivation of 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB1954)--I. 
Purification and properties of a nitroreductase enzyme from Escherichia coli--a 
potential enzyme for antibody-directed enzyme prodrug therapy (ADEPT)", Biochem 
Pharmacol., vol. 44, no. 12, pp. 2289-2295. 
  11.   Anlezark, G. M., Melton, R. G., Sherwood, R. F., Wilson, W. R., Denny, W. A., Palmer, 
B. D., Knox, R. J., Friedlos, F., & Williams, A. 1995, "Bioactivation of dinitrobenzamide 
mustards by an E.coli B nitroreductase", Biochem Pharmacol., vol. 50, no. 5, pp. 609-
618. 
  12.   Appelbaum, F. R., Meyers, J. D., Deeg, H. J., Graham, T., Schuening, F., & Storb, R. 
1988, "Toxicity trial of prophylactic 9-[2-hydroxy-1-
(hydroxymethyl)ethoxymethyl]guanine (ganciclovir) after marrow transplantation in 
dogs", Antimicrob Agents Chemother., vol. 32, no. 2, pp. 271-273. 
  13.   Appella, E. & Anderson, C. W. 2000, "Signaling to p53: breaking the posttranslational 
modification code", Pathol Biol (Paris)., vol. 48, no. 3, pp. 227-245. 
  14.   Aprikian, A. G., Sarkis, A. S., Fair, W. R., Zhang, Z., Fuks, Z., & Cordon-Cardo, C. 
1994, "Immunohistochemical determination of p53 protein nuclear accumulation in 
prostatic adenocarcinoma", J Urol., vol. 151, pp. 1276-1280. 
  15.   Arendt, M., Nasir, L., & Morgan, I. M. 2009, "Oncolytic gene therapy for canine 
cancers: teaching old dog viruses new tricks", Vet Comp Oncol., vol. 7, no. 3, pp. 153-
161. 
  16.   Argyle, D. J. 1999, "Gene therapy in veterinary medicine", Vet Record, vol. 144, pp. 
369-376. 
  17.   Argyle, D. J. 2005, "The benefits of comparative medicine -- a hundred years to come 
to our senses”, Vet J., vol. 170, no. 2, pp. 147-148. References 
 
241 
  18.   Argyle, D. J. 2007, "Molecular/Targeted Therapy of Cancer - Section A: Gene Therapy 
for Cancer," in Withrow & MacEwen's Small Animal Clinical Oncology, Fourth edn, S. J. 
Withrow & D. M. Vail, eds., Saunders Elsevier, Missouri, pp. 236-242. 
  19.   Ashcroft, M. & Vousden, K. H. 1999, "Regulation of p53 stability", Oncogene, vol. 18, 
pp. 7637-7643. 
  20.   Atencio, I. A., Avanzini, J. B., Johnson, D., Neuteboom, S., Vaillancourt, M. T., 
Nielsen, L. L., Hajian, G., Sutjipto, S., Sugarman, B. J., Philopena, J., McAllister, D. 
L., Beltran, J. C., Nodelman, M., Ramachandra, M., & Wills, K. N. 2001, "Enhanced 
apoptotic activity of a p53 variant in tumors resistant to wild-type p53 treatment”, 
Mol Ther., vol. 4, no. 1, pp. 5-12. 
  21.   Atwell, G. J., Yang, S., Pruijn, F. B., Pullen, S. M., Hogg, A., Patterson, A. V., Wilson, 
W. R., & Denny, W. A. 2007, "Synthesis and structure-activity relationships for 2,4-
dinitrobenzamide-5-mustards as prodrugs for the Escherichia coli nfsB nitroreductase in 
gene therapy”, J Med Chem., vol. 50, no. 6, pp. 1197-1212. 
  22.   Auvinen, A., Isola, J., Visakorpi, T., Koivula, T., Virtanen, S., & Hakama, M. 1994, 
"Overexpression of p53 and long-term survival in colon carcinoma", Br J Cancer, vol. 
70, pp. 293-296. 
  23.   Bacon, N. J., Ehrhart, N. P., Dernell, W. S., Lafferty, M., & Withrow, S. J. 2008, "Use 
of alternating administration of carboplatin and doxorubicin in dogs with microscopic 
metastases after amputation for appendicular osteosarcoma: 50 cases (1999-2006)”, J 
Am Vet Med Assoc., vol. 232, no. 10, pp. 1504-1510. 
  24.   Bailey, D., Erb, H., Williams, L., Ruslander, D., & Hauck, M. 2003, "Carboplatin and 
doxorubicin combination chemotherapy for the treatment of appendicular 
osteosarcoma in the dog”, J Vet Intern Med., vol. 17, no. 2, pp. 199-205. 
  25.   Bailey, S. M. & Hart, I. R. 1997, "Nitroreductase activation of CB1954 - an alternative 
'suicide' gene system", Gene Ther., vol. 4, no. 2, pp. 80-81. 
  26.   Bailey, S. M., Knox, R. J., Hobbs, S. M., Jenkins, T. C., Mauger, A. B., Melton, R. G., 
Burke, PJ, Connors, T. A., & Hart, I. R. 1996, "Investigation of alternative prodrugs for 
use with E. coli nitroreductase in 'suicide gene' approaches to cancer therapy", Gene 
Ther., vol. 3, no. 12, pp. 1143-1150. 
  27.   Baines, S. J., Lewis, S., & White, R. A. S. 2002, "Primary thoracic wall tumours of 
mesenchymal origin in dogs: a retrospective study of 46 cases", Vet Record, vol. 150, 
pp. 335-339. 
  28.   Baker, S. J., Fearon, E. R., Nigro, J. M., Hamilton, S. R., Preisinger, A. C., Jessup, J. 
M., vanTuinen, P., Ledbetter, D. H., Barker, D. F., Nakamura, Y., White, R., & 
Vogelstein, B. 1989, "Chromosome 17 deletions and p53 gene mutations in colorectal 
carcinomas", Science, vol. 244, no. 4901, pp. 217-221. 
  29.   Bakhshi, S., Gupta, A., Sharma, M. C., Khan, S. A., & Rastogi, S. 2009, "Her-2/neu, p-
53, and their coexpression in osteosarcoma”, J Pediatr Hematol Oncol., vol. 31, no. 4, 
pp. 245-251. 
  30.   Barger, A., Graca, R., Bailey, K., Messick, J., Lorimer, L.-P., Fan, T., & Hoffman, W. 
2005, "Use of alkaline phosphatase staining to differentiate canine osteosarcoma from 
other vimentin-positive tumours”, Vet Pathol., vol. 42, pp. 161-165. 
  31.   Bargonetti, J., Manfredi, J. J., Chen, X., Marshak, D. R., & Prives, C. 1993, "A 
proteolytic fragment fom the central region of p53 has marked sequence-specific DNA-
binding activity when generated from wild-type but not from oncogenic mutant p53 
protein", Genes Dev., vol. 7, no. 12, pp. 2565-2574. References 
 
242 
  32.   Bargonetti, J., Reynisdottir, I., Friedman, P. N., & Prives, C. 1992, "Site-specific 
binding of wild-type p53 to cellular DNA is inhibited by SV40 T antigen and mutant 
p53", Genes Dev., vol. 6, no. 10, pp. 1886-1898. 
  33.   Barnett, B. G., Tillman, B. W., Curiel, D. T., & Douglas, J. T. 2002, "Dual targeting of 
adenoviral vectors at the levels of transduction and transcription enhances the 
specificity of gene expression in cancer cells”, Mol Ther., vol. 6, no. 3, pp. 377-385. 
  34.   Bartek, J., Bartkova, J., Vojtesek, B., Staskova, Z., Lukas, J., Rejthar, A., Kovarik, J., 
Midgley, C. A., Gannon, J. V., & Lane, D. P. 1991, "Aberrant expression of the p53 
oncoprotein is a common feature of a wide spectrum of human malignancies", 
Oncogene, vol. 6, no. 9, pp. 1699-1703. 
  35.   Bartsch, H. & Malaveille, C. 1990, "Screening assays for carcinogenic agents and 
mixtures: an appraisal based on data in the IARC Monograph series", IARC Sci Publ., 
vol. 104, pp. 65-74. 
  36.   Bartsch, H. & Tomatis, L. 1983, "Comparison between carcinogenicity and mutagenicity 
based on chemicals evaluated in the IARC monographs", Environ Health Perspect., vol. 
47, pp. 305-317. 
  37.   Bassett, E. A., Wang, W., Rastinejad, F., & El-Deiry, W. S. 2008, "Structural and 
functional basis for therapeutic modulation of p53 signaling”, Clin Cancer Res., vol. 14, 
no. 20, pp. 6376-6386. 
  38.   Bech-Nielsen, S., Haskins, M. E., Reif, J. S., Brodey, R. S., Patterson, D. F., Spielman, 
& R. 1978, "Frequency of osteosarcoma among first-degree relatives of St. Bernard 
dogs", J Natl Cancer Inst., vol. 60, no. 2, pp. 349-353. 
  39.   Belinsky, M. & Jaiswal, A. K. 1993, "NAD(P)H:quinone oxidoreductase1 (DT-diaphorase) 
expression in normal and tumor tissues”, Cancer Metastasis Rev., vol. 12, no. 2, pp. 
103-117. 
  40.   Benjamin, R., Helman, L., Meyers, P., & Reaman, G. 2001, "A phase I/II dose 
escalation and activity study of intravenous injections of OCaP1 for subjects with 
refractory osteosarcoma metastatic to lung", Hum Gene Ther., vol. 12, no. 12, pp. 
1591-1593. 
  41.   Berg, J., Gebhardt, M. C., & Rand, W. M. 1997, "Effect of timing of postoperative 
chemotherapy on survival of dogs with osteosarcoma”, Cancer, vol. 79, no. 7, pp. 
1343-1350. 
  42.   Berg, J., Lamb, C. R., & O'Callaghan, M. W. 1990, "Bone scintigraphy in the initial 
evaluation of dogs with primary bone tumors”, J Am Vet Med Assoc., vol. 196, no. 6, 
pp. 917-920. 
  43.   Berg, J., Weinstein, M. J., Schelling, S. H., & Rand, W. M. 1992, "Treatment of dogs 
with osteosarcoma by administration of cisplatin after amputation or limb-sparing 
surgery: 22 cases (1987-1990)", J Am Vet Med Assoc., vol. 200, no. 12, pp. 2005-2008. 
  44.   Berg, J., Weinstein, M. J., Springfield, D. S., & Rand, W. M. 1995, "Results of surgery 
and doxorubicin chemotherapy in dogs with osteosarcoma", J Am Vet Med Assoc., vol. 
206, no. 10, pp. 1555-1560. 
  45.   Bergman, P. J., MacEwen, E. G., Kurzman, I. D., Henry, C. J., Hammer, A. S., Knapp, 
D. W., Hale, A, Kruth, S. A., Klein, M. K., Klausner, J., Norris, A. M., McCaw, D., 
Straw, R. C., & Withrow, S. J. 1996, "Amputation and carboplatin for treatment of dogs 
with osteosarcoma: 48 cases (1991 to 1993)", J Vet Intern Med., vol. 10, no. 2, pp. 76-
81. References 
 
243 
  46.   Bert, A. G., Burrows, J., Osborne, C. S., & Cockerill, P. N. 2000, "Generation of an 
improved luciferase reporter gene plasmid that employs a novel mechanism for high-
copy replication", Plasmid, vol. 44, pp. 173-182. 
  47.   Bertheau, P., Espie, M., Turpin, E., Lehmann, J., Plassa, L. F., Varna, M., Janin, A., & 
de The, H. 2008, "TP53 status and response to chemotherapy in breast cancer”, 
Pathobiology, vol. 75, no. 2, pp. 132-139. 
  48.   Bhaumik, S., Lewis, X. Z., & Gambhir, S. S. 2004, "Optical imaging of Renilla 
luciferase, synthetic Renilla luciferase, and firefly luciferase reporter gene expression 
in living mice", J Biomed Opt., vol. 9, no. 3, pp. 578-586. 
  49.   Bischoff, J. R., Kirn, D. H., Williams, A., Heise, S., Horn, S., Muna, M., Ng, L., Nye, J. 
A., Sampson-Johannes, A., Fattaey, A., & McCormick, F. 1996, "An adenovirus mutant 
that replicates selectively in p53-deficient human tumour cells", Science, vol. 274, pp. 
373-376. 
  50.   Bishop, Y. M. 1996, The Veterinary Formulary, Third edn, The Royal Pharmaceutical 
Society of Great Britain, London. 
  51.   Blackwood, L., O'Shaughnessy, P. J., Reid, S. W. J., & Argyle, D. J. 2001, "E.coli 
Nitroreductase/CB1954: In vitro studies into a potential system for feline cancer gene 
therapy", Vet J., vol. 161, pp. 269-279. 
  52.   Blagbrough, I. S. & Zara, C. 2009, "Animal models for target diseases in gene therapy--
using DNA and siRNA delivery strategies”, Pharm Res., vol. 26, no. 1, pp. 1-18. 
  53.   Blagosklonny, M. V. 2002, "P53: an ubiquitous target of anticancer drugs”, Int J 
Cancer, vol. 98, no. 2, pp. 161-166. 
  54.   Boland, M. P., Knox, R. J., & Roberts, J. J. 1991, "The differences in kinetics of rat and 
human DT diaphorase result in a differential sensitivity of derived cell lines to CB 1954 
(5-(Aziridin-1-yl)-2,4-dinitrobenzamide)", Biochem Pharmacol., vol. 41, no. 6/7, pp. 
867-875. 
  55.   Boshart, M., Kluppel, M., Schmidt, A., Schutz, G., & Luckow, B. 1992, "Reporter 
constructs with low background activity utilizing the cat gene", Gene, vol. 110, pp. 
129-130. 
  56.   Bossi, G. & Sacchi, A. 2007, "Restoration of wild-type p53 function in human cancer: 
relevance for tumor therapy”, Head Neck, vol. 29, no. 3, pp. 272-284. 
  57.   Boston, S. E., Ehrhart, N. P., Dernell, W. S., Lafferty, M., & Withrow, S. J. 2006, 
"Evaluation of survival time in dogs with stage III osteosarcoma that undergo 
treatment: 90 cases (1985-2004)”, J Am Vet Med Assoc., vol. 228, no. 12, pp. 1905-
1908. 
  58.   Bourdon, J. C., Fernandes, K., Murray-Zmijewski, F., Liu, G., Diot, A., Xirodimas, D. 
P., Saville, M. K., & Lane, D. P. 2005, "p53 isoforms can regulate p53 transcriptional 
activity", Genes Dev., vol. 19, no. 18, pp. 2122-2137. 
  59.   Bradford, M. M. 1976, "A rapid and sensitive method for the quantitation of microgram 
quantities of protein utilizing the principle of protein-dye binding", Anal Biochem., vol. 
72, pp. 248-254. 
  60.   Braidwood, L., Dunn, P. D., Hardy, S., Evans, T. R., & Brown, S. M. 2009, "Antitumor 
activity of a selectively replication competent herpes simplex virus (HSV) with enzyme 
prodrug therapy”, Anticancer Res., vol. 29, no. 6, pp. 2159-2166. 
  61.   Breen, M. 2008, "Canine cytogenetics--from band to basepair”, Cytogenet Genome 
Res., vol. 120, no. 1-2, pp. 50-60. References 
 
244 
  62.   Bridgewater, J. A., Knox, R. J., Pitts, J. D., Collins, M. K., & Springer, C. J. 1997, "The 
bystander effect of the nitroreductase/CB1954 enzyme/prodrug system is due to a 
cell-permeable metabolite", Hum Gene Ther., vol. 8, no. 6, pp. 709-717. 
  63.   Bridgewater, J. A., Springer, C. J., Knox, R. J., Minton, N. P., Michael, N. P., & 
Collins, M. K. 1995, "Expression of the bacterial nitroreductase enzyme in mammalian 
cells renders them selectively sensitive to killing by the prodrug CB1954", Eur J Cancer, 
vol. 31A, no. 13-14, pp. 2362-2370. 
  64.   Britt, T., Clifford, C., Barger, A., Moroff, S., Drobatz, K., Thacher, C., & Davis, G. 
2007, "Diagnosing appendicular osteosarcoma with ultrasound-guided fine-needle 
aspiration: 36 cases”, J Small Anim Pract., vol. 48, no. 3, pp. 145-150. 
  65.   Brodey, R. S. 1979, "The use of naturally occurring cancer in domestic animals for 
research into human cancer: general considerations and a review of canine skeletal 
osteosarcoma", Yale J Biol Med., vol. 52, pp. 345-361. 
  66.   Brodey, R. S. & Abt, D. A. 1976, "Results of surgical treatment in 65 dogs with 
osteosarcoma", J Am Vet Med Assoc., vol. 168, no. 11, pp. 1032-1035. 
  67.   Brodey, R. S. & Riser, W. H. 1969, "Canine osteosarcoma. A clinicopathologic study of 
194 cases", Clin Orthop Relat Res., vol. 62, pp. 54-64. 
  68.   Bronden, L. B., Flagstad, A., & Kristensen, A. T. 2007, "Veterinary cancer registries in 
companion animal cancer: a review", Vet Comp Oncol., vol. 5, no. 3, pp. 133-144. 
  69.   Brunetti-Pierri, N., Nichols, T. C., McCorquodale, S., Merricks, E., Palmer, D. J., 
Beaudet, A. L., & Ng, P. 2005, "Sustained phenotypic correction of canine hemophilia B 
after systemic administration of helper-dependent adenoviral vector", Hum Gene 
Ther., vol. 16, no. 7, pp. 811-820. 
  70.   Buller, R. E., Runnebaum, I. B., Karlan, B. Y., Horowitz, J. A., Shahin, M., Petrauskas, 
S., Kreienberg, R., Slamon, D., & Pegram, M. 2002, "A phase I/II trial of rAd/p53 (SCH 
58500) gene replacement in recurrent ovarian cancer", Cancer Gene Ther., vol. 9, no. 
7, pp. 553-566. 
  71.   Bupp, K. & Roth, M. J. 2002, "Altering retroviral tropism using a random-display 
envelope library", Mol Ther., vol. 5, no. 3, pp. 329-335. 
  72.   Campbell, S. E., Nasir, L., Argyle, D. J., & Bennett, D. 2001, "Molecular cloning and 
characterization of canine metalloproteinase-9 gene promoter", Gene, vol. 273, pp. 
81-87. 
  73.   Carlsson, J., Soussi, T., & Persson, B. 2009, "Investigation and prediction of the 
severity of p53 mutants using parameters from structural calculations”, FEBS J., vol. 
276, no. 15, pp. 4142-4155. 
  74.   Carroll, J. L., Nielsen, L. L., Pruett, S. B., & Mathis, J. M. 2001, "The role of natural 
killer cells in adenovirus-mediated p53 gene therapy”, Mol Cancer Ther., vol. 1, no. 1, 
pp. 49-60. 
  75.   Caspari, T. 2000, "Checkpoints: how to activate p53", Curr Biol., vol. 10, p. R315-R317. 
  76.   Charissoux, J. L., Grossin, L., Leboutet, M. J., & Rigaud, M. 1999, "Treatment of 
experimental osteosarcoma tumors in rat by herpes simplex thymidine kinase gene 
transfer and ganciclovir", Anticancer Res., vol. 19, no. 1A, pp. 77-80. 
  77.   Chawla, S. P., Chua, V. S., Fernandez, L., Quon, D., Saralou, A., Blackwelder, W. C., 
Hall, F. L., & Gordon, E. M. 2009, "Phase I/II and Phase II Studies of Targeted Gene 
Delivery In Vivo: Intravenous Rexin-G for Chemotherapy-resistant Sarcoma and 
Osteosarcoma”, Mol Ther., Jun 16, Epub ahead of print. References 
 
245 
  78.   Cheah, P. L. & Looi, L. M. 2001, "p53: an overview of over two decades of study", 
Malays J Pathol., vol. 23, no. 1, pp. 9-16. 
  79.   Chen, C. B., Pan, J. J., & Xu, L. Y. 2003, "Recombinant adenovirus p53 agent injection 
combined with radiotherapy in treatment of nasopharyngeal carcinoma: a phase II 
clinical trial", Zhonghua Yi Xue Za Zhi, vol. 83, no. 23, pp. 2033-2035. 
  80.   Chen, D. S., Zhu, N.-L., Hung, G., Skotzko, M. J., Hinton, D. R., Tolo, V., Hall, F. L., 
Anderson, W. F., & Gordon, E. M. 1997, "Retroviral vector-mediated transfer of an 
antisense cyclin G1 construct inhibits osteosarcoma tumour growth in nude mice", Hum 
Gene Ther., vol. 8, pp. 1667-1674. 
  81.   Chen, W., Cooper, T. K., Zahnow, C. A., Overholtzer, M., Zhao, Z., Ladanyi, M., Karp, 
J. E., Gokgoz, N., Wunder, J. S., Andrulis, I. L., Levine, A. J., Mankowski, J. L., & 
Baylin, S. B. 2004, "Epigenetic and genetic loss of Hic1 function accentuates the role of 
p53 in tumorigenesis”, Cancer Cell, vol. 6, no. 4, pp. 387-398. 
  82.   Chene, P. & Bechter, E. 1999, "p53 mutants without a functional tetramerisation 
domain are not oncogenic", J Mol Biol., vol. 286, no. 5, pp. 1269-1274. 
  83.   Cheng, P. W. 1996, "Receptor ligand-facilitated gene transfer: enhancement of 
liposome-mediated gene transfer and expression by transferrin", Hum Gene Ther., vol. 
7, no. 3, pp. 275-282. 
  84.   Chiarugi, V., Cinelli, M., & Magnelli, L. 1998, "Acetylation and phosphorylation of the 
carboxy-terminal domain of p53: regulative significance”, Oncol Res., vol. 10, no. 2, 
pp. 55-57. 
  85.   Cho, Y., Gorina, S., Jeffrey, P. D., & Pavletich, N. P. 1994, "Crystal structure of a p53 
tumour suppressor-DNA complex: understanding tumourigenic mutations", Science, vol. 
265, pp. 346-355. 
  86.   Christofferson, A. & Wilkie, J. 2009, "Mechanism of CB1954 reduction by Escherichia 
coli nitroreductase”, Biochem Soc Trans., vol. 37, no. Pt 2, pp. 413-418. 
  87.   Chu, L. L., Rutteman, G. R., Kong, J. M. C., Ghahremani, M., Schmeing, M., Misdorp, 
W., Van Garderen, E., & Pelletier, J. 1998, "Genomic organization of the canine p53 
gene and its mutational status in canine mammary neoplasia", Breast Cancer Res 
Treat., vol. 50, pp. 11-25. 
  88.   Chun, R. & de Lorimier, L. P. 2003, "Update on the biology and management of canine 
osteosarcoma", Vet Clin North Am Small Anim Pract., vol. 33, no. 3, pp. 491-516. 
  89.   Chung-Faye, G., Palmer, D., Anderson, D., Clark, J., Downes, M., Baddeley, J., 
Hussain, S., Murray, P. I., Searle, P., Seymour, L., Harris, P. A., Ferry, D., & Kerr, D. J. 
2001, "Virus-directed, enzyme prodrug therapy with nitroimidazole reductase: a phase 
I and pharmacokinetic study of its prodrug, CB1954”, Clin Cancer Res., vol. 7, no. 9, 
pp. 2662-2668. 
  90.   Cimoli, G., Malacarne, D., Ponassi, R., Valenti, M., Alberti, S., & Parodi, S. 2004, 
"Meta-analysis of the role of p53 status in isogenic systems tested for sensitivity to 
cytotoxic antineoplastic drugs", Biochim Biophys Acta, vol. 1705, pp. 103-120. 
  91.   Clark, A. J., Iwobi, M., Cui, W., Crompton, M., Harold, G., Hobbs, S., Kamalati, T., 
Knox, R., Neil, C., Yull, F., & Gusterson, B. 1997, "Selective cell ablation in transgenic 
mice expression E. coli nitroreductase", Gene Ther., vol. 4, no. 2, pp. 101-110. 
  92.   Clayman, G. L., El-Naggar, A. K., Lippman, S. M., Henderson, Y. C., Frederick, M., 
Merritt, J. A., Zumstein, L. A., Timmons, T. M., Liu, T. J., Ginsberg, L., Roth, J. A., 
Hong, W. K., Bruso, P., & Goepfert, H. 1998, "Adenovirus-mediated p53 gene transfer References 
 
246 
in patients with advanced recurrent head and neck squamous cell carcinoma", J Clin 
Oncol., vol. 16, no. 6, pp. 2221-2232. 
  93.   Clore, G. M., Omichinski, J. G., Sakaguchi, K., Zambrano, N., Sakamoto, H., Appella, 
E., & Gronenborn, A. M. 1994, "High-resolution structure of the oligomerization domain 
of p53 by multidimensional NMR", Science, vol. 265, no. 5170, pp. 386-391. 
  94.   Cobb, L. M., Connors, T. A., Elson, L. A., Khan, A. H., Mitchley, B. C. V., Ross, W. C. 
J., & Whisson, M. E. 1969, "2,4-dinitro-5-ethyleneiminobenzamide (CB 1954): a potent 
and selective inhibitor of the growth of the walker carcinoma 256", Biochem 
Pharmacol., vol. 18, pp. 1519-1527. 
  95.   Collins, S. J., Howard, M., Andrews, D. F., Agura, E., & Radich, J. 1989, "Rare 
occurrence of N-ras point mutations in Philadelphia chromosome positive chronic 
myeloid leukemia", Blood, vol. 73, no. 4, pp. 1028-1032. 
  96.   Connors, T. A. 1995, "The choice of prodrugs for gene directed enzyme prodrug 
therapy of cancer", Gene Ther., vol. 2, pp. 705-709. 
  97.   Connors, T. A. & Melzack, D. H. 1971, "Studies on the mechanism of action of 5-
aziridinyl-2,4-dinitrobenzamide (CB 1954), a selective inhibitor of the Walker tumour", 
Int J Cancer, vol. 7, no. 1, pp. 86-92. 
  98.   Cooley, D. M., Beranek, B. C., Schlittler, D. L., Glickman, N. W., Glickman, L. T., & 
Waters, D. J. 2002, "Endogenous gonadal hormone exposure and bone sarcoma risk”, 
Cancer Epidemiol Biomarkers Prev., vol. 11, no. 11, pp. 1434-1440. 
  99.   Coomber, B. L., Denton, J., Sylvestre, A., & Kruth, S. 1998, "Blood vessel density in 
canine osteosarcoma", Can J Vet Res., vol. 62, pp. 199-204. 
  100.   Coomer, A., Farese, J., Milner, R., Liptak, J., Bacon, N., & Lurie, D. 2009, "Radiation 
therapy for canine appendicular osteosarcoma”, Vet Comp Oncol., vol. 7, no. 1, pp. 
15-27. 
  101.   Cote, R. J., Esrig, D., Groshen, S., Jones, P. A., & Skinner, D. G. 1997, "p53 and 
treatment of bladder cancer", Nature, vol. 385, pp. 123-125. 
  102.   Cui, W., Gusterson, B., & Clark, A. J. 1999, "Nitroreductase-mediated cell ablation is 
very rapid and mediated by a p53-independent apoptotic pathway", Gene Ther., vol. 6, 
no. 5, pp. 764-770. 
  103.   Da Costa, L. T., Jen, J., He, T.-C., Chan, T. A., Kinzler, K., & Vogelstein, B. 1996, 
"Converting cancer genes into killer genes", Proc Natl Acad Sci USA., vol. 93, pp. 4192-
4196. 
  104.   Dahlin, D. C. & Unni, K. K. 1977, "Osteosarcoma of bone and its important recognizable 
varieties", Am J Surg Pathol., vol. 1, no. 1, pp. 61-72. 
  105.   Danthinne, X. & Imperiale, M. J. 2000, "Production of first generation adenovirus 
vectors: a review", Gene Ther., vol. 7, pp. 1707-1714. 
  106.   Dass, C. R. & Choong, P. F. 2008, "Gene therapy for osteosarcoma: steps towards 
clinical studies", J Pharm Pharmacol., vol. 60, no. 4, pp. 405-413. 
  107.   Davis, G. J., Kapatkin, A. S., Craig, L. E., Heins, G. S., & Wortman, J. A. 2002, 
"Comparison of radiography, computed tomography, and magnetic resonance imaging 
for evaluation of appendicular osteosarcoma in dogs”, J Am Vet Med Assoc., vol. 220, 
no. 8, pp. 1171-1176. References 
 
247 
  108.   Davis, S. T., Joyner, S. S., Baccanari, D. P., & Spector, T. 1994, "5-Ethynyluracil 
(776C85): protection from 5-fluorouracil-induced neurotoxicity in dogs", Biochem 
Pharmacol., vol. 48, no. 2, pp. 233-236. 
  109.   De Maria, R., Miretti, S., Iussich, S., Olivero, M., Morello, E., Bertotti, A., Christensen, 
J. G., Biolatti, B., Levine, R. A., Buracco, P., & Di Renzo, M. F. 2009, "met oncogene 
activation qualifies spontaneous canine osteosarcoma as a suitable pre-clinical model 
of human osteosarcoma”, J Pathol., vol. 218, no. 3, pp. 399-408. 
  110.   Degreve, B., Andrei, G., Izquierdo, M., Piette, J., Morin, K., Knaus, E. E., Wiebe, L. I., 
Basrah, I., Walker, R. T., De Clercq, E., & Balzarini, J. 1997, "Varicella-zoster virus 
thymidine kinase gene and antiherpetic pyrimidine nucleoside analogues in a combined 
gene/chemotherapy treatment for cancer", Gene Ther., vol. 4, no. 10, pp. 1107-1114. 
  111.   Denny, W. A. 2003, "Prodrugs for gene-directed enzyme-prodrug therapy (suicide gene 
therapy)", J Biomed Biotechnol., vol. 2003, no. 1, pp. 48-70. 
  112.   Densmore, C. L., Kleinerman, E. S., Gautam, A., Jia, S. F., Xu, B., Worth, L. L., 
Waldrep, J. C., Fung, Y. K., T'Ang, A., & Knight, V. 2001, "Growth suppression of 
established human osteosarcoma lung metastases in mice by aerosol gene therapy with 
PEI-p53 complexes", Cancer Gene Ther., vol. 8, no. 9, pp. 619-627. 
  113.   Dernell, W. S., Ehrhart, N. P., Straw, R. C., & Vail, D. M. 2007, "Tumours of the 
skeletal system.," in Withrow & MacEwen's Small Animal Clinical Oncology, 4th edn, S. 
J. Withrow & D. M. Vail, eds., Saunders, Missouri, pp. 540-582. 
  114.   Dittmer, D., Pati, S., Zambetti, G., Chu, S., Teresky, A. K., Moore, M., Finlay, C., & 
Levine, A. J. 1993, "Gain of function mutations in p53", Nat Genet., vol. 4, no. 1, pp. 
42-46. 
  115.   Djeha, A. H., Hulme, A., Dexter, M. T., Mountain, A., Young, L. S., Searle, P. F., Kerr, 
D. J., & Wrighton, C. J. 2000, "Expression of Escherichia coli B nitroreductase in 
established human tumor xenografts in mice results in potent antitumoral and 
bystander effects upon systemic administration of the prodrug CB1954”, Cancer Gene 
Ther., vol. 7, no. 5, pp. 721-731. 
  116.   Dobson, J. M., Samuel, S., Milstein, H., Rogers, K., & Wood, J. L. N. 2002, "Canine 
neoplasia in the UK: estimates of incidence rates from a population of insured dogs", J 
Small Anim Pract., vol. 43, no. 6, pp. 240-246. 
  117.   Donehower, L. A., Harvey, M., Slagle, B. L., McArthur, M. J., Montgomery, C. A., 
Butel, J. S., & Bradley, A. 1992, "Mice deficient for p53 are developmentally normal 
but susceptible to spontaneous tumours", Nature, vol. 356, no. 6366, pp. 215-221. 
  118.   Dorman, D. C., Coddington, K. A., & Richardson, R. C. 1990, "5-Fluorouracil toxicosis in 
the dog", J Vet Intern Med., vol. 4, no. 5, pp. 254-257. 
  119.   Dow, S., Elmslie, R., Kurzman, I., MacEwen, G., Pericle, F., & Liggitt, D. 2005, "Phase I 
study of liposome-DNA complexes encoding the interleukin-2 gene in dogs with 
osteosarcoma lung metastases", Hum Gene Ther., vol. 16, no. 8, pp. 937-946. 
  120.   Drabek, D., Guy, J., Craig, R., & Grosveld, F. 1997, "The expression of bacterial 
nitroreductase in transgenic mice results in specific cell killing by the prodrug CB1954", 
Gene Ther., vol. 4, no. 2, pp. 93-100. 
  121.   Dridi, W., Fetni, R., Lavoie, J., Poupon, M. F., & Drouin, R. 2003, "The dominant-
negative effect of p53 mutants and p21 induction in tetraploid G1 arrest depends on 
the type of p53 mutation and the nature of the stimulus”, Cancer Genet Cytogenet., 
vol. 143, no. 1, pp. 39-49. References 
 
248 
  122.   Duan, X., Jia, S. F., Koshkina, N., & Kleinerman, E. S. 2006, "Intranasal interleukin-12 
gene therapy enhanced the activity of ifosfamide against osteosarcoma lung 
metastases", Cancer, vol. 106, no. 6, pp. 1382-1388. 
  123.   Dubielzig, R. R., Biery, D. N., & Brodey, R. S. 1981, "Bone sarcomas associated with 
multifocal medullary bone infarction in dogs", J Am Vet Med Assoc., vol. 179, no. 1, 
pp. 64-68. 
  124.   DuBois, S. & Demetri, G. 2007, "Markers of angiogenesis and clinical features in 
patients with sarcoma”, Cancer, vol. 109, no. 5, pp. 813-819. 
  125.   Dyce, K. M., Sack, W. O., & Wensing, C. J. G. 1987, Textbook of Veterinary Anatomy 
W.B. Saunders Company, Philadelphia. 
  126.   Edelstein, M. L., Abedi, M. R., & Wixon, J. 2007, "Gene therapy clinical trials 
worldwide to 2007--an update”, J Gene Med., vol. 9, no. 10, pp. 833-842. 
  127.   EEC 1995, "Community procedure for the establishment of maximum residue limits of 
veterinary medicinal products in foodstuffs of animal origin", EEC No.2377/90, vol. 
Appendix IV. 
  128.   Egenvall, A., Nodtvedt, A., & von Euler, H. 2007, "Bone tumors in a population of 400 
000 insured Swedish dogs up to 10 y of age: incidence and survival”, Can J Vet Res., 
vol. 71, no. 4, pp. 292-299. 
  129.   Egilmez, N. K., Iwanuma, Y., & Bankert, R. B. 1996, "Evaluation and optimization of 
different cationic liposome formulations for in vivo gene transfer", Biochem Biophys 
Res Commun., vol. 221, no. 1, pp. 169-173. 
  130.   Ehrhart, N., Dernell, W. S., Hoffman, W. E., Weigel, R. M., Powers, B. E., & Withrow, 
S. J. 1998, "Prognostic importance of alkaline phosphatase activity in serum from dogs 
with appendicular osteosarcoma: 75 cases (1990-1996)”, J Am Vet Med Assoc., vol. 
213, no. 7, pp. 1002-1006. 
  131.   El-Deiry, W. S. 1998, "Regulation of p53 downstream genes", Semin Cancer Biol., vol. 
8, no. 5, pp. 345-357. 
  132.   El-Deiry, W. S., Kern, S. E., Pietenpol, J. A., Kinzler, K. W., & Vogelstein, B. 1992, 
"Definition of a consensus binding site for p53", Nat Genet., vol. 1, no. 1, pp. 45-49. 
  133.   Emptage, C. D., Knox, R. J., Danson, M. J., & Hough, D. W. 2009, "Nitroreductase from 
Bacillus licheniformis: a stable enzyme for prodrug activation”, Biochem Pharmacol., 
vol. 77, no. 1, pp. 21-29. 
  134.   Endo, K., Kuratate, I., Watanabe, M., Yoshida, H., Teshima, R., Osaki, M., & Ito, H. 
2001, "Wild-type p53 gene transfection in human cultured sarcomas: effect of CDDP", 
Oncol Rep., vol. 8, no. 3, pp. 637-642. 
  135.   Esrig, D., Spruck, C. H., III, Nichols, P. W., Chaiwun, B., Steven, K., Groshen, S., Chen, 
S. C., Skinner, D. G., Jones, P. A., & Cote, R. J. 1993, "p53 nuclear protein 
accumulation correlates with mutations in the p53 gene, tumor grade, and stage in 
bladder cancer", Am J Pathol., vol. 143, no. 5, pp. 1389-1397. 
  136.   Fan, T. M., Barger, A. M., Sprandel, I. T., & Fredrickson, R. L. 2008, "Investigating TrkA 
Expression in Canine Appendicular Osteosarcoma”, J Vet Intern Med., vol. 22, no. 5, 
pp. 1181-1188. 
  137.   Fan, T. M., Charney, S. C., de Lorimier, L. P., Garrett, L. D., Griffon, D. J., Gordon-
Evans, W. J., & Wypij, J. M. 2009, "Double-blind placebo-controlled trial of adjuvant 
pamidronate with palliative radiotherapy and intravenous doxorubicin for canine 
appendicular osteosarcoma bone pain”, J Vet Intern Med., vol. 23, no. 1, pp. 152-160. References 
 
249 
  138.   Fang, B. & Roth, J. A. 2001, "Gene Therapy," in The Molecular Basis of Cancer, 2nd 
edn, Mendelsohn J et al., eds., W.B. Saunders Company, Philadelphia, pp. 589-604. 
  139.   Farese, J. P., Fox, L. E., Detrisac, C. J., van Gilder, J. M., Roberts, S. L., & Baldwin, J. 
M. 2004, "Effect of thalidomide on growth and metastasis of canine osteosarcoma cells 
after xenotransplantation in athymic mice”, Am J Vet Res., vol. 65, no. 6, pp. 659-664. 
  140.   Farr, A. & Roman, A. 1992, "A pitfall of using a second plasmid to determine 
transfection efficiency", Nucleic Acids Res., vol. 20, no. 4, p. 920. 
  141.   Felgner, P. L. 1997, "Nonviral strategies for gene therapy", Sci Am., vol. 276, no. 6, pp. 
102-106. 
  142.   Ferracini, R., Angelini, P., Cagliero, E., Linari, A., Martano, M., Wunder, J., & 
Buracco, P. 2000, "MET oncogene aberrant expression in canine osteosarcoma", J 
Orthop Res., vol. 18, no. 2, pp. 253-256. 
  143.   Fieten, H., Spee, B., Ijzer, J., Kik, M., Penning, L., & Kirpensteijn, J. 2009, "Expression 
of Hepatocyte Growth Factor and the proto-oncogenic receptor c-Met in canine 
osteosarcoma”, Vet Pathol., May 9, Epub ahead of print. 
  144.   Finlay, C. A., Hinds, P. W., & Levine, A. J. 1989, "The p53 proto-oncogene can act as a 
suppressor of transformation", Cell, vol. 57, no. 7, pp. 1083-1093. 
  145.   Finocchiaro, L. M., Fiszman, G. L., Karara, A. L., & Glikin, G. C. 2008, "Suicide gene 
and cytokines combined nonviral gene therapy for spontaneous canine melanoma”, 
Cancer Gene Ther., vol. 15, no. 3, pp. 165-172. 
  146.   Flint, A. F., U'Ren, L., Legare, M. E., Withrow, S. J., Dernell, W., & Hanneman, W. H. 
2004, "Overexpression of the erbB-2 proto-oncogene in canine osteosarcoma cell lines 
and tumours", Vet Pathol., vol. 41, no. 3, pp. 291-296. 
  147.   Forrest, L. J., Dodge, R., Page, R. L., Heidner, G. L., McEntee, M. C., Novotney, C. A., 
& Thrall, D. E. 1992, "Relationship between quantitative tumour scintigraphy and time 
to metastasis in dogs with osteosarcoma", J Nucl Med., vol. 33, no. 8, pp. 1542-1547. 
  148.   Fossey, S. L., Liao, A. T., McCleese, J. K., Bear, M. D., Lin, J., Li, P. K., Kisseberth, W. 
C., & London, C. A. 2009, "Characterization of STAT3 activation and expression in 
canine and human osteosarcoma”, BMC Cancer, vol. 9, no. 81. 
  149.   Freeman, S. S., Allen, S. W., Ganti, R., Wu, J., Ma, J., Su, X., Neale, G., Dome, J. S., 
Daw, N. C., & Khoury, J. D. 2008, "Copy number gains in EGFR and copy number losses 
in PTEN are common events in osteosarcoma tumors”, Cancer, vol. 113, no. 6, pp. 
1453-1461. 
  150.   Friedlos, F., Biggs, P. J., Abrahamson, J. A., & Knox, R. J. 1992a, "Potentiation of CB 
1954 cytotoxicity by reduced pyridine nucleotides in human tumour cells by stimulation 
of DT diaphorase activity", Biochem Pharmacol., vol. 44, no. 9, pp. 1739-1743. 
  151.   Friedlos, F., Jarman, M., Davies, L. C., Boland, M. P., & Knox, R. J. 1992b, 
"Identification of novel reduced pyridinium derivatives as synthetic co-factors for the 
enzyme DT diaphorase (NAD(P)H dehydrogenase (quinone), EC 1.6.99.2)", Biochem 
Pharmacol., vol. 44, no. 1, pp. 25-31. 
  152.   Friedlos, F. & Knox, R. J. 1992, "Metabolism of NAD(P)H by blood components: 
Relevance to bioreductively activated prodrugs in a targeted enzyme therapy system", 
Biochem Pharmacol., vol. 44, no. 4, pp. 631-635. 
  153.   Friedlos, F., Quinn, J., Knox, R. J., & Roberts, J. J. 1992c, "The properties of total 
adducts and interstrand crosslinks in the DNA of cells treated with CB 1954. References 
 
250 
Exceptional frequency and stability of the crosslink", Biochem Pharmacol., vol. 43, no. 
6, pp. 1249-1254. 
  154.   Fujiwara, T., Grimm, E. A., Mukhopadhyay, T., Zhang, W. W., Owen-Schaub, L. B., & 
Roth, J. A. 1994, "Induction of chemosensitivity in human lung cancer cells in vivo by 
adenovirus-mediated transfer of the wild-type p53 gene", Cancer Res., vol. 54, no. 9, 
pp. 2287-2291. 
  155.   Fujiwara, T., Kataoka, M., & Tanaka, N. 2000, "Adenovirus-mediated p53 gene therapy 
for human cancer”, Mol Urol., vol. 4, no. 2, pp. 51-54. 
  156.   Fujiwara, T., Tanaka, N., Kanazawa, S., Ohtani, S., Saijo, Y., Nukiwa, T., Yoshimura, 
K., Sato, T., Eto, Y., Chada, S., Nakamura, H., & Kato, H. 2006, "Multicenter phase I 
study of repeated intratumoral delivery of adenoviral p53 in patients with advanced 
non-small-cell lung cancer”, J Clin Oncol., vol. 24, no. 11, pp. 1689-1699. 
  157.   Fulci, G., Labuhn, M., Maier, D., Lachat, Y., Hausmann, O., Hegi, M. E., Janzer, R. C., 
Merlo, A., & Van Meir, E. G. 2000, "p53 gene mutation and ink4a-arf deletion appear to 
be two mutually exclusive events in human glioblastoma", Oncogene, vol. 19, no. 33, 
pp. 3816-3822. 
  158.   Gallardo, D., Drazan, K. E., & McBride, W. H. 1996, "Adenovirus-based transfer of wild-
type p53 gene increases ovarian tumor radiosensitivity", Cancer Res., vol. 56, no. 21, 
pp. 4891-4893. 
  159.   Gamblin, R. M., Sagartz, J. E., & Couto, C. G. 1997, "Overexpression of p53 tumour 
suppressor protein in spontaneously arising neoplasms of dogs", Am J Vet Res., vol. 58, 
no. 8, pp. 857-863. 
  160.   Ganjavi, H., Gee, M., Narendran, A., Parkinson, N., Krishnamoorthy, M., Freedman, M. 
H., & Malkin, D. 2006, "Adenovirus-mediated p53 gene therapy in osteosarcoma cell 
lines: sensitization to cisplatin and doxorubicin”, Cancer Gene Ther., vol. 13, no. 4, 
pp. 415-419. 
  161.   Gannon, J. V., Greaves, R., Iggo, R., & Lane, D. P. 1990, "Activating mutations in p53 
produce a common conformational effect. A monoclonal antibody specific for the 
mutant form", EMBO J., vol. 9, no. 5, pp. 1595-1602. 
  162.   Gao, Y. S., Mei, J., Tong, T. L., Hu, M., Xue, H. M., & Cai, X. S. 2009, "Inhibitory 
effects of VEGF-siRNA mediated by adenovirus on osteosarcoma-bearing nude mice”, 
Cancer Biother Radiopharm., vol. 24, no. 2, pp. 243-247. 
  163.   Garcia-Escudero, V., Gargini, R., & Izquierdo, M. 2008, "Glioma regression in vitro and 
in vivo by a suicide combined treatment”, Mol Cancer Res., vol. 6, no. 3, pp. 407-417. 
  164.   Garritano, S., Gemignani, F., Voegele, C., Nguyen-Dumont, T., Le Calvez-Kelm, F., De 
Silva, D., Lesueur, F., Landi, S., & Tavtigian, S. V. 2009, "Determining the 
effectiveness of High Resolution Melting analysis for SNP genotyping and mutation 
scanning at the TP53 locus”, BMC Genet., vol. 10, no. 5. 
  165.   Garzotto, C. K., Berg, J., Hoffman, W. E., & Rand, W. M. 2000, "Prognostic significance 
of serum alkaline phosphatase activity in canine appendicular osteosarcoma", J Vet 
Intern Med., vol. 14, no. 6, pp. 587-592. 
  166.   Gaush, C. R., Hard, W. L., & Smith, T. F. 1966, "Characterization of an established line 
of canine kidney cells (MDCK)", Proc Soc Exp Biol Med., vol. 122, no. 3, pp. 931-935. 
  167.   Gohler, T., Jager, S., Warnecke, G., Yasuda, H., Kim, E., & Deppert, W. 2005, "Mutant 
p53 proteins bind DNA in a DNA structure-selective mode”, Nucleic Acids Res., vol. 33, 
no. 3, pp. 1087-1100. References 
 
251 
  168.   Gomez-Manzano, C., Fueyo, J., Kyritsis, A. P., Steck, P. A., Roth, J. A., McDonnell, T. 
J., Steck, K. D., Levin, V. A., & Yung, W. K. 1996, "Adenovirus-mediated transfer of 
the p53 gene produces rapid and generalized death of human glioma cells via 
apoptosis", Cancer Res., vol. 56, no. 4, pp. 694-699. 
  169.   Gopalan, B., Ito, I., Branch, C. D., Stephens, C., Roth, J. A., & Ramesh, R. 2004, 
"Nanoparticle based systemic gene therapy for lung cancer: molecular mechanisms and 
strategies to suppress nanoparticle-mediated inflammatory response", Technol Cancer 
Res Treat., vol. 3, no. 6, pp. 647-657. 
  170.   Gordon, I. K., Ye, F., & Kent, M. S. 2008, "Evaluation of the mammalian target of 
rapamycin pathway and the effect of rapamycin on target expression and cellular 
proliferation in osteosarcoma cells from dogs”, Am J Vet Res., vol. 69, no. 8, pp. 1079-
1084. 
  171.   Green, E. M., Adams, W. M., & Forrest, L. J. 2002, "Four fraction palliative 
radiotherapy for osteosarcoma in 24 dogs”, J Am Anim Hosp Assoc., vol. 38, no. 5, pp. 
445-451. 
  172.   Green, N. K., Youngs, D. J., Neoptolemos, J. P., Friedlos, F., Knox, R. J., Springer, C. 
J., Anlezark, G. M., Michael, N. P., Melton, R. G., Ford, M. J., Young, L. S., Kerr, D. 
J., & Searle, P. F. 1997, "Sensitization of colorectal and pancreatic cancer cell lines to 
the prodrug 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB1954) by retroviral transduction 
and expression of the E.coli nitroreductase gene", Cancer Gene Ther., vol. 4, no. 4, 
pp. 229-238. 
  173.   Greenblatt, M. S., Bennett, W. P., Hollstein, M., & Harris, C. C. 1994, "Mutations in the 
p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis", 
Cancer Res., vol. 54, no. 18, pp. 4855-4878. 
  174.   Gu, J., Nie, L., Wiederschain, D., & Yuan, Z. M. 2001a, "Identification of p53 sequence 
elements that are required for MDM2-mediated nuclear export”, Mol Cell Biol., vol. 
21, no. 24, pp. 8533-8546. 
  175.   Gu, J., Rubin, R. M., & Yuan, Z. M. 2001b, "A sequence element of p53 that determines 
its susceptibility to viral oncoprotein-targeted degradation”, Oncogene, vol. 20, no. 
27, pp. 3519-3527. 
  176.   Gu, L., Zhu, N., Findley, H. W., Woods, W. G., & Zhou, M. 2004, "Identification and 
characterization of the IKKalpha promoter: positive and negative regulation by ETS-1 
and p53, respectively”, J Biol Chem., vol. 279, no. 50, pp. 52141-52149. 
  177.   Guevara-Fujita, M. L., Loechel, R., Venta, P. J., Yuzbasiyan-Gurkan, V., & Brewer, G. 
J. 1996, "Chromosomal assignment of seven genes on canine chromosomes by 
fluorescence in situ hybridization", Mamm Genome, vol. 7, pp. 268-270. 
  178.   Haga, S., Nakayama, M., Tatsumi, K., Maeda, M., Imai, S., Umesako, S., Yamamoto, 
H., Hilgers, J., & Sarkar, N. H. 2001, "Overexpression of the p53 gene product in 
canine mammary tumours", Oncol Rep., vol. 8, no. 6, pp. 1215-1219. 
  179.   Hahn, K. A., Legendre, A. M., & Schuller, H. M. 1997, "Amputation and dexniguldipine 
as treatment for canine appendicular osteosarcoma”, J Cancer Res Clin Oncol., vol. 
123, no. 1, pp. 34-38. 
  180.   Hahn, K. A., Legendre, A. M., & Talbott, J. R. 1996, "The frequency of micronuclei in 
lymphocytes of dogs with osteosarcoma: a predictive variable for tumor response 
during cisplatin chemotherapy”, Cancer Epidemiol Biomarkers Prev., vol. 5, no. 8, pp. 
653-656. 
  181.   Hainaut, P., Hernandez, T., Robinson, A., Tome-Rodriguez, P., Flores, T., Hollstein, 
M., Harris, C. C., & Montesano, R. 1998, "IARC database of p53 gene mutations in References 
 
252 
human tumours and cell lines: updated compilation, revised formats and new 
visualisation tools", Nucleic Acids Res., vol. 26, no. 1, pp. 205-213. 
  182.   Hainaut, P. & Hollstein, M. 2000, "p53 and human cancer: the first ten thousand 
mutations", Adv Cancer Res., vol. 77, pp. 81-137. 
  183.   Hall, P. A. & Lane, D. P. 1994, "p53 in tumour pathology: can we trust 
immunohistochemistry? - revisited!", J Pathol., vol. 172, no. 1, pp. 1-4. 
  184.   Hammer, A. S., Carothers, M. A., Harris, C. L., O'Keefe, D. A., Ayl, R. D., Peterson, J. 
L., Shank, K. A., & Couto, C. G. 1994, "Unexpected neurotoxicity in dogs receiving a 
cyclophosphamide, dactinomycin, and 5-fluorouracil chemotherapy protocol", J Vet 
Intern Med., vol. 8, no. 3, pp. 240-243. 
  185.   Hammer, A. S., Weeren, F. R., Weisbrode, S. E., & Padgett, S. L. 1995, "Prognostic 
factors in dogs with osteosarcomas of the flat or irregular bones”, J Am Anim Hosp 
Assoc., vol. 31, no. 4, pp. 321-326. 
  186.   Hann, B. C. & Lane, D. P. 1995, "The dominating effect of mutant p53", Nat Genet., 
vol. 9, no. 3, pp. 221-222. 
  187.   Harris, M. P., Sutjipto, S., Wills, K. N., Hancock, W., Cornell, D., Johnson, D. E., 
Gregory, R. J., Shepard, H. M., & Maneval, D. C. 1996, "Adenovirus-mediated p53 gene 
transfer inhibits growth of human tumor cells expressing mutant p53 protein", Cancer 
Gene Ther., vol. 3, no. 2, pp. 121-130. 
  188.   Harvey, M., Vogel, H., Morris, D., Bradley, A., Bernstein, A., & Donehower, L. A. 1995, 
"A mutant p53 transgene accelerates tumour development in heterozygous but not 
nullizygous p53-deficient mice", Nat Genet., vol. 9, no. 3, pp. 305-311. 
  189.   Haupt, Y., Maya, R., Kazaz, A., & Oren, M. 1997, "Mdm2 promotes the rapid 
degradation of p53", Nature, vol. 387, pp. 296-299. 
  190.   Hawkins, E., Unch, J., Murphy, N., Vidugiriene, J., Scurria, M., Klaubert, D. H., & 
Wood, K. V. 2005, "Bright Light, No Lysis -  measuring Renilla luciferase luminescence 
in living cells", Promega Notes, vol. 90, no. 5, pp. 10-14. 
  191.   Heidner, G. L., Page, R., McEntee, M. C., Dodge, R., & Thrall, D. E. 1991, "Treatment 
of canine appendicular osteosarcoma using cobalt 60 radiation and intraarterial 
cisplatin", J Vet Intern Med., vol. 5, pp. 313-316. 
  192.   Helfand, S. C., Hank, J. A., Gan, J., & Sondel, P. M. 1996, "Lysis of human tumor cell 
lines by canine complement plus monoclonal antiganglioside antibodies or natural 
canine xenoantibodies”, Cell Immunol., vol. 167, no. 1, pp. 99-107. 
  193.   Hellmen, E. 1992, "Characterization of four in vitro established canine mammary 
carcinoma and one atypical benign mixed tumor cell lines", In Vitro Cell Dev Biol., vol. 
28A, no. 5, pp. 309-319. 
  194.   Hellwinkel, O. J., Muller, J., Pollmann, A., & Kabisch, H. 2005, "Osteosarcoma cell 
lines display variable individual reactions on wildtype p53 and Rb tumour-suppressor 
transgenes”, J Gene Med., vol. 7, no. 4, pp. 407-419. 
  195.   Helton, E. S. & Chen, X. 2007, "p53 modulation of the DNA damage response”, J Cell 
Biochem., vol. 100, no. 4, pp. 883-896. 
  196.   Hemminki, A., Kanerva, A., Kremer, E. J., Bauerschmitz, G. J., Smith, B. F., Liu, B., 
Wang, M., Desmond, R. A., Keriel, A., Barnett, B., Baker, H. J., Siegal, G. P., & Curiel, 
D. T. 2003, "A canine conditionally replicating adenovirus for evaluating oncolytic 
virotherapy in a syngeneic animal model", Mol Ther., vol. 7, no. 2, pp. 163-173. References 
 
253 
  197.   Hendrix, D. V. & Gelatt, K. N. 2000, "Diagnosis, treatment and outcome of orbital 
neoplasia in dogs: a retrospective study of 44 cases”, J Small Anim Pract., vol. 41, no. 
3, pp. 105-108. 
  198.   Hershey, A. E., Kurzman, I. D., Forrest, L. J., Bohling, C. A., Stonerook, M., Placke, M. 
E., Imondi, A. R., & Vail, D. M. 1999, "Inhalation chemotherapy for macroscopic 
primary or metastatic lung tumours: proof of principle using dogs with spontaneously 
occurring tumours as a model", Clin Cancer Res., vol. 5, pp. 2653-2659. 
  199.   Heyman, S. J., Diefenderfer, D. L., Goldschmidt, M. H., & Newton, C. D. 1992, "Canine 
axial skeletal osteosarcoma. A retrospective study of 116 cases (1986 to 1989)", Vet 
Surg., vol. 21, no. 4, pp. 304-310. 
  200.   Hillers, K. R., Dernell, W. S., Lafferty, M. H., Withrow, S. J., & Lana, S. E. 2005, 
"Incidence and prognostic importance of lymph node metastases in dogs with 
appendicular osteosarcoma: 228 cases (1986-2003)”, J Am Vet Med Assoc., vol. 226, 
no. 8, pp. 1364-1367. 
  201.   Hiraku, Y., Sekine, A., Nabeshi, H., Midorikawa, K., Murata, M., Kumagai, Y., & 
Kawanishi, S. 2004, "Mechanism of carcinogenesis induced by a veterinary antimicrobial 
drug, nitrofurazone, via oxidative DNA damage and cell proliferation", Cancer Lett., 
vol. 215, no. 2, pp. 141-150. 
  202.   Hirao, K., Sugita, T., Kubo, T., Igarashi, K., Tanimoto, K., Murakami, T., Yasunaga, Y., 
& Ochi, M. 2003, "Targeted gene delivery to human osteosarcoma cells with magnetic 
cationic liposomes under a magnetic field", Int J Oncol., vol. 22, no. 5, pp. 1065-1071. 
  203.   Ho, C. K. M. & Strauss, J. F. 2004, "Activation of the control reporter plasmids pRL-TK 
and pRL-SV40 by a multiple GATA transcription factors can lead to aberrant 
normalization of transfection efficiency", BMC Biotechnol., vol. 4, pp. 10-15. 
  204.   Holliday, R. & Grigg, G. W. 1993, "DNA methylation and mutation", Mutat Res., vol. 
285, no. 1, pp. 61-67. 
  205.   Holzwarth, J. A., Middleton, R. P., Roberts, M., Mansourian, R., Raymond, F., & 
Hannah, S. S. 2005, "The development of a high-density canine microarray”, J Hered., 
vol. 96, no. 7, pp. 817-820. 
  206.   Hussein, D., Holt, S. V., Brookes, K. E., Klymenko, T., Adamski, J. K., Hogg, A., Estlin, 
E. J., Ward, T., Dive, C., & Makin, G. W. 2009, "Preclinical efficacy of the bioreductive 
alkylating agent RH1 against paediatric tumours”, Br J Cancer, vol. 101, no. 1, pp. 55-
63. 
  207.   Iavarone, A., Matthay, K. K., Steinkirchner, T. M., & Israel, M. A. 1992, "Germ-line and 
somatic p53 gene mutations in multifocal osteogenic sarcoma", Proc Natl Acad Sci 
USA., vol. 89, no. 9, pp. 4207-4209. 
  208.   Imamura, J., Miyoshi, I., & Koeffler, H. P. 1994, "p53 in hematologic malignancies", 
Blood, vol. 84, no. 8, pp. 2412-2421. 
  209.   Inoue, M. & Shiramizu, K. 1999, "Immunohistochemical detection of p53 and c-myc 
proteins in canine mammary tumours", J Comp Pathol., vol. 120, pp. 169-175. 
  210.   Jackson, J. C., Duffy, S. P., Hess, K. R., & Mehl, R. A. 2006, "Improving nature's 
enzyme active site with genetically encoded unnatural amino acids”, J Am Chem Soc., 
vol. 128, no. 34, pp. 11124-11127. 
  211.   Jaffe, M. H., Hosgood, G., Taylor, H. W., Kerwin, S. C., Hedlund, C. S., Lopez, M. K., 
Davidson, J. R., Miller, D. M., & Paranjpe, M. 2000, "Immunohistochemical and clinical 
evaluation of p53 in canine cutaneous mast cell tumours", Vet Pathol., vol. 37, pp. 40-
46. References 
 
254 
  212.   Jaiswal, A. K. 1994, "Human NAD(P)H:quinone oxidoreductase2. Gene structure, 
activity, and tissue-specific expression”, J Biol Chem., vol. 269, no. 20, pp. 14502-
14508. 
  213.   Janicke, R. U., Sohn, D., & Schulze-Osthoff, K. 2008, "The dark side of a tumor 
suppressor: anti-apoptotic p53”, Cell Death Differ., vol. 15, no. 6, pp. 959-976. 
  214.   Janowski, M. K., Steyn, P. F., Lana, S. E., Dernell, W. S., Blom, C. M., Uhrig, J. L., 
Lafferty, M., & Withrow, S. J. 2003, "Nuclear scanning with 
99mTc-HDP for the initial 
evaluation of osseous metastasis in canine osteosarcoma”, Vet Comp Oncol., vol. 1, 
no. 3, pp. 152-158. 
  215.   Jarrom, D., Jaberipour, M., Guise, C. P., Daff, S., White, S. A., Searle, P. F., & Hyde, 
E. I. 2009, "Steady-state and stopped-flow kinetic studies of three Escherichia coli NfsB 
mutants with enhanced activity for the prodrug CB1954”, Biochemistry, vol. 48, no. 
32, pp. 7665-7672. 
  216.   Jiang, Y., Han, J., Yu, C., Vass, S. O., Searle, P. F., Browne, P., Knox, R. J., & Hu, L. 
2006, "Design, synthesis, and biological evaluation of cyclic and acyclic 
nitrobenzylphosphoramide mustards for E. coli nitroreductase activation”, J Med 
Chem., vol. 49, no. 14, pp. 4333-4343. 
  217.   Johnson, A. S., Couto, C. G., & Weghorst, C. M. 1998, "Mutation of the p53 tumor 
suppressor gene in spontaneously occurring osteosarcomas of the dog", Carcinogenesis, 
vol. 19, no. 1, pp. 213-217. 
  218.   Jones, S. N., Roe, A. E., Donehower, L. A., & Bradley, A. 1995, "Rescue of embryonic 
lethality in Mdm2-deficient mice by absence of p53", Nature, vol. 378, no. 6553, pp. 
206-208. 
  219.   Jongeward, S. J. 1985, "Primary bone tumors", Vet Clin North Am Small Anim Pract., 
vol. 15, no. 3, pp. 609-641. 
  220.   Kadosawa, T., Nozaki, K., Sasaki, N., & Takeuchi, A. 1999, "Establishment and 
characterization of a new cell line from a canine osteosarcoma", J Vet Med Sci., vol. 
56, no. 6, pp. 1167-1169. 
  221.   Kamijo, T., Weber, J. D., Zambetti, G., Zindy, F., Roussel, M. F., & Sherr, C. J. 1998, 
"Functional and physical interactions of the ARF tumour suppressor with p53 and 
mdm2", Proc Natl Acad Sci USA., vol. 95, pp. 8292-8297. 
  222.   Kanaya, N., Yazawa, M., Mochizuki, M., Nishimura, R., Sasaki, N., Setoguchi, A., Ohno, 
K., & Tsujimoto, H. 2005, "Anti-tumor effect of adenovirus-mediated P53 gene therapy 
on the growth of canine osteosarcoma transplanted into nude mice", Vet Comp Oncol., 
vol. 3, no. 1, pp. 32-59. 
  223.   Kanczler, J. M., Millar, T. M., Bodamyali, T., Blake, D. R., & Stevens, C. R. 2003, 
"Xanthine oxidase mediates cytokine-induced, but not hormone-induced bone 
resorption", Free Radic Res., vol. 37, no. 2, pp. 179-187. 
  224.   Kansara, M. & Thomas, D. M. 2007, "Molecular pathogenesis of osteosarcoma”, DNA 
Cell Biol., vol. 26, no. 1, pp. 1-18. 
  225.   Karayannopoulou, M., Kaldrymidou, E., Constantinidis, T. C., & Dessiris, A. 2001, 
"Adjuvant post-operative chemotherapy in bitches with mammary cancer", J Vet Med A 
Physiol Pathol Clin Med., vol. 48, no. 2, pp. 85-96. 
  226.   Kastan, M. B. 2007, "Wild-type p53: tumors can't stand it”, Cell, vol. 128, no. 5, pp. 
837-840. References 
 
255 
  227.   Kastan, M. B., Onyekwere, O., Sidransky, D., Vogelstein, B., & Craig, R. W. 1991, 
"Participation pf p53 protein in the cellular response to DNA damage", Cancer Res., vol. 
51, pp. 6304-6311. 
  228.   Kato, T., Shimamoto, Y., Uchida, J., Ohshimo, H., Abe, M., Shirasaka, T., & 
Fukushima, M. 2001, "Possible regulation of 5-fluorouracil-induced neuro- and oral 
toxicities by two biochemical modulators consisting of S-1, a new oral formulation of 5-
fluorouracil", Anticancer Res., vol. 21, no. 3B, pp. 1705-1712. 
  229.   Kaur, S., Larramendy, M. L., Vauhkonen, H., Bohling, T., & Knuutila, S. 2007, "Loss of 
TP53 in sarcomas with 17p12 to approximately p11 gain. A fine-resolution 
oligonucleotide array comparative genomic hybridization study", Cytogenet Genome 
Res., vol. 116, no. 3, pp. 153-157. 
  230.   Kent, M. S., Strom, A., London, C. A., & Seguin, B. 2004, "Alternating carboplatin and 
doxorubicin as adjunctive chemotherapy to amputation or limb-sparing surgery in the 
treatment of appendicular osteosarcoma in dogs”, J Vet Intern Med., vol. 18, no. 4, 
pp. 540-544. 
  231.   Ketola, A., Maatta, A. M., Pasanen, T., Tulimaki, K., & Wahlfors, J. 2004, 
"Osteosarcoma and chondrosarcoma as targets for virus vectors and herpes simplex 
virus thymidine kinase/ ganciclovir gene therapy", Int J Mol Med., vol. 13, no. 5, pp. 
705-710. 
  232.   Khanna, C., Anderson, P. M., Hasz, D. E., Katsanis, E., Neville, M., & Klausner, J. S. 
1997, "Interleukin-2 liposome inhalation therapy is safe and effective for dogs with 
spontaneous pulmonary metastases", Cancer, vol. 79, no. 7, pp. 1409-1421. 
  233.   Khanna, C., Hasz, D. E., Klausner, J. S., & Anderson, P. M. 1996, "Aerosol delivery of 
interleukin 2 liposomes is nontoxic and biologically effective: canine studies”, Clin 
Cancer Res., vol. 2, no. 4, pp. 721-734. 
  234.   Khanna, C., Prehn, J., Hayden, D., Cassaday, R. D., Caylor, J., Jacob, S., Bose, S. M., 
Hong, S. H., Hewitt, S. M., & Helman, L. J. 2002, "A randomized controlled trial of 
octreotide pamoate long-acting release and carboplatin versus carboplatin alone in 
dogs with naturally occurring osteosarcoma: evaluation of insulin-like growth factor 
suppression and chemotherapy”, Clin Cancer Res., vol. 8, no. 7, pp. 2406-2412. 
  235.   Khanna, C. & Vail, D. M. 2003, "Targeting the lung: preclinical and comparative 
evaluation of anticancer aerosols in dogs with naturally occurring cancers”, Curr 
Cancer Drug Targets, vol. 3, no. 4, pp. 265-273. 
  236.   Khanna, C., Wan, X., Bose, S., Cassaday, R., Olomu, O., Mendoza, A., Yeung, C., 
Gorlick, R., Hewitt, S. M., & Helman, L. J. 2004, "The membrane-cytoskeleton linker 
ezrin is necessary for osteosarcoma metastasis", Nat Med., vol. 10, no. 2, pp. 182-186. 
  237.   Kim, E. & Deppert, W. 2004, "Transcriptional activities of mutant p53: when mutations 
are more than a loss”, J Cell Biochem., vol. 93, no. 5, pp. 878-886. 
  238.   Kim, M., Sgagias, M., Deng, X., Jung, Y. J., Rikiyama, T., Lee, K., Ouellette, M., & 
Cowan, K. 2004, "Apoptosis induced by adenovirus-mediated p14ARF expression in 
U2OS osteosarcoma cells is associated with increased Fas expression", Biochem Biophys 
Res Commun., vol. 320, no. 1, pp. 138-144. 
  239.   Kirpensteijn, J., Kik, M., Rutteman, G. R., & Teske, E. 2002a, "Prognostic significance 
of a new histologic grading system for canine osteosarcoma", Vet Pathol., vol. 39, pp. 
240-246. 
  240.   Kirpensteijn, J., Kik, M., Teske, E., & Rutteman, G. R. 2008, "TP53 gene mutations in 
canine osteosarcoma”, Vet Surg., vol. 37, pp. 454-460. References 
 
256 
  241.   Kirpensteijn, J., Timmermans-Sprang, E. P., van Garderen, E., Rutteman, G. R., 
Lantinga-van Leeuwen, I. S., & Mol, J. A. 2002b, "Growth hormone gene expression in 
canine normal growth plates and spontaneous osteosarcoma”, Mol Cell Endocrinol., 
vol. 197, no. 1-2, pp. 179-185. 
  242.   Kisseberth, W. C., Murahari, S., London, C. A., Kulp, S. K., & Chen, C. S. 2008, 
"Evaluation of the effects of histone deacetylase inhibitors on cells from canine cancer 
cell lines”, Am J Vet Res., vol. 69, no. 7, pp. 938-945. 
  243.   Knapp-Hoch, H. M., Fidel, J. L., Sellon, R. K., & Gavin, P. R. 2009, "An expedited 
palliative radiation protocol for lytic or proliferative lesions of appendicular bone in 
dogs”, J Am Anim Hosp Assoc., vol. 45, no. 1, pp. 24-32. 
  244.   Knox, R. J., Friedlos, F., & Boland, M. P. 1993, "The bioactivation of CB 1954 and its 
use as a prodrug in antibody-directed enzyme prodrug therapy (ADEPT)", Cancer 
Metastasis Rev., vol. 12, pp. 195-212. 
  245.   Knox, R. J., Friedlos, F., Jarman, M., Davies, L. C., Goddard, P., Anlezark, G. M., 
Melton, D. W., & Sherwood, R. F. 1995, "Virtual cofactors for an Escherichia coli 
nitroreductase enzyme: relevance to reductively activated prodrugs in antibody 
directed enzyme prodrug therapy (ADEPT)", Biochem Pharmacol., vol. 49, no. 11, pp. 
1641-1647. 
  246.   Knox, R. J., Friedlos, F., Jarman, M., & Roberts, J. J. 1988, "A new cytotoxic, DNA 
interstrand crosslinking agent, 5-(aziridin-1-yl)-4-hydroxylamino-2-nitrobenzamide, is 
formed from 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB 1954) by a nitroreductase 
enzyme in Walker carcinoma cells", Biochem Pharmacol., vol. 37, no. 24, pp. 4661-
4669. 
  247.   Knox, R. J., Friedlos, F., Marchbank, T., & Roberts, J. J. 1991, "Bioactivation of CB 
1954: reaction of the active 4-hydroxylamino derivative with thioesters to form the 
ultimate DNA-DNA interstrand crosslinking species", Biochem Pharmacol., vol. 42, no. 
9, pp. 1691-1697. 
  248.   Knox, R. J., Friedlos, F., Sherwood, R. F., Melton, R. G., & Anlezark, G. M. 1992, "The 
bioactivation of 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB1954)-II. A comparison of an 
Escherichia coli nitroreductase and Walker DT diaphorase", Biochem Pharmacol., vol. 
44, no. 12, pp. 2297-2301. 
  249.   Ko, L. J. & Prives, C. 1996, "p53: puzzle and paradigm", Genes Develop., vol. 10, pp. 
1054-1072. 
  250.   Kobierska-Szeliga, M. & Czeczot, H. 1994, "Characterization of the genotoxic 
properties of nitrofurans: Nitrofurazone and furazolidone", Acta Biochim Pol., vol. 41, 
no. 1, pp. 1-6. 
  251.   Kochevar, D. T., Kochevar, J., & Garrett, L. 1990, "Low level amplification of c-sis and 
c-myc in a spontaneous osteosarcoma model”, Cancer Lett., vol. 53, no. 2-3, pp. 213-
222. 
  252.   Kosovsky, J. K., Matthiesen, D. T., Marretta, S. M., & Patnaik, A. K. 1991, "Results of 
partial mandibulectomy for the treatment of oral tumors in 142 dogs”, Vet Surg., vol. 
20, no. 6, pp. 397-401. 
  253.   Kraegel, S. A., Pazzi, K. A., & Madewell, B. R. 1995, "Sequence analysis of canine p53 
in the region of exons 3-8", Cancer Lett., vol. 92, no. 2, pp. 181-186. 
  254.   Kruse, J.-P. & Gu, W. 2008, "Snapshot: p53 posttranslational modifications", Cell, vol. 
133, pp. 930-931. References 
 
257 
  255.   Kruse, J.-P. & Gu, W. 2009, "Modes of p53 regulation”, Cell, vol. 137, no. 4, pp. 609-
622. 
  256.   Kumar, S., Gao, L., Yeagy, B., & Reid, T. 2008, "Virus combinations and chemotherapy 
for the treatment of human cancers”, Curr Opin Mol Ther., vol. 10, no. 4, pp. 371-379. 
  257.   Kumaraguruparan, R., Subapriya, R., Balachandran, C., Manohar, B. M., Thangadurai, 
A., & Nagini, S. 2006, "Xenobiotic-metabolizing enzymes in canine mammary tumours”, 
Vet J., vol. 172, no. 2, pp. 364-368. 
  258.   Kuntz, C. A., Asselin, T. L., Dernell, W. S., Powers, B. E., Straw, R. C., & Withrow, S. 
J. 1998a, "Limb salvage surgery for osteosarcoma of the proximal humerus: outcome in 
17 dogs”, Vet Surg., vol. 27, no. 5, pp. 417-422. 
  259.   Kuntz, C. A., Dernell, W. S., Powers, B. E., & Withrow, S. J. 1998b, "Extraskeletal 
osteosarcomas in dogs: 14 cases", J Am Anim Hosp Assoc., vol. 34, no. 1, pp. 26-30. 
  260.   Lamb, C. R. 1987, "Bone scintigraphy in small animals", J Am Vet Med Assoc., vol. 191, 
no. 12, pp. 1616-1622. 
  261.   Lana, S. E., Ogilvie, G. K., Hansen, R. A., Powers, B. E., Dernell, W. S., & Withrow, S. 
J. 2000, "Identification of matrix metalloproteinases in canine neoplastic tissue", Am J 
Vet Res., vol. 61, no. 2, pp. 111-114. 
  262.   Lane, D. P. 1992, "p53, guardian of the genome", Nature, vol. 358, pp. 15-17. 
  263.   Lane, D. P. & Crawford, L. V. 1979, "T antigen is bound to a host protein in SV40-
transformed cells", Nature, vol. 278, no. 5701, pp. 261-263. 
  264.   Lane, D. P. & Lain, S. 2002, "Therapeutic exploitation of the p53 pathway", Trends Mol 
Med., vol. 8, no. 4, p. S38-S42. 
  265.   Langenbach, A., Anderson, M. A., Dambach, D. M., Sorenmo, K. U., & Shofer, F. D. 
1998, "Extraskeletal osteosarcomas in dogs: a retrospective study of 169 cases (1986-
1996)", J Am Anim Hosp Assoc., vol. 34, no. 2, pp. 113-120. 
  266.   Laptenko, O. & Prives, C. 2006, "Transcriptional regulation by p53: one protein, many 
possibilities”, Cell Death Differ., vol. 13, no. 6, pp. 951-961. 
  267.   Larue, S. M., Fox, M. H., Withrow, S. J., Powers, B. E., Straw, R. C., Cote, I. M., & 
Gillette, E. L. 1994, "Impact of heterogeneity in the predictive value of kinetic 
parameters in canine osteosarcoma”, Cancer Res., vol. 54, no. 14, pp. 3916-3921. 
  268.   Lascelles, B. D., Dernell, W. S., Correa, M. T., Lafferty, M., Devitt, C. M., Kuntz, C. A., 
Straw, R. C., & Withrow, S. J. 2005, "Improved survival associated with postoperative 
wound infection in dogs treated with limb-salvage surgery for osteosarcoma”, Ann Surg 
Oncol., vol. 12, no. 12, pp. 1073-1083. 
  269.   Latonen, L. & Laiho, M. 2005, "Cellular UV damage responses--functions of tumor 
suppressor p53”, Biochim Biophys Acta, vol. 1755, no. 2, pp. 71-89. 
  270.   Lattimer, J. C., Corwin, L. A., Stapleton, J., Volkert, W. A., Ehrhardt, G. J., Ketring, 
A. R., Anderson, S. K., Simon, J., & Goeckeler, W. F. 1990, "Clinical and 
clinicopathologic response of canine bone tumor patients to treatment with samarium-
153-EDTMP”, J Nucl Med., vol. 31, no. 8, pp. 1316-1325. 
  271.   Le, L. P., Rivera, A. A., Glasgow, J. N., Ternovoi, V. V., Wu, H., Wang, M., Smith, B. 
F., Siegal, G. P., & Curiel, D. T. 2006, "Infectivity enhancement for adenoviral 
transduction of canine osteosarcoma cells", Gene Ther., vol. 13, no. 5, pp. 389-399. References 
 
258 
  272.   Leach, F. S., Tokino, T., Meltzer, P., Burrell, M., Oliner, J. D., Smith, S., Hill, D. E., 
Sidransky, D., Kinzler, K. W., & Vogelstein, B. 1993, "p53 mutation and mdm2 
amplification in human soft tissue sarcomas", Cancer Res., vol. 53, pp. 2231-2234. 
  273.   Legros, Y., Meyer, A., Ory, K., & Soussi, T. 1994, "Mutations in p53 produce a common 
conformational effect that can be detected with a panel of monoclonal antibodies 
directed toward the central part of the p53 protein", Oncogene, vol. 9, no. 12, pp. 
3689-3694. 
  274.   Leibman, N. F., Kuntz, C. A., Steyn, P. F., Fettman, M. J., Powers, B. E., Withrow, S. 
J., & Dernell, W. S. 2001, "Accuracy of radiography, nuclear scintigraphy, and 
histopathology for determining the proximal extent of distal radius osteosarcoma in 
dogs”, Vet Surg., vol. 30, no. 3, pp. 240-245. 
  275.   Lemmon, M. J., van Zijl, P., Fox, M. E., Mauchline, M. L., Giaccia, A. J., Minton, N. P., 
& Brown, J. M. 1997, "Anaerobic bacteria as a gene delivery system that is controlled 
by the tumor microenvironment”, Gene Ther., vol. 4, no. 8, pp. 791-796. 
  276.   Leng, R. P., Lin, Y., Ma, W., Wu, H., Lemmers, B., Chung, S., Parant, J. M., Lozano, 
G., Hakem, R., & Benchimol, S. 2003, "Pirh2, a p53-induced ubiquitin-protein ligase, 
promotes p53 degradation", Cell, vol. 112, no. 6, pp. 779-791. 
  277.   Lester, P. & Gaynor, J. S. 2000, "Management of cancer pain”, Vet Clin North Am 
Small Anim Pract., vol. 30, no. 4, pp. 951-966. 
  278.   Levine, A. J. 1997, "p53, the cellular gatekeeper for growth and division", Cell, vol. 88, 
pp. 323-331. 
  279.   Levine, A. J., Hu, W., & Feng, Z. 2006, "The P53 pathway: what questions remain to be 
explored?", Cell, vol. 13, no. 6, pp. 1027-1036. 
  280.   Levine, A. J., Wu, M. C., Chang, A., Silver, A., Attiyeh, E. F., Lin, J., & Epstein, C. B. 
1995, "The spectrum of mutations at the p53 locus. Evidence for tissue-specific 
mutagenesis, selection of mutant alleles, and a "gain of function" phenotype", Ann N Y 
Acad Sci., vol. 768, pp. 111-128. 
  281.   Levine, R. A. 2002, "Overexpression of the sis oncogene in a canine osteosarcoma cell 
line", Vet Pathol., vol. 39, no. 3, pp. 411-412. 
  282.   Levine, R. A. & Fleischli, M. A. 2000, "Inactivation of p53 and retinoblastoma family 
pathways in canine osteosarcoma cell lines", Vet Pathol., vol. 37, pp. 54-61. 
  283.   Levine, R. A., Forest, T., & Smith, C. 2002, "Tumour suppressor PTEN is mutated in 
canine osteosarcoma cell lines and tumours", Vet Pathol., vol. 39, no. 3, pp. 372-378. 
  284.   Li, D., Gan, Y., Wientjes, M. G., Badalament, R. A., & Au, J. L. 2001, "Distribution of 
DT-diaphorase and reduced nicotinamide adenine dinucleotide phosphate: cytochrome 
p450 oxidoreductase in bladder tissues and tumors”, J Urol., vol. 166, no. 6, pp. 2500-
2505. 
  285.   Li, M., Chen, D., Shiloh, A., Luo, J., Nikolaev, A. Y., Qin, J., & Gu, W. 2002, 
"Deubiquitination of p53 by HAUSP is an important pathway for p53 stabilization”, 
Nature, vol. 416, no. 6881, pp. 648-653. 
  286.   Li, X., Jung, C., Liu, Y. H., Bae, K. H., Zhang, Y. P., Zhang, H. J., Vanderputten, D., 
Jeng, M. H., Gardner, T. A., & Kao, C. 2006, "Anti-tumor efficacy of a transcriptional 
replication-competent adenovirus, Ad-OC-E1a, for osteosarcoma pulmonary 
metastasis", J Gene Med., vol. 8, no. 6, pp. 679-689. References 
 
259 
  287.   Liao, A. T., McCleese, J., Kamerling, S., Christensen, J., & London, C. A. 2007, "A 
novel small molecule Met inhibitor, PF2362376, exhibits biological activity against 
osteosarcoma", Vet Comp Oncol., vol. 5, no. 3, pp. 177-196. 
  288.   Liao, A. T., McMahon, M., & London, C. A. 2006, "Identification of a novel germline 
MET mutation in dogs”, Anim Genet., vol. 37, no. 3, pp. 248-252. 
  289.   Lin, J., Teresky, A. K., & Levine, A. J. 1995, "Two critical hydrophobic amino acids in 
the N-terminal domain of the p53 protein are required for the gain of function 
phenotypes of human p53 mutants", Oncogene, vol. 10, no. 12, pp. 2387-2390. 
  290.   Lindblad-Toh, K., Wade, C. M., Mikkelsen, T. S., Karlsson, E. K., Jaffe, D. B., Kamal, 
M., Clamp, M., Chang, J. L., Kulbokas, E. J., Zody, M. C., Mauceli, E., Xie, X., Breen, 
M., Wayne, R. K., Ostrander, E. A., Ponting, C. P., Galibert, F., Smith, D. R., DeJong, 
P. J., Kirkness, E., Alvarez, P., Biagi, T., Brockman, W., Butler, J., Chin, C. W., Cook, 
A., Cuff, J., Daly, M. J., DeCaprio, D., Gnerre, S., Grabherr, M., Kellis, M., Kleber, M., 
Bardeleben, C., Goodstadt, L., Heger, A., Hitte, C., Kim, L., Koepfli, K. P., Parker, H. 
G., Pollinger, J. P., Searle, S. M., Sutter, N. B., Thomas, R., Webber, C., Broad 
Institute Genome Sequencing Platform, & Lander, E. S. 2005, "Genome sequence, 
comparative analysis and haplotype structure of the domestic dog", Nature, vol. 438, 
no. 7069, pp. 803-819. 
  291.   Ling, G. V., Morgan, J. P., & Pool, R. R. 1974, "Primary bone tumors in the dog: A 
combined clinical, radiographic, and histologic approach to early diagnosis", J Am Vet 
Med Assoc., vol. 165, no. 1, pp. 55-67. 
  292.   Link Jr, C. J., Moorman, D. W., Ackerman, M., Levy, J. P., & Seregina, T. 2000, 
"Murine retroviral vector producer cells survival and toxicity in the peritoneal cavity of 
dogs", In Vivo, vol. 14, no. 5, pp. 635-641. 
  293.   Linzer, D. I. & Levine, A. J. 1979, "Characterization of a 54K dalton cellular SV40 tumor 
antigen present in SV40-transformed cells and uninfected embryonal carcinoma cells", 
Cell, vol. 17, no. 1, pp. 43-52. 
  294.   Lipinski, K. S., Djeha, A. H., Krausz, E., Lane, D. P., Searle, P. F., Mountain, A., & 
Wrighton, C. J. 2001, "Tumour-specific therapeutic adenovirus vectors: repression of 
transgene expression in healthy cells by endogenous p53”, Gene Ther., vol. 8, no. 4, 
pp. 274-281. 
  295.   Ljungman, M. & Lane, D. P. 2004, "Transcription - guarding the genome by sensing DNA 
damage”, Nat Rev Cancer, vol. 4, no. 9, pp. 727-737. 
  296.   Lohrum, M. A., Woods, D. B., Ludwig, R. L., Balint, E., & Vousden, K. H. 2001, "C-
terminal ubiquitination of p53 contributes to nuclear export”, Mol Cell Biol., vol. 21, 
no. 24, pp. 8521-8532. 
  297.   Lord, L. K., Yaissle, J. E., Marin, L., & Couto, C. G. 2007, "Results of a web-based 
health survey of retired racing Greyhounds”, J Vet Intern Med., vol. 21, no. 6, pp. 
1243-1250. 
  298.   Loukopoulos, P., O'Brien, T., Ghoddusi, M., Mungall, B. A., & Robinson, W. F. 2004, 
"Characterisation of three novel canine osteosarcoma cell lines producing high levels of 
matrix metalloproteinases", Res Vet Sci., vol. 77, no. 2, pp. 131-141. 
  299.   Loukopoulos, P. & Robinson, W. F. 2007, "Clinicopathological Relevance of Tumour 
Grading in Canine Osteosarcoma", J Comp Pathol., vol. 136, no. 1, pp. 65-73. 
  300.   Loukopoulos, P., Thornton, J. R., & Robinsin, W. F. 2003, "Clinical and pathologic 
relevance of p53 index in canine osseous tumours", Vet Pathol., vol. 40, pp. 237-248. References 
 
260 
  301.   Lowe, S., Ruley, H. E., Jacks, T., & Housman, D. E. 1993, "p53-dependent apoptosis 
modulates the cytotoxicity of anticancer agents", Cell, vol. 74, pp. 957-967. 
  302.   Lu, H., Zhang, Y., Roberts, D. D., Osborne, C. K., & Templeton, N. S. 2002, "Enhanced 
gene expression in breast cancer cells in vitro and tumors in vivo", Mol Ther., vol. 6, 
no. 6, pp. 783-792. 
  303.   Lucas, P. W., Fan, T. M., Garrett, L. D., Griffon, D. J., & Wypij, J. M. 2008, "A 
comparison of five different bone resorption markers in osteosarcoma-bearing dogs, 
normal dogs, and dogs with orthopedic diseases”, J Vet Intern Med., vol. 22, no. 4, pp. 
1008-1113. 
  304.   Luckow, B. & Schutz, G. 1987, "CAT constructions with multiple unique restriction sites 
for the functional analysis of eukaryotic promoters and regulatory elements", Nucleic 
Acids Res., vol. 15, no. 13, p. 5490. 
  305.   Lumniczky, K. & Safrany, G. 2006, "Cancer gene therapy: combination with radiation 
therapy and the role of bystander cell killing in the anti-tumor effect”, Pathol Oncol 
Res., vol. 12, no. 2, pp. 118-124. 
  306.   MacEwen, E. G., Kutzke, J., Carew, J., Pastor, J., Schmidt, J. A., Tsan, R., Thamm, D. 
H., & Radinsky, R. 2003, "c-Met tyrosine kinase receptor expression and function in 
human and canine osteosarcoma cells", Clin Exp Metastasis, vol. 20, no. 5, pp. 421-
430. 
  307.   MacEwen, E. G., Pastor, J., Kutzke, J., Tsan, R., Kurzman, I. D., Thamm, D. H., 
Wilson, M., & Radinsky, R. 2004, "IGF-1 receptor contributes to the malignant 
phenotype in human and canine osteosarcoma", J Cell Biochem., vol. 92, no. 1, pp. 77-
91. 
  308.   Majumdar, A. S., Hughes, D. E., Lichtsteiner, S. P., Wang, Z., Lebkowski, J. S., & 
Vasserot, A. P. 2001, "The telomerase reverse transcriptase promoter drives efficacious 
tumour suicide gene therapy while preventing hepatoxicity encountered with 
constitutive promoters", Gene Ther., vol. 8, no. 7, pp. 568-578. 
  309.   Marselos, M. & Vainio, H. 1991, "Carcinogenic properties of pharmaceutical agents 
evaluated in the IARC Monographs programme", Carcinogenesis, vol. 12, no. 10, pp. 
1751-1766. 
  310.   Matsukura, N., Hoshino, A., Igarashi, T., Hasegawa, H., Okino, T., Onda, M., Iijima, O, 
Akiyama, K., Goto, T., Takubo, K., Suzuki, S., & Shimada, T. 1999, "In situ gene 
transfer and suicide gene therapy of gastric cancer induced by N-ethyl-N'-nitro-N-
nitrosoguanidine in dogs", Jpn J Cancer Res., vol. 90, no. 9, pp. 1039-1049. 
  311.   Matthiesen, D. T., Clark, G. N., Orsher, R. J., Pardo, A. O., Glennon, J., & Patnaik, A. 
K. 1992, "En bloc resection of primary rib tumors in 40 dogs", Vet Surg., vol. 21, no. 3, 
pp. 201-204. 
  312.   Matuszyk, J., Ziolo, E., Cebrat, M., Kochel, I., & Strzadala, L. 2002, "Nurr1 affects pRL-
TK but not phRG-B internal control plasmid in genetic reporter system", Biochem 
Biophys Res Commun., vol. 294, no. 5, pp. 1036-1039. 
  313.   Mauldin, G. N., Matus, R. E., Withrow, S. J., & Patnaik, A. K. 1988, "Canine 
osteosarcoma. Treatment by amputation versus amputation and adjuvant 
chemotherapy using doxorubicin and cisplatin", J Vet Intern Med., vol. 2, no. 4, pp. 
177-180. 
  314.   Mayr, B., Eschborn, U., Loupal, G., & Schleger, W. 1991, "Characterisation of complex 
karyotype changes in two canine bone tumours", Res Vet Sci., vol. 51, pp. 341-343. References 
 
261 
  315.   McChesney-Gillette, S., Gillette, E. L., Powers, B. E., & Withrow, S. J. 1990, 
"Radiation-induced osteosarcoma in dogs after external beam or intraoperative 
radiation therapy", Cancer Res., vol. 50, pp. 54-57. 
  316.   McCleese, J. K., Bear, M. D., Fossey, S. L., Mihalek, R. M., Foley, K. P., Ying, W., 
Barsoum, J., & London, C. A. 2009, "The novel HSP90 inhibitor STA-1474 exhibits 
biologic activity against osteosarcoma cell lines”, Int J Cancer, Jun 19, Epub ahead of 
print. 
  317.   McCormack, W. M., Seiler, M. P., Bertin, T. K., Ubhayakar, K., Palmer, D. J., Ng, P., 
Nichols, T. C., & Lee, B. 2006, "Helper-dependent adenoviral gene therapy mediates 
long-term correction of the clotting defect in the canine hemophilia A model", J 
Thromb Haemost., vol. 4, no. 6, pp. 1218-1225. 
  318.   McEntee, M. C., Page, R. L., Theon, A., Erb, H. N., & Thrall, D. E. 2004, "Malignant 
tumour formation in dogs previously irradiated for acanthomatous epulis", Vet Radiol 
Ultrasound., vol. 45, no. 4, pp. 357-361. 
  319.   McIntyre, J. F., Smith-Sorensen, B., Friend, S. H., Kassell, J., Borresen, A. L., Yan, YX, 
Russo, C., Sato, J., Barbier, N., & Miser, J. 1994, "Germline mutations of the p53 
tumor suppressor gene in children with osteosarcoma", J Clin Oncol., vol. 12, no. 5, 
pp. 925-930. 
  320.   McNeish, I. A., Gilligan, M. G., Green, N. K., Roberts, S. M., Kerr, D. J., Friedlos, F., 
Springer, C. J., & Searle, P. F. 1998a, "Virus-directed enzyme prodrug therapy using 
retrovirally delivered E.coli nitroreductase and CB1954", Br J Cancer, vol. 78, no. 2, 
pp. 141-158. 
  321.   McNeish, I. A., Green, N. K., Gilligan, M. G., Ford, M. J., Mautner, V., Young, L. S., 
Kerr, D. E., & Searle, P. F. 1998b, "Virus directed enzyme prodrug therapy for ovarian 
and pancreatic cancer using retrovirally delivered E. coli nitroreductase and CB1954", 
Gene Ther., vol. 5, no. 8, pp. 1061-1069. 
  322.   Meek, D. W. 1998, "Multisite phosphorylation and the integration of stress signals at 
p53", Cell Signal., vol. 10, no. 3, pp. 159-166. 
  323.   Mehl, M. L., Seguin, B., Dernell, W. S., Lafferty, M., Kass, P. H., & Withrow, S. J. 
2005, "Survival analysis of one versus two treatments of local delivery cisplatin in a 
biodegradable polymer for canine osteosarcoma”, Vet Comp Oncol., vol. 3, no. 2, pp. 
81-86. 
  324.   Mei, J., Gao, Y., Zhang, L., Cai, X., Qian, Z., Huang, H., & Huang, W. 2008, "VEGF-
siRNA silencing induces apoptosis, inhibits proliferation and suppresses vasculogenic 
mimicry in osteosarcoma in vitro”, Exp Oncol., vol. 30, no. 1, pp. 29-34. 
  325.   Mendoza, S., Konishi, T., Dernell, W. S., Withrow, S. J., & Miller, C. W. 1998, "Status 
of the p53, Rb and MDM2 genes in canine osteosarcoma", Anticancer Res., vol. 18, no. 
6A, pp. 4449-4453. 
  326.   Merlo, D. F., Rossi, L., Pellegrino, C., Ceppi, M., Cardellino, U., Capurro, C., Ratto, A., 
Sambucco, P. L., Sestito, V., Tanara, G., & Bocchini, V. 2008, "Cancer incidence in pet 
dogs: findings of the Animal Tumor Registry of Genoa, Italy”, J Vet Intern Med., vol. 
22, no. 4, pp. 976-984. 
  327.   Merritt, J. A., Roth, J. A., & Logothetis, C. J. 2001, "Clinical evaluation of adenoviral-
mediated p53 gene transfer: review of INGN 201 studies", Semin Oncol., vol. 28, no. 5 
Suppl. 16, pp. 105-114. 
  328.   Millau, J. F., Bastien, N., & Drouin, R. 2009, "P53 transcriptional activities: a general 
overview and some thoughts”, Mutat Res., vol. 681, no. 2-3, pp. 118-133. References 
 
262 
  329.   Miller, C. W., Aslo, A., Tsay, C., Slamon, D., Ishizaki, K., Toguchida, J., Yamamuro, T, 
Lampkin, B., & Koeffler, H. P. 1990, "Frequency and structure of p53 rearrangements 
in human osteosarcoma", Cancer Res., vol. 50, no. 24, pp. 7950-7954. 
  330.   Miller, C. W., Aslo, A., Won, A., Tan, M., Lampkin, B., & Koeffler, H. P. 1996, 
"Alterations of the p53, Rb and MDM2 genes in osteosarcoma", J Cancer Res Clin 
Oncol., vol. 122, no. 9, pp. 559-565. 
  331.   Misdorp, W. 1980, "Skeletal osteosarcoma. Animal model: canine osteosarcoma", Am J 
Pathol., vol. 98, no. 1, pp. 285-288. 
  332.   Misdorp, W. & Hart, A. A. 1979, "Some prognostic and epidemiologic factors in canine 
osteosarcoma", J Natl Cancer Inst., vol. 62, no. 3, pp. 537-545. 
  333.   Mizumoto, M., Arii, S., Furutani, M., Mori, A., & Imamura, M. 2002, "A novel suicide 
gene therapy system for p53-mutated cells using a wild-type p53-specific promoter and 
Cre/loxP switch", Surg Today, vol. 32, no. 1, pp. 53-58. 
  334.   Mohammed, S. I., Coffman, K., Glickman, N. W., Hayek, M. G., Waters, D. J., 
Schlittler, D., DeNicola, D. B., & Knapp, D. W. 2001, "Prostaglandin E2 concentrations 
in naturally occurring canine cancer”, Prostaglandins Leukot Essent Fatty Acids, vol. 
64, no. 1, pp. 1-4. 
  335.   Mohammed, S. I., Khan, K. N., Sellers, R. S., Hayek, M. G., DeNicola, D. B., Wu, L., 
Bonney, P. L., & Knapp, D. W. 2004, "Expression of cyclooxygenase-1 and 2 in 
naturally-occurring canine cancer", Prostaglandins Leukot Essent Fatty Acids, vol. 70, 
no. 5, pp. 479-483. 
  336.   Momand, J., Jung, D., Wilczynski, S. P., & Niland, J. 1998, "The MDM2 gene 
amplification database", Nucleic Acids Res., vol. 26, no. 15, pp. 3453-3459. 
  337.   Montes de Oca, L. R., Wagner, D. S., & Lozano, G. 1995, "Rescue of early embryonic 
lethality in mdm2-deficient mice by deletion of p53", Nature, vol. 378, no. 6553, pp. 
203-206. 
  338.   Mueller, F., Fuchs, B., & Kaser-Hotz, B. 2007, "Comparative biology of human and 
canine osteosarcoma”, Anticancer Res., vol. 27, no. 1A, pp. 155-164. 
  339.   Mueller, F., Poirier, V., Melzer, K., Nitzl, D., Roos, M., & Kaser-Hotz, B. 2005, 
"Palliative radiotherapy with electrons of appendicular osteosarcoma in 54 dogs”, In 
Vivo, vol. 19, no. 4, pp. 713-716. 
  340.   Mulholland, D. J., Cox, M., Read, J., Rennie, P., & Nelson, C. 2004, "Androgen 
responsiveness of Renilla luciferase reporter vectors is promoter, transgene, and cell 
line dependent", Prostate, vol. 59, no. 2, pp. 115-119. 
  341.   Mullins, M. N., Lana, S. E., Dernell, W. S., Ogilvie, G. K., Withrow, S. J., & Ehrhart, E. 
J. 2004, "Cyclooxygenase-2 expression in canine appendicular osteosarcomas", J Vet 
Intern Med., vol. 18, no. 6, pp. 859-865. 
  342.   Murray-Zmijewski, F., Lane, D. P., & Bourdon, J. C. 2006, "p53/p63/p73 isoforms: an 
orchestra of isoforms to harmonise cell differentiation and response to stress”, Cell 
Death Differ., vol. 13, no. 6, pp. 962-972. 
  343.   Muto, T., Wakui, S., Takahashi, H., Maekawa, S., Masaoka, T., Ushigome, S., & 
Furusato, M. 2000, "p53 gene mutations occurring in spontaneous benign and malignant 
mammary tumours of the dog", Vet Pathol., vol. 37, pp. 248-253. 
  344.   Nagano, S., Yuge, K., Fukunaga, M., Terazaki, Y., Fujiwara, H., Komiya, S., & Kosai, K. 
2004, "Gene therapy eradicating distant disseminated micro-metastases by optimal References 
 
263 
cytokine expression in the primary lesion only: novel concepts for successful cytokine 
gene therapy", Int J Oncol., vol. 24, no. 3, pp. 549-558. 
  345.   Nakase, M., Inui, M., Okumura, K., Kamei, T., Nakamura, S., & Tagawa, T. 2005a, "p53 
gene therapy of human osteosarcoma using a transferrin-modified cationic liposome”, 
Mol Cancer Ther., vol. 4, no. 4, pp. 625-631. 
  346.   Nakase, M., Okumura, K., Kamei, T., Nakamura, S., Inui, M., & Tagawa, T. 2005b, "The 
influence of oral tumor cell proliferation activity and membrane potential on the 
transfection efficiency of a cationic liposome", Oncol Rep., vol. 14, no. 6, pp. 1487-
1491. 
  347.   Nasir, L. & Argyle, D. J. 1999, "Mutational analysis of the tumour suppressor gene p53 
in lymphosarcoma in two bull mastiffs", Vet Record, vol. 145, pp. 23-24. 
  348.   Nasir, L., Rutteman, G. R., Reid, S. W. J., Schulze, Ch., & Argyle, D. J. 2001, "Analysis 
of p53 mutational events and MDM2 amplification in canine soft-tissue sarcomas", 
Cancer Lett., vol. 174, pp. 83-89. 
  349.   National Toxicology Program 1988, "Toxicology and carcinogenesis studies of 
nitrofurazone in F334/N rats and B6C3F1 mice", NTP TR-337, NIH Publication No.88-
2593. 
  350.   Nemunaitis, J., Cunningham, C., Buchanan, A., Blackburn, A., Edelman, G., Maples, 
P., Netto, G., Tong, A., Randlev, B., Olson, S., & Kirn, D. 2001, "Intravenous infusion 
of a replication-selective adenovirus (ONYX-015) in cancer patients: safety, feasibility 
and biological activity", Gene Ther., vol. 8, no. 10, pp. 746-759. 
  351.   Nemunaitis, J., Swisher, S. G., Timmons, T., Connors, D., Mack, M., Doerksen, L., 
Weill, D., Wait, J., Lawrence, D. D., Kemp, B. L., Fossella, F., Glisson, B. S., Hong, W. 
K., Khuri, F. R., Kurie, J. M., Lee, J. J., Lee, J. S., Nguyen, D. M., Nesbitt, J. C., 
Perez-Soler, R., Pisters, K. M. W., Putnam, J. B., Richli, W. R., Shin, D. M., Walsh, G. 
L., Merritt, J., & Roth, J. 2000, "Adenovirus-mediated p53 gene transfer in sequence 
with cisplatin to tumours of patients with non-small-cell lung cancer", J Clin Oncol., 
vol. 18, no. 3, pp. 609-622. 
  352.   Nishikawa, M. & Huang, L. 2001, "Nonviral vectors in the new millennium: delivery 
barriers in gene transfer", Hum Gene Ther., vol. 12, no. 8, pp. 861-870. 
  353.   Nishizaki, M., Fujiwara, T., Tanida, T., Hizuta, A., Nishimori, H., Tokino, T., 
Nakamura, Y., Bouvet, M., Roth, J. A., & Tanaka, N. 1999, "Recombinant adenovirus 
expressing wild-type p53 is antiangiogenic: a proposed mechanism for bystander 
effect”, Clin Cancer Res., vol. 5, no. 5, pp. 1015-1023. 
  354.   O'Brien, M. G., Straw, R. C., Withrow, S. J., Powers, B. E., Jameson, V. J., Lafferty, 
M., Ogilvie, G. K., & Larue, S. M. 1993, "Resection of pulmonary metastases in canine 
osteosarcoma: 36 cases (1983-1992)", Vet Surg., vol. 22, no. 2, pp. 105-109. 
  355.   O'Farrell, T. J., Ghosh, P., Dobashi, N., Sasaki, C. Y., & Longo, D. L. 2004, "Comparison 
of the effect of mutant and wild-type p53 on global gene expression”, Cancer Res., 
vol. 64, no. 22, pp. 8199-8207. 
  356.   Ogilvie, G. K., Straw, R. C., Jameson, V. J., Walters, L. M., Lafferty, M. H., Powers, B. 
E., & Withrow, S. J. 1993, "Evaluation of single-agent chemotherapy for treatment of 
clinically evident osteosarcoma metastases in dogs: 45 cases (1987-1991)", J Am Vet 
Med Assoc., vol. 202, no. 2, pp. 304-306. 
  357.   Ohta, G., Sakai, H., Kachi, S., Hirata, A., Yonemaru, K., Kitajima, A., Yanai, T., & 
Masegi, T. 2004, "Assessment of proliferative potentials of canine osteosarcomas and 
chondrosarcomas by MIB-1 immunohistochemistry and bromodeoxyuridine 
incorporation”, J Comp Pathol., vol. 131, no. 1, pp. 18-27. References 
 
264 
  358.   Okuda, M., Umeda, A., Matsumoto, Y., Momoi, Y., Watari, T., Goitsuka, R., O'Brien, S. 
J., Tsujimoto, H., & Hasegawa, A. 1993, "Molecular cloning and chromosomal mapping 
of feline p53 tumour suppressor gene", J Vet Med Sci., vol. 55, no. 5, pp. 801-805. 
  359.   Okumura, K., Nakase, M., Nakamura, S., Kamei, T., Inui, M., & Tagawa, T. 2007, "Bax 
gene therapy for human osteosarcoma using cationic liposomes in vivo”, Oncol Rep., 
vol. 17, no. 4, pp. 769-773. 
  360.   Olivier, M., Petitjean, A., Marcel, V., Petre, A., Mounawar, M., Plymoth, A., de 
Fromentel, C. C., & Hainaut, P. 2009, "Recent advances in p53 research: an 
interdisciplinary perspective", Cancer Gene Ther., vol. 16, pp. 1-12. 
  361.   Oosterhoff, D., Witlox, M. A., van Beusechem, V. W., Haisma, H. J., Schaap, G. R., 
Bras, J., Kruyt, F. A., Molenaar, B., Boven, E., Wuisman, P. I., Pinedo, H. M., & 
Gerritsen, W. R. 2003, "Gene-directed enzyme prodrug therapy for osteosarcoma: 
sensitization to CPT-11 in vitro and in vivo by adenoviral delivery of a gene encoding 
secreted carboxylesterase-2", Mol Cancer Ther., vol. 2, no. 8, pp. 765-771. 
  362.   Oshima, Y., Sasaki, Y., Negishi, H., Idogawa, M., Toyota, M., Yamashita, T., Wada, T., 
Nagoya, S., Kawaguchi, S., Yamashita, T., & Tokino, T. 2007, "Antitumor effect of 
adenovirus-mediated p53 family gene transfer on osteosarcoma cell lines”, Cancer Biol 
Ther., vol. 6, no. 7, pp. 1058-1066. 
  363.   Osuna, D. & de Alava, E. 2009, "Molecular pathology of sarcomas”, Rev Recent Clin 
Trials, vol. 4, no. 1, pp. 12-26. 
  364.   Overholtzer, M., Rao, P. H., Favis, R., Lu, X. Y., Elowitz, M. B., Barany, F., Ladanyi, 
M., Gorlick, R., & Levine, A. J. 2003, "The presence of p53 mutations in human 
osteosarcomas correlates with high levels of genomic instability", Proc Natl Acad Sci 
USA., vol. 100, no. 20, pp. 11547-11552. 
  365.   Owen, L. N. & Steel, G. G. 1969, "The growth and cell population kinetics of 
spontaneous tumours in domestic animals", Br J Cancer, vol. 23, no. 3, pp. 493-509. 
  366.   Ozaki, T., Schaefer, K. L., Wai, D., Buerger, H., Flege, S., Lindner, N., Kevric, M., 
Diallo, R., Bankfalvi, A., Brinkschmidt, C., Juergens, H., Winkelmann, W., Dockhorn-
Dworniczak, B., Bielack, S. S., & Poremba, C. 2002, "Genetic imbalances revealed by 
comparative genomic hybridization in osteosarcomas”, Int J Cancer, vol. 102, no. 4, 
pp. 355-365. 
  367.   Paguio, A., Almond, B., Fan, F., Stecha, P., Garvin, D., Wood, M., & Wood, K. 2005, 
"Luciferase reporters: Less is more", Promega Notes, vol. 89, pp. 7-9. 
  368.   Pakos, E. E., Kyzas, P. A., & Ioannidis, J. P. 2004, "Prognostic significance of TP53 
tumor suppressor gene expression and mutations in human osteosarcoma: a meta-
analysis", Clin Cancer Res., vol. 10, no. 18 Pt 1, pp. 6208-6214. 
  369.   Palmer, D. H., Mautner, V., Mirza, D., Oliff, S., Gerritsen, W., van der Sijp, J. R., 
Hubscher, S., Reynolds, G., Bonney, S., Rajaratnam, R., Hull, D., Horne, M., Ellis, J., 
Mountain, A., Hill, S., Harris, P. A., Searle, P. F., Young, L. S., James, N. D., & Kerr, 
D. J. 2004, "Virus-directed enzyme prodrug therapy: intratumoral administration of a 
replication-deficient adenovirus encoding nitroreductase to patients with resectable 
liver cancer”, J Clin Oncol., vol. 22, no. 9, pp. 1546-1552. 
  370.   Palmer, D. H., Young, L. S., & Mautner, V. 2006, "Cancer gene-therapy: clinical trials”, 
Trends Biotechnol., vol. 24, no. 2, pp. 76-82. 
  371.   Pang, L. Y. & Argyle, D. J. 2009, "Using naturally occurring tumours in dogs and cats to 
study telomerase and cancer stem cell biology”, Biochim Biophys Acta, vol. 1792, no. 
4, pp. 380-391. References 
 
265 
  372.   Paoloni, M. & Khanna, C. 2008, "Translation of new cancer treatments from pet dogs to 
humans”, Nat Rev Cancer, vol. 8, no. 2, pp. 147-156. 
  373.   Paoloni, M. C. & Khanna, C. 2007, "Comparative oncology today”, Vet Clin North Am 
Small Anim Pract., vol. 37, no. 6, pp. 1023-1032. 
  374.   Park, H. S., Cheon, J., Cho, H. Y., Ko, Y. H., Bae, J. H., Moon, D. G., & Kim, J. J. 
2003, "In vivo characterization of a prostate-specific antigen promoter-based suicide 
gene therapy for the treatment of benign prostatic hyperplasia", Gene Ther., vol. 10, 
no. 13, pp. 1129-1134. 
  375.   Patel, P., Young, J. G., Mautner, V., Ashdown, D., Bonney, S., Pineda, R. G., Collins, 
S. I., Searle, P. F., Hull, D., Peers, E., Chester, J., Wallace, D. M., Doherty, A., Leung, 
H., Young, L. S., & James, N. D. 2009, "A phase I/II clinical trial in localized prostate 
cancer of an adenovirus expressing nitroreductase with CB1984”, Mol Ther., vol. 17, 
no. 7, pp. 1292-1299. 
  376.   Patnaik, A. K. 1990, "Canine extraskeletal osteosarcoma and chondrosarcoma: a 
clinicopathologic study of 14 cases", Vet Pathol., vol. 27, no. 1, pp. 46-55. 
  377.   Pavletich, N. P., Chambers, K. A., & Pabo, C. O. 1993, "The DNA-binding domain of p53 
contains the four conserved regions and the major mutation hot spots", Genes Dev., 
vol. 7, no. 12, pp. 2556-2564. 
  378.   Petitjean, A., Achatz, M. I., Borresen-Dale, A.-L., Hainaut, P., & Olivier, M. 2007a, 
"TP53 mutations in human cancers: functional selection and impact on cancer 
prognosis and outcomes”, Oncogene, vol. 26, no. 15, pp. 2157-2165. 
  379.   Petitjean, A., Mathe, E., Kato, S., Ishioka, C., Tavtigian, S. V., Hainaut, P., & Olivier, 
M. 2007b, "Impact of mutant p53 functional properties on TP53 mutation patterns and 
tumor phenotype: lessons from recent developments in the IARC TP53 database”, Hum 
Mutat., vol. 28, no. 6, pp. 622-629. 
  380.   Phillips, B., Powers, B. E., Dernell, W. S., Straw, R. C., Khanna, C., Hogge, G. S., & 
Vail, D. M. 2009, "Use of single-agent carboplatin as adjuvant or neoadjuvant therapy 
in conjunction with amputation for appendicular osteosarcoma in dogs”, J Am Anim 
Hosp Assoc., vol. 45, no. 1, pp. 33-38. 
  381.   Phillips, J. C., Stephenson, B., Hauck, M., & Dillberger, J. 2007, "Heritability and 
segregation analysis of osteosarcoma in the Scottish deerhound”, Genomics, vol. 90, 
no. 3, pp. 354-363. 
  382.   Pirie-Shepherd, S. R., Coffman, K. T., Resnick, D., Chan, R., Kisker, O., Folkman, J., & 
Waters, D. J. 2002, "The role of angiostatin in the spontaneous bone and prostate 
cancers of pet dogs”, Biochem Biophys Res Commun., vol. 292, no. 4, pp. 886-891. 
  383.   Pirkey-Ehrhart, N., Withrow, S. J., Straw, R. C., Ehrhart, J. C., Page, R. L., Hottinger, 
H. L., Hahn, K. A., Morrison, W. B., Albrecht, M. R., & Hedlund, C. S. 1995, "Primary 
rib tumours in 54 dogs", J Am Anim Hosp Assoc., vol. 31, no. 1, pp. 65-69. 
  384.   Pirollo, K. F., Xu, L., & Chang, E. H. 2000, "Non-viral gene delivery for p53", Curr Opin 
Mol Ther., vol. 2, no. 2, pp. 168-175. 
  385.   Pluquet, O. & Hainaut, P. 2001, "Genotoxic and non-genotoxic pathways of p53 
induction", Cancer Lett., vol. 174, no. 1, pp. 1-15. 
  386.   Pocard, M., Chevillard, S., Villaudy, J., Poupon, M. F., Dutrillaux, B., & Remvikos, Y. 
1996, "Different p53 mutations produce distinct effects on the ability of colon 
carcinoma cells to become blocked at the G1/S boundary after irradiation”, Oncogene, 
vol. 12, no. 4, pp. 875-882. References 
 
266 
  387.   Poirier, V. J., Hershey, A. E., Burgess, K. E., Phillips, B., Turek, M. M., Forrest, L. J., 
Beaver, L., & Vail, D. M. 2004, "Efficacy and toxicity of paclitaxel (Taxol) for the 
treatment of canine malignant tumors”, J Vet Intern Med., vol. 18, no. 2, pp. 219-222. 
  388.   Portsmouth, D., Hlavaty, J., & Renner, M. 2007, "Suicide genes for cancer therapy”, 
Mol Aspects Med., vol. 28, no. 1, pp. 4-41. 
  389.   Powers, B. E., Gillette, E. L., McChesney, S. L., LeCouteur, R. A., & Withrow, S. J. 
1989, "Bone necrosis and tumour induction following experimental intraoperative 
irradiation", Int J Radiat Oncol Biol Phys., vol. 17, no. 3, pp. 559-567. 
  390.   Pratt, C. B., Meyer, W. H., Howlett, N., Douglass, E. C., Bowman, L. C., Poe, D., 
Mounce, K., Kun, L. E., & Houghton, J. A. 1994, "Phase II study of 5-
fluorouracil/leucovorin for pediatric patients with malignant solid tumor", Cancer, vol. 
74, no. 9, pp. 2593-2598. 
  391.   Priester, W. A. & McKay, F. W. 1980, "The occurrence of tumors in domestic animals", 
NCI Monogr., vol. 54. 
  392.   Promega Corporation 1999, "Dual-luciferase reporter assay system", Technical Manual, 
vol. TM040. 
  393.   Promega Corporation 2001, "pRL-CMV Vector", Technical Bulletin, vol. TB237. 
  394.   Promega Corporation 2003, "Renilla Luciferase Assay System", Technical Manual, vol. 
TM055. 
  395.   Rainov, N. G., Koch, S., Sena-Esteves, M., & Berens, M. E. 2000, "Characterization of a 
canine glioma cell line as related to established experimental brain tumor models", J 
Neuropathol Exp Neurol., vol. 59, no. 7, pp. 607-613. 
  396.   Ramesh, R., Ito, I., Saito, Y., Wu, Z., Mhashikar, A. M., Wilson, D. R., Branch, C. D., 
Roth, J. A., & Chada, S. 2004, "Local and systemic inhibition of lung tumor growth 
after nanoparticle-mediated mda-7/IL-24 gene delivery", DNA Cell Biol., vol. 23, no. 
12, pp. 850-857. 
  397.   Ramesh, R., Saeki, T., Templeton, N. S., Ji, L., Stephens, L. C., Ito, I., Wilson, D. R., 
Wu, Z., Branch, C. D., Minna, J. D., & Roth, J. A. 2001, "Successful treatment of 
primary and disseminated human lung cancers by systemic delivery of tumor suppressor 
genes using an improved liposome vector”, Mol Ther., vol. 3, no. 3, pp. 337-350. 
  398.   Ramirez, O., Dodge, R. K., Page, R. L., Price, G. S., Hauck, M. L., LaDue, T. A., 
Nutter, F., & Thrall, D. E. 1999, "Palliative radiotherapy of appendicular osteosarcoma 
in 95 dogs”, Vet Radiol Ultrasound., vol. 40, no. 5, pp. 517-522. 
  399.   Ramnaraine, M., Pan, W., Goblirsch, M., Lynch, C., Lewis, V., Orchard, P., Mantyh, P., 
& Clohisy, D. R. 2003, "Direct and bystander killing of sarcomas by novel cytosine 
deaminase fusion gene", Cancer Res., vol. 63, no. 20, pp. 6847-6854. 
  400.   Reddick, R. L., Michelitch, H. J., Levine, A. M., & Triche, T. J. 1980, "Osteogenic 
sarcoma", Cancer, vol. 45, pp. 64-71. 
  401.   Reich, N. C., Oren, M., & Levine, A. J. 1983, "Two distinct mechanisms regulate the 
levels of a cellular tumor antigen, p53", Mol Cell Biol., vol. 3, no. 12, pp. 2143-2150. 
  402.   Reinhardt, S., Stockhaus, C., Teske, E., Rudolph, R., & Brunnberg, L. 2005, 
"Assessment of cytological criteria for diagnosing osteosarcoma in dogs”, J Small Anim 
Pract., vol. 46, no. 2, pp. 65-70. References 
 
267 
  403.   Rideout, W. M., III, Coetzee, G. A., Olumi, A. F., & Jones, P. A. 1990, "5-
Methylcytosine as an endogenous mutagen in the human LDL receptor and p53 genes", 
Science, vol. 249, no. 4974, pp. 1288-1290. 
  404.   Riggs, J. L., McAllister, R. M., & Lennette, E. H. 1974, "Immunofluorescent studies of 
RD-114 virus replication in cell culture", J Gen Virol., vol. 25, pp. 21-29. 
  405.   Riley, T., Sontag, E., Chen, P., & Levine, A. 2008, "Transcriptional control of human 
p53-regulated genes”, Nat Rev Mol Cell Biol., vol. 9, no. 5, pp. 402-412. 
  406.   Rodriguez, N. I., Hoots, W. K., Koshkina, N. V., Morales-Arias, J. A., Arndt, C. A., 
Inwards, C. Y., Hawkins, D. S., Munsell, M. F., & Kleinerman, E. S. 2008, "COX-2 
expression correlates with survival in patients with osteosarcoma lung metastases”, J 
Pediatr Hematol Oncol., vol. 30, no. 7, pp. 507-512. 
  407.   Roldan, M. D., Perez-Reinado, E., Castillo, F., & Moreno-Vivian, C. 2008, "Reduction of 
polynitroaromatic compounds: the bacterial nitroreductases”, FEMS Microbiol Rev., 
vol. 32, no. 3, pp. 474-500. 
  408.   Rosenberg, S. A., Aebersold, P., Cornetta, K., Kasid, A., Morgan, R. A., Moen, R., 
Karson, E. M., Lotze, M. T., Yang, J. C., Topalian, S. L., Merino, M. J., Culver, K., 
Miller, A. D., Blaese, M., & Anderson, W. F. 1990, "Gene transfer into humans--
immunotherapy of patients with advanced melanoma, using tumor-infiltrating 
lymphocytes modified by retroviral gene transduction”, N Engl J Med., vol. 323, no. 9, 
pp. 570-578. 
  409.   Rosenberger, J. A., Pablo, N. V., & Crawford, P. C. 2007, "Prevalence of and intrinsic 
risk factors for appendicular osteosarcoma in dogs: 179 cases (1996-2005)”, J Am Vet 
Med Assoc., vol. 231, no. 7, pp. 1076-1080. 
  410.   Roth, J. A. & Grammer, S. F. 2004, "Gene replacement therapy for non-small cell lung 
cancer: a review", Hematol Oncol Clin North Am., vol. 18, no. 1, pp. 215-229. 
  411.   Roth, J. A. & Grammer, S. F. 2005, "Tumour Suppressor Gene Replacement for 
Cancer," in Cancer Gene Therapy, 1st edn, D. T. Curiel & Douglas JT, eds., Humana 
Press, Totowa, New Jersey, pp. 19-33. 
  412.   Rowan, S., Ludwig, R. L., Haupt, Y., Bates, S., Lu, X., Oren, M., & Vousden, K. H. 
1996, "Specific loss of apoptotic but not cell-cycle arrest function in a human tumor 
derived p53 mutant”, EMBO J., vol. 15, no. 4, pp. 827-838. 
  413.   Ru, G., Terracini, B., & Glickman, L. T. 1998, "Host related risk factors for canine 
osteosarcoma", Vet J., vol. 156, no. 1, pp. 31-39. 
  414.   Sabine, V. S., Nasir, L., Burr, P. D., McFarlane, S., & Argyle, D. J. 1999, 
"Characterisation of p53 (tumour suppressor) mutational status in a canine 
osteosarcoma cell line (D17)", Res Vet Sci., vol. 66A, p. 8. 
  415.   Sadikovic, B., Yoshimoto, M., Al-Romaih, K., Maire, G., Zielenska, M., & Squire, J. A. 
2008, "In vitro analysis of integrated global high-resolution DNA methylation profiling 
with genomic imbalance and gene expression in osteosarcoma”, PLoS One, vol. 3, no. 
7, p. e2834. 
  416.   Sagartz, J. E., Bodley, W. L., Gamblin, R. M., Couto, C. G., Tierney, L. A., & Capen, C. 
C. 1996, "p53 tumor suppressor protein overexpression in osteogenic tumors of dogs", 
Vet Pathol., vol. 33, no. 2, pp. 213-221. 
  417.   Saif, M. W., Syrigos, K. N., & Katirtzoglou, N. A. 2009, "S-1: a promising new oral 
fluoropyrimidine derivative”, Expert Opin Investig Drugs, vol. 18, no. 3, pp. 335-348. References 
 
268 
  418.   Salomoni, P. & Pandolfi, P. P. 2002, "p53 De-ubiquitination: at the edge between life 
and death”, Nat Cell Biol., vol. 4, no. 6, p. E152-E153. 
  419.   Sambrook, J., Fritsch, E. F., & Maniatis, T. 1989, Molecular Cloning: A laboratory 
manual, II edn, Cold Spring Harbour Press, New York. 
      420.   Sandberg, A. A. & Bridge, J.A. 2003, "Updates on the cytogenetics and molecular 
genetics of bone and soft tissue tumours: osteosarcoma and related tumours”, Cancer 
Genet Cytogenet., vol. 145, no. 1, pp. 1-30. 
 
  421.   Schmidt, E. V., Christoph, G., Zeller, R., & Leder, P. 1990, "The cytomegalovirus 
enhancer: a pan-active control element in transgenic mice", Mol Cell Biol., vol. 10, pp. 
4406-4411. 
  422.   Schuler, M., Herrmann, R., De Greve, J. L., Stewart, A. K., Gatzemeier, U., Stewart, 
D. J., Laufman, L., Gralla, R., Kuball, J., Buhl, R., Heussel, C. P., Kommoss, F., 
Perruchoud, A. P., Shepherd, F. A., Fritz, M. A., Horowitz, J. A., Huber, C., & 
Rochlitz, C. 2001, "Adenovirus-mediated wild-type p53 gene transfer in patients 
receiving chemotherapy for advanced non-small-cell lung cancer: results of a 
multicenter phase II study”, J Clin Oncol., vol. 19, no. 6, pp. 1750-1758. 
  423.   Searle, P. F., Chen, M. J., Hu, L., Race, P. R., Lovering, A. L., Grove, J. I., Guise, C., 
Jaberipour, M., James, N. D., Mautner, V., Young, L. S., Kerr, D. J., Mountain, A., 
White S.A., Hyde, E. I., &  2004, "Nitroreductase: a prodrug-activating enzyme for 
cancer gene therapy”, Clin Exp Pharmacol Physiol., vol. 31, no. 11, pp. 811-816. 
  424.   Senzer, N. & Nemunaitis, J. 2009, "A review of contusugene ladenovec (Advexin) p53 
therapy”, Curr Opin Mol Ther., vol. 11, no. 1, pp. 54-61. 
  425.   Seo, Y. R. & Jung, H. J. 2004, "The potential roles of p53 tumor suppressor in 
nucleotide excision repair (NER) and base excision repair (BER)”, Exp Mol Med., vol. 
36, no. 6, pp. 505-509. 
  426.   Seth, P., Brinkmann, U., Schwartz, G. N., Katayose, D., Gress, R., Pastan, I., & Cowan, 
K. 1996, "Adenovirus-mediated gene transfer to human breast tumor cells: an approach 
for cancer gene therapy and bone marrow purging", Cancer Res., vol. 56, no. 6, pp. 
1346-1351. 
  427.   Setoguchi, A., Okuda, M., Nishida, E., Yazawa, M., Ishizaka, T., Hong, S. H., Hisasue, 
M., Nishimura, R., Sasaki, N., Yoshikawa, H., Masuda, K., Ohno, K., & Tsujimoto, H. 
2001a, "Results of hyperamplification of centrosomes in naturally developing tumours 
of dogs", Am J Vet Res., vol. 62, no. 7, pp. 1134-1141. 
  428.   Setoguchi, A., Sakai, T., Okuda, M., Minehata, K., Yazawa, M., Ishizaka, T., Watari, T., 
Nishimura, R., Sasaki, N., Hasegawa, A., & Tsujimoto, H. 2001b, "Aberrations of the 
p53 tumour suppressor gene in various tumours in dogs", Am J Vet Res., vol. 62, no. 3, 
pp. 433-439. 
  429.   Shaulsky, G., Goldfinger, N., Ben Ze'ev, A., & Rotter, V. 1990, "Nuclear accumulation 
of p53 protein is mediated by several nuclear localization signals and plays a role in 
tumorigenesis", Mol Cell Biol., vol. 10, no. 12, pp. 6565-6577. 
  430.   Sherf, B. A., Navarro, S. L., Hannah, R. R., & Wood, K. V. 1996, "Dual-luciferase
TM 
Reporter Assay: An Advanced Co-Reporter Technology Integrating Firefly and Renilla 
Luciferase Assays", Promega Notes, vol. 57, pp. 2-8. 
  431.   Shieh, S. Y., Ikeda, M., Taya, Y., & Prives, C. 1997, "DNA damage-induced 
phosphorylation of p53 alleviates inhibition by MDM2", Cell, vol. 91, no. 3, pp. 325-
334. References 
 
269 
  432.   Shiomitsu, K., Sajo, E., Xia, X., Hunley, D. W., Mauldin, G. E., Li, S., & Mauldin, G. N. 
2008, "Radiosensitivity of canine osteosarcoma cells transfected with wild-type p53 in 
vitro”, Vet Comp Oncol., vol. 6, no. 3, pp. 193-200. 
  433.   Shirakawa, T., Ko, S.-C., Gardner, T. A., Cheon, J., Miyamoto, T., Gotoh, A., Chung, 
L. W. K., & Kao, C. 1998, "In vivo suppression of osteosarcoma pulmonary metastasis 
with intravenous osteocalcin promoter-based toxic gene therapy", Cancer Gene Ther., 
vol. 5, no. 5, pp. 274-280. 
  434.   Singleton, D. C., Li, D., Bai, S. Y., Syddall, S. P., Smaill, J. B., Shen, Y., Denny, W. A., 
Wilson, W. R., & Patterson, A. V. 2007, "The nitroreductase prodrug SN 28343 enhances 
the potency of systemically administered armed oncolytic adenovirus ONYX-411(NTR)”, 
Cancer Gene Ther., vol. 14, no. 12, pp. 953-967. 
  435.   Sjogren, S., Inganas, M., Norberg, T., Lindgren, A., Nordgren, H., & Bergh, J. 1996, 
"The p53 gene in breast cancer: prognostic value of complementary DNA sequencing 
versus immunohistochemistry", J Natl Cancer Inst., vol. 88, no. 3/4, pp. 173-182. 
  436.   Smith, B. F., Curiel, D. T., Ternovoi, V. V., Borovjagin, A. V., Baker, H. J., Cox, N., & 
Siegal, G. P. 2006, "Administration of a conditionally replicative oncolytic canine 
adenovirus in normal dogs”, Cancer Biother Radiopharm., vol. 21, no. 6, pp. 601-606. 
  437.   Solaroli, N., Johansson, M., Balzarini, J., & Karlsson, A. 2006, "Substrate specificity of 
three viral thymidine kinases (TK): vaccinia virus TK, feline herpesvirus TK, and canine 
herpesvirus TK”, Nucleosides Nucleotides Nucleic Acids, vol. 25, no. 9-11, pp. 1189-
1192. 
  438.   Song, S. U. & Boyce, F. M. 2001, "Combination treatment for osteosarcoma with 
baculoviral vector mediated gene therapy (p53) and chemotherapy (adriamycin)", Exp 
Mol Med., vol. 33, no. 1, pp. 46-53. 
  439.   Soussi, T. 2007, "p53 alterations in human cancer: more questions than answers”, 
Oncogene, vol. 26, no. 15, pp. 2145-2156. 
  440.   Soussi, T. & Beroud, C. 2001, "Assessing TP53 status in human tumours to evaluate 
clinical outcome", Nat Rev Cancer, vol. 1, no. 3, pp. 233-240. 
  441.   Soussi, T. & May, P. 1996, "Structural aspects of the p53 protein in relation to gene 
evolution: a second look", J Mol Biol., vol. 260, pp. 623-637. 
  442.   Spitz, F. R., Nguyen, D., Skibber, J. M., Meyn, R. E., Cristiano, R. J., & Roth, J. A. 
1996, "Adenoviral-mediated wild-type p53 gene expression sensitizes colorectal cancer 
cells to ionizing radiation", Clin Cancer Res., vol. 2, no. 10, pp. 1665-1671. 
  443.   Spodnick, G. J., Berg, J., Rand, W. M., Schelling, S. H., Couto, G., Harvey, J., 
Henderson, R. A., MacEwen, E. G., Mauldin, N., McCaw, D. L., Moore, A. S., Morrison, 
W., Norris, A. M., O'Bradovich, J., O'Keefe, D. A., Page, R., Ruslander, D., Klausner, J., 
Straw, R. C., Thompson, J. P., & Withrow, S. J. 1992, "Prognosis for dogs with 
appendicular osteosarcoma treated by amputation alone: 162 cases (1978-1988)", J Am 
Vet Med Assoc., vol. 200, no. 7, pp. 995-999. 
  444.   Stein, G. S., Lian, J. B., Stein, J. L., & van Wijnen, A. J. 2000, "Bone tissue specific 
transcriptional control: options for targeting gene therapy to the skeleton", Cancer, 
vol. 88, no. 12 Suppl, pp. 2899-2902. 
  445.   Stevenson, S. 1991, "Fracture-associated sarcomas", Vet Clin North Am Small Anim 
Pract., vol. 21, no. 4, pp. 859-872. 
  446.   Stoica, G., Kim, H. T., Hall, D. G., & Coates, J. R. 2004, "Morphology, 
immunohistochemistry, and genetic alterations in dog astrocytomas", Vet Pathol., vol. 
41, no. 1, pp. 10-19. References 
 
270 
  447.   Stommel, J. M., Marchenko, N. D., Jimenez, G. S., Moll, U. M., Hope, T. J., & Wahl, G. 
M. 1999, "A leucine-rich nuclear export signal in the p53 tetramerization domain: 
regulation of subcellular localization and p53 activity by NES masking", EMBO J., vol. 
18, no. 6, pp. 1660-1672. 
  448.   Strano, S., Dell'Orso, S., Di Agostino, S., Fontemaggi, G., Sacchi, A., & Blandino, G. 
2007, "Mutant p53: an oncogenic transcription factor”, Oncogene, vol. 26, no. 15, pp. 
2212-2219. 
  449.   Straw, R. C., LeCouteur, R. A., Powers, B. E., & Withrow, S. J. 1989, "Multilobular 
osteochondrosarcoma of the canine skull: 16 cases (1978-1988)", J Am Vet Med Assoc., 
vol. 195, no. 12, pp. 1764-1769. 
  450.   Straw, R. C., Powers, B. E., Klausner, J., Henderson, R. A., Morrison, WB, McCaw, D. 
L., Harvey, H. J., Jacobs, R. M., & Berg, R. J. 1996, "Canine mandibular osteosarcoma: 
51 cases (1980-1992)", J Am Anim Hosp Assoc., vol. 32, no. 3, pp. 257-262. 
  451.   Straw, R. C., Withrow, S. J., & Powers, B. E. 1990, "Management of canine 
appendicular osteosarcoma", Vet Clin North Am Small Anim Pract., vol. 20, no. 4, pp. 
1141-1161. 
  452.   Straw, R. C., Withrow, S. J., Richter, S. L., Powers, B. E., Klein, M. K., Postorino, N. 
C., Larue, S. M., Ogilvie, G. K., Vail, D. M., Morrison, W., McGee, M., & Dickinson, K. 
1991, "Amputation and cisplatin for treatment of canine osteosarcoma", J Vet Intern 
Med., vol. 5, pp. 205-210. 
  453.   Stubbert, L. J., Smith, J. M., Hamill, J. D., Arcand, T. L., & McKay, B. C. 2009, "The 
anti-apoptotic role for p53 following exposure to ultraviolet light does not involve 
DDB2”, Mutat Res., vol. 663, no. 1-2, pp. 69-76. 
  454.   Sunters, A., Baer, J., & Bagshawe, K. D. 1991, "Cytotoxicity and activation of CB1954 
in a human tumour cell line", Biochem Pharmacol., vol. 41, no. 9, pp. 1293-1298. 
  455.   Swisher, S. G., Roth, J. A., Komaki, R., Gu, J., Lee, J. J., Hicks, M., Ro, J. Y., Hong, 
W. K., Merritt, J. A., Ahrar, K., Atkinson, N. E., Correa, A. M., Dolormente, M., 
Dreiling, L., El-Naggar, A. K., Fossella, F., Francisco, R., Glisson, B., Grammer, S., 
Herbst, R., Huaringa, A., Kemp, B., Khuri, F. R., Kurie, J. M., Liao, Z., McDonnell, T. 
J., Morice, R., Morello, F., Munden, R., Papadimitrakopoulou, V., Pisters, K. M., 
Putnam, J. B., Sarabia, A. J., Shelton, T., Stevens, C., Shin, D. M., Smythe, W. R., 
Vaporciyan, A. A., Walsh, G. L., & Yin, M. 2003, "Induction of p53-regulated genes and 
tumor regression in lung cancer patients after intratumoral delivery of adenoviral p53 
(INGN 201) and radiation therapy”, Clin Cancer Res., vol. 9, no. 1, pp. 93-101. 
  456.   Swisher, S. G., Roth, J. A., Nemunaitis, J., Lawrence, D. D., Kemp, B. L., Carrasco, C. 
H., Connors, D. G., El-Naggar, A. K., Fossella, F., Glisson, B. S., Hong, W. K., Khuri, F. 
R., Kurie, J. M., Lee, J. J., Lee, J. S., Mack, M., Merritt, J. A., Nguyen, D. M., Nesbitt, 
J. C., Perez-Soler, R., Pisters, K. M., Putnam, J. B. Jr., Richli, W. R., Savin, M., 
Waugh, M. K., & et al., 1999, "Adenovirus-mediated p53 gene transfer in advanced 
non-small-cell lung cancer”, J Natl Cancer Inst., vol. 91, no. 9, pp. 763-771. 
  457.   Takahashi, H., Furusato, M., Allsbrook, W. C., Nishii, H., Wakui, S., Barrett, J. C., & 
Boyd, J. 1995, "Prevalence of androgen receptor gene mutations in latent prostatic 
carcinoma from Japanese men", Cancer Res., vol. 55, pp. 1621-1624. 
  458.   Tang, H. J., Qian, D., Sondak, V. K., Stachura, S., & Lin, J. 2004, "A modified p53 
enhances apoptosis in sarcoma cell lines mediated by doxorubicin”, Br J Cancer, vol. 
90, no. 6, pp. 1285-1292. 
  459.   Tang, N., Song, W. X., Luo, J., Haydon, R. C., & He, T. C. 2008, "Osteosarcoma 
development and stem cell differentiation”, Clin Orthop Relat Res., vol. 466, no. 9, 
pp. 2114-2130. References 
 
271 
  460.   Taubert, H., Meye, A., & Wurl, P. 1996, "Prognosis is correlated with p53 mutation 
type for soft tissue sarcoma patients", Cancer Res., vol. 56, pp. 4134-4136. 
  461.   Tennis, M., Krishnan, S., Bonner, M., Ambrosone, C. B., Vena, J. E., Moysich, K., 
Swede, H., McCann, S., Hall, P., Shields, P. G., & Freudenheim, J. L. 2006, "p53 
Mutation analysis in breast tumors by a DNA microarray method", Cancer Epidemiol 
Biomarkers Prev., vol. 15, no. 1, pp. 80-85. 
  462.   Ternovoi, V. V., Curiel, D. T., Smith, B. F., & Siegal, G. P. 2006, "Adenovirus-mediated 
p53 tumor suppressor gene therapy of osteosarcoma”, Lab Invest., vol. 86, no. 8, pp. 
748-766. 
  463.   Thamm, D. H., O'Brien, M. G., & Vail, D. M. 2008, "Serum vascular endothelial growth 
factor concentrations and postsurgical outcome in dogs with osteosarcoma”, Vet Comp 
Oncol., vol. 6, no. 2, pp. 126-132. 
  464.   Thavathiru, E. & Das, G. M. 2001, "Activation of pRL-TK by 12s E1A oncoprotein: 
drawbacks of using an internal reference reporter in transcription assays", 
Biotechniques, vol. 31, no. 3, pp. 528-530. 
  465.   The Journal of Gene Medicine Gene Therapy Clinical Trials Worldwide 2009, 
www.wiley.co.uk/genmed/clinical. 
  466.   Thirunavukkarasu, K., Miles, R. R., Halladay, D. L., & Onyia, J. E. 2000, "Cryptic 
enhancer elements in luciferase reporter vectors respond to the osteoblast-specific 
transcription factor Osf2/Cbfa1", Biotechniques, vol. 28, no. 3, pp. 506-510. 
  467.   Thomas, M., Pim, D., & Banks, L. 1999, "The role of the E6-p53 interaction in the 
molecular pathogenesis of HPV", Oncogene, vol. 18, pp. 7690-7700. 
  468.   Thomas, R., Duke, S. E., Karlsson, E. K., Evans, A., Ellis, P., Lindblad-Toh, K., 
Langford, C. F., & Breen, M. 2008, "A genome assembly-integrated dog 1 Mb BAC 
microarray: a cytogenetic resource for canine cancer studies and comparative genomic 
analysis”, Cytogenet Genome Res., vol. 122, no. 2, pp. 110-121. 
  469.   Thomas, R., Scott, A., Langford, C. F., Fosmire, S. P., Jubala, C. M., Lorentzen, T. D., 
Hitte, C., Karlsson, E. K., Kirkness, E., Ostrander, E. A., Galibert, F., Lindblad-Toh, K., 
Modiano, J. F., & Breen, M. 2005, "Construction of a 2-Mb resolution BAC microarray 
for CGH analysis of canine tumors", Genome Res., vol. 15, no. 12, pp. 1831-1837. 
  470.   Thomas, R., Wang, H. J., Tsai, P. C., Langford, C. F., Fosmire, S. P., Jubala, C. M., 
Getzy, D. M., Cutter, G. R., Modiano, J. F., & Breen, M. 2009, "Influence of genetic 
background on tumor karyotypes: evidence for breed-associated cytogenetic 
aberrations in canine appendicular osteosarcoma”, Chromosome Res., vol. 17, no. 3, 
pp. 365-377. 
  471.   Thomas, R. K., Nickerson, E., Simons, J. F., Janne, P. A., Tengs, T., Yuza, Y., 
Garraway, L. A., LaFramboise, T., Lee, J. C., Shah, K., O'Neill, K., Sasaki, H., 
Lindeman, N., Wong, K. K., Borras, A. M., Gutmann, E. J., Dragnev, H., DeBiasi, R., 
Chen, T. H., Glatt, K. A., Greulich, H., Desany, B., Lubeski, C. K., Brockman, W., 
Alvarez, P., Hutchison, S. K., Leamon, J. H., Ronan, M. T., Turenchalk, G. S., Egholm, 
M., Sellers, W. R., Rothberg, J. M., & Meyerson, M. 2006, "Sensitive mutation detection 
in heterogeneous cancer specimens by massively parallel picoliter reactor sequencing", 
Nat Med., vol. 12, no. 7, pp. 852-855. 
  472.   Thorstensen, K. & Romslo, I. 1993, "The transferrin receptor: its diagnostic value and 
its potential as therapeutic target”, Scand J Clin Lab Invest Suppl., vol. 215, pp. 113-
120. References 
 
272 
  473.   Thurman, G. B., Mays, C. W., Taylor, G. N., Keane, A. T., & Sissons, H. A. 1973, 
"Skeletal location of radiation-induced and naturally occurring osteosarcomas in man 
and dog", Cancer Res., vol. 33, no. 7, pp. 1604-1607. 
  474.   Tjalma, R. A. 1966, "Canine bone sarcoma: estimation of relative risk as a function of 
body size", J Natl Cancer Inst., vol. 36, no. 6, pp. 1137-1150. 
  475.   Toguchida, J. & Nakayama, T. 2009, "Molecular genetics of sarcomas: Applications to 
diagnoses and therapy”, Cancer Sci., Epub ahead of print. 
  476.   Toguchida, J., Yamaguchi, T., Ritchie, B., Beauchamp, R. L., Dayton, S. H., Herrera, 
GE, Yamamuro, T., Kotoura, Y., Sasaki, M. S., & Little, J. B. 1992, "Mutation spectrum 
of the p53 gene in bone and soft tissue sarcomas", Cancer Res., vol. 52, no. 22, pp. 
6194-6199. 
  477.   Tomlin, J. L., Sturgeon, C., Pead, M. J., & Muir, P. 2000, "Use of the bisphosphonate 
drug alendronate for palliative management of osteosarcoma in two dogs”, Vet 
Record, vol. 147, no. 5, pp. 129-132. 
  478.   Tornaletti, S. & Pfeifer, G. P. 1995, "Complete and tissue-independent methylation of 
CpG sites in the p53 gene: implications for mutations in human cancers", Oncogene, 
vol. 10, pp. 1493-1499. 
  479.   Toyota, H., Kondo, S., Kyo, S., & Mizuguchi, J. 2006, "Enforced expression of a 
truncated form of Bax-alpha (tBax) driven by human telomerase reverse transcriptase 
(hTERT) promoter sensitizes tumor cells to chemotherapeutic agents or tumor necrosis 
factor-related apoptosis-inducing ligand (TRAIL)", Anticancer Res., vol. 26, no. 1A, pp. 
99-105. 
  480.   Trotman, L. C. & Pandolfi, P. P. 2003, "PTEN and p53: Who will get the upper hand?", 
Cancer Cell, vol. 3, no. 2, pp. 97-99. 
  481.   Tsuchiya, H., Mori, Y., Ueda, Y., Okada, G., & Tomita, K. 2000, "Sensitization and 
caffeine potentiation of cisplatin cytotoxicity resulting from introduction of wild-type 
p53 gene in human osteosarcoma", Anticancer Res., vol. 20, no. 1A, pp. 235-242. 
  482.   Tsujii, H., Kawaguchi, S., Wada, T., Nagoya, S., Inobe, M., Yagita, H., Okumura, K., 
Yamashita, T., & Uede, T. 2003, "Concurrent induction of T-cell activation and 
apoptosis of osteosarcoma cells by adenovirus-mediated B7-1/Fas chimeric gene 
transfer", Cancer Gene Ther., vol. 10, no. 9, pp. 717-725. 
  483.   Tsujii, H., Kawaguchi, S., Wada, T., Nagoya, S., Inobe, M., Yamashita, T., Ishii, S., & 
Uede, T. 2002, "Adenovirus-mediated in vivo B7-1 gene transfer induces anti-tumor 
immunity against pre-established primary tumor and pulmonary metastasis of rat 
osteosarcoma", Cancer Gene Ther., vol. 9, no. 9, pp. 747-755. 
  484.   Ueda, Y., Roessner, A., & Grundmann, E. 1993, "Pathological diagnosis of 
osteosarcoma: the validity of the subclassification and some new diagnostic 
approaches using immunohistochemistry", Cancer Treat Res., vol. 62, pp. 109-124. 
  485.   unknown 2007, "INGN 201: Ad-p53, Ad5CMV-p53, adenoviral p53, p53 gene therapy--
introgen, RPR/INGN 201”, Drugs R D., vol. 8, no. 3, pp. 176-187. 
  486.   Urfer, S. R., Gaillard, C., & Steiger, A. 2007, "Lifespan and disease predispositions in 
the Irish Wolfhound: a review”, Vet Q., vol. 29, no. 3, pp. 102-111. 
  487.   US National Institutes of Health 2009, "ClinicalTrials.gov", http://clinicaltrials.gov/. 
  488.   Van Leeuwen, I. S., Cornelisse, C. J., Misdorp, W., Goedegebuure, S. A., Kirpensteijn, 
J., & Rutteman, G. R. 1997, "P53 gene mutations in osteosarcomas in the dog", Cancer 
Lett., vol. 111, no. 1-2, pp. 173-178. References 
 
273 
  489.   Van Leeuwen, I. S., Hellmen, E., Cornelisse, C. J., Van den, B. B., & Rutteman, G. R. 
1996, "P53 mutations in mammary tumor cell lines and corresponding tumor tissues in 
the dog", Anticancer Res., vol. 16, no. 6B, pp. 3737-3744. 
  490.   van Ommen, G. J., Bakker, E., & den Dunnen, J. T. 1999, "The human genome project 
and the future of diagnostics, treatment, and prevention", Lancet, vol. 354, no. 
Suppl.1, p. SI5-SI10. 
  491.   Vass, S. O., Jarrom, D., Wilson, W. R., Hyde, E. I., & Searle, P. F. 2009, "E. coli NfsA: 
an alternative nitroreductase for prodrug activation gene therapy in combination with 
CB1954”, Br J Cancer, vol. 100, no. 12, pp. 1903-1911. 
  492.   Vassilev, L. T., Vu, B. T., Graves, B., Carvajal, D., Podlaski, F., Filipovic, Z., Kong, N., 
Kammlott, U., Lukacs, C., Klein, C., Fotouhi, N., & Liu, E. A. 2004, "In vivo activation 
of the p53 pathway by small-molecule antagonists of MDM2”, Science, vol. 303, no. 
5659, pp. 844-848. 
  493.   Vazquez, A., Bond, E. E., Levine, A. J., & Bond, G. L. 2008, "The genetics of the p53 
pathway, apoptosis and cancer therapy”, Nat Rev Drug Discov., vol. 7, no. 12, pp. 979-
987. 
  494.   Vecil, G. G. & Lang, F. F. 2003, "Clinical trials of adenoviruses in brain tumors: a 
review of Ad-p53 and oncolytic adenoviruses”, J Neurooncol., vol. 65, no. 3, pp. 237-
246. 
  495.   Veldhoen, N. & Milner, J. 1998, "Isolation of canine p53 cDNA and detailed 
characterization of the full length canine p53 protein", Oncogene, vol. 16, pp. 1077-
1084. 
  496.   Veldhoen, N., Watterson, J., Brash, M., & Milner, J. 1999, "Identifications of tumour-
associated and germ line p53 mutations in canine mammary cancer", Br J Cancer, vol. 
81, no. 3, pp. 409-415. 
  497.   Vogelstein, B., Lane, D., & Levine, A. J. 2000, "Surfing the p53 network”, Nature, vol. 
408, no. 6810, pp. 307-310. 
  498.   Vousden, K. H. 2006, "Outcomes of p53 activation--spoilt for choice”, J Cell Sci., vol. 
119, no. Pt 24, pp. 5015-5020. 
  499.   Vousden, K. H. & Lane, D. P. 2007, "p53 in health and disease”, Nat Rev Mol Cell Biol., 
vol. 8, no. 4, pp. 275-283. 
  500.   Wadler, S., Makower, D., Yu, B., Tan, J. Y., Rozenblit, A., Kaufman, H., Edelman, M., 
Lane, M. E., & Zwiebel, J. 2002, "Clinical applications of p53-directed gene therapy”, 
Suppl Tumori, vol. 1, no. 6, p. S21. 
  501.   Walker, D. R., Bond, J. P., Tarone, R. E., Harris, C. C., Makalowski, W., Boguski, M. S., 
& Greenblatt, M. S. 1999, "Evolutionary conservation and somatic mutation hotspots 
maps of p53: correlation with p53 protein structural and functional features", 
Oncogene, vol. 18, no. 1, pp. 211-218. 
  502.   Walker, K. K. & Levine, A. J. 1996, "Identification of a novel p53 functional domain 
that is necessary for efficient growth suppression", Proc Natl Acad Sci USA., vol. 93, 
no. 26, pp. 15335-15340. 
  503.   Wallace, J., Matthiesen, D. T., & Patnaik, A. K. 1992, "Hemimaxillectomy for the 
treatment of oral tumors in 69 dogs”, Vet Surg., vol. 21, no. 5, pp. 337-341. 
  504.   Wallack, S. T., Wisner, E. R., Werner, J. A., Walsh, P. J., Kent, M. S., Fairley, R. A., & 
Hornof, W. J. 2002, "Accuracy of magnetic resonance imaging for estimating References 
 
274 
intramedullary osteosarcoma extent in pre-operative planning of canine limb-salvage 
procedures”, Vet Radiol Ultrasound., vol. 43, no. 5, pp. 432-441. 
  505.   Walter, C. U., Dernell, W. S., Larue, S. M., Lana, S. E., Lafferty, M. H., LaDue, T. A., 
& Withrow, S. J. 2005a, "Curative-intent radiation therapy as a treatment modality for 
appendicular and axial osteosarcoma: a preliminary retrospective evaluation of 14 dogs 
with the disease", Vet Comp Oncol., vol. 3, pp. 1-7. 
  506.   Walter, K., Warnecke, G., Bowater, R., Deppert, W., & Kim, E. 2005b, "Tumor 
suppressor p53 binds with high affinity to CTG.CAG trinucleotide repeats and induces 
topological alterations in mismatched duplexes”, J Biol Chem., vol. 280, no. 52, pp. 
42497-42507. 
  507.   Wang, W., Rastinejad, F., & El-Deiry, W. S. 2003, "Restoring p53-dependent tumor 
suppression”, Cancer Biol Ther., vol. 2, no. 4 Suppl 1, p. S55-S63. 
  508.   Wang, Y. H., Wang, Z. X., Qiu, Y., Xiong, J., Chen, Y. X., Miao, D. S., & De, W. 2009, 
"Lentivirus-mediated RNAi knockdown of insulin-like growth factor-1 receptor inhibits 
growth, reduces invasion, and enhances radiosensitivity in human osteosarcoma cells”, 
Mol Cell Biochem., vol. 327, no. 1-2, pp. 257-266. 
  509.   Watanabe, T. & Sullenger, B. A. 2000, "Induction of wild-type p53 activity in human 
cancer cells by ribozymes that repair mutant p53 transcripts", Proc Natl Acad Sci USA., 
vol. 97, no. 15, pp. 8490-8494. 
  510.   Weedon, S. J., Green, N. K., McNeish, I. A., Gilligan, M. G., Mautner, V., Wrighton, C. 
J., Mountain, A., Young, L. S., Kerr, D. J., & Searle, P. F. 2000, "Sensitisation of 
human carcinoma cells to the prodrug CB1954 by adenovirus vector-mediated 
expression of E.coli nitroreductase", Int J Cancer, vol. 86, no. 6, pp. 848-854. 
  511.   Wen, S. F., Mahavni, V., Quijano, E., Shinoda, J., Grace, M., Musco-Hobkinson, M. L., 
Yang, T. Y., Chen, Y., Runnenbaum, I., Horowitz, J., Maneval, D., Hutchins, B., & 
Buller, R. 2003, "Assessment of p53 gene transfer and biological activities in a clinical 
study of adenovirus-p53 gene therapy for recurrent ovarian cancer", Cancer Gene 
Ther., vol. 10, no. 3, pp. 224-238. 
  512.   Wergin, M. C. & Kaser-Hotz, B. 2004, "Plasma vascular endothelial growth factor 
(VEGF) measured in seventy dogs with spontaneously occurring tumours”, In Vivo, vol. 
18, no. 1, pp. 15-19. 
  513.   White, C. L., Menghistu, T., Twigger, K. R., Searle, P. F., Bhide, S. A., Vile, R. G., 
Melcher, A. A., Pandha, H. S., & Harrington, K. J. 2008, "Escherichia coli 
nitroreductase plus CB1954 enhances the effect of radiotherapy in vitro and in vivo”, 
Gene Ther., vol. 15, no. 6, pp. 424-433. 
  514.   Wikman, F. P., Lu, M. L., Thykjaer, T., Olesen, S. H., Andersen, L. D., Cordon-Cardo, 
C., & Orntoft, T. F. 2000, "Evaluation of the performance of a p53 sequencing 
microarray chip using 140 previously sequenced bladder tumor samples", Clin Chem., 
vol. 46, no. 10, pp. 1555-1561. 
  515.   Wills, K. N., Maneval, D. C., Menzel, P., Harris, M. P., Sutjipto, S., Vaillancourt, M. T., 
Huang, W. M., Johnson, D. E., Anderson, S. C., Wen, S. F., Bookstein, R., Shepard, H. 
M., & Gregory, R. J. 1994, "Development and characterization of recombinant 
adenoviruses encoding human p53 for gene therapy of cancer", Hum Gene Ther., vol. 
5, no. 9, pp. 1079-1088. 
  516.   Wilson, D. R. 2002, "Viral-mediated gene transfer for cancer treatment”, Curr Pharm 
Biotechnol., vol. 3, no. 2, pp. 151-164. References 
 
275 
  517.   Wilson, H., Huelsmeyer, M. K., Chun, R., Young, K. M., Friedrichs, K., & Argyle, D. J. 
2008, "Isolation and characterisation of cancer stem cells from canine osteosarcoma”, 
Vet J., vol. 175, no. 1, pp. 69-75. 
  518.   Winiarczyk, S., Gradski, Z., Kosztolich, B., Gabler, C., Konig, G., Renner, M., Saller, R. 
M., Prosl, H., Salmons, B., Gunzburg, W. H., & Hain, J. 2002, "A clinical protocol for 
treatment of canine mammary tumors using encapsulated, cytochrome P450 
synthesizing cells activating cyclophosphamide: a phase I/II study", J Mol Med., vol. 
80, no. 9, pp. 610-614. 
  519.   Withrow, S. J., Powers, B. E., Straw, R. C., & Wilkins, R. M. 1991, "Comparative 
aspects of osteosarcoma", Clin Orthop Relat Res., vol. 270, pp. 159-180. 
  520.   Witlox, M. A., Lamfers, M. L., Wuisman, P. I., Curiel, D. T., & Siegal, G. P. 2007, 
"Evolving gene therapy approaches for osteosarcoma using viral vectors: review”, 
Bone, vol. 40, no. 4, pp. 797-812. 
  521.   Witlox, M. A., Van Beusechem, V. W., Grill, J., Haisma, H. J., Schaap, G., Bras, J., Van 
Diest, P., De Gast, A., Curiel, D. T., Pinedo, H. M., Gerritsen, W. R., & Wuisman, P. I. 
J. M. 2002, "Epidermal growth factor receptor targeting enhances adenoviral vector 
based suicide gene therapy of osteosarcoma", J Gene Med., vol. 4, no. 5, pp. 510-516. 
  522.   Wolfe, L. G., Oliver, J. L., Smith, B. B., Toivio-Kinnucan, M. A., Powers, R. D., 
Brawner, W. R., Henderson, R. A., & Hankes, G. H. 1987, "Biologic characterization of 
canine melanoma cell lines", Am J Vet Res., vol. 48, no. 11, pp. 1642-1648. 
  523.   Wolfesberger, B., Tonar, Z., Gerner, W., Skalicky, M., Heiduschka, G., Egerbacher, M., 
Thalhammer, J. G., & Walter, I. 2009, "The tyrosine kinase inhibitor sorafenib 
decreases cell number and induces apoptosis in a canine osteosarcoma cell line”, Res 
Vet Sci., Aug 6, Epub ahead of print. 
  524.   Wolkowicz, R. & Rotter, V. 1997, "The DNA binding regulatory domain of p53: see the 
C”, Pathol Biol (Paris)., vol. 45, no. 10, pp. 785-796. 
  525.   Wood, K. V. 1998, "The chemistry of bioluminescent reporter assays", Promega Notes, 
vol. 65, pp. 14-20. 
  526.   Wood, S. A. 2002, "Dubble or nothing? Is HAUSP deubiquitylating enzyme the final 
arbiter of p53 levels?", Sci STKE., vol. 143, p. PE34. 
  527.   Workman, P., Morgan, J. E., Talbot, K., Wright, K. A., Donaldson, J., & Twentyman, P. 
R. 1986a, "CB 1954 revisited. II. Toxicity and antitumour activity", Cancer Chemother 
Pharmacol., vol. 16, no. 1, pp. 9-14. 
  528.   Workman, P., White, R. A., & Talbot, K. 1986b, "CB 1954 revisited. I. Disposition 
kinetics and metabolism", Cancer Chemother Pharmacol., vol. 16, no. 1, pp. 1-8. 
  529.   Wrigley, R. H. 2000, "Malignant versus nonmalignant bone disease”, Vet Clin North Am 
Small Anim Pract., vol. 30, no. 2, pp. 315-347. 
  530.   Wynford-Thomas, D. 1992, "P53 in tumour pathology: can we trust 
immunocytochemistry?", J Pathol., vol. 166, no. 4, pp. 329-330. 
  531.   Xu, L., Pirollo, K. F., & Chang, E. H. 1997, "Transferrin-liposome-mediated p53 
sensitization of squamous cell carcinoma of the head and neck to radiation in vitro”, 
Hum Gene Ther., vol. 8, no. 4, pp. 467-475. 
  532.   Xu, L., Pirollo, K. F., & Chang, E. H. 2001a, "Tumour-targeted p53-gene therapy 
enhances the efficacy of conventional chemo/radiotherapy", J Control Release, vol. 
74, pp. 115-128. References 
 
276 
  533.   Xu, L., Tang, W. H., Huang, C. C., Alexander, W., Xiang, L. M., Pirollo, K. F., Rait, A., 
& Chang, E. H. 2001b, "Systemic p53 gene therapy of cancer with immunolipoplexes 
targeted by anti-transferrin receptor scFv”, Mol Med., vol. 7, no. 10, pp. 723-734. 
  534.   Yamaguchi, T., Toguchida, J., Yamamuro, T., Kotoura, Y., Takada, N., Kawaguchi, N., 
Kaneko, Y., Nakamura, Y., Sasaki, M. S., & Ishizaki, K. 1992, "Allelotype analysis in 
osteosarcomas: frequent allele loss on 3q, 13q, 17p, and 18q", Cancer Res., vol. 52, 
no. 9, pp. 2419-2423. 
  535.   Yamashita, A., Maruo, K., Suzuki, K., Shirota, K., Kobayashi, K., & Hioki, K. 2001, 
"Experimental chemotherapy against canine mammary cancer xenograft in SCID mice 
and its prediction of clinical effect", J Vet Med Sci., vol. 63, no. 8, pp. 831-836. 
  536.   Yazawa, M., Okuda, M., Kanaya, N., Hong, S. H., Takahashi, T., Ohashi, E., Nakagawa, 
T., Nishimura, R., Sasaki, N., Masuda, K., Ohno, K., & Tsujimoto, H. 2003a, "Molecular 
cloning of the canine telomerase reverse transcriptase gene and its expression in 
neoplastic and non-neoplastic cells", Am J Vet Res., vol. 64, no. 11, pp. 1395-1400. 
  537.   Yazawa, M., Setoguchi, A., Hong, S. H., Uyama, R., Nakagawa, T., Kanaya, N., 
Nishimura, R., Sasaki, N., Masuda, K., Ohno, K., & Tsujimoto, H. 2003b, "Effect of an 
adenoviral vector that expresses the canine p53 gene on cell growth of canine 
osteosarcoma and mammary adenocarcinoma cell lines", Am J Vet Res., vol. 64, no. 7, 
pp. 880-888. 
  538.   Yoshida, T., Yoshino, J., Hayashi, M., & Saruta, T. 2002, "Identification of a renal 
proximal tubular cell-specific enhancer in the mouse 25-hydroxyvitamin d 1alpha-
hydroxylase gene", J Am Soc Nephrol., vol. 13, no. 6, pp. 1455-1463. 
  539.   Yotnda, P., Chen, D. H., Chiu, W., Piedra, P. A., Davis, A., Templeton, N. S., & 
Brenner, M. K. 2002, "Bilamellar cationic liposomes protect adenovectors from 
preexisting humoral immune responses", Mol Ther., vol. 5, no. 3, pp. 233-241. 
  540.   Zachos, T. A., Aiken, S. W., DiResta, G. R., & Healey, J. H. 2001, "Interstitial fluid 
pressure and blood flow in canine osteosarcoma and other tumors”, Clin Orthop Relat 
Res., vol. 385, pp. 230-236. 
  541.   Zakut-Houri, R., Bienz-Tadmor, B., Givol, D., & Oren, M. 1985, "Human p53 cellular 
tumor antigen: cDNA sequence and expression in COS cells", EMBO J., vol. 4, no. 5, pp. 
1251-1255. 
  542.   Zambetti, G. & Levine, A. J. 1993, "A comparison of the biological activities of wild-
type and mutant p53", FASEB J., vol. 7, no. 10, pp. 855-865. 
  543.   Zeimet, A. G. & Marth, C. 2003, "Why did p53 gene therapy fail in ovarian cancer?", 
Lancet Oncol., vol. 4, no. 7, pp. 415-422. 
  544.   Zhang, J., Chen, X., Kent, M. S., Rodriguez, C. O., & Chen, X. 2009, "Establishment of 
a dog model for the p53 family pathway and identification of a novel isoform of p21 
cyclin-dependent kinase inhibitor”, Mol Cancer Res., vol. 7, no. 1, pp. 67-78. 
  545.   Zhang, S. W., Xiao, S. W., Liu, C. Q., Sun, Y., Su, X., Li, D. M., Xu, G., Cai, Y., Zhu, G. 
Y., Xu, B., & Lu, Y. Y. 2003, "Treatment of head and neck squamous cell carcinoma by 
recombinant adenovirus-p53 combined with radiotherapy: a phase II clinical trial of 42 
cases", Zhonghua Yi Xue Za Zhi, vol. 83, no. 23, pp. 2023-2028. 
  546.   Zhu, J., Gao, B., Zhao, J., & Balmain, A. 2000, "Targeting gene expression to tumour 
cells with loss of wild-type p53 function", Cancer Gene Ther., vol. 7, no. 1, pp. 4-12. 
      547.  Zhuang, Y., Butler, B., Hawkins, E., Paguio, A., Orr, L., Wood, M. G., & Wood, K. V. 
2001, "A new age of enlightenment: new synthetic Renilla gene assay system increase 
expression reliability and sensitivity", Promega Notes, vol. 79, pp. 6-11.  
 
277 
 
Appendices Appendix A: Solutions & General Reagents 
 
278 
Appendix A: Solutions & general reagents  
 
CB1954: 10mM solution in DMSO, prepared immediately prior to use. Kindly 
donated by Dr. N. Keith, University of Glasgow, following manufacture by Cobra 
Therapeutics, University of Keele. Supplied as a powder and stored at 4
oC. 
DNA Size Marker: 100-2072 bp DNA ladder consisting of 15 blunt-ended DNA 
fragments from 100-1500 bp at 100 bp increments and an additional fragment at 
2072 bp. 3-5g loaded per lane. 
E. coli NTR enzyme: Donated by Dr. G. Anlezark, Porton Down, Salisbury 
(Anlezark et al., 1995). Supplied as a 1x stock solution and stored at 4
oC.   
HiFCS: Heated at 56
oC for 30 minutes and then stored in 50ml aliquots at -20
oC 
(GIBCO BRL). 
Freezing Media: 40% medium without antibiotics, 50% FCS and 10% dimethyl 
sulphoxide (DMSO). Prepared immediately before use. 
Gel loading buffer: 0.25% bromophenol blue, 30% glycerol and 70% TE buffer 
(2.1.8 xix). Stored at RT. 
Laemmli Running buffer: 0.025M Trizma base, 0.192M glycine, 0.1% sodium 
dodecyl sulphate (SDS). Stored at RT. 
Low DNA Mass Marker: 6 blunt-ended DNA fragments of 2000, 1200, 800, 400, 
200 and 100 bp, electrophoresis of 4l, gives bands containing 200, 120, 80, 40, 
20 and 10 ng DNA, respectively. Mixed 4:1 (v:v) with gel loading buffer.  
Lysis Buffer for DNA Extractions (300ml): 3ml of 0.5M EDTA, 30ml of 10% SDS, 
6ml of 2.5M NaCl, 15ml of 1M Tris pH 8.0, 4.7ml of Proteinase K (20mg/ml; 
Roche) and 241.3ml of sterile H2O. Made immediately prior to use. 
NADH: 50mM solution prepared immediately before use in PBS, kept on ice and 
used at 100M in cell culture medium. Supplied as a powder (Sigma) and stored 
at 4
oC. Appendix A: Solutions & General Reagents 
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NFZ: 1M solution in DMSO made immediately before use (Sigma).  
PBS: Each sachet of dry powder (Sigma) produces 1 litre of PBS pH 7.4, 
containing NaCl (120mM), KCl (2.7mM) and phosphate buffer salts (10mM).   
Protein ladder: Pre-stained PAGE standards low range: phosphorylase B 113kDa; 
BSA 82kDa; ovalbumin 52.4kDa; carbonic anhydrase 36.2kDa; soybean trypsin 
inhibitor 29.6kDa; lysozyme 20.3kDa.  
Protein treatment sample buffer (2x): 0.125M Tris-Cl, 4% SDS, 20% glycerol, 
0.2M dithiothreitol, 4% bromophenol blue. Stored at -20
oC for up to 6 months. 
Protein transfer buffer: 0.016M Trizma base, 0.12M glycine. Stored at RT. 
TAE (50x): 2M Tris-HCl pH 8.15, 1.5M NaOAc, 1M NaCl and 0.1M EDTA. Stored at 
RT. 
TBE (10x): 0.9M Tris-HCl, 0.9M Boric acid and 25mM EDTA, pH 8.3. Stored at RT. 
TE buffer (10x): 10mM Tris-HCl and 1mM disodium EDTA, pH 8.0. Stored at RT.  
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Appendix B: Bacterial strains, culture media & antibiotics  
 
E. coli DH5Subcloning MAX Efficiency DH5 Competent Cells, F
- 
80dlacZM15 (lacZYA-argF)U169 deoR recA1 endA1 hsdR17(rK
-, mK
+) phoA 
supE44 
- thi-1 gyrA96 relA1 (GIBCO BRL). The 80dlacZM15 marker provides -
complementation of vectors containing the -gal gene. Used for blue/white 
colony screening on plates containing X-gal. 
E. coli JM109: Subcloning JM109 High Efficiency Competent Cells, endA1, recA1, 
gyrA96, thi, hsdR17 (rK
-, mK
+), relA1, supE44, (lac-proAB), [F‟, traD36, proAB, 
lacI
qZM15] (Promega). Used for blue/white screening with IPTG and X-gal. 
E. coli TOP10: Subcloning One Shot
TM TOP10 Competent Cells, F
- mcrA (mrr-
hsdRMS-mcrBC) 80dlacZM15 lacX74 recA1 deoR araD139 d(ara-leu)7697 galU 
galK rpsL (Str
R) endA1 nupG (Invitrogen). Used for blue/white screening with X-
gal.  
IPTG: 100mM solution in ddH2O and stored at -20oC in the dark. 40l applied to 
LB agar plate and spread evenly (in addition to X-gal), then incubated at 37oC 
for ~30 minutes prior to bacteria being plated out. Supplied as a powder (Sigma) 
and stored at 4oC. 
X-gal: 50mg/ml solution in dimethylformamide and stored at -20
oC in the dark. 
30l applied to LB agar plate and spread evenly, then incubated at 37
oC for ~30 
minutes prior to bacteria being plated out. Supplied as a powder (Sigma) and 
stored at -20
oC.  
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Appendix C: Vector maps  
 
 
 
Figure C1: pCR
®2.1-TOPO
®. Plasmid vector (lacZ
+, amp
r, kan
r) with single 3‟-
thymidine overhangs for TA Cloning
® and Topoisomerase I covalently bound to 
the vector for direct ligation of PCR products (Invitrogen). This is because 
thermostable enzymes, such as Taq polymerase, possess template independent 
terminal transferase activity, which adds a single deoxyadenosine to the 3‟-ends 
of PCR products. Multiple cloning sites, T7 promoter/priming site, M13 forward 
and reverse primer annealing sites, pUC origin and f1 origin are present.  
 
 
 
Figure C2: pTargeT
TM Mammalian Expression Vector. A linearised plasmid 
vector (lacZ
+, amp
r, Neo) which facilitates the direct insertion of PCR products 
by possessing single 3‟-thymidine overhangs that can be ligated to the single 
deoxyadenosine at the 3‟-ends of PCR products introduced by thermostable 
enzymes (Promega). Multiple cloning sites, CMV intermediate early 
enhancer/promoter (IE) region, SV40 late poly(A) signal and T7 
promoter/priming site are present.  Appendix C: Vector Maps 
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Figure C3: pHybLex/Zeo. A plasmid vector (Zeocin
®) containing a multiple 
cloning site upstream of an open reading frame for a LexA DNA binding domain 
(Invitrogen). pHybLex/Zeo is designed to express LexA fusion bait proteins and 
can be used with vectors containing LexA operator-based reporters. ADH 
promoter, ADH transcription termination region (ADH TT), 2 origin of 
replication (2  ori), TEF1 promoter (PTEF1), EM-7 promoter (PEM-7), CYC1 
transcription termination region (CYC1) and pUC origin of replication (pUC ori) 
are present.  
 
 
 
Figure C4: pSH18-34. A pRB322-derived reporter plasmid (lacZ
+, amp
r) 
possessing 8 LexA operator sites which allow the transcriptional activation of the 
lacZ gene by LexA-containing bait plasmids (e.g. pHybLex/Zeo), that facilitate 
the detection of LexA-mediated protein-protein interactions (Invitrogen). URA3 
gene (URA3), 2 origin of replication (2  ori) and pUC origin of replication (pUC 
ori) are present.   
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Figure C5: pGL3 Luciferase Reporter Vectors. 4 plasmid vectors, pGL3-Basic, 
pGL3-Enhancer, pGL3-Promoter and pGL3-Control, which enable the quantitative 
analysis of factors that potentially regulate mammalian gene expression 
(Promega). They are structurally identical, each containing cDNA encoding the 
modified firefly luciferase enzyme (luc+), gene conferring ampicillin resistance 
in E. coli (Amp
r), origin of replication in E. coli (f1 ori), origin of plasmid 
replication in E. coli (ori), multiple cloning sites and SV40 late poly(A) signal, 
except for the inclusion/exclusion of SV40 promoter and enhancer sequences: 
(i), pGL3-Basic – lacks the SV40 promoter and enhancer sequences; 
(ii), pGL3-Enhancer – contains the SV40 enhancer located downstream of luc+; 
(iii), pGL3-Promoter – possesses the SV40 promoter upstream of luc+; 
(iv), pGL3-Control – contains the SV40 promoter and enhancer sequences 
upstream and downstream of luc+, respectively, which result in the strong 
expression of luc+ in many types of mammalian cell types. This plasmid is useful 
for monitoring transfection efficiency and provides an internal standard for 
promoter and enhancer activities expressed by pGL3 recombinants. 
Arrows within the luc+ and Amp
r genes indicate the direction of transcription 
and the arrow in the f1 ori indicates the direction of ssDNA strand synthesis 
(Promega Corporation 1999).  
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Figure C6: pRL Reporter Vectors. 2 plasmid vectors, pRL-TK and pRL-CMV, each 
possessing cDNA encoding Renilla luciferase enzyme (Rluc), SV40 late poly(A) 
signal, gene conferring ampicillin resistance in E. coli (Amp
r), origin of plasmid 
replication in E. coli (ori) and position of intron (_/\_) (Promega). They are 
isolated from a dam/dcm
- E. coli K host strain to enable digestion with restriction 
enzymes that are sensitive to dam and dcm methylation. The pRL vectors are 
intended for use as internal control reporters and so may be used in combination 
with any experimental reporter vector to co-transfect mammalian cells.  pRL-TK 
and pRL-CMV are structurally identical except for different promoter sequences 
located upstream of the Rluc reporter gene: 
(i), pRL-TK - contains the herpes simplex virus thymidine kinase (HSV-TK) 
promoter region which provides a low to moderate level, constitutive expression 
of the Rluc reporter in co-transfected mammalian cells from both embryonic and 
mature mammalian tissues (GenBank Accession No. AF025846);  
(ii), pRL-CMV - possesses the cytomegalovirus (CMV) intermediate early 
enhancer/promoter that provides a strong, constitutive expression of Rluc in a 
variety of cell types, e.g. the transcriptional activity of the CMV intermediate 
early enhancer/promoter has been observed in transgenic mice, where its 
transcriptional activity was observed in 24 of the 28 murine tissues examined 
(Schmidt et al., 1990). Arrows within the Rluc and Amp
r genes indicate the 
direction of transcription (Promega Corporation 2001; Sherf et al., 1996). 
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Figure C7: pBLCAT6. A pUC18-derived plasmid (amp
r) which contains the 
reporter gene chloramphenicol acetyl transferase (cat), -lactamase gene (bla), 
multiple cloning sites, SV40 small t intron sequence (SV40) and SV40 
polyadenylation (poly(A)) signals (black boxes, AAUAAA) (GenBank Accession No. 
M80484). The multiple cloning sites are upstream and downstream of the cat 
gene and the SV40 small t intron is downstream of the cat gene (Boshart et al., 
1992; Luckow & Schutz 1987). Arrows outside the cat and bla genes indicate the 
direction of transcription (Boshart et al., 1992). Kindly donated by Dr. L. 
Blackwood. This plasmid has been designed for the analysis of promoter and 
enhancer sequences in mammalian cells (Boshart et al., 1992; Luckow & Schutz 
1987). Appendix C: Vector Maps 
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Figure C8: pCMVNTR. A pCMVCAT6-derived plasmid which contains the E.coli B 
nitroreductase (NTR) gene, instead of the CAT gene, under the control of CMV IE 
(Blackwood et al., 2001). Multiple cloning sites and SV40 poly(A) signals are 
present. Kindly donated by Dr. L. Blackwood, Department of Veterinary Clinical 
Studies, University of Glasgow.  
 
 
 
Figure C9: pCMVCAT6. A pBLCAT6-derived plasmid which contains the 
chloramphenicol acetyl transferase gene (cat) gene under the control of CMV IE 
(Blackwood et al., 2001). Multiple cloning sites and SV40 poly(A) signals are 
present. Kindly donated by Dr. L. Blackwood, Department of Veterinary Clinical 
Studies, University of Glasgow.   
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Appendix D: Alignment of nucleotide sequence for canine 
TP53 exons 5-8  
Control (DNA)          ----------------CCCTCTCCTCAACAAGTTGTTTTGCCAGCTGGCGAAGACCTGCC 44 
U62133 (DNA) (732)     TTTTCTTACAGT---CCCCTCTCCTCAACAAGTTGTTTTGCCAGCTGGCGAAGACCTGCC 788 
U51857 (DNA)           -----------------------------------------CAGCTGGCGAAGACCTGCC 19 
L27630 (DNA)           ------------------------------------------------------------ 
NC_006587 (DNA) (1087) TTTTCTTACAGTACTCCCCTCTCCTCAACAAGTTGTTTTGCCAGCTGGCGAAGACCTGCC 1146 
S77819 (mRNA) (265)    -----------TACTCCCCTCTCCTCAACAAGTTGTTTTGCCAGCTGGCGAAGACCTGCC 313 
L37107 (mRNA) (53)     -----------TACTCCCCTCTCCTCAACAAGTTGTTTTGCCAGCTGGCGAAGACCTGCC 101 
AF159062 (mRNA) (23)   -----------TACTCCCCTCTCCTCAACAAGTTGTTTTGCCAGCTGGCGAAGACCTGCC 71 
DN444655 (mRNA) (471)  -----------TACTCCCCTCTCCTCAACAAGTTGTTTTGCCAGCTGGCGAAGACCTGCC 519 
AF060514 (mRNA) (353)  -----------TACTCCCCTCTCCTCAACAAGTTGTTTTGCCAGCTGGCGAAGACCTGCC 401 
AB020761 (mRNA) (383)  -----------TACTCCCCTCTCCTCAACAAGTTGTTTTGCCAGCTGGCGAAGACCTGCC 431 
 
Control (DNA)          CCGTGCAGCTGTGGGTCAGCTCCCCACCCCCACCCAATACCTGCGTCCGCGCTATGGCCA 104 
U62133 (DNA)           CCGTGCAGCTGTGGGTCAGCTCCCCACCCCCACCCAATACCTGCGTCCGCGCTATGGCCA 848 
U51857 (DNA)           CCGTGCAGCTGTGGGTCAGCTCCCCACCCCCACCCAATACCTGCGTCCGCGCTATGGCCA 79 
L27630 (DNA)           ------------------------------------------------------------ 
NC_006587 (DNA)        CCGTGCAGCTGTGGGTCAGCTCCCCACCCCCACCCAATACCTGCGTCCGCGCTATGGCCA 1206 
S77819 (mRNA)          CCGTGCAGCTGTGGGTCAGCTCCCCACCCCCACCCAATACCTGCGTCCGCGCTATGGCCA 373 
L37107 (mRNA)          CCGTGCAGCTGTGGGTCAGCTCCCCACCCCCACCCAATACCTGCGTCCGCGCTATGGCCA 161 
AF159062 (mRNA)        CCGTGCAGCTGTGGGTCAGCTCCCCACCCCCACCCAATACCTGCGTCCGCGCTATGGCCA 131 
DN444655 (mRNA)        CCGTGCAGCTGTGGGTCAGCTCCCCACCCCCACCCAATACCTGCGTCCGCGCTATGGCCA 579 
AF060514 (mRNA)        CCGTGCAGCTGTGGGTCAGCTCCCCACCCCCACCCAATACCTGCGTCCGCGCTATGGCCA 461 
AB020761 (mRNA)        CCGTGCAGCTGTGGGTCAGCTCCCCACCCCCACCCAATACCTGCGTCCGCGCTATGGCCA 491 
 
Control (DNA)          TCTATAAGAAGTCGGAGTTCGTGACCGAGGTTGTGCGGCGCTGCCCCCACCATGAACGCT 164 
U62133 (DNA)           TCTATAAGAAGTCGGAGTTCGTGACCGAGGTTGTGCGGCGCTGCCCCCACCATGAACGCT 908 
U51857 (DNA)           TCTATAAGAAGTCGGAGTTCGTGACCGAGGTTGTGCGGCGCTGCCCCCACCATGAACGCT 139 
L27630 (DNA)           -------GAAGTCGGAGTTCGTGACCGAGGTTGTGCGGCGCTGCCCCCACCATGAACGCT 53 
NC_006587 (DNA)        TCTATAAGAAGTCGGAGTTCGTGACCGAGGTTGTGCGGCGCTGCCCCCACCATGAACGCT 1266 
S77819 (mRNA)          TCTATAAGAAGTCGGAGTTCGTGACCGAGGTTGTGCGGCGCTGCCCCCACCATGAACGCT 433 
L37107 (mRNA)          TCTATAAGAAGTCGGAGTTCGTGACCGAGGTTGTGCGGCGCTGCCCCCACCATGAACGCT 221 
AF159062 (mRNA)        TCTATAAGAAGTCGGAGTTCGTGACCGAGGTTGTGCGGCGCTGCCCCCACCATGAACGCT 191 
DN444655 (mRNA)        TCTATAAGAAGTCGGAGTTCGTGACCGAGGTTGTGCGGCGCTGCCCCCACCATGAACGCT 639 
AF060514 (mRNA)        TCTATAAGAAGTCGGAGTTCGTGACCGAGGTTGTGCGGCGCTGCCCCCACCATGAACGCT 521 
AB020761 (mRNA)        TCTATAAGAAGTCGGAGTTCGTGACCGAGGTTGTGCGGCGCTGCCCCCACCATGAACGCT 551 
                              ***************************************************** 
 
Control (DNA)          GCTCTGACAGTAGTGACGGTAAGCCATCGGGGGCTACAGATGGGACAAGGCTGCTCCCCA 224 
U62133 (DNA)           GCTCTGACAGTAGTGACGGTAAGCCATCGGGGGCTACAGATGGGACAAGGCTGCTCCCCA 968 
U51857 (DNA)           GCTCTGACAGTAGTGACGGTAAGCCATCGGGGGCTACAGATGGGACAAGGCTGCTCCCCA 199 
L27630 (DNA)           GCTCTGACAGTAGTGACGGTAAGCCATCGGGGGCTACAGATGGGACAAGGCTGCTCCCCA 113 
NC_006587 (DNA)        GCTCTGACAGTAGTGACGGTAAGCCATCGGGGGCTACAGATGGGACAAGGCTGCTCCCCA 1326 
S77819 (mRNA)          GCTCTGACAGTAGTGACG------------------------------------------ 451 
L37107 (mRNA)          GCTCTGACAGTAGTGACG------------------------------------------ 239 
AF159062 (mRNA)        GCTCTGACAGTAGTGACG------------------------------------------ 209 
DN444655 (mRNA)        GCTCTGACAGTAGTGACG------------------------------------------ 657 
AF060514 (mRNA)        GCTCTGACAGTAGTGACG------------------------------------------ 539 
AB020761 (mRNA)        GCTCTGACAGTAGTGACG------------------------------------------ 569 
 
Control (DNA)          GAGGGCCCAAAGCCCTGATTCCTCCCCGATGGCTCTTAGGTCTTGCCCCTCCTCAGCATC 284 
U62133 (DNA)           GAGG-CCCAAAGCCCTGATTCCTCCCCGATGGCTCTTAGGTCTTGCCCCTCCTCAGCATC 1027 
U51857 (DNA)           GAGGGCCCAAAGCCCTGATTCCTCCCCGATGGCTCTTAGGTCTTGCCCCTCCTCAGCATC 259 
L27630 (DNA)           GAGG-CCCAAAGCCCTGATTCCTCCCCGATGGCTCTTAGGTCTTGCCCCTCCTCAGCATC 172 
NC_006587 (DNA)        GAGGGCCCAAAGCCCTGATTCCTCCCCGATGGCTCTTAGGTCTTGCCCCTCCTCAGCATC 1386 
S77819 (mRNA)          ---------------------------------------GTCTTGCCCCTCCTCAGCATC 472 
L37107 (mRNA)          ---------------------------------------GTCTTGCCCCTCCTCAGCATC 260 
AF159062 (mRNA)        ---------------------------------------GTCTTGCCCCTCCTCAGCATC 230 
DN444655 (mRNA)        ---------------------------------------GTCTTGCCCCTCCTCAGCATC 678 
AF060514 (mRNA)        ---------------------------------------GTCTTGCCCCTCCTCAGCATC 560 
AB020761 (mRNA)        ---------------------------------------GTCTTGCCCCTCCTCAGCATC 590 
                  ********************* 
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Control (DNA)          TCATCCGAGTGGAAGGAAATTTGCGGGCCAAGTACCTGGACGACAGAAACACTTTTCGAC 344 
U62133 (DNA)           TCATCCGAGTGGAAGGAAATTTGCGGGCCAAGTACCTGGACGACAGAAACACTTTTCGAC 1087 
U51857 (DNA)           TCATCCGAGTGGAAGGAAATTTGCGGGCCAAGTACCTGGACGACAGAAACACTTTTCGAC 319 
L27630 (DNA)           TCATCCGAGTGGAAGGAAATTTGCGGGCCAAGTACCTGGACGACAGATACACTTTTCGAC 232 
NC_006587 (DNA)        TCATCCGAGTGGAAGGAAATTTGCGGGCCAAGTACCTGGACGACAGAAACACTTTTCGAC 1446 
S77819 (mRNA)          TCATCCGAGTGGAAGGAAATTTGCGGGCCAAGTACCTGGACGACAGAAACACTTTTCGAC 532 
L37107 (mRNA)          TCATCCGAGTGGAAGGAAATTTGCGGGCCAAGTACCTGGACGACAGAAACACTTTTCGAC 320 
AF159062 (mRNA)        TCATCCGAGTGGAAGGAAATTTGCGGGCCAAGTACCTGGACGACAGAAACACTTTTCGAC 290 
DN444655 (mRNA)        TCATCCGA---------------------------------------------------- 686 
AF060514 (mRNA)        TCATCCGAGTGGAAGGAAATTTGCGGGCCAAGTACCTGGACGACAGAAACACTTTTCGAC 620 
AB020761 (mRNA)        TCATCCGAGTGGAAGGAAATTTGCGGGCCAAGTACCTGGACGACAGAAACACTTTTCGAC 650 
                       ******** 
 
Control (DNA)          ACAGTGTGGTGGTGCCTTATGAGCCACCCGAGGTCTGGTTTGGCATCTGAGGGGTCTCTG 404 
U62133 (DNA)           ACAGTGTGGTGGTGCCTTATGAGCCACCCGAGGTCTGGTTTGGCATCTGAGGGGTCTCTG 1147 
U51857 (DNA)           ACAGTGTGGTGGTGCCTTATGAGCCACCCGAGGTCTGGTTTGGCATCTGAGGGGTCTCTG 379 
L27630 (DNA)           ACAGTGTGGTGGTGCCTTATGAGCCACCCGAGGTCTGGTTTGGCATCTGAGGGGTCTCTG 292 
NC_006587 (DNA)        ACAGTGTGGTGGTGCCTTATGAGCCACCCGAGGTCTGGTTTGGCATCTGAGGGGTCTCTG 1506 
S77819 (mRNA)          ACAGTGTGGTGGTGCCTTATGAGCCACCCGAG---------------------------- 564 
L37107 (mRNA)          ACAGTGTGGTGGTGCCTTATGAGCCACCCGAG---------------------------- 352 
AF159062 (mRNA)        ACAGTGTGGTGGTGCCTTATGAGCCACCCGAG---------------------------- 322 
DN444655 (mRNA)        ------------------------------------------------------------ 
AF060514 (mRNA)        ACAGTGTGGTGGTGCCTTATGAGCCACCCGAG---------------------------- 652 
AB020761 (mRNA)        ACAGTGTGGTGGTGCCTTATGAGCCACCCGAG---------------------------- 682 
 
Control (DNA)          GGAGGAGGGGGCTGGAGGGATTTGTGAGGCGGGAGTTGAGGGGGCTTTCTCCTCCTTCAA 464 
U62133 (DNA)           GGAGGAGGGGGCTGGAGGGATTTGTGAGGCGGGAGTTGAGGGGGCTTTCTCCTCCTTCAG 1207 
U51857 (DNA)           GGAGGAGGGGGCTGGAGGGATTTGTGAGGCGGGAGTTGAGGGGGCTTTCTCCTCCTTCAA 439 
L27630 (DNA)           GGAGGAGGGGGCTGGAGGGATTTGTGAGGCGGGAGTTGAGGGGGCTTTCTCCTCCTTCAG 352 
NC_006587 (DNA)        GGAGGAGGGGGCTGGAGGGATTTGTGAGGCGGGAGTTGAGGGGGCTTTCTCCTCCTTCAA 1566 
S77819 (mRNA)          ------------------------------------------------------------ 
L37107 (mRNA)          ------------------------------------------------------------ 
AF159062 (mRNA)        ------------------------------------------------------------ 
DN444655 (mRNA)        ------------------------------------------------------------ 
AF060514 (mRNA)        ------------------------------------------------------------ 
AB020761 (mRNA)        ------------------------------------------------------------ 
 
Control (DNA)          CCTCCCCGCAGCCCTGTGAGGAGTGCAGAGGCAGGTGGGTCATCCCATTCTGCGGTTGGG 524 
U62133 (DNA)           CCTCCCCGCAGCCCTGTGAGGAGTGCAGAGGCAGGTGGGTCATCCCATTCTGCGGTTGGG 1267 
U51857 (DNA)           CCTCCCCGCAGCCCTGTGAGGAGTGCAGAGGCAGGTGGGTCATCCCATTCTGCGGTTGGG 499 
L27630 (DNA)           CCTCCCCGCAGCCCTGTGAGGAGTGCAGAGGCAGGTGGGTCATCCCATTCTGCGGTTGGG 412 
NC_006587 (DNA)        CCTCCCCGCAGCCCTGTGAGGAGTGCAGAGGCAGGTGGGTCATCCCATTCTGCGGTTGGG 1626 
S77819 (mRNA)          ------------------------------------------------------------ 
L37107 (mRNA)          ------------------------------------------------------------ 
AF159062 (mRNA)        ------------------------------------------------------------ 
DN444655 (mRNA)        ------------------------------------------------------------ 
AF060514 (mRNA)        ------------------------------------------------------------ 
AB020761 (mRNA)        ------------------------------------------------------------ 
 
Control (DNA)          AAAGACTGAGGCTGATAGACTACAGGCCTGCCCAGGGCTGAGTGGCCCGACCCTGGGCCT 584 
U62133 (DNA)           AAAGACTGAGGCTGATAGACTACAGGCCTGCCCAGGGCTGAGTGGCCCGACCCTGGGCCT 1327 
U51857 (DNA)           AAAGACTGAGGCTGATAGACTACAGGCCTGCCCAGGGCTGAGTGGCCCGACCCTGGGCCT 559 
L27630 (DNA)           AAAGACTGAGGCTGATAGACTACAGGCCTGCCCAGGGCTGAGTGGCCCGACCCTGGGCCT 472 
NC_006587 (DNA)        AAAGACTGAGGCTGATAGACTACAGGCCTGCCCAGGGCTGAGTGGCCCGACCCTGGGCCT 1686 
S77819 (mRNA)          ------------------------------------------------------------ 
L37107 (mRNA)          ------------------------------------------------------------ 
AF159062 (mRNA)        ------------------------------------------------------------ 
DN444655 (mRNA)        ------------------------------------------------------------ 
AF060514 (mRNA)        ------------------------------------------------------------ 
AB020761 (mRNA)        ------------------------------------------------------------ 
 
Control (DNA)          ACCTTCTACCTCAGGTTGGCTCTGACTATACCACCATCCACTACAACTACATGTGTAACA 644 
U62133 (DNA)           ACCTTCTACCTCAGGTTGGCTCTGACTATACCACCATCCACTACAACTACATGTGTAACA 1387 
U51857 (DNA)           ACCTTCTACCTCAGGTTGGCTCTGACTATACCACCATCCACTACAACTACATGTGTAACA 619 
L27630 (DNA)           ACCTTCTACCTCAGGTTGGCTTTGACTATACCACCATCCACTACAACTACATGTGTAACA 532 
NC_006587 (DNA)        ACCTTCTACCTCAGGTTGGCTCTGACTATACCACCATCCACTACAACTACATGTGTAACA 1746 
S77819 (mRNA)          --------------GTTGGCTCTGACTATACCACCATCCACTACAACTACATGTGTAACA 610 
L37107 (mRNA)          --------------GTTGGCTCTGACTATACCACCATCCACTACAACTACATGTGTAACA 398 
AF159062 (mRNA)        --------------GTTGGCTCTGACTATACCACCATCCACTACAACTACATGTGTAACA 368 
DN444655 (mRNA)        ------------------------------------------------------------ 
AF060514 (mRNA)        --------------GTTGGCTCTGACTATACCACCATCCACTACAACTACATGTGTAACA 698 
AB020761 (mRNA)        --------------GTTGGCTCTGACTATACCACCATCCACTACAACTACATGTGTAACA 728 
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Control (DNA)          GTTCCTGCATGGGAGGCATGAACCGGCGGCCCATCCTCACTATCATCACCCTGGAAGACT 704 
U62133 (DNA)           GTTCCTGCATGGGAGGCATGAACCGGCGGCCCATCCTCACTATCATCACCCTGGAAGACT 1447 
U51857 (DNA)           GTTCCTGCATGGGAGGCATGAACCGGCGGCCCATCCTCACTATCATCACCCTGGAAGACT 679 
L27630 (DNA)           GT---------------------------------------------------------- 534 
NC_006587 (DNA)        GTTCCTGCATGGGAGGCATGAACCGGCGGCCCATCCTCACTATCATCACCCTGGAAGACT 1806 
S77819 (mRNA)          GTTCCTGCATGGGAGGCATGAACCGGCGGCCCATCCTCACTATCATCACCCTGGAAGACT 670 
L37107 (mRNA)          GTTCCTGCATGGGAGGCATGAACCGGCGGCCCATCCTCACTATCATCACCCTGGAAGACT 458 
AF159062 (mRNA)        GTTCCTGCATGGGAGGCATGAACCGGCGGCCCATCCTCACTATCATCACCCTGGAAGACT 428 
DN444655 (mRNA)        ------------------------------------------------------------ 
AF060514 (mRNA)        GTTCCTGCATGGGAGGCATGAACCGGCGGCCCATCCTCACTATCATCACCCTGGAAGACT 758 
AB020761 (mRNA)        GTTCCTGCATGGGAGGCATGAACCGGCGGCCCATCCTCACTATCATCACCCTGGAAGACT 788 
 
Control (DNA)          CCAGGTAGGGACCTGCCTGCCACCCTGCTCCTGGCCACTTCCTTACTGTACCCCCCTCCA 764 
U62133 (DNA)           CCAGGTAGGGACCTGCCTGCCACCCTGCTCCTGGCCACTTCCTT-CTGTACCCCCCTCCA 1506 
U51857 (DNA)           CCAGGTAGGGACCTGCCTGCCACCCTGCTCCTGGCCACTTCCTTACTGTACCCCCCTCCA 739 
L27630 (DNA)           ------------------------------------------------------------ 
NC_006587 (DNA)        CCAGGTAGGGACCTGCCTGCCACCCTGCTCCTGGCCACTTCCTTACTGTACCCCCCTCCA 1866 
S77819 (mRNA)          CCAG-------------------------------------------------------- 674 
L37107 (mRNA)          CCAG-------------------------------------------------------- 462 
AF159062 (mRNA)        CCAG-------------------------------------------------------- 432 
DN444655 (mRNA)        ------------------------------------------------------------ 
AF060514 (mRNA)        CCAG-------------------------------------------------------- 762 
AB020761 (mRNA)        CCAG-------------------------------------------------------- 792 
 
Control (DNA)          TCCTTCCCATCCATTCCTGTCCCAATGTGGAATCTCCTCTGCCATCCG-CCTCCCCTGG- 824 
U62133 (DNA)           TCCTTCCCATCCATTCCTGTCCCAATGTGGAATCTCCTCTGCCATCCGGCCTCCCCTGGG 1566 
U51857 (DNA)           TCCTTCCCATCCATTCCTGTCCCAATGTGGAATCTCCTCTGCCATCCG-CCTCCCCTGG- 797 
L27630 (DNA)           ------------------------------------------------------------ 
NC_006587 (DNA)        TCCTTCCCATCCATTCCTGTCCCAATGTGGAATCTCCTCTGCCATCCG-CCTCCCCTGG- 1924 
S77819 (mRNA)          ------------------------------------------------------------ 
L37107 (mRNA)          ------------------------------------------------------------ 
AF159062 (mRNA)        ------------------------------------------------------------ 
DN444655 (mRNA)        ------------------------------------------------------------ 
AF060514 (mRNA)        ------------------------------------------------------------ 
AB020761 (mRNA)        ------------------------------------------------------------ 
 
Control (DNA)          TTTTCTTTCCTCTGGCTTTGGGACCTCCCTGACCTGTGGCTTCTCAATAGTCTGTAGGCT 884 
U62133 (DNA)           TTTTCTTTCCTCTGGCTTTGGAGCCTCCCTGACCTGTGGCTTCTCAATAGTCTGTAGGCT 1626 
U51857 (DNA)           TTTTCTTTCCTCTGGCTTTGGGACCTCCCTGACCTGTGGCTTCTCAATAGTCTGTAGGCT 857 
L27630 (DNA)           ------------------------------------------------------------ 
NC_006587 (DNA)        TTTTCTTTCCTCTGGCTTTGGGACCTCCCTGACCTGTGGCTTCTCAATAGTCTGTAGGCT 1984 
S77819 (mRNA)          ------------------------------------------------------------ 
L37107 (mRNA)          ------------------------------------------------------------ 
AF159062 (mRNA)        ------------------------------------------------------------ 
DN444655 (mRNA)        ------------------------------------------------------------ 
AF060514 (mRNA)        ------------------------------------------------------------ 
AB020761 (mRNA)        ------------------------------------------------------------ 
 
Control (DNA)          TTGGCTCTACGTAGGATGAGGGTGGCTAGGAGTCAGTGGGGCCCACCACCCTCACGGCCC 944 
U62133 (DNA)           TTGGCTCTACGTAGGATGAGGGTGGCTAGGAGTCAGTGGGGCCCACCACCCTCACGGCCC 1686 
U51857 (DNA)           TTGGCTCTACGTAGGATGAGGGTGGCTAGGAGTCAGTGGGGCCCACCACCCTCACGGCCC 917 
L27630 (DNA)           ------------------------------------------------------------ 
NC_006587 (DNA)        TTGGCTCTACGTAGGATGAGGGTGGCTAGGAGTCAGTGGGGCCCACCACCCTCACGGCCC 2044 
S77819 (mRNA)          ------------------------------------------------------------ 
L37107 (mRNA)          ------------------------------------------------------------ 
AF159062 (mRNA)        ------------------------------------------------------------ 
DN444655 (mRNA)        ------------------------------------------------------------ 
AF060514 (mRNA)        ------------------------------------------------------------ 
AB020761 (mRNA)        ------------------------------------------------------------ 
 
Control (DNA)          CCTGCTTCTCTCTTCTCACCTGGGTAGTGGAAACGTGCTGGGACGCAACAGCTTTGAGGT 1004 
U62133 (DNA)           CCTGCTTCTCTCTTCTCACCTGGGTAGTGGAAACGTGCTGGGACGCAACAGCTTTGAGGT 1746 
U51857 (DNA)           CCTGCTTCTCTCTTCTCACCTGGGTAGTGGAAACGTGCTGGGACGCAACAGCTTTGAAGT 977 
L27630 (DNA)           ------------------------------------------------------------ 
NC_006587 (DNA)        CCTGCTTCTCTCTTCTCACCTGGGTAGTGGAAACGTGCTGGGACGCAACAGCTTTGAGGT 2104 
S77819 (mRNA)          ---------------------------TGGAAACGTGCTGGGACGCAACAGCTTTGAGGT 707 
L37107 (mRNA)          ---------------------------TGGAAACGTGCTGGGACGCAACAGCTTTGAGGT 495 
AF159062 (mRNA)        ---------------------------TGGAAACGTGCTGGGACGCAACAGCTTTGAGGT 465 
DN444655 (mRNA)        ------------------------------------------------------------ 
AF060514 (mRNA)        ---------------------------TGGAAACGTGCTGGGACGCAACAGCTTTGAGGT 795 
AB020761 (mRNA)        ---------------------------TGGAAACGTGCTGGGACGCAACAGCTTTGAGGT 825 
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Control (DNA)          ACGCGTTTGTGCCTGTCCCGGGAGAGACCGCCGGACTGAGGAGGAGAATTTCCACAAGAA 1064 
U62133 (DNA)           ACGCGTTTGTGCCTGTCCCGGGAGAGACCGCCGGACTGAGGAGGAGAATTTCCACAAGAA 1806 
U51857 (DNA)           ACGCGTTTGTGCCTGTCCCGGGAGAG---------------------------------- 1003 
L27630 (DNA)           ------------------------------------------------------------ 
NC_006587 (DNA)        ACGCGTTTGTGCCTGTCCCGGGAGAGACCGCCGGACTGAGGAGGAGAATTTCCACAAGAA 2164 
S77819 (mRNA)          ACGCGTTTGTGCCTGTCCCGGGAGAGACCGCCGGACTGAGGAGGAGAATTTCCACAAGAA 767 
L37107 (mRNA)          ACGCGTTTGTGCCTGTCCCGGGAGAGACCGCCGGACTGAGGAGGAGAATTTCCACAAGAA 555 
AF159062 (mRNA)        ACGCGTTTGTGCCTGTCCCGGGAGAGACCGCCGGACTGAGGAGGAGAATTTCCACAAGAA 525 
DN444655 (mRNA)        ------------------------------------------------------------ 
AF060514 (mRNA)        ACGCGTTTGTGCCTGTCCCGGGAGAGACCGCCGGACTGAGGAGGAGAATTTCCACAAGAA 855 
AB020761 (mRNA)        ACGCGTTTGTGCCTGTCCCGGGAGAGACCGCCGGACTGAGGAGGAGAATTTCCACAAGAA 885 
 
Control (DNA)          GGGGGAGCCTTGTCCTGAGCCACCCCCCGGGAGTACCAAGCG--GTAAGCAAGCAAGACA 1122 
U62133 (DNA)           GGGGGAGCCTTGTCCTGAGCCACCCCCCGGGAGTACCAAGCG--GTAAGCAAGCAAGACA 1864 
U51857 (DNA)           ------------------------------------------------------------ 
L27630 (DNA)           ------------------------------------------------------------ 
NC_006587 (DNA)        GGGGGAGCCTTGTCCTGAGCCACCCCCCGGGAGTACCAAGCGAGGTAAGCAAGCAAGACA 2224 
S77819 (mRNA)          GGGGGAGCCTTGTCCTGAGCCACCCCCCGGGAGTACCAAGCGAG---------------- 811 
L37107 (mRNA)          GGGGGAGCCTTGTCCTGAGCCACCCCCCGGGAGTACCAAGCGAG---------------- 599 
AF159062 (mRNA)        GGGGGAGCCTTGTCCTGAGCCACCCCCCGGGAGTACCAAGCGAG---------------- 569 
DN444655 (mRNA)        ------------------------------------------------------------ 
AF060514 (mRNA)        GGGGGAGCCTTGTCCTGAGCCACCCCCCGGGAGTACCAAGCGAG---------------- 899 
  AB020761 (mRNA)        GGGGGAGCCTTGTCCTGAGCCACCCCCCGGGAGTACCAAGCGAG---------------- 929 
 
Figure D1: Alignment of the nucleotide sequence for canine TP53 exons 5-8  from 
control DNA (normal canine lung tissue) and 10 canine wild-type TP53 nucleotide 
sequences accessible in GenBank (accession numbers listed): partial DNA - U62133, 
U51857, L27630; complete DNA - NC_006587;  partial mRNA - S77819, L37107, 
AF159062, DN444655; complete mRNA - AF060514, AB020761 (differences between 
nucleotide sequences are highlighted in red; „*‟ indicate nucleotide similarities 
between all 11 sequences). Based on NC_006587 sequence: exon 5, 1098-1284 bp; exon 
6, 1366-1478 bp; exon 7, 1701-1810 bp; exon 8, 2072-2208 bp. 
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E1: AVTRW Conference, April 1999 - Characterisation of p53 (tumour 
suppressor) mutational status in a canine osteosarcoma cell line (D17).  
Sabine VS, Nasir L, Burr PD, McFarlane S, Argyle DJ. 
Department of Veterinary Clinical Studies, University of Glasgow Veterinary 
School 
P53 is a tumour suppressor gene which functions to protect the organism from 
genetic damage by either inducing growth arrest or apoptosis. Alterations of the 
p53 gene have been shown to occur in many human carcinomas, including 
osteosarcoma. The loss of the normal function of p53 has also been shown to 
occur in canine osteosarcoma which is a highly aggressive disease associated 
with high mortality. The aim of the present study was to characterise the 
mutational status of p53 in a number of canine cell lines with the view to 
developing an in vitro system to investigate the efficacy of p53 directed gene 
therapy protocols. The status of p53 in MDCK, D17, CML10 cells was examined by 
immunocytochemistry using a CM-1 polyclonal anti-p53 antibody. 
Immunohistochemical analyses failed to demonstrate aberrant p53 expression in 
the cell lines and the absence of p53 gene mutations was confirmed by cloning 
and direct DNA sequence analysis of p53 cDNA isolated from the D17 cell line. 
These data suggest that the melanoma cell line (CML-10) and osteosarcoma cell 
line (D17) harbour wildtype p53. 
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